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Background: Smoking is the biggest cause of preventable death in industrialised countries.  
Quit rates after use of current Nicotine Replacement Therapy (NRT) are low.  Animal studies 
suggest nicotine is more rewarding when it is delivered rapidly to the brain, and human 
clinical trials of the current NRT that delivers nicotine to the brain most rapidly (nicotine 
nasal spray), demonstrate quit rates are improved if it is used in combination with nicotine 
transdermal patches.  However, nicotine nasal spray is aversive and other rapid nicotine 
delivery systems are required.  The lung is the most rapid delivery route to the brain; 
however, inhalation of nicotine is aversive, and delivery of substances to the lung is 
technically difficult.  In 2008, when these trials were designed, apart from bench-top 
nebulisers, waterpipes, cigarettes, and some electronic cigarettes, no device was capable of 
pulmonary nicotine delivery.  Nicotine mouthsprays are amongst the most rapid NRT at 
delivering nicotine to the brain and may be more tolerable than nasal spray. 
Objectives:  
1. Develop a nicotine pressurised metered-dose inhaler (pMDI).   
2. Test the long-term abstinence rates of active nicotine mouthspray plus active patch, 
and of active nicotine inhaler plus active patch, compared to placebo plus active patch.   
Methods:   
1. Double-blind, Randomised Controlled Trial (RCT) of active nicotine mouthspray and 
active nicotine patch cf. placebo mouthspray plus active nicotine patch (ZAP). 
2. A cross-over, non-randomised, open-label, pharmacokinetic, pharmacodynamic, and 
tolerability trial of a free-base nicotine pressurised metered-dose inhaler (pMDI). 
3. A cross-over, non-randomised, open-label, pharmacodynamic, preference and 
tolerability trial of free-base nicotine, and nicotine lactate, and the effects of 
flavouring, delivered by pMDI. 
4. Double-blind, RCT of active nicotine lactate pMDI and active patch cf. placebo pMDI 
plus active nicotine patch (INHALE). 
 
Results:  Ten smokers enrolled in the pharmacokinetic trial, which showed that nicotine was 
delivered, at least in part, via the lung, and rapidly quenched urges to smoke.   
 
ZAP enrolled 1,423 smokers.  Nicotine mouthspray plus nicotine patch, significantly 
increased abstinence to six months cf. placebo and nicotine patch (15.5% vs 10.6%; p=0.006).  
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The prolonged twelve-month abstinence was 10.1% with the active combination cf. 7.1% 
(p=0.045).  At all follow-up time-points urges to smoke reduced significantly compared to 
baseline in both active and control groups, and this reduction was significantly greater in the 
active cf. control group.  Withdrawal scores reduced at all follow-ups compared to the one-
month visit in both groups, with no significant difference between groups after Bonferroni 
correction.  The variables recorded before randomisation that were statistically significant 
predictors of lower rates of abstinence after Bonferroni correction were Māori ethnicity; 
enrolment at a Māori community trial site; previous use of NRT, and higher scores of the 
Social/Environmental Goads scale of the brief-WISDM psychological battery.  Pre-
randomisation variables significantly predictive of higher odds of abstinence were being 50 
years or older; having started smoking daily aged sixteen years or older; how prepared 
subjects’ felt they were to handle stress without smoking; the number of subjects’ personal 
acquaintances who have quit.   
 
Six variables measured after randomisation statistically decreased abstinence after Bonferroni 
correction: MNWS Craving score at one-, three-, and six-months post-target quit date; 
MNWS Negative Affect score at three-months post-target quit date; and brief-QSU total score 
at one- and three-months post-target quit date.  Eleven variables recorded post-randomisation 
predicted increase abstinence: having quit on or before the target quit date; fully completed 
the record of CPD for the first fortnight of the trial, strongly wanting to continue trying to quit 
or remain abstinent and continue to participate in the trial (recorded the day after the target 
quit date); being highly confident that one will quit/stay abstinent (measured a day after the 
target quit date); how well subjects reported they were coping with their urges to smoke 
reported a day after the target quit date;, and how much Zonnic subjects reported using a day 
after the target quit date.  Of the eight Likert scales conceived by the author, none predicted 
abstinence after Bonferroni correction for sixteen comparisons, while one was significant 
after correction for eight comparisons.  
 
Twelve smokers enrolled in the preference trial; menthol nicotine lactate was tolerable. 
 
Five-hundred-and-two smokers enrolled in INHALE.  Prolonged six-months abstinence rates 
were 78/246 (31.71%) vs. 46/256 (17.97%), p=0.00042 in the active and control group, 
respectively. Subjects in the active group had a significantly greater reduction in their brief 
Questionnaire of Smoking Urges (QSU) scores at baseline cf. the control group, and 
continued to have lower scores at the one-, three- and six-month follow-ups in the active- 
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compared to control-group.  Subjects in the two groups had similar nicotine withdrawal scores 
(MNWS scores) at all timepoints except the active group had significantly lower scores at 
three- and six-months.  Of the ten variables recoded at baseline that were analysed as a 
potential predictor of prolonged abstinence, only FTND was statistically significant, albeit, 
weakly significant.  At every follow-up beyond a week after baseline, the number of days the 
inhalers were used predicted abstinence in both groups.  Favourable scores on the Cigarette 
Evaluation Questionnaire scales used to rate the inhalers, predicted abstinence at many 
follow-ups for many of the scales.     
 
Although, in the active groups, abstinence rates were significantly higher in INHALE cf. 
ZAP, the trials were underpowered to find a significant difference in the ORs of abstinence 
between the trials.  In both trials, the sensory qualities of the rapid-acting NRT and its placebo 
equivalent, had a significant bearing on abstinence, and subject who correctly guessed their 
treatment assignment had higher abstinence than those who guessed incorrectly or were 
unsure. 
 
Conclusions:  The combination of nicotine patches and each of two rapid nicotine delivery 
devices assisted more smokers to quit smoking than use of nicotine patch and placebo.  
Further research is required to reduce the aversive sensory effects of nicotine mouthsprays 
and inhalers, and to find effective methods to encourage smokers to use these therapies 
regularly to replace the roles of smoking. 
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The addiction to smoking tobacco takes a substantial toll on health, quality of life, and the 
economy.  This dissertation is based on several clinical trials of nicotine delivery devices that 
were used to assist smokers to quit smoking.   
This introductory chapter briefly outlines the nature of addiction, and the addiction to 
cigarette smoking in particular; along with the chemical, sensory, perceptual and behavioural 
elements involved in the onset, maintenance, and treatment of the smoking addiction.  This is 
followed by an outline of the development of Nicotine Replacement Therapy (NRT), its 
deficiencies, and the reasons improved nicotine delivery devices are needed.  The introduction 
concludes with a description of the trials and their methodologies, upon which this 
dissertation is based.  
Chapter Two outlines the nature of addiction and the various attempts to define addiction.  
Chapter Two also describes the early work that elucidated the mechanisms of behaviour and 
addiction, followed by a summary of the modern neurological understanding of the 
mechanisms of behaviour and addiction.  Furthermore, Chapter Two gives an overview of 
how characteristics of nicotine delivery devices influence their pharmacokinetics and both 
their desirable and undesirable effects.  Methodological issues pertaining to trials that test the 
efficacy of NRT are outlined in Chapter Two.  Chapter Three describes the methodology and 
results of the randomised placebo-controlled trial of nicotine Zonnic mouthspray plus nicotine 
patch (ZAP).  Chapter Four outlines the science behind nicotine inhalation, leading to Chapter 
Five which presents a pilot study of a nicotine free-base pressurised metered-dose inhalers 
(pMDI) trials, while Chapter Six presents a pilot study of pMDIs containing different forms 
of nicotine and different flavourings.  Chapter Seven presents the INHALE RCT (RCT of 
nicotine pressurised-metered dose inhaler plus active nicotine patch cf. placebo inhaler plus 
active patch), and Chapter Eight compares the results of the mouthspray and the inhaler trials.  
The final chapter, Chapter Nine, draws conclusions from the trials and offers 
recommendations.   
Tables whose numbers are preceded by a letter are supplementary tables located in Appendix 
A for Chapter Two, Appendix B for the mouthspray trial, and Appendix C for the inhaler 
trial.  Appendix D shows the items for each of the psychological batteries used in the trials 
reported in this dissertation.  Appendix E outlines the Generalized Linear Model building 
strategy for multivariate analyses in ZAP and the principal component analyses.  Appendix F 
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displays a supplementary table.  Appendix G contains copies of the publications arising from 
this dissertation. 
1.1 The smoking addiction  
Smoking is one of the leading causes of preventable death and morbidity worldwide, causing 
twelve percent of global adult preventable deaths in the year 2000 and,(1) five to six million 
deaths annually world-wide.(2)  Half of all smokers will die on average sixteen years 
prematurely,(3) and although seventy percent of smokers say they want to quit, only three 
percent of smokers who attempt to quit remain tobacco-free for a year.(4)  Furthermore, 
tobacco smoking is far and away the biggest cause of preventable death and loss of disability 
adjusted life-years in high-income countries in the west-Pacific region where it is responsible 
for eighteen percent of deaths.(5)  Globally, 1.1 billion people smoke tobacco, eighty percent 
of whom live in low- to middle-income countries.(6) 
During 2015, in the United States of America (USA), slightly over two-thirds of adult 
smokers wanted to quit smoking, over half had tried to do so in the previous year but, only 
seven percent had recently quit smoking, despite 57.2% having been advised to do so by a 
health professional, and 31.2% having used medication and/or counselling during their 
attempt.(7)  These observations attest to both the absence of voluntary control smokers have 
over their smoking, and the low quit rates despite behavioural and medicinal assistance.  
Given the considerable toll that smoking has on the health of smokers and the health systems 
of nations, and the low unassisted abstinence rates of twenty percent one month after 
attempting to quit,(8) and three to five percent twelve months after attempting to quit,(9) more 
effective methods to help smokers quit smoking are urgently required. 
1.2 Treatment of the smoking addiction 
Governments have taken a wide range of approaches to encourage smokers to quit and 
discourage people from taking up the habit, including: 
1. Taxing cigarette sales. 
2. Publishing treatment guidelines that advocate documenting the smoking status of all 
patients; giving all smokers brief advice to quit; offering all smokers counselling and 
medication (including NRT); providing more intense therapy to gain the benefits of 
proven dose-response relationships (10). 
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3. Regulating the sale and advertising of cigarettes (licensing retailers, age restrictions on 
purchasers). 
4. Regulating smoke-free environments. 
5. Mass-media anti-smoking campaigns. 
A range of medications have been shown to assist smokers to quit smoking, including NRT, 
bupropion, and varenicline.  This dissertation is focussed on NRT. 
1.2.1 The development of NRT 
Nicotine Replacement Therapy (NRT) was developed to offer smokers a safe medicinal 
source of nicotine as an alternative to gaining nicotine from cigarette smoking, based on 
evidence that components of cigarette smoke other than nicotine, were primarily responsible 
for the harmful effects of smoking.  NRT was formulated to have a slower pharmacokinetic 
profile than cigarette smoking, in order to wean smokers from experiencing peaks of nicotine 
in their blood, which are responsible for nicotine addiction and the abuse liability of tobacco 
smoking.(11)  The slower pharmacokinetic profiles of NRTs makes them less rewarding than 
smoking, less addictive than smoking, less able to quench smokers’ urges to smoke, and as a 
result, some experts have argued that NRT needs to have more rapid pharmacokinetics in 
order to compete with cigarette smoking and replace it.(12)  Indeed, this is the rationale of the 
two RCTs reported in this dissertation.  The history of the development of NRT is presented 
in greater detail in Chapter Four. 
1.3 Smoking and its treatment in New Zealand  
A history of smoking and its treatment in New Zealand has been published by Thompson and 
Wilson.(13)  In the adult New Zealand population, the prevalence of smoking has reduced 
from 40% and 32% in males and females, respectively (58% among Māori) in 1972; to 24% 
and 23% in males and females, respectively (51% among Māori) in 2006.(14)  Thus many 
smokers have quit smoking since the 1970s, however smokers continue to be a considerable 
minority of the population, comprising sixteen percent of the adult New Zealand population in 
2018.(15) 
In 1990 the Smoke-free Environments Act mandated that public transport and indoor 
workplaces must be smoke-free, strengthened regulation of tobacco marketing and banned the 
sale of tobacco products to people aged under sixteen years old (this was raised to eighteen 
years in 1998). 
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In 1995 all tobacco sponsorship was banned.  Regular tax increases on tobacco sales have 
occurred.   
Quitline began as a nationwide publicly funded service in 1999, it offered brief smoking 
cessation counselling via the telephone, and late in the year 2000 also provided vouchers to 
redeem subsidised NRT (nicotine gum, patches, and lozenges) from pharmacies.(16, 17)  
Subsidised bupropion, varenicline, and other smoking cessation medications are available on 
prescription from registered doctors.  In 2000 Aukati Kai Paipa, a Māori smoking cessation 
programme, was launched. 
At the end of 2009, the New Zealand Smokefree Coalition published their Tobacco Free New 
Zealand by 2020 Vision, which outlined what would be required to achieve this goal.(18)  
In March 2011 the government delayed the original “Smokefree by 2020” vision by five years 
and reset the goal to aim for New Zealand to be smoke-free by 2025, and formally adopted 
the Smokefree 2025 goal as government policy in response to the recommendations of a 
watershed Parliamentary inquiry by the Māori Affairs select committee.(19)  The Smokefree 
2025 Vision aimed to bring smoking prevalence down to a minimal level (five percent) by 
2025.(20, 21) 
1.4 Deficiencies in NRT and the need for new and improved NRT 
Currently available NRTs have a number of deficiencies due to their slow pharmacokinetics 
and/or route of administration: 
1. Less than twenty percent of smokers use NRT when they attempt to quit, and because 
so few smokers use NRT, its availability has had a negligible impact on smoking 
prevalence.(22) 
2. Inadequacies of the current dosage strengths and formulations of standard NRTs are 
two reasons why smokers do not use NRT.(22)  Indeed, a number of studies have 
shown that NRT replaces only 25-75% of nicotine from smoking.(23) 
3. Smokers' concerns about the safety and efficacy of nicotine medications discourage 
smokers from using NRT.(22) 
4. NRTs do not replicate the arterial boli of nicotine produced by smoking and instead 
result in a much slower rise and fall in plasma nicotine concentrations.(24) 
5. NRTs have common adverse effects, with the prevalence of adverse effects being 25% 
within a fortnight after starting therapy, rising to 42% after three months.(25) 
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1.4.1 How NRT may be improved 
Research has suggested a number of changes be made to NRT formulations or, to the way 
NRTs are used, in an attempt to increase abstinence rates: 
1. Higher doses may be more effective however, they have more common and more 
severe adverse effects.(26, 27) 
2. A faster pharmacokinetic profile may be more effective.  Russell proposed that 
smokers could be dichotomised according to whether they preferred a 
pharmacokinetic profile with a rapid onset/offset of nicotine concentration, or a 
constant level of nicotine, (peak seeker and trough maintainer, respectively.(28)  The 
slow pharmacokinetics of conventional NRT would not satisfy peak-seekers. 
3. Several experts have suggested that new forms of NRT are required which deliver 
nicotine to the brain as rapidly as smoking can, even though that would increase the 
abuse liability of the new NRT.(29, 30) 
1.5 Rapid-delivery of nicotine to the brain 
The speed with which rewarding drugs are delivered to the brain, is directly proportional to 
the amount of rewarding neurotransmitters that are released when those drugs bind to 
receptors in the brain, and the psychological reward that results, and hence their addictive 
potential.(31)  This is particularly true in the case of nicotine, for which cigarettes are 
amongst the fastest methods for transporting nicotine to the brain.(28, 32)   
At the time the trials, on which this dissertation is based, were being designed, the fastest 
commercially available medicinal NRTs were nicotine nasal spray and Nicorette nicotine 
mouthspray, both of which are somewhat aversive, and have a much slower Time to 
Maximum Plasma Concentrations (Tmax) than cigarette smoking.(32, 33)  This has limited the 
research that has been able to be conducted, to test the hypothesis that more rapid-acting NRT 
would be more effective at aiding smoking cessation.  The two nicotine delivery devices 
studied in this dissertation had pharmacokinetic profiles that were well suited to assess the 
role of rapid delivery of nicotine to the brain.   
The nicotine mouthspray used in this dissertation (Zonnic, manufactured by Niconovum) has 
a Tmax which is twice as fast as nicotine gum, and has a similar delivery speed as nicotine 
nasal spray.(34)  The pharmacokinetic profile of the nicotine pressurised metered-dose inhaler 
(pMDI) used in the pharmacokinetic trial, suggested it is at least partially absorbed via the 
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lung, and therefore is capable of rapid cerebral nicotine delivery, however, it shares many of 
the aversive qualities of other rapid-acting NRTs.(35)   
The lung has several advantages over other parts of the body for the delivery of rewarding 
drugs to the brain.(36, 37)  Pulmonary delivery is the fastest route for delivering drugs to the 
brain, with drugs reaching the brain within six heart beats after inspiration.  Furthermore, the 
large surface area of the lung enables a big dose to be absorbed very rapidly, leading to a high 
nicotine concentration in the blood.  Pulmonary delivery of nicotine also has disadvantages, 
the most prominent being the sensory receptors and protective reflexes that cause aversion 
and cough in response to nicotine.  Further detail about the advantages and disadvantages of 
pulmonary delivery of nicotine and the rapid delivery of nicotine to the brain are given under 
the heading “Role of Pharmacokinetics” in Chapter Three, and in Chapter Nine. 
1.6 Ororespiratory sensory reward 
Smoking repeatedly pairs the release of rewarding neurotransmitters, caused by nicotine 
binding to neuronal nicotinic acetylcholine receptors (nAChR), with a range of distinct strong 
ororespiratory sensations that are provoked by nicotine and other components of tobacco 
smoke, such as tar.  This repeated pairing leads to learning, through mechanisms such as 
Pavlovian conditioning and operant conditioning (these forms of learning are described under 
the “Behavioural Research” heading in Chapter 2.2), so that ororespiratory sensory 
experiences become rewarding in their own right, even in the absence of nicotine.(38, 39)  
Sensory experiences can therefore cause the release of rewarding neurotransmitters even 
when nAChRs are desensitised and can no longer respond when nicotine binds to them.  This 
conditioning is very strong in experienced smokers, considering that the average smoker will 
take ten to twelve puffs per cigarette,(40) so a smoker of twenty cigarettes per day (CPD) will 
experience at least 73,000 episodes per year when the rewarding effects of nicotine are paired 
with the ororespiratory sensations of smoking.  The replacement of the ororespiratory 
sensations of smoking can be effective in aiding smoking cessation, even without the 
replacement of nicotine.(38, 41)   
1.7 Perceptions about placebo or active therapy 
This dissertation reports statistical analyses, conducted by its author, that examine the 
potential role of the effects of subjects’ and research staff-members’ perceptions about 
whether subjects had been assigned to active or placebo therapy.  The role of unblinding and 
its potential to introduce bias, is not commonly addressed in published trials of NRT, 
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therefore this dissertation adds to the limited knowledge in this area.  Bailey and colleagues 
found that smokers’ perceptions of whether they were taking an active or placebo NRT, is just 
as important in determining their chances of quitting as whether they are in the active or 
placebo group.(42)   
1.8 Motives for smoking 
Smoking fulfils a variety of purposes in smokers’ lives, and smokers’ motives for smoking 
vary between individuals.  It may be important to take account of smokers’ motives for 
smoking when planning smokers’ treatment because, their motives for smoking predict failure 
to maintain abstinence(43), and may guide individual tailoring of NRTs and behavioural 
therapies.   
The brief-Wisconsin Inventory of Smoking Dependence Motive (WISDM-37) indexes a 
variety of motives for smoking, and was made available to me before it was published in 
2010,(44) enabling it to be administered in the mouthspray study.  
1.9 Self-efficacy and motivation to quit 
Self-efficacy, in the context of smoking cessation, is the degree of confidence a smoker has in 
his or her ability to quit smoking.(45)  At least seven psychological batteries that measure 
self-efficacy have been published.  Scores from these batteries are predictive of the amount of 
smoking reduction, and success at quitting smoking, however higher self-efficacy has only a 
moderate effect of increasing the odds of quitting and remaining abstinent.(46)  Because of 
the wide range of different situations in which smoker’s self-efficacy may change,(45, 46) 
existing psychological batteries are long and impractical to administer in complex clinical 
trials in which time is limited, hence I constructed three single-item Likert scales to measure 
self-efficacy, and two single-item scales to index motivation to quit, and motivation to reduce 
smoking, which were administered at baseline in the ZAP trial.  These scales were not piloted 
nor their psychometric properties measured prior to their use in the ZAP trial. 
Evidence from some trials and observational studies, suggests that smokers who are more 
motivated, and more determined to quit smoking, are six times more likely to attempt to quit 
and,(47) are significantly more likely to achieve biochemically-verified abstinence.(48-50)  
However, Borland and colleagues found that the degree of people’s motivation to quit was not 
predictive of abstinence.(51)  The lack of a long-term effect of motivation on abstinence in 
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Borland’s study may be due to his use of a single question to index motivation instead of a 
formal multi-item psychological battery used in other trials. 
A range of interventions to increase smokers’ motivation to quit have been studied and been 
shown to increase abstinence,(52) by as much as OR=1.26; 95%CI 1.16–1.36).(53)  One 
potential mechanism, by which higher motivation increases abstinence, was suggested by the 
observation that smokers who were more motivated to quit, used more NRT.(54)   
The results of the scales, designed by me, to measure self-efficacy and motivation to 
reduce/quit smoking, were analysed to determine if their scores were predictive of abstinence.  
The results are reported in the ZAP chapter (Chapter Eight).  
1.10 Outline of the trials in this dissertation 
This dissertation investigated the efficacy of two new pharmacotherapies to induce and 
maintain six- to twelve-months smoking abstinence.   
The major focus of the therapies that were tested as part of this dissertation, was the 
replacement of nicotine derived from smoking cigarettes, with medicinal nicotine, and an 
attempt to more closely match the pharmacokinetics of cigarette smoking cf. conventional 
NRT.  This dissertation also acknowledges that the causes of the smoking addiction are 
multifactorial, and therefore, this dissertation investigated the role of psychological and non-
pharmacological factors that affect smokers’ ability to quit smoking (through the use of 
psychological batteries that index nicotine withdrawal, urges to smoke, and motives for 
smoking).   
1.10.1 Research questions  
The primary research question was: 
1. to what extent does the addition of a rapid nicotine delivery device (mouthspray or 
pMDI), to the slow delivery of nicotine via a transdermal nicotine patch, improve 
abstinence compared to transdermal patch plus placebo?   
Secondary research questions included: 
2. Did the combination of rapid-acting NRT plus patch improve factors that are known to 
be involved in relapse, such as withdrawal symptoms and urges to smoke? 




4. Would simple single-item Likert scales designed by me significantly predict 
abstinence?  These scales were designed to index smokers’ desire and determination to 
quit and/or reduce their smoking, and their degree of self-efficacy to forgo the 
pleasure of smoking and handle stressful events without smoking. 
5. What are the roles of the speed of nicotine delivery, ororespiratory sensations, and 
people’s perceptions about whether they are on active or placebo therapy, in predicting 
the likelihood that smokers quit smoking? 
1.10.2 The clinical trials 
This dissertation is based on data from four trials, three of which have been published:  
1. a small pilot open-label cross-over pharmacokinetic study of a nicotine free-base 
pMDI; 
2. a small open-label cross-over trial of the tolerability and effect on urges to smoke of 
pMDIs containing different types of nicotine and flavouring (unpublished) and 
3.  two double-blind randomised placebo-controlled trials (RCTs), one of a nicotine 
mouthspray (Zonnic) plus nicotine patch (ZAP), the other of a nicotine lactate inhaler 
plus nicotine patch (INHALE), the control groups received active nicotine patches 
plus placebo rapid-acting NRT.   
The focus of this dissertation was to test the null hypothesis that more rapid delivery of 
nicotine to the brain, in combination with a constant background level of nicotine in the blood 
from a nicotine transdermal patch, would not improve abstinence rates.  This was 
accomplished by testing two nicotine delivery devices that were likely to be at least as fast as 
the fastest of the current NRTs (a nicotine mouthspray called Zonnic, and a novel nicotine 
pMDI).  A cross-over trial(34) found that the mean time to maximum concentration (Tmax) of 
Nicorette 4mg gum and Zonnic 1mg mouthspray were 46 and 14 minutes, respectively, and 
the pharmacokinetic study conducted for this dissertation(35) demonstrated the median 
(Interquartile Range (IQR)) Tmax of a 100µg pMDI was five (three to seven) minutes.   
Evidence suggests that the speed with which nicotine is delivered to the brain after the 
nicotine is administered, is positively correlated with the magnitude and speed of onset of the 
rewarding and reinforcing psychological effects of nicotine, hence NRT should ideally have 
as short a Tmax as possible in order to mimic and replace the rewarding effects of smoking, 
which had a mean venous Tmax of five minutes in one study and a median (IQR) of two (one 
to five) minutes in another trial.(35, 55-59)  Yet no current conventional NRT is capable of 
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matching cigarette smoking’s rapid delivery of nicotine to the brain (with the potential 
exception of some newer brands of electronic cigarettes, if they are puffed by experienced 
users).  As a result, the only evidence currently available regarding the effect of a medicinal 
NRT’s Tmax on quit rates, comes from a small number of trials that investigated the two 
medicines with the fastest pharmacokinetic profiles of currently available medicinal therapies: 
nasal spray and Nicorette mouthspray.  This dissertation contributes further data to the limited 
evidence regarding the efficacy of rapid-acting NRT, by measuring the effects of a novel 
pMDI which has a Tmax that is at least as fast as nasal spray, measuring the effect of Zonnic 
mouthspray which has a faster Tmax than nicotine gum; and by examining the efficacy of the 
combination of rapid-acting and slow-release NRT in the form of a transdermal patch.   
Nicotine may not be the only element of smoking that needs to be replaced in order to help 
smokers quit smoking, a wide range of factors are involved in instigating and maintaining the 
smoking addiction, which this dissertation addresses: 
1. The role of ororespiratory sensations of NRT in aiding abstinence. 
2. Subjects perceptions of their treatment assignment. 
3. People’s motivations for smoking and their sense of self-efficacy. 
The role of the speed of nicotine delivery, ororespiratory sensations, people’s perceptions 
about whether they are on active or placebo therapy, their motives for smoking, and self-
efficacy with respect to specific aspects of quitting, have not been fully explored to date.  The 
aim of this dissertation was to examine the roles that these factors have, collectively, in 
helping or hindering people’s attempts to quit smoking.   
1.11 The ZAP trial 
The ZAP trial(60) was a double-blind randomised placebo-controlled trial of a nicotine 
mouthspray (Zonnic).  Zonnic delivers nicotine to the blood-stream more rapidly than nicotine 
gum, and in a manner that is fairly well tolerated by smokers but which, like smoking, is 
harsh when used for the first time.  ZAP randomised subjects to either active nicotine 
mouthspray plus active nicotine patch or, placebo mouthspray plus active nicotine patch.  The 
hypothesis of the trial was that faster delivery of nicotine, along with sensory experiences, and 
a slow background level of nicotine in the blood from nicotine patches, will result in higher 
long-term abstinence rates compared to a placebo that also has a sensory impact but no 
nicotine plus the background nicotine from the nicotine patch.   
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In the ZAP trial, the personal characteristics of smokers were measured using standard 
psychological scales, as well as single-item scales that were developed as part of this 
dissertation but which were not piloted or validated before being used in the ZAP trial.  Data 
from these psychological scales may provide new insights into the treatment of smoking 
addiction because they have not previously been used in New Zealand or among Māori.   
The ZAP trial gave subjects six months of mouthspray and five months of nicotine patches 
and followed subjects for twelve months after their target quit dates. 
1.12 First pilot pMDI study 
The first pilot pMDI study tested whether a pMDI containing nicotine (nicotine free-base) at 
two doses, plus a trace of menthol, could match the effects of cigarette smoking in terms of 
pharmacokinetics, pharmacodynamics, and reduction of the urge to smoke.(35)  This pilot 
study was a non-randomized, open-label cross-over trial of ten current smokers. Three 
interventions were given on separate days: 
1. one cigarette was smoked ad libitum;   
2. ten puffs of 50µg pMDI via a spacer; 
3. ten puffs of100µg pMDI via a spacer. 
Nicotine pharmacokinetics, changes in heart rate and blood pressure, smoking urges, side-
effects, the sensory qualities of the inhalers and cigarette smoke, and the acceptability of the 
inhalers, were measured.   
The pilot study showed that nicotine administered by the pMDI relieved urges to smoke but, 
was aversive, so in an attempt to improve the tolerability of the pMDI, I, explored the 
literature and patents on pulmonary drug delivery, the chemistry of nicotine, and conducted a 
systematic literature review of nicotine delivery devices that aimed to achieve pulmonary 
deposition of nicotine.(61)  Knowledge gleaned from this reading informed the design of a 
second pilot study. 
1.13 Second pilot pMDI trial 
A second pilot study was conducted to quickly determine if changes to the formulation, which 
had been suggested by the aforementioned literature review and patent search, improved the 
tolerability of the pMDI.  The trial tested the tolerability and effect on urges to smoke of 
nicotine free-base, nicotine lactate, and two flavours, the results of which are reported in 
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Chapter Eleven.  All formulations were tolerable, with some suggestion that the 200µg/puff 
nicotine lactate plus 2.5% menthol was preferable. 
1.14 The INHALE trial 
The INHALE trial was a double-blind randomised placebo-controlled trial of: 
1. nicotine lactate and menthol pMDI plus active nicotine transdermal patch versus  
2. placebo pMDI with a similar menthol flavour as the active pMDI, plus active nicotine 
patch.(62)   
Subjects were given six months of pMDIs and five months of nicotine patches and were 
followed-up for six months after their target quit dates. 
1.15 Methodology 
The main hypotheses of this dissertation were tested using the gold standard methodology of a 
double-blind randomised placebo-controlled trial.  Moreover, the placebos used in both RCTs 
had an identical appearance, and similar sensory qualities, to their active counterparts, thereby 
ensuring they may be capable of engendering a similar placebo-effect to that experienced by 
the active groups, and may be able to assist in the maintenance of blinding of subjects and 
staff to subjects’ treatment assignments.  Hence the conclusions of this dissertation may be 
less likely to be tainted by bias, confounding, or residual influences of the placebo effect, than 
if the trials had used less robust methodologies.   
1.16 Rationale of the trials presented in this dissertation 
The principal aim of the trials that formed the basis for this dissertation, was to compare the 
efficacy and tolerability of two rapid acting NRTs in combination with one of the most 
commonly used and less rapid-acting active therapy (nicotine patch) compared to nicotine 
patch plus placebo.  The rationale for using active nicotine patches rather than placebo 
patches, as the comparator, was to answer a more clinically useful question, since almost any 
active nicotine medicinal therapy is likely to have a superior abstinence rate compared to 
placebo, and what clinicians need to know is the extent to which new therapies are superior to 
current active therapies.   
The nicotine patch was chosen as the comparator because it has a long and proven history of 
efficacy, it is one of the most common NRTs prescribed to smokers, it has the slowest time to 
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maximum concentration, and it is one of the most common forms of NRT to be used in 
combination with other NRTs.(63) 
There are at least two placebo-controlled study designs that could be used to test the relative 
efficacy of a novel NRT compared to nicotine patches, one that gives only the control group 
an active patch, and one that gives both groups an active patch.  One study design would 
randomise subjects to: 
• Condition 1: active novel treatment plus a placebo patch 
• Condition 2: placebo novel treatment plus active nicotine patch.   
This study design would ensure that any difference in abstinence rates between the two 
groups was solely the result of the difference in the efficacy of the novel therapy compared to 
the efficacy of nicotine patches, as long as, inter alia (such as effectiveness of randomisation 
and blinding):  
1. the effects on abstinence of the placebo patch and the placebo novel therapy are 
identical to each other so that they cancel each other out when the outcomes of the 
two groups are compared in each trial.   
2. the placebo effects of the active novel therapy are identical to the placebo effects of 
the placebo version of the novel therapy, and the placebo effects of the placebo patch 
are equivalent to the placebo effects of the active nicotine patch.    
The second study design would randomise subjects to: 
• Condition 1: active novel treatment plus active patch. 
• Condition 2: placebo novel treatment plus active nicotine patch.   
The second study design would ensure that any difference in abstinence rates between the two 
groups was solely the result of the difference in efficacy between the active novel therapy and 
placebo novel therapy, as long as, inter alia: 
1. the placebo effects of the placebo novel therapy are identical to the placebo effects of 
the active novel therapy. 
The second study design tests the efficacy of the active novel therapies in combination with 
active nicotine patch, which would increase the likelihood of finding a significant difference 
in effect size, between the trial conditions, if the combination of active novel treatment plus 
active patch was synergistic or additive, rather than antagonistic.   
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Giving nicotine patches to both the active and control groups has several advantages.  Firstly, 
it may assist with blinding because both groups will experience amelioration of their 
withdrawal symptoms by the patches.  Secondly, it will reduce the required sample size by 
increasing the abstinence rates in both groups.  Given that the second study design provided a 
comparison between interventions that was more clear-cut and less prone to confounding by 
the unknown differences in effects of a placebo patch compared to a placebo novel therapy, 
the second study design was utilised in the trials reported in this dissertation. 
It was decided that patches should be given for five months after the target quit date and the 
mouthspray/pMDI for six months after the target quit date.  Although this was longer than the 
three month treatment duration commonly prescribed in New Zealand at the time that the 
trials were designed, it is biologically plausible that a longer duration of therapy may assist in 
relapse prevention, and there was a precedent for this approach, with some published trials 
having provided NRT for six months, such as trials of nicotine nasal spray,(64) nicotine oral 
inhalator,(65) and nicotine gum,(66) and in one trial subjects were given nicotine nasal spray 
for a year.(67)  The mouthspray/inhaler was provided for one month longer than the patch to 
produce evidence, from a medicines regulatory pharmacological point-of-view, that it was 
primarily the mouthspray/inhaler rather than the patch that caused the long-term abstinence 
rate beyond five months after initiation of treatment.  It was decided not to provide the patch 
and mouthspray/inhaler for longer than five and six months, respectively after the target quit 
date, in order to preserve the external validity of the trials because it was thought the New 
Zealand Government would be unwilling to fund NRT for a longer duration than six months, 
due to the cost; and it is likely that only a small minority of smokers would adhere to such a 
long course of treatment. 
The rationale for the frequency of follow-up, was based on the fact that relapse is most 
common early after quitting, which necessitates more frequent follow-up early on to offer 
support and counselling to subjects and encourage them to use sufficient amounts of the NRT 
to quench their urge to smoke.  The twenty-four-hour post target quit date and nine months 
follow-ups, were performed by telephone rather than face-to-face visits, in an attempt to 
reduce the burden on subjects and the time required by researcher staff to undertake those 
follow-ups. 
The rationale for the use of a four week grace period (during which smoking is not counted as 
a failure of treatment) after the target quit date, and the duration of pre-cessation NRT in the 
two RCTs (three weeks in the mouthspray study and four weeks in the inhaler trial), was that 
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although it is recommended to have a two-week grace period,(68) and previous trials of pre-
cessation NRT have most often used a two-week pre-loading period,(69) a longer duration of 
use of NRT prior to the target quit date and longer grace period was used in these two trials, 
in the hope that this would increase abstinence rates in both groups by enabling subjects to 
gain familiarity with using the new NRTs, and abstaining from smoking in situations where 
they would normally smoke.  A meta-analysis of pre-cessation NRT found that it non-
significantly increased long-term abstinence by a Relative Risk (RR) of 1.16, 95%CI:0.97–
1.38 compared to starting NRT on the target quit date; and there was a small short-term 
benefit to the use of patches rather than gum for pre-loading.(69)  Another meta-analysis of 
pre-cessation use of nicotine patches compared to starting patches on the target quit date 
found that it doubled continuous abstinence rates at twenty-eight days and six months, but 
was unable to assess if the effect remained after six months because all trials of pre-cessation 
NRT followed subjects for six months or less.(70)  
Diary cards, that displayed individualised prescribed smoking reduction targets, were given to 
participants, rather than leaving it up to them to decide how much to reduce their smoking by 
each day leading up to their target quit date, because a trial of smoking reduction observed 
that people who reduced their smoking according to a predefined schedule had a greater 
chance of being quit a year later than people who were simply told to reduce ad libitum before 
their quit attempt.(71)  
The ZAP trial was conducted before the INHALE trial, and prior to the start of the INHALE 
trial, its study design was altered so that it no longer matched the ZAP trial because, lessons 
learned from the ZAP trial suggested changes to the trial design may improve abstinence, and 
substantial delays in the manufacture of the inhalers depleted the money available to spend on 
the INHALE trial, thus its duration was reduced so that subjects would be followed for six- 
rather than twelve-months, and the number of questions asked of subjects was reduced to 
allow more subjects to be assessed per hour, hence the WISDM psychological battery was not 
administered in the INHALE trial. 
1.17 Conclusion 
Smoking is the leading cause of preventable death in the developed world.  The addiction to 
smoking is primarily maintained by addiction to inhalation of nicotine, yet components of 
smoking, other than nicotine, are responsible for the harmful health effects of smoking.  
Medicinal nicotine delivery systems have been developed to replace the nicotine derived from 
smoking, and have been proven to increase abstinence rates.  However, quit rates with 
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conventional NRT are modest.  Evidence suggests that the delivery of nicotine more rapidly 
to the brain, and in combination with slow nicotine delivery via a transdermal patch, may 
improve abstinence rates.  This was tested by two RCTs that measured abstinence rates with 
two rapid-acting NRTs, a nicotine mouthspray and a nicotine inhaler.   
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2 Background to nicotine, addiction, medicinal nicotine, 
and trial methodology 
2.1 Nicotine and tobacco addiction 
In this chapter, a variety of definitions of addiction are described; an explanation is given of 
behavioural research on addiction; followed by an outline of the neurological basis of 
behaviour; then a description is given of the neurological basis for how nicotine establishes 
and maintains addiction to tobacco smoking; this leads to an outline of the sine qua non of 
nicotine addiction, which is followed by an introduction to the theoretical models of 
addiction.   
A thorough understanding of what addiction is, and its neurological mechanisms, may 
usefully assist in the rational design of effective new therapies; methods to deliver those 
therapies to smokers; ways to communicate with smokers, and accurately measure how 
effective those therapeutic methodologies are compared to existing treatments.(72)  
Moreover, a thorough understanding of the neurological activity responsible for the addiction 
to smoking cigarettes, and smokers’ loss of autonomy over their smoking, may, or may not, 
engender empathy and compassion in those who seek to assist smokers to quit.   
2.1.1 Definitions of addiction 
Early research into the causes and treatment of addiction may have been hampered by the 
absence of a useful general definition of addiction, which did not begin to be developed until 
the publication of the Diagnostic and Statistical Manual of Mental Disorders III Revised 
(DSM-III-R) in 1987.(73)  Below, the evolution of definitions of addiction is described in 
chronological order.  Prior to the publication of the DSM-III-R, addictions were defined in 
terms of the particular substance or behaviour involved, with each type of addiction conceived 
of as a separate entity.(73)  In the late 1980s psychologists and psychiatrists developed 
definitions of addictive behaviour that were not tied to a particular substance or behaviour, 
instead, addictions were defined more generally, as behaviours that seek pleasure or avoid 
pain and which are conducted despite multiple attempts to stop or alter the behaviour, and 
regardless of the negative consequences of that behaviour (Figure 2.1, page 18).   
In 1964 The US Surgeon General reported that tobacco smoking was an habitual behaviour, 
and that nicotine was the key element of smoking that was responsible for smokers’ 
addiction.(74)  The 1988 US Surgeon General report laid out the criteria for addiction (Figure 





Figure 2.1 DSM-III criteria of psychoactive substance dependence 
 
The American Psychiatric Association publishes and regularly updates the Diagnostic 
Statistical Manual (DSM) which sets out criteria to standardise the diagnosis of mental 
disorders such as addictions.  Collectively the DSM manuals, from the DSM-III, which was 
first published in 1980,(76) to the DSM-IV, did not define addiction per se.   
The revised fourth edition of this manual (DSM-IV-TR), published in 2000, explicitly defined 
addiction, stating that addiction is characterised by a long-term dysfunction of the parts of the 
brain which are involved in reward, motivation, and memory, which leads people to spend 
1. consumption of the drug in larger amounts, over a longer duration of time, than initially 
intended; 
2. the person recognises that their substance use is excessive and has either tried but failed 
to reduce or quit, or, has not attempted to reduce or quit; 
3. a lot of time is spent obtaining and imbibing the substance, often leading to the 
abandonment of other activities; also, much time is spent recovering from the adverse 
effects of the substance use; 
4. the person may suffer symptoms of intoxication or withdrawal at times when he or she 
is supposed to be carrying out his or her responsibilities, particularly responsibilities 
that are hazardous to conduct while intoxicated or while suffering withdrawal 
symptoms; 
5. important obligations, social intercourse, and recreation activities are abandoned in 
favour of substance use and spending time with other substance users; 
6. social, psychological, and physical ailments occur with increasing substance use, and 
the person continues to use the substance despite it causing and exacerbating those 
ailments; 
7. significant tolerance has developed, enabling the user to use increasingly higher doses 
than would previously been tolerable, in order to gain the same positive effects as they 
had previously experienced; 
8. withdrawal symptoms, characteristic of the particular substance being used, develop 
when the person quits or reduces their substance use; 




considerable time and resources in the pursuit of a drug or behaviour.(77)  According to the 
DSM-IV-TR, the defining feature of a drug addiction or behavioural addiction is people’s loss 
of control over their pursuit of the drug or behaviour, and their experience of strong cravings 
and urges.  If they abstain from the drug or behaviour, they experience mental and functional 
impairment, which leads to symptoms that are collectively known as the withdrawal 
syndrome.  Typically, people who have an addiction are unaware of the compulsive nature of 
their desire, and the negative effects that it has on them.  Those who are aware of the negative 
effects of their addiction are unable to desist, despite this awareness.  People who suffer from 
an addiction may be capable of short periods of abstinence, but they usually relapse.  This 
cycle is repeated chronically and can lead to considerable morbidity and mortality.  Hence the 
DSM-IV-TR established a definition for all substance addictions, as well as specific 
definitions for the various specific kinds of addictions.  Addiction to nicotine is classified as 
“Nicotine Use Disorder”, which is a specific kind of “Substance Use Disorder.”(77) 
A Substance Use Disorder is defined in the DSM-IV-TR as the compulsive and continued use 
of a substance, despite experience of adverse side-effects, and is characterised by 
development of tolerance and withdrawal symptoms.(77)  Tolerance occurs when the same 
 
Figure 2.2 US Surgeon General’s criteria for Addiction.(75)  
 
1. Primary Criteria 
1.1. Highly controlled or compulsive use 
1.2. Psychoactive effects 
1.3. Drug-reinforced behaviour 
2. Additional Criteria 
2.1. Addictive behaviour often involves: 
2.1.1. stereotypic patterns of use 
2.1.2. use despite harmful effects 
2.1.3. relapse following abstinence 
2.1.4. recurrent drug cravings 
2.2. Dependence-producing drugs often produce: 
2.2.1. tolerance (reduced efficacy of drug after repeated administration, leading to the 
need to take higher doses to achieve the same effect) 
2.2.2. physical dependence (severe symptoms on withdrawal of drug) 
2.2.3. pleasant (euphoric) effects 
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dose of drug provides less and less of an effect, which leads to use of progressively higher 
doses to achieve the same level of reward.  Withdrawal symptoms are unpleasant effects that 
occur when blood-levels of a rewarding drug are lowered.  For those who are addicted to 
nicotine, typical withdrawal symptoms include negative affect, poor concentration, and 
increased appetite which are discussed in detail below.  Typically, addicts will avoid 
withdrawal symptoms by reinstating their use of the drug.  In addition to tolerance and 
withdrawal, a Substance Use Disorder is characterised by the use of higher doses for a longer 
period of time than was originally intended; frequent unsuccessful attempts to cut down or 
quit; the devotion of considerable time to sourcing the drug and recovering from its ill effects; 
and the use of the drug disrupts the person’s daily activities.  The DSM-IV criteria for 
Nicotine Use Disorder are outlined in Figure 2.3, page 21 of this dissertation.(77) 
Published in 2013, the fifth edition of the DSM explicitly used the term “addictive” in the title 
of one of its sub-chapters within the chapter: “Substance-Related and Addictive Disorders”; 
and acknowledged that nicotine is not the only addictive component of smoking tobacco, by 
naming a diagnosis of “tobacco-related disorders” rather than the earlier versions of the DSM 
that referred to nicotine addiction instead of tobacco addiction.(78)  However, a global 
definition of the features of addiction is not given.  
In 2011, the American Society of Addiction Medicine (ASAM) updated its definition of 
tobacco addiction, to a definition that emphasised the physical biological basis of tobacco 
addiction, and the structural changes in neural circuitry which underpin it.(79)  The ASAM 
definition also explicitly mentioned the diverse effects of addiction on people’s lives and the 
chronic relapsing nature of addiction.   
In conclusion, the conceptualisation of addictive behaviour has evolved over time from one 
that focused on overuse of particular drugs, and were conceived of as separate behaviours; to 
the development of a unifying definition of addiction that encompassed all compulsive 
behaviours, both drug-taking as well as behaviours such as gambling, and that emphasized 
people’s loss of autonomy and the chronic relapsing nature of addiction. 
2.1.1.1 Addiction to nicotine and smoking cigarettes 
Although nicotine is the primary cause of the addictiveness of smoking, other aspects of 
smoking contribute to its addictive power, which NRT does not replicate, such as the other 




Figure 2.3 DSM-IV Nicotine Use Disorder criteria(77) 
A maladaptive pattern of nicotine use, leading to clinically significant impairment or distress, 
as manifested by three (or more) of the following, occurring at any time in the same 12-month 
period: 
1. Tolerance, as defined by either of the following two criteria, a or b: 
a) a more intense effect of nicotine the first time it is used during the day; markedly 
diminished effect with continued use of the same amount of nicotine containing 
products, and a need for markedly increased amounts of nicotine to achieve 
intoxication or desired effect 
b) absence of nausea and dizziness with repeated intake, despite use of substantial 
amounts of nicotine 
2. Withdrawal, as manifested by either Criterion A or Criterion B plus the Criteria D 
through to Criteria E: 
a) the characteristic withdrawal syndrome for nicotine: 
i. Criterion A. Daily use of nicotine for at least several weeks. 
ii. Criterion B. Abrupt cessation of nicotine use, or reduction in the amount of 
nicotine used, followed within 24 hours by four (or more) of the following signs: 
a. dysphoric or depressed mood 
b. insomnia 
c. irritability, frustration, or anger 
d. anxiety 
e. difficulty concentrating 
f. restlessness 
g. decreased heart rate 
h. increased appetite or weight gain 
iii. Criterion C. The symptoms in Criterion B cause clinically significant distress 
or impairment in social, occupational, or other important areas of functioning 
iv. Criterion D. The symptoms are not due to a general medical condition and are 
not better accounted for by another mental disorder 
v. Criterion E. Nicotine, or a closely related substance, is taken to relieve or avoid 
withdrawal symptoms 
3. Nicotine is often taken in larger amounts or over a longer period than was intended 




Figure 2.3 (continued).  DSM-IV Nicotine Use Disorder criteria (77) 
 
anabasine (80, 81)); Monoamine Oxidase Inhibitors (MAOIs) produced by combustion 
(harman and norharman(82, 83)); and acetaldehyde(84)]; sensory experiences(39, 85) 
(respiratory sensations, hand-to-mouth action); ritual behaviours(86) (taking the cigarette out 
of its packet or rolling loose tobacco, lighting the cigarette); and smoking’s facilitation of 
social interaction and its association with other pleasurable activities(11, 87) (such as drinking 
alcohol or coffee, eating a good meal).  Researchers have developed psychological batteries to 
characterise smokers’ reasons for smoking, such as the brief-Wisconsin Inventory of Smoking 
Dependence Motives WISDM-37) which was administered as part of the ZAP trial and is 
explored in this dissertation. 
Knowledge of the nature of addiction and its neurological basis has come from Pavlov’s 
behavioural experiments in the early 20th century, followed by modern research on the neural 
basis of addiction.  This knowledge provides a rational framework to guide research and 
attempts to explore seemingly unresolvable dilemmas, such as why addiction to smoking is so 
intractable despite nicotine not being an extremely potent reinforcer of behaviour in 
laboratory animals, and why nicotine replacement therapy helps only ten percent of smokers 
to remain abstinent from smoking for more than a year.  The development and maintenance of 
addictions is primarily a learned process.  The following sub-chapters of this dissertation 
explicate the mechanisms of learning and how learning leads to addiction. 
2.1.2 Behavioural research: conditioning, learning 
Here, a very brief history of research on behavioural learning is outlined.  The subsequent 
sub-chapter reveals the neurological underpinnings of this behavioural learning.  The laws 
derived from behavioural research are outlined in Appendix A. 
5. A great deal of time is spent in activities necessary to obtain the nicotine (e.g., visiting 
multiple doctors or driving long distances), use the nicotine (e.g., chain-smoking), or 
recover from its effects 
6. Important social, occupational, or recreational activities are given up or reduced 
because of nicotine use 
7. Nicotine use is continued despite knowledge of having a persistent or recurrent 
physical or psychological problem that is likely to have been caused or exacerbated by 
the nicotine use 
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Early investigators of learning, studied the behaviour of laboratory animals, and observed that 
learning occurred via a process the investigators called ‘conditioning’.  Classical conditioning, 
also known as Pavlovian conditioning, is a reflexive (automatic, sub-conscious) type of 
learning, in which a feature of the environment that initially does not stimulate any response, 
takes on the ability to evoke the same response as a stimulus that naturally (innately) causes a 
response (an unconditioned stimulus), by being repeatedly presented at the same time the 
animal experiences the unconditioned stimulus, thereby turning what was a neutral feature of 
the environment into a conditioned stimulus.  Classical conditioning relies on the 
development of reflexive behaviour that is beyond conscious control, and which allows the 
conditioned stimulus to evoke the behavioural response even in the absence of the 
unconditioned stimulus, providing that there has been sufficient pairing of the conditioned 
stimulus with the unconditioned stimulus.  An example of classical conditioning in the 
genesis of addiction to cigarette smoking, is the reward that smokers gain from the respiratory 
sensations of inhaling tobacco smoke, because these sensations have been paired with the 
release of rewarding neurotransmitters as a result of nicotine’s activation of nAChRs.(88)    
Following on from the work of Pavlov, behavioural researchers developed the concept of 
operant conditioning.  Operant conditioning, also known as instrumental learning, is a kind of 
learning process in which whether or not a behaviour is repeated, depends on the nature of the 
consequences of performing that behaviour.(89)   
A behavioural definition of a reinforcer, defines a reinforcer as a stimulus which motivates an 
animal to behave in a manner that ensures the stimulus is re-administered.(89, 90)  A drug or 
an activity is defined as a punishment if its consequences lead the animal to reduce or 
completely stop administering the drug or performing the activity.  Reinforcement and 
punishment are categorised as positive or negative, depending on whether they are caused by 
something being added or removed from the animal’s experience.  Nicotine administration 
produces positive reinforcement by the release of neurotransmitters that cause enjoyable 
affective states, and causes negative reinforcement by removing the unpleasant withdrawal 
symptoms that develop after a period of nicotine abstinence in animals that have become 
accustomed to regular nicotine administration.   
2.1.2.1 Neurological basis of behaviour and addiction 
This section of the dissertation outlines the neural mechanisms of behaviour and addiction, in 
general, and in relation to nicotine addiction.   
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By definition, addictive drugs are reinforcing, that is, their action on the nervous system 
increases the likelihood that an animal will seek to re-administer the drug.  Addictive drugs 
exert this reinforcement by a number of neurological processes, some of which are 
consciously sensed (such as hedonic reward [hedonic reward is the conscious appreciation of 
an enjoyable state of mind that results from performing a specific behaviour] and withdrawal 
symptoms);, and some which are not consciously perceived (such as neuroadaptations).(91)  
Reinforcement which is not consciously perceived has been referred to as ‘unsensed 
incentives’.(91)   
Drugs of addiction add to their reinforcement by stimulating neural structures involved in 
learning, memory and the focus of attention.  This improves learning that a drug is rewarding, 
and how to re-administer it.   
In humans, reward that is consciously felt, is mediated by the release of a range of 
neurotransmitters, which causes enjoyable changes in mood and perceptions.(90)  Nicotine 
exerts its reinforcing effects by binding to neuronal nicotinic Acetylcholine Receptors 
(nAChRs) located at post-, pre-, peri- and extra-synaptic sites, which leads to a cascade of 
neuronal activity, resulting in modulation of neuronal activity, and the release of a wide range 
of reinforcing neurotransmitters (dopamine, serotonin, noradrenaline, acetylcholine, 
glutamate, endogenous opioids, and GABA).(92-94)   
Neuronal nAChRs mediate the reinforcing and addictive properties of a wide range of drugs 
of abuse such as cocaine, amphetamines, and nicotine,(95) which may explain why the 
withdrawal syndrome of nicotine is similar to that of cocaine.  There are a broad range of 
actions nAChRs can exert as a consequence of the wide variety of different nAChR 
subtypes.(95-97)  The most common of the five proteins in nAChRs, are alpha and beta 
protein chains(95), each of which has a variety of forms, for instance there are at least seven 
different types of alpha chains.  This gives the potential for a wide variety of receptors to 
exist, each with its own characteristic actions.  Neuronal nAChRs on the peri-synaptic and 
extra-synaptic areas of the neuronal soma and dendrites, and on the axonal boutons, are 
thought to have a predominately modulatory function.(98)  The various combinations of alpha 
and beta subtypes differ in their pharmacological and physical properties, including how long 
it takes to upregulate or downregulate their manufacture, how strongly nicotine binds (the 
receptor’s nicotine affinity), how readily the receptor becomes desensitized, and how quickly 
it regains its sensitivity after nicotine concentrations decline.  After overnight abstinence, 
nicotine levels reach a nadir,(99) which is sufficiently low for some nAChR subtypes to 
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regain their sensitivity to nicotine, which explains why highly nicotine-dependant smokers 
derive the most pleasure from the first cigarette of the day.     
The principal mechanism of nicotine’s reinforcing and addictive properties, is its stimulation 
of dopamine signalling by binding to α4β2 nAChRs.(95)  Dopamine does not mediate the 
hedonic reward of drugs but instead, it encodes reward prediction, and enhances the incentive 
salience of cues associated with taking those drugs, thereby promoting learning of goal-
directed behaviour.(100, 101)  These neural adaptations that cause incentive salience are an 
example of the development and strengthening of addiction which is not sensed and is not 
accessible to smokers’ introspection, which may explain smokers’ loss of autonomy over their 
smoking and the automaticity of smoking.   
Serotonin is also released by nicotine binding to nAChRs.(102)  Serotonin is involved in the 
regulation of sleep, appetite, aggression, learning, pain perception, libido, and mood; while 
low serotonin levels are associated with depression, alcoholism, and risk-taking and impulsive 
behaviour.(103)  Neuronal nAChRs are also present on neurons that release noradrenaline 
which is involved in attention, arousal, waking, learning, and memory.(104)   
Additionally, nicotine’s reinforcement of smoking, occurs by the release of other 
neurotransmitters including GABA and glutamate.(95, 105)  Glutamate, which enhances fast 
excitatory synaptic transmission, may be responsible for nicotine’s enhancement of memory 
and cognitive function.(99)  Recent studies have demonstrated that GABA, glutamate, and 
endocannabinoids play a role in relapse to nicotine-seeking in response to nicotine-associated 
conditioned cues, nicotine-associated stressors, and nicotine re-exposure in nicotine-
dependent animals.(105) 
Endogenous opiates play a role in the neurological mechanisms of nicotine and smoking 
addiction.(94)  Further mechanisms by which nicotine reinforces its administration, include 
stimulating the release of a range of peptides and hormones which play a variety of roles 
including regulating the release of hormones, modulating the activity of post-synaptic 
neurons, mediating nicotine’s positive reinforcement; regulating sleep and appetite for food; 
ameliorating negative affect and modulating brain reward threshold.(101, 104)  
Nicotine not only stimulates the release of neurotransmitters into the synapse, nicotine also 
inhibits the removal and degradation of neurotransmitters in the synaptic cleft, thereby 
prolonging their rewarding effects.  Nicotine binds to nAChRs that modulate the activity of 
monoamine transporters which are responsible for the reuptake of monoamine 
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neurotransmitters (dopamine, serotonin, adrenaline, noradrenaline) from the synapse.(83)  The 
activity of the transporters which accomplish this, is not only regulated by nicotine, but also 
other components of tobacco smoke, such as: 
1. the monoamine oxidase inhibitors harman and norharman which are products of 
tobacco combustion), 
2.  the presence of other tobacco alkaloids (such as anabasine and anatabine),  
3. the dose of nicotine, 
4. the route of nicotine administration (inhaled, subcutaneous, intravenous),  
5. whether nicotine is acutely or chronically administered and whether its administration 
is voluntary or involuntary.(83)  
The absence of harman, norharman, and other minor alkaloids such as anatabine, from NRT, 
may partially explain its inability to match the reward and reinforcement of tobacco smoking. 
Nicotine also exerts its reinforcement by stimulating the release of hormones into the systemic 
blood circulation, such as catecholamines and hormones involved in psychological stress, 
such as Adreno-Corticotrophin Releasing Hormone (ACTH), cortisol, corticosterone, and 
noradrenaline as well as the release of hormones that interact with the dopaminergic system 
such as prolactin.(40, 99, 104)  Corticosterone released by ACTH, in turn, stimulates 
glycolysis and has a role in memory.(106)  Nicotine exerts its reinforcing properties by the 
complex interaction between its effects on the various subtypes of nAChRs and the various 
neurotransmitters and other substances that are released when these receptors are activated by 
nicotine.   
The perception of the ‘high’ produced by addictive drugs is correlated with the amount of 
dopamine that is released in response to the drug binding to dopaminergic neurons.(107)  
Drugs of addiction, stimulate the release of a greater amount of rewarding neurotransmitters 
than innate reinforcers (such as food), and do so more rapidly than innate reinforcers, which 
leads to compulsive drug administration that overshadows the pursuit of innately rewarding 
behaviours.(91)   
Not only do addictive drugs produce reward and reinforcement by the drug binding to 
neuronal receptors causing the neurons to release rewarding/reinforcing neurotransmitters, 
drugs can also reward and reinforce their own use, by indirect stimulation of the release of 
rewarding neurotransmitters by classical conditioning.  For instance, when nAChRs are 
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desensitized due to high levels of nicotine, tobacco smoke retains its reinforcing properties by 
the sensory stimuli of tobacco smoke being able to provoke the release of neurotransmitters 
because the sensory stimuli have been so often paired with the release of rewarding 
neurotransmitters when the nAChRs were in a sensitive state.(108) 
When nicotine is delivered very rapidly, it is able to reward by causing physiological 
perturbations.(37)  The unsensed reinforcement from nicotine, nicotine’s reward via 
physiological changes, and the neuroadaptations to repeated nicotine administration, may 
explain why novice smokers are often unaware that they are becoming addicted until their 
addiction is well established, and they are not readily able to consciously interrogate their 
reactions to cigarette smoking, or appreciate the reasons why they smoke, which limits their 
conscious control over their behaviour and hampers their efforts to quit. 
Examples of neuroadaptations, which result in addiction without conscious reward, include, 
changes in receptor sensitivity, alteration of the number of receptors, and strengthening of 
neural synapses.(96)  These neuroadaptations occur shortly after the initial dose of an 
addictive drug (within five minutes in the case of nicotine).(109)  Neuroadaptation may 
explain why drug seeking behaviour for cocaine and heroin in rats increases for several weeks 
or even months after the initial use of those drugs despite no further doses of these drugs 
being administered during that time.(110, 111)  In the case of nicotine, neuroadaptations are 
partially responsible for why cue-induced cravings to smoke in abstinent human smokers have 
been shown to increase progressively for at least the first thirty-five days of abstinence.(112)  
These observations explain why so many smokers relapse back to smoking despite being 
abstinent for a considerable period of time.   
Neuroadaptations are responsible for three processes that cause future compulsive drug use: 
sensitisation, tolerance, and withdrawal symptoms.(91)  These three processes are the 
defining features of drugs of addiction, and are essential to both the negative and positive 
reinforcement that are responsible for the development and maintenance of addiction.  For 
instance, neuroadaptation (such as changes to nAChR responsiveness to nicotine) leads to 
aversive withdrawal symptoms when drug levels in the blood are lowered during a brief 
period of abstinence and can cause positive reinforcement by accentuating the hedonic 
response to a lapse to drug use after a period of abstinence.   
Sensitisation is a process by which the response of a neuron to administration of a drug (such 
as the amount of neurotransmitter released) is much greater in an animal that has been primed 
(sensitised) by prior exposure to that drug, compared to the response to that drug in an animal 
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that is naïve to that drug.  Sensitisation to nicotine is clearly demonstrated with increased 
release of dopamine in animals that have previously been primed with nicotine.(113)  The 
likelihood that sensitisation will occur, is directly proportional to the drug dose and the speed 
with which it reaches the brain after its administration.(114)  Sensitisation also heightens the 
power of drug-related cues to evoke drug seeking behaviour in the future.(114)  A search of 
Medline, conducted by me, identified only two studies of nicotine sensitization in human 
subjects.  Perkins and colleagues demonstrated that pre-treatment with nicotine significantly 
sensitised three effects of nicotine: nicotine’s increase in pain threshold, increased hand 
unsteadiness, and improved memory.(115)  The second study, was conducted by Heishman 
and Henningfield, who observed that, after giving non-smokers nicotine gum, the only 
outcome that demonstrated sensitisation was blood pressure.(116)   
Tolerance is defined as the reduction in the effect of a drug after it has been administered 
repeatedly.  Tolerance to the rewarding effects of a drug, occurs as a result of 
neuroadaptations, such as, desensitisation of receptors, relocation of the receptors from the 
cell surface to the cytoplasm (where the receptors can no longer be activated by ligands in the 
extracellular space), and increased transcription of receptor RNA.(96, 117)  Tolerance to the 
rewarding effects of nicotine nasal spray, has been demonstrated, with some changes in mood 
retaining the effects of tolerance for more than two hours.(115)  Tolerance to the aversive 
effects of nicotine has also been observed.(118)   
The third defining characteristic of addiction is the withdrawal syndrome.  Withdrawal 
symptoms are unpleasant psychological and physical symptoms that develop after a period of 
abstinence in animals that have become accustomed to regular intake of an addictive drug.  
Typical nicotine withdrawal symptoms include negative affect, poor concentration, increased 
appetite, dysphoria, depressed mood, insomnia, irritability, frustration, anger, difficulty 
concentrating, restlessness, decreased heart rate, and cravings to smoke.(75)  A review of 
trials that investigated withdrawal, concluded that heavy smokers experience the onset of 
withdrawal symptoms within one day after abstinence, these symptoms peak within the first 
week, and last for two to four weeks.(119)  The negative affect of the withdrawal syndrome 
can start as early as four hours after smoking a cigarette, peak after three days of abstinence, 
and still be detectable a month after quitting smoking.(120)  The neural basis of withdrawal 
symptoms is thought to be the reduction in levels of rewarding neurotransmitters when their 
release is no longer stimulated because the addictive drug is no longer being taken.(121)  An 
additional mechanism, in the case of nicotine, is the increase in manufacture of nAChRs when 
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nicotine blood concentrations are high (during smoking) and the decrease in their manufacture 
when nicotine levels fall.(109, 117)       
Usually smokers are so distressed by withdrawal symptoms, that they are unable to ignore or 
withstand them, and lapse to smoking to reinstate their usual levels of plasma nicotine and 
thereby relieve their withdrawal symptoms.(77)  The intensity of withdrawal symptoms 
predicts relapse, for instance, smokers who had higher withdrawal symptoms on their quit 
date were more likely to relapse.(122)  Withdrawal symptoms are not only caused by the 
absence of nicotine but, also the absence of other non-nicotine components of smoking,(120) 
and withdrawal from the endogenous opiates produced in response to nicotine.  The craving 
and urge components of the withdrawal syndrome, can also be triggered by external cues to 
smoke, such as sights, smells, times-of-day, and activities that have been frequently paired 
with smoking in the past.(123, 124)  
Smokers learn to subconsciously recognise the precursors of withdrawal symptoms, that are 
not as aversive as the withdrawal symptoms themselves, and respond to those precursors by 
smoking in order to ward off and avoid the development of withdrawal symptoms.(125)  
Smoking without being aware of having taken a cigarette out of its packet and lighting it, is 
known as “automaticity” and is indexed in psychological batteries such as the brief-Wisconsin 
Index of Smoking Dependence Motives.(44)   
The role played by withdrawal symptoms in altering the chances that smokers will quit and 
remain quit were measured in the two RCTs within this dissertation, by measuring withdrawal 
on the Minnesota Nicotine Withdrawal Scale.(126)    
The process of conditioning, by which a neutral stimulus develops the ability to cause the 
same response as an unconditioned stimulus, is mediated by the nature of dopaminergic 
neurons and how they respond to stimuli that occur shortly before an unconditioned 
stimulus.(91, 127-129)  The ability of cues associated with a drug, to evoke the same response 
as the drug, enables the reward of the drug to be felt more quickly because the conditioned 
stimuli (cues, such as the sight of a cigarette or the taste of cigarette smoke) are often 
experienced quite a while before the unconditioned stimulus (such as nicotine) reaches the 
brain.  This decreases the delay between drug administration and reward, thereby increasing 
the neurotransmitter release, which in turn, strengthens the learning (conditioned incentive 
learning) that the reward is associated with the drug administration, and increases the drug’s 
addictiveness.(90)  For instance, action potentials encoding the sight and smell of a cigarette 
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travel more quickly to the brain than the time it takes for nicotine to be absorbed into the 
blood and travel in the blood-stream to the brain. 
A further consequence of the transferral of the ability to stimulate reward, from a drug itself, 
to the cues and sensory qualities of the drug, is that it enables reward to occur even when the 
receptors for the drug are desensitized.  This mechanism is also responsible for the reduction 
in reward that is produced by a drug when it is administered in the absence of the conditioned 
stimulus (such as nicotine not being as rewarding when it is not accompanied by the 
sensations of cigarette smoke in the oropharynx).   
The amount of reward that is produced by a conditioned stimulus is proportional to the 
intensity of the learning process that associated the conditioned stimulus with the 
unconditioned stimulus, and is influenced by the current physiological and affective state of 
the animal (91, 130)  For instance the salience of cues to smoke is not as great, when a 
smoker’s mood has been boosted by nicotine from NRT, compared to when a smoker has low 
mood due to not having recently smoked or used NRT.(131)   
Addictive drugs facilitate the learning process that lead to addiction, by enhancing and 
consolidating the storage of memory about the learned behaviour through the strengthening of 
new synaptic connections that store that information.(90)  This memory enhancement occurs 
automatically within dopaminergic neurons, and is not reliant on the motivating effects of 
consciously experienced reward.(90)  The reinforcement of smoking by classical and operant 
conditioning and learning is extremely strong because it is repeated very often, considering 
the large number of puffs that a smoker inhales per day (for example, ten puffs per cigarette 
and twenty CPD provides 200 puffs per day, or 200 learning episodes per day).   
In conclusion, addiction to smoking is maintained by a complex interaction of nicotine and 
other components of cigarette smoking, which is modulated by the pharmacokinetics and 
route of nicotine delivery, and by conditioned internal and environmental cues.  This 
dissertation aimed to add to current knowledge by exploring the efficacy of two nicotine 
delivery devices that have pharmacokinetic profiles that are at least as fast as the fastest 
conventional NRTs, and that possess novel sensory qualities. 
2.1.3 The chemistry of nicotine 
Knowledge of the chemical properties of nicotine may assist in understanding how nicotine 
delivery devices exert their wanted and unwanted effects, and may guide the rational design 
of new nicotine delivery devices.   
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Nicotine is a tertiary amine, consisting of a pyridine and a pyrrolidine ring, and can accept 
two protons (at 15ºC the pK1 and pK2 are 6.16 and 10.96 respectively, a 0.05 molar solution 
has a pH of 10.2.(132)  The pH of tobacco smoke varies from 5.5 to 8.5 in flue-cured and air-
cured tobacco, respectively.(99)  The pH of nicotine has a considerable bearing on its 
absorption into the blood-stream and passage across the blood-brain barrier, as well as how 
tolerable it is to inhale.  Nicotine will not readily diffuse across the lipid bilayer of cell 
membranes if it is in either of its two protonated states because, in these states nicotine is 
lipophobic due to its electrical charge, whereas nicotine rapidly crosses cell membranes when 
it is in its non-polar (uncharged) lipophilic unprotonated state (in this state it is commonly 
referred to as free-base nicotine).  For this reason, oral and transdermal NRTs are buffered to 
an alkaline pH.   
At physiologic pH approximately a quarter of nicotine exists in its unprotonated (free base) 
form.(133)  The cells in some tissues possess transporters in their cell membranes, that can 
actively transport nicotine regardless of whether it is protonated or not, such as the lung and 
the brain,(134) however, active transporters can become saturated, limiting their ability to 
transport a large dose rapidly, hence passive diffusion retains a substantial role in rapid 
delivery of large doses of drugs across plasma membranes. 
When nicotine is inhaled, the considerable buffering capacity of the large surface area of the 
lung, ensures that the pH of the inhaled nicotine rapidly equilibrates with the pH of the lung 
(pH=6.9) and the portion that is unprotonated rapidly crosses the pneumocytes, passes 
through the vascular endothelial cells and is carried away by the blood-stream.(99, 134)  The 
vascular route between the lung and brain is very short, which is why nicotine reaches the 
brain within seven to ten seconds after each puff of a cigarette(135), and why nicotine reaches 
the brain at a much higher concentration if it is inhaled cf. delivered orally or intravenously, 
because the nicotine-laden blood from the lung does not have the opportunity to mix with 
much blood draining from other parts of the body before it reaches the brain so the nicotine 
concentration is not diluted.  Once nicotine reaches the brain, it is rapidly absorbed across the 
blood-brain barrier within microseconds by passive diffusion of uncharged nicotine and by 
active transport of both charged and uncharged nicotine.(134, 136)   
This sub-chapter has outlined the chemical characteristics of nicotine and its delivery to and 
within the body.  Pure nicotine exists as one of three forms (one uncharged and two charged) 
which affect its ability to cross cell membranes, it is highly chemically reactive, and is both 




Having an understanding of the mechanisms by which people relapse back to the smoking 
habit after a period of abstinence, may potentially be useful for the rational design of more 
effective methods to prevent relapse.   
A survey of smokers in the United Kingdom stop smoking service found that, of the people 
who had relapsed, only a quarter had consciously decided to abandon their attempt to quit 
when they first lapsed, and almost half had only intended to have a few puffs when they first 
lapsed but, this quickly led to full relapse.(137)  This highlights the need for people 
attempting to quit to not allow themselves even a puff, and also demonstrates the role of 
subconscious processes in addiction.  
Smokers relapse for a variety of reasons, with inability to withstand withdrawal symptoms, 
particularly low mood, playing a bigger role than the desire for the positive reward of 
smoking.(137, 138)  This points to the need to maintain sufficiently high nicotine levels in the 
blood to avoid low affect.   
A number of risk factors for relapse have been identified.  Of eleven potential predictors of 
relapse, (such as Fagerström Tolerance Questionnaire scores), only the level of craving 
experienced forty-eight hours after abstinence, predicted abstinence two months later in one 
prospective study, while only nicotine dependence measured by a modified version of the 
Fagerström Tolerance Questionnaire predicted abstinence two years after the attempt to quit 
in another trial.(139, 140)  Trials have consistently demonstrated that nicotine dependence is 
positively correlated with relapse.(141)  Stapleton observed that levels of craving early after 
an attempt to quit (within the first week) predicted relapse within twelve weeks.(142)   
Internal and external cues to smoke, such as negative affect, and activities associated with 
smoking, such as eating and drinking coffee or alcohol, can engender strong urges to 
smoke.(143)  People whose lapses were triggered by stress progressed to relapse more quickly 
than people whose lapses were provoked by eating or drinking.(144)  In one trial subjects’ 
sensitivity to anxiety predicted early lapses, even after controlling for gender, nicotine 
dependence, and nicotine withdrawal symptoms but, did not predict early relapse during the 
first fortnight of quitting.(145)  Environments with cues to smoke, and cues that cigarettes are 
available and smoking is permitted, can elicit powerful urges to smoke, which can prompt 




People’s reactions to a lapse have a big impact on whether their lapse turns into a relapse, an 
effect that is known as the Abstinence Violation Effect.(144, 146)  People who lapse and 
instigate methods of coping with the lapse, and any negative affect associated with it, are less 
likely to have a second lapse on the same day as their first lapse.(144)  People who experience 
a large pleasurable effect from a lapse, have a greater risk of relapse.(147)  Those who 
continue to use NRT after a lapse, are four times more likely to achieve ten-week 
abstinence.(148) 
The shape of the relapse curves in trials of smoking cessation, consistently show that the vast 
majority of smokers relapse within a week of commencing an attempt to quit, regardless of 
the method they used to quit.(9)  This implies that a new treatment would be more likely to 
produce substantially superior abstinence outcomes, if it induced higher abstinence rates 
shortly after treatment is commenced.   
In conclusion, relapse is common, and most often occurs early in a quit attempt.  It may not 
be possible to prevent all smokers from lapsing or from relapsing, but it may be possible to 
find effective methods to overcome the Abstinence Violation Effect, and encourage people 
who have lapsed or relapsed, to continue to use NRT and to make a further attempt to quit as 
soon as possible, before they expose themselves to potentially irreversible ill-health from their 
smoking.   
2.1.5 Theories of addiction 
A variety of theoretical models have been proposed to explain how neurological mechanisms 
combine with behavioural and social factors to cause addiction.   
Stolerman’s psychopharmacological model of drug-seeking behaviour, states that four 
processes underlie the development and maintenance of compulsive drug use:  
1. positive reinforcing effects,  
2. aversive effects,  
3. discriminative (cue) effects, and  
4. stimulus-conditioned effects of the drug.(149)   
The Incentive-Sensitization Theory postulates that addictive drugs enhance dopamine neural 
systems, to attribute incentive salience to events and sensations associated with the enhanced 
dopamine activity, causing those events and sensations to be ‘wanted’ stimuli, and in some 
individuals, with repeated administration of the drug, the dopamine activity becomes 
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increasingly hypersensitized, leading to compulsive drug-taking; furthermore, the neural 
processes by which incentive salience develops are independent of the pleasurable effects of 
the drug, hence a drug can be compulsively wanted without being enjoyed.(150)    
Incentive salience is a pivotal concept of incentive sensitisation theory.  Incentive salience is 
the process by which the sensory qualities of a drug (its colour, shape, taste) and cues of drug 
availability, develop the ability to instigate a strong, deep, visceral, desire and urge to 
consume the drug, which is not necessarily consciously thought through, or expressed in 
language, or understood by the person experiencing it, but rather, it is an instinctive, visceral 
urge – a powerful urgent and attention-riveting, all-consuming desire.(114, 151)  In incentive 
learning models of addiction, cues are imbued with incentive motivation, and become the 
focus of attention and behaviour, for instance, smokers often enjoy the process of taking a 
cigarette out of its packet or rolling up tobacco with cigarette paper.  The sensory qualities of 
the drug, and the cues of its availability, become mesmerising and almost more important than 
the drug itself.(114)   
The reason why incentive salience, also known as “wanting”, is not fully consciously 
experienced, but rather is a pressing urgent need, is that it is mediated by mesolimbic 
dopamine neurons which are subcortical, whereas desires that are consciously perceived are 
mediated by higher cortical structures.(114)  
Two concepts lie at the heart of incentive sensitisation theory: “wanting”, and “liking,” which 
have been given quotation marks in this dissertation to distinguish them from the non-
technical meanings of those words.  “Wanting” has a similar definition to incentive salience, 
it refers to a strong compulsive urge, which is not an intellectually thought-through desire but, 
rather, it is a powerful visceral urge, that is produced by opioid and dopamine inputs.(114, 
152)  “Liking” is the hedonic effect of a drug, and is activated by distinct neurocircuitry, 
specifically by opioid and endocannabinoids but not by dopamine stimulation.(114)   
Incentive sensitisation theory explains the observation that people compulsively use an 
addictive drug long after it has stopped being rewarding to do so, by hypothesizing that 
repeated drug administration causes desensitisation of the euphoric and pleasurable drug 
effects (“liking” the drug), but sensitizes the motivational drug effects (“wanting” the 
drug).(153)  Because incentive salience is such a strong visceral urge, and occurs even when 
the drug is no longer pleasurable, it may explain the chronic relapsing, and often treatment-
resistant, nature of addictions.(153)   
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DiFranza and colleagues’ observations of the relationship between non-daily smokers’ 
withdrawal symptoms and their smoking patterns, detected behaviour that could not be 
explained by the traditional view that the principal reason why people are addicted to smoking 
is their need to relieve the withdrawal symptoms that occur when their blood nicotine levels 
are lowered after a period of abstinence.  For example, non-daily smokers experience strong 
withdrawal symptoms but do not smoke in response to them, and go for days without 
smoking, even though this meant that their plasma nicotine levels would be close to 
zero.(154)   
This led DiFranza and colleagues to operationalise the incentive sensitization model of 
smoking outlined above, by positing that people go through three distinct phases when they 
first start to smoke while their nicotine addiction is developing, and invariably proceed 
through these three stages in the same temporal order, the stages being: wanting, craving, and 
needing.(154-156)   
“Wanting” was described by DiFranza and colleagues as a strong compulsion and desire to 
smoke, which is often perceived to arise from an external force, and is impossible to resist.  
“Craving” was described as similar to but, stronger than “wanting”, more persistent, more 
intrusive on thoughts, and more difficult to ignore.  “Needing” was the sense that a cigarette 
must urgently be smoked in order to regain one’s equanimity.   
The development of a theoretical conceptualisation of addiction may aid in bringing a rational 
scientific approach to the development of treatments for addictions generally and smoking 
tobacco in particular.  Basing treatment modalities on rational design and knowledge of the 
physical and psychological substrates the treatments need to act on, may help to make the 
treatments more effective.  Over time, theories of addiction have incorporated a broader range 
of factors that are involved in addiction, from Stolerman’s focus on pharmacology to the 
ASAM definition which encompasses pharmacology and psychology.  
In conclusion, incentive sensitisation and incentive motivation models give a compelling 
theoretical framework for the mechanisms of addiction, and highlight the need for treatments 
that are capable of influencing neurological and psychological processes that are beyond the 
conscious appreciation and control of addicts.  A variety of theoretical models of addiction 
have been proposed, which share some features in common, such as, a defined progression of 
stages as addictions develop and become solidified, and the lack of conscious awareness of 
the processes involved in the onset and maintenance of addiction.  
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2.2 Nicotine Delivery Devices 
This chapter begins by describing the aspects of nicotine delivery devices that influence their 
effectiveness for replacing the roles of smoking tobacco; their acceptability, and their 
tolerability.  The rationale for Nicotine Replacement Therapies (NRTs) is then outlined; 
conventional NRTs are described; followed by an overview of newer nicotine delivery 
devices. 
2.2.1 The Effects of Characteristics of Nicotine Delivery Devices, and the 
manner they are used, on their Tolerability and Efficacy 
Nicotine delivery devices’ palatability and potential to evoke reward, are influenced by a wide 
range of characteristics of those delivery devices, and the interplay between those 
characteristics, which are described in the following paragraphs.  
2.2.1.1 Role of Pharmacokinetics 
Previous paragraphs of this dissertation have established that the primary drivers of addiction 
to smoking tobacco are: nicotine, the speed of its delivery to the brain, and the delivery of 
highly concentrated nicotine-laden blood to the brain.(28, 55, 121, 135, 157)   
The fast delivery of nicotine is what is essential for nicotine to be psychologically rewarding 
and addictive,(28) indeed, rapid delivery of nicotine promotes behavioural sensitization and 
alters nicotine’s neurobiological impact.(158, 159)  Positron Emission Tomography shows 
that during drug intoxication, increases in striatal dopamine are only associated with a drug’s 
reinforcing effects, if the changes in dopamine concentration in the synapses occur rapidly, 
and drugs that take a long time to accumulate in the brain and leave the brain, cease to be 
rewarding shortly after they are administered and have less abuse liability.(107)  Indeed, as 
mentioned earlier, nicotine has different neurological effects depending on whether its 
delivery is tonic or clonic, with greater reward being produced when nicotine delivery 
produced a rapid rise and fall of plasma nicotine concentrations, and less reward when 
nicotine concentrations rise and fall slowly.(160) 
Yet the rationale behind conventional NRT is to reduce the speed and intensity of nicotine 
delivery to diminish the nicotine addiction.(11)  For this reason, Schneider and colleagues 
suggested that NRT is a misnomer and should stand for ‘nicotine reduction therapy’ as it is 
not really ‘nicotine replacement therapy’ because it does not replace the arterial boli produced 
by cigarette smoking.(24)  As a result of the slow pharmacokinetics of conventional NRT, 
most smokers report NRT to be much less satisfying than cigarette smoke.(56)  Rapid 
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delivery of nicotine via novel NRT may be particularly suitable for smokers who are peak 
seekers. 
Despite the evidence that supports the nicotine bolus hypothesis (that the rapid delivery of 
highly concentrated nicotine-laden blood to the brain is essential for nicotine to be 
rewarding), this hypothesis is not universally accepted, as some evidence appears to 
contradict it, and some researchers have dismissed the hypothesis completely.(161)  Sceptics 
of the nicotine bolus hypothesis are correct in stating that the speed of delivery of nicotine in 
cigarette smoke is sometimes overstated, because research has shown that nicotine does not 
always reach the brain as quickly as five or seven seconds after each puff of cigarette smoke, 
as originally thought, but instead, the lung acts as a reservoir of nicotine so it is not until 
twenty seconds or so before an appreciable proportion of the nicotine that was inhaled reaches 
the brain.(162)  However, this slightly slower Tmax is not inconsistent with the nicotine boli 
hypothesis, the delivery speed of twenty seconds is still fast and is vastly faster than the speed 
with which nicotine nasal spray, the fastest of the conventional NRTs, delivers nicotine into 
the blood.  On balance, it appears that the nicotine bolus hypothesis is likely to be correct, 
even though nicotine inhalation might not deliver nicotine to the brain as quickly as five to 
seven seconds after each puff.   
In conclusion, the rapid onset and offset of nicotine blood levels in the brain is essential to 
ensure that the nicotine will stimulate the release of rewarding neurotransmitters, and cause 
transient physiological fluctuations.  The pharmacokinetic profiles of conventional NRT fall 
well short of that of cigarette smoking, hence NRT are much less rewarding than smoking, 
which may explain the low abstinence rates NRTs produce.  This dissertation argues that in 
order for more smokers to successfully quit smoking, they should be given the opportunity to 
switch from getting rapid-delivery of nicotine from smoking cigarettes, to deriving nicotine 
from safe devices that match the rapid highly concentrated pharmacokinetic profile of 
cigarette smoking, and for many smokers it is too great a hurdle to switch in a single step 
from the rapid rewarding nicotine delivery from a cigarette to the much less rewarding 
relatively slow nicotine delivery from conventional NRT.  The need for faster safe nicotine 
delivery devices in order to improve abstinence rates has been recognised by some workers in 
the nicotine and tobacco research field.(12, 57)  The next section of the dissertation examines 
the role of the site of absorption on the rapidity of nicotine delivery to the brain.   
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2.2.1.2 Role of site of nicotine delivery and route of absorption 
Although the lung is an ideal site for the delivery of nicotine, there are a number of technical 
difficulties in creating a safe nicotine aerosol capable of reaching deep into the lung where 
there is the greatest surface area for absorption.  The barriers to pulmonary nicotine delivery 
are discussed here and in Chapter Nine. 
Potential sites for nicotine administration differ in their propensity for nicotine to provoke 
adverse effects, the intensity of those effects, and the ability of people to cope with those 
adverse effects.  There is also individual variation in the intensity of the adverse effects of 
nicotine at different administration sites.  For instance, a minority of people suffer severe skin 
irritation and blistering from topical nicotine, while many people only suffer mild irritation, 
and most people have no skin irritation.  Some people are able and willing to ignore mild skin 
irritation, but are not able to cope with irritation in their nasal mucosa, and hence can wear 
nicotine patches but not use nicotine nasal spray.  For instance, in a trial that randomised 
smokers to use either nasal spray, gum or patches, only fifteen percent of subjects used the 
recommended amount of nasal spray, compared to 82% for nicotine patch, and 38% for 
nicotine gum.(163)   
As has been discussed previously, the pH of nicotine affects its ability to cross lipid-bilayers.  
When nicotine is inhaled, the ease with which free-base nicotine crosses cell membranes, has 
to be balanced against the propensity for alkaline aerosols to irritate the airway and provoke 
cough and the reflex interruption of inspiration.  This is especially important because of the 
very high pH of pure nicotine (free base nicotine).  When highly alkaline aerosols are inhaled, 
the high pH activates C-fibres in the upper airway(164, 165) and in the carotid arch, causing a 
reflex interruption of inspiration and cough.(166)  Cigarette manufacturers control the pH of 
cigarette smoke by a number of methods: whether the tobacco is flue-cured or air-dried, 
adding acids to the tobacco leaf, adding sugar (which lowers the pH when it is burned), or 
conversely adding sodium hydroxide to the tobacco leaf which raises the pH and assists in the 
volatilisation of nicotine out of the tobacco leaf.(167) 
These considerations suggest that the mouthspray and inhaler, tested in this dissertation, 
deliver nicotine by two of the fastest routes to deliver high doses of medication to the brain. 
2.2.1.3 Role of mode of use of NRT 
The manner in which NRT is used, and whether it is used often enough and for long enough, 
has a bearing on its efficacy.  However, unless subjects were randomised to use NRT in a 
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different manner, the mode in which NRT is used will be a post-randomisation effect, and 
therefore including it in statistical analyses of the treatment outcome, poses a risk to validity, 
which is outlined below in the chapter on methodological issues (Chapter Six).   
2.2.1.3.1 Manner in which NRT is used 
The manner with which people use NRT can have a substantial bearing on its effectiveness, 
and it is important that smokers are educated on the ideal way to use each type of NRT that 
they are prescribed.  For instance, if nicotine gum is chewed as often as people typically chew 
ordinary chewing gum, large quantities of nicotine-laden saliva will be produced, which when 
swallowed cause indigestion, hiccoughing, and burping.  A further example is that the site 
within the mouth where people choose to place their nicotine gum/lozenge effects how well 
nicotine is absorbed, with greater absorption in the lower buccal mucosa.(168)   
2.2.1.3.2 Treatment compliance 
It is biologically plausible to argue that the smokers who adhere to recommended dosing of 
NRT, will achieve higher concentrations of nicotine in their blood, and this will lead to 
reduced withdrawal symptoms, and a higher chance of achieving and maintaining abstinence, 
compared to smokers who use less than recommended amounts of NRT.   
However, it is difficult to test this hypothesis because the relationship between compliance 
and abstinence is confounded by, inter alia, people’s level of motivation to quit.  Trials that 
examined the effect of adherence on abstinence, and the statistical methods they used to 
minimise confounding, are discussed below.   
Adherence to the use of NRT and counselling is frequently low.(169, 170)  Researchers have 
explored a variety of methods for encouraging adherence to taking NRT.  For example, in one 
trial, the intervention for the active group resulted in compliance rates of fifty-five percent 
compared to twenty-nine percent in the control group.  In that trial, the active group was 
informed that their bottles of bupropion were able to count and record the time each dose was 
taken, and were given graphical feedback on their compliance and weekly nurse-delivered 
reminders of methods to improve compliance.  The control groups were not told their pill 
bottles could record their compliance and were not given any feedback about 
compliance.(171) 
Despite the inherent risks of confounding, some researchers have tested whether there is an 
association between treatment compliance and abstinence,(170, 172), and an association 
between treatment compliance and secondary outcomes such as weight-gain after 
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cessation.(173)  Similar trials have tested the association between adherence and abstinence, 
in a manner that attempted to minimise confounding and reverse-causation, which concluded 
that greater compliance is associated with higher abstinence.(174-176)  In this context, 
reverse causation would be considered to have occurred if higher abstinence led subjects to 
have increased compliance, rather than increased compliance being the cause of higher 
abstinence rates.  
In conclusion, research on the association between adherence to the use of recommended 
amounts of smoking-cessation treatment and subsequent abstinence status, is able to be 
performed, using methods to limit reverse-causation and confounding, and such analyses 
demonstrate that increased treatment compliance has a beneficial effect on treatment success.  
The effect of treatment compliance on abstinence was a secondary analysis in both of the 
RCTs in this dissertation. 
2.2.1.4 Role of Sensory Stimulation 
The myriad sensory qualities of smoking, play a considerable role in the reinforcement of 
smoking behaviour: the sensation of smoke in the oropharynx and chest, the flavour and smell 
of the smoke, the sight of the cigarette packet, the sight and sensations of taking the cigarette 
out of the packet, placing it between one’s lips, holding the cigarette lighter, the act of lighting 
it and seeing the flame, the feeling of inhaling and exhaling the smoke, the sight and taste of 
the smoke being exhaled, and the sensation of nicotine in the lungs.  Nicotine is not nearly as 
rewarding when given on its own, without the cues and sensory experiences that normally 
accompany its delivery, which may partially explain why nicotine from NRT does not have as 
big an effect as nicotine from smoking – the sensory elements of smoking enhance the amount 
of dopamine that is released in response to nicotine.(177)   
Jed Rose was one of the earliest investigators to publish on the vital role that the sensory 
experiences of smoking play in reinforcing smoking and hindering attempts to quit.  Rose and 
colleagues demonstrated that, shortly after the initiation of smoking, the sensory experiences 
of smoking become more powerful reinforcers of smoking behaviour than nicotine itself.(178)  
This is consistent with the Incentive Sensitisation Theory of addiction discussed previously.  
Smoking pairs rapid, addictive nicotine delivery, with respiratory sensory stimuli 
characteristic of the particular brand of cigarettes being smoked.(178-180)  Sensory stimuli, 
and the conditioned reinforcement they provide, are essential to the maintenance of the 
addiction to smoking because, nicotine exposure may desensitize nAChRs for hours, 
rendering them unable to respond to nicotine, but a Pavlovian response to conditioned stimuli, 
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such as the respiratory sensory experiences of smoking, provides a second reward pathway 
that can be activated even when the nAChRs are desensitized.(177, 180)   
The work of Rose and colleagues has been confirmed and extended by investigators who 
observed that, the importance of sensory stimuli in producing reward from smoking, differs 
between smokers, and varies according to smokers’ mental and emotional states.  Perkins and 
colleagues, found that the sensory effects of smoking are more important than nicotine for 
relief from negative mood.(181)  The taste and sensory perception of cigarettes and cigarette 
smoke, is more important to smokers with the highest nicotine dependence.(41, 182)  Sensory 
mediated reward is especially important under times of stress and high mental workload.(41, 
183)  Since stress is a common cause of relapse, NRTs that have appealing sensory qualities, 
and that are sufficiently rewarding to motivate people to use the NRT often enough to learn 
that its sensory qualities are paired with reward, may assist in mitigating the effects of stress 
on the risk of lapsing to smoking. 
Conventional NRTs are not used often enough to engender the learning required for their 
sensory effects to become conditioned reinforcers, and without the conditioned sensory 
reinforcement, the reward of the nicotine they provide will be smaller than the reward from 
the nicotine derived from smoking.(184)  The slow pharmacokinetic profile of conventional 
NRT results in a considerable delay between the administration of NRT with the immediate 
sensory experiences it produces, and the subsequent slower onset of the appreciation of 
psychological reward produced by nicotine, which may make the association (pairing) of the 
sensory qualities of NRT and reward less likely to be learned either consciously, or by 
subconscious neural mechanisms.  This may substantially limit the capacity of NRTs, whose 
sensory qualities differ from those of smoking, to act as substitutes for smoking.(22, 185) 
Following Russell’s logic, researchers have explored the potential of assisting smokers to quit 
by first swapping their conventional cigarettes for very low nicotine cigarettes that still have a 
normal level of tar and therefore provide similar tastes and sensory qualities as regular 
cigarettes but, are less addictive due to their lower nicotine content, and have demonstrated 
this therapeutic modality improves abstinence RR=1.18 cf. Quitline care, p=0.037.(186) 
The active and placebo NRTs used in the two RCTs conducted as part of this dissertation, 
possessed substantial sensory effects, which may enable them to develop into secondary 
reinforcers of the NRTs.  The sensory qualities of the therapies were recorded using a 
standard questionnaire and the effect of these scores on abstinence was measured.   
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This section of this dissertation has shown that sensory stimuli are an important ingredient in 
the satisfaction and addictiveness of tobacco smoke, and suggests that the appeal and 
effectiveness of NRT may be increased, if it replicates as closely as possible the sensory 
effects of tobacco smoking, and provides sufficient reward to motivate smokers to use it often 
enough for its sensory effects to be paired with the reward of nicotine delivery thereby 
heightening the reward of the NRT.   
2.2.1.5 Nicotine Replacement Therapy (NRT) 
2.2.1.5.1 Rationale for NRT and a history of its development 
This chapter outlines the development and rationale of NRT, and why more effective 
therapies are required.  The role of nicotine in the addictiveness of tobacco smoking was 
recognised in 1942 by Lennox L. Johnston, who wrote a brief report under the “Notes and 
News” section of The Lancet, in which he outlined an experiment he conducted to determine 
if nicotine was to tobacco smoking what morphine was to opium smoking.(187)  He 
administered nicotine hypodermically to thirty-five human subjects, and both oral and 
hypodermic nicotine to himself plus one patient.  Smokers in his sample noted that 
hypodermic nicotine had similar effects to those of smoking and; the non-smokers 
experienced dizziness, the sensation of increased stroke volume, vomiting and syncope.   
Because nicotine is the principal cause of addiction to smoking tobacco, and nicotine is 
relatively safe compared to other components of tobacco smoke (such as polyaromatic 
hydrocarbons caused by burning tobacco, and tobacco specific nitrosamines caused by 
oxidation of tobacco), it was hypothesised that smokers could be assisted to quit smoking, by 
providing them with an alternative source of nicotine to maintain their nicotine blood levels, 
and thereby avoid, or at least minimise, strong urges to smoke and other withdrawal 
symptoms after ceasing to smoke.  This led to the development of a range of medicinal 
devices for the delivery of nicotine without the harmful substances contained in tobacco 
smoke.   
The first medicinal, non-tobacco, nicotine delivery system, was nicotine gum which was 
developed by Ove Ferno in the early 1970s.(188)  Systematic literature reviews have 
consistently shown that in clinical trials, NRTs increase the chance of abstinence for at least 
six months compared to placebo therapy by just over one-and-a-half times [1.58 (95%CI 
1.50—1.66)].(27, 189)  However, the abstinence rates with NRT are lower when used in the 
community, under ‘real-world’ conditions’ cf. clinical trials.(190)   
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Although Ferno and colleagues desired to replicate as much as possible the factors that 
maintain the addictiveness of smoking, and provide a pharmacological reward commensurate 
with that of smoking, the nicotine gum that they developed, was unable to fully replicate the 
positive reinforcement of smoking, for reasons that will be outlined below.  Furthermore, 
some influential experts have taken had concerns about therapies that might potentially be 
addictive, and preferred to wean smokers off rapid boli of nicotine, not just wean them off 
smoking.(32)  The reluctance of medicines licensing authorities to licence potentially 
addictive nicotine delivery devices, and the reluctance of some doctors to prescribe them, may 
have dissuaded pharmaceutical companies from investing in the design of rapid pulmonary 
nicotine delivery devices.(12, 30, 191)  
Current forms of NRT include nicotine patches, lozenges, mouthsprays, nasal-sprays, nicotine 
gum and nicotine inhalators.  Collectively they double one-year abstinence from five percent 
with placebo therapy to ten percent with NRT.(189)  No commercially available medicinal 
NRT is capable of pulmonary delivery of nicotine (except some brands of electronic cigarettes 
when used by experienced users).  Nasal-spray is the only NRT to rapidly deliver nicotine to 
the brain, however it is highly aversive. 
2.2.1.5.2 The need for better NRT 
Despite the proven efficacy of NRT,(192) it has had limited impact on smoking 
prevalence.(22)  Smoking, like all addictions, is a chronic relapsing disease of brain reward, 
motivation, memory and related circuitry,(79) hence most smokers will require multiple 
treatments, and may tire of being treated with the same limited range of therapies each time 
they relapse.  The development of new forms of NRT, with different pharmacokinetic 
profiles, routes of administration, side-effect profiles, and sensory qualities, may attract more 
smokers to try to quit, including smokers who continue to smoke despite a strong desire not 
to,(193) the 62% of smokers who have not used NRT before,(194) and smokers who have had 
multiple treatments with standard NRT but failed to remain abstinent.(195)  These new 
therapies may be more effective than conventional NRT, which would also increase cessation. 
Current NRTs have numerous shortcomings, many of which have been mentioned previously.  
1. NRT produces low absolute quit rates of ten percent a year after treatment,(27) 
dropping to four percent after six years.(196) 
2. NRTs only replace one- to three-quarters of the nicotine that smokers previously 
derived from smoking.(23, 197, 198)  Under-dosing by conventional NRT is a serious 
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problem because, only NRTs that deliver a sufficiently high level of nicotine, are 
effective in assisting heavy smokers to reduce or quit.(189, 199)  Achieving a greater 
percentage of nicotine replacement may increase the efficacy of nicotine patch 
therapy.(198)  Higher doses of nicotine patch increase quit rates, hence higher dosages 
need to be made available.(200) 
3. Inadequacies in current dosage strengths and formulations of conventional NRT may 
be responsible for why few smokers use NRT and why NRT has not had much of an 
impact in reducing rates of smoking.(22)   
4. Nicotine patches are ineffective at expunging acute urges to smoke.(201)  NRT does 
not control urges to smoke that develop in response to conditioned cues to 
smoke.(202)   
5. Many smokers are put off using NRT because they find its route of administration 
unpleasant or embarrassing.(203)   
6. Most smokers attempt to quit without assistance, yet only four percent will remain 
abstinent twelve-months later.(9)   
7. Smokers typically use less than the recommended dose and discontinue NRT 
prematurely.(57)  
The prevalence of smoking may be reduced if more smokers could be attracted to use NRT 
when they try to quit.(204)  Quitters may be inspired to use newer pharmacotherapies if they 
had a better reputation for efficacy and tolerability than current products.(22)  A greater 
variety of available NRTs may help treatment-resistant smokers find a product that best suits 
their needs.(22, 193) 
Table 2.1, page 45, reports pharmacokinetic data extracted by me from the literature which 
illustrates how inferior the pharmacokinetic profiles of NRTs are compared to that of smoking 
cigarettes.  Higher quit rates may be achieved by developing faster-acting NRT, and using 
them in combination with a slow-release nicotine patch.   
Due to the shortcomings outlined above, tobacco control experts have publicly called for the 
development of improved NRT and the promotion of recreational use of addictive 
pharmaceutical-quality nicotine.(12, 205)  Indeed, the purpose of the trials upon which this 
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2.2.2 Recent developments in NRT  
This section outlines the new methods of using conventional NRT, followed by a description 
of the new nicotine-based therapies.   
2.2.2.1.1 More effective ways to use established NRT 
New ways of using conventional NRT have been investigated, including: 
1. using NRT before the target quit date,  
2. using a combination of NRTs simultaneously, and  
3. using higher than usual doses of nicotine.   
These approaches are discussed below, the two RCTs that this dissertation, utilised pre-
cessation NRT; smoking reduction as a prelude to quitting and; combination therapy.   
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2.2.2.1.2 Pre-cessation NRT 
There are a number of reasons to hypothesize that use of NRT before the target quit date, 
instead of waiting until the target quit date, would increase quit rates: 
1. It may take time to learn how best to use NRT in a manner that strikes a balance between 
getting a sufficiently large dose of nicotine to quench cravings to smoke, but not such a 
high dose that adverse-effects occur.  Learning how to attain this balance before 
quitting, may assist smokers to gain the most therapeutic effects from their NRT.   
2. It may take some time to develop a habit of using NRT, remembering to use it often 
enough, and developing an automatic habit of using it in response to internal and 
external cues to smoke.   
3. Initially, smokers will be relatively unfamiliar with the sensory effects of NRT 
compared to those of smoking, so the sensory effects of NRT will not have been paired 
with the rewarding effects of nicotine and will not act as secondary reinforcers of NRT 
use.  Pre-cessation NRT may allow time for NRTs’ sensory qualities to have become 
secondary reinforcers by the target quit date, which may make NRT more rewarding 
and more desirable as an alternative to smoking. 
4. Use of NRT prior to the target quit date may desensitize nAChRs which may make 
smoking less rewarding.   
A meta-analysis from 2008 of pre-cessation nicotine patch therapy, found it significantly 
increased abstinence rates compared to starting nicotine patches on the quit date, doubling 
six-month abstinence OR=2.17, 95%CI:1.46—3.22.(70)  However, this meta-analysis was 
unable to assess if the effect of pre-cessation NRT on abstinence remained after six months 
because that was the maximum follow-up in the trials it identified.  Two years later, a 
Cochrane Review showed that six-month abstinence rates were equivalent between abrupt 
quitting and smoking-reduction.(210)  This is reassuring because it counters any concerns that 
because pre-cessation NRT delays the target quit date this may adversely affect abstinence, 
since smokers who choose to delay their quit attempt are less successful.(211) 
A systematic review, published in 2011, found that pre-cessation NRT did not increase long-
term abstinence cf. NRT commencing on the target quit date, however, short-term abstinence 
rates were higher for pre-cessation patches cf. pre-cessation lozenges or gum.(69)  For long-
term abstinence, patches were no longer significantly more effective that gum or lozenges, but 
patches continued to have a significant effect on abstinence, with a relative risk of preloading 
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with nicotine patches compared to starting patches on the quit date of RR=1.26, 95%CI: 1.03-
1.55.  The following year a Cochrane review came to similar conclusions (Table 2.2).(212)   
Table 2.2.  Pre-cessation initiation of NRT versus initiation of NRT on the target quit 
date, reproduced from Comparison 14, Analysis 14.1 from the publication by Stead 
and colleagues.(212) 
Outcome or subgroup title No. of studies No. of 
participants 
Effect size 
Risk ratio 95%CI 
1 Smoking cessation 8 2774 1.18 [0.98, 1.41] 
 1.1 Patch 6 1772 1.34 [1.08, 1.65] 
 1.2 Gum 2 406 0.96 [0.65, 1.43] 
 1.3 Lozenge 1 596 0.60 [0.30, 1.21] 
 
Given the evidence that pre-cessation use of nicotine patches increases abstinence, this 
approach was used in both RCTs within this dissertation.   
2.2.2.1.3 NRT-assisted smoking reduction 
Smoking reduction may be the ultimate aim of an intervention or, it may be used as an 
intermediate step towards the ultimate goal of complete abstinence from smoking.   
The latter was the case in the two RCTs upon which this dissertation is based, as smoking 
reduction was the aim between baseline and the target quit date, during which subjects used 
NRT and reduced their smoking by a set amount each week.  The aims of pre-cessation NRT 
were for smokers to gain experience and skills in abstaining from smoking some of their usual 
cigarettes; gain experience with using NRT prior to the target quit date, and absorb sufficient 
nicotine from the NRT to supress compensatory smoking (inhaling more deeply, holding the 
cigarette smoke in the lungs for longer).  Although this will delay the target quit date, and 
delaying an attempt to quit reduces the chance of quitting, a qualitative review found that 
delaying the target quit date while using NRT and reducing smoking, did not diminish 
peoples’ resolve to try to quit, and in fact increases their chances of achieving 
abstinence.(213)   
Smoking reduction is an effective method of encouraging smokers who are currently 
unmotivated to quit, to use NRT, and leads to higher abstinence rates than requiring 
unmotivated smokers to quit without reducing their smoking beforehand.(214)  Reduction, as 
an initial step towards abstinence, is clearly supported by evidence.(215)  Smoking reduction 
increases smokers’ interest in and motivation to quit, increases their self-efficacy regarding 
their ability to abstain from smoking, is a strategy that has particular appeal for heavy 
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smokers, and is a strategy that General Practitioners in the United Kingdom commonly advise 
their patients to adopt.(216) 
2.2.2.1.4 Smoking reduction in lieu of complete abstinence  
Due to the low abstinence rates after NRT treatment, and a third of smokers reporting not 
being interested in quitting,(217) some experts have suggested that smokers who cannot quit 
smoking should be advised to reduce their smoking.(4) 
A greater than fifty-percent smoking reduction was thought to be a worthwhile goal for 
people who could not completely quit smoking because, at that point it was not possible for 
compensatory smoking to lead to the absorption of the same dose of toxicants from cigarette 
smoking as was absorbed during prior usual smoking, and is associated with improved 
cardiovascular risk factors and respiratory symptoms, and a twenty-five percent decline in 
biomarkers and incidence of lung cancer.(218) 
Etter and colleagues observed that when heavy smokers who had no intention of quitting 
within the next six months, were given information on the benefits of smoking reduction, and 
were randomised to receive six months of either NRT, placebo, or no treatment,(219) two 
years after starting the trial, the amount of smoking reduction was significantly greater in both 
the NRT and placebo groups compared to the no-treatment group.  Abstinence was rare in this 
trial, and was not significantly different between groups. 
A Cochrane Review identified thirteen trials of smoking reduction, and calculated that NRT 
significantly increased the odds of reducing smoking by half or more compared to placebo 
(OR=2.02, 95%CI:1.55–2.62); and significantly increased the odds of quitting (OR=1.90, 
95%CI:1.46–2.47).(220)  This review did not report the efficacy of nicotine patches, for 
smoking reduction, separately from other NRT, as many of the trials in the review gave 
subjects a choice of what NRT they used. 
In conclusion, the published evidence suggests smoking reduction is an effective method to 
engage heavy smokers, and those who do not intend to quit in the near future, in reducing 
their smoking, and if they use NRT this increases their self-efficacy and interest in quitting, 
and those who reduce their smoking by half or more expose themselves to less toxicants and 
have higher odds of quitting smoking altogether. 
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2.2.2.1.5 High-dose monotherapy 
The neurobiology of nicotine addiction suggests that administration of higher doses of 
nicotine may be more effective at reducing urges to smoke and other withdrawal symptoms, 
and that this is likely to translate into higher abstinence rates.  Higher doses may more 
effectively activate desensitised nAChRs to stimulate neurotransmitter release.  This 
hypothesis has been tested in clinical trials of high dose monotherapy, most commonly 
nicotine patch therapy, but a few trials have been conducted of high dose gum monotherapy.   
Side-effects are a considerable barrier to increasing the dose of monotherapy because side-
effects are dose-dependent and are often associated with the site of nicotine delivery.  A more 
tolerable way to achieve higher doses may be to use a combination of NRTs that use different 
routes of administration.  High dose monotherapy with patches and gum are outlined below, 
followed by a discussion of combination therapy.   
2.2.2.1.5.1 High dose patch 
High-dose (42mg) patch, but not the standard 21mg patch, reduced urges to smoke and cue-
elicited withdrawal symptoms following brief enforced abstinence.(26)  Standard-dose 
nicotine patches do not prevent acute urges to smoke, and do not control urges to smoke in 
response to conditioned cues to smoke.(201, 202) 
In 2012 a Cochrane Review identified eight trials that compared a high dose patch to standard 
dose (Analysis 7.1),(212) which showed the combined estimate of the effect of higher dose 
nicotine patch on long-term abstinence was small but statistically significant (RR=1.14; 
95%CI:1.01–1.29).     
The Transdermal Nicotine Study Group investigated abstinence rates achieved with three-
months of 7mg, 14mg, 21mg or placebo patches.  By twenty-four weeks only the abstinence 
rates for 21mg patch remained significantly higher than placebo, and after four years there 
was a trend for a dose-dependent effect of patches on abstinence.(221, 222) 
Higher doses of patches have been shown to be more effective than lower doses, but the use 
of higher doses is limited by their greater propensity to cause adverse effects.  This is 
especially concerning since 54% of people who use standard-dose of nicotine patches suffer 
skin irritation (although usually this irritation was mild).(212)  Also, in a trial of 42mg 
nicotine patches, a third of subjects suffered abnormal dreams, a quarter suffered nausea, and 
a sixth had dizziness.(23) 
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2.2.2.1.5.2 High dose gum 
The 2012 Cochrane meta-analysis found that long-term abstinence with 4mg gum was 
significantly higher compared to 2mg gum, among highly nicotine dependent smokers 
(RR=1.85, 95%CI 1.36—2.50); but there was no significant difference for smokers with a low 
nicotine dependence (RR=0.77, 95%CI 0.49—1.21).(212) 
This illustrates the need to tailor treatment to the nicotine dependence of smokers, as clearly 
there would be no benefit of giving 4mg gum to smokers who had a low nicotine dependence 
score, and to do so, might give them unnecessary adverse effects. 
2.2.2.1.6 Combination therapy 
There are several biologically plausible reasons to hypothesize that combination therapy 
would be more effective than monotherapy: 
1. By delivering nicotine via a combination of delivery sites, a high total dose can be 
absorbed by splitting the dose between several routes of administration so each route 
is exposed to a lower dose than the total dose, thus resulting in fewer dose-dependent 
adverse effects cf. delivering nicotine to one site. 
2. Each NRT has its own particular sensory effects, duration of action, side-effects, and 
impact on the day-to-day activities (such as drinking coffee since coffee is acidic 
which will reduce buccal absorption of nicotine).(223)  It may be the case, that use of 
combination therapy will enable people to use an NRT whose sensory, 
pharmacokinetic and adverse effects, are suited to the particular circumstances they 
find themselves in at any given moment in time. 
3. It may be the case that, a particular blend of pharmacokinetic profiles, which can be 
achieved by using more than one kind of NRT, may evoke a particular neurological 
response due to the variety of nAChR subtypes, which is effective at replacing 
nicotine from smoking cigarette and could not be achieved by the single 
pharmacokinetic profile of a monotherapy.  Although I am not aware of any evidence 
that supports or negates this possibility. 
4. Combination therapy enables people to choose the NRTs that suit their specific 
preferences, which may encourage people to use the NRT more often, thereby 
avoiding under-dosing, and improving cessation.(193)   
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5. The nicotine patch will deliver a baseline elevated level of nicotine, so that the rapid-
acting nicotine can reach therapeutic levels faster than if the rapid-acting NRT had 
been used as monotherapy. 
Evidence that higher abstinence rates could be obtained using a combination of NRTs was 
reported in three Cochrane meta-analyses.(27, 63, 212)  The most recent of these reviews 
found combination NRT was more effective than nicotine patch monotherapy by OR=1.43 
(95%CredibleIndex:1.08–1.91).  The lower end of the 95%CI of this meta-analysis is close to 
unity because some large trials did not find that combination therapy increased abstinence.   
Croghan and colleagues observed a less than additive improvement in abstinence with 
combination therapy (nasal spray plus patch) early-on cf. monotherapy but, by six-months the 
improvement was no longer statistically significant.(224)  Blondal and colleagues’ trial of 
nasal spray plus patch showed one of the greatest improvements in abstinence for 
combination therapy cf. monotherapy (one year abstinence OR=3.03; p=0.001), Table 
2.3.(67)  There are a number of differences between these two trials, that potentially explain 
why combination therapy was no longer superior at six-months in the trial by Croghan 
whereas the higher efficacy for combination therapy remained significant until at least one 
year in the trial by Blondal, such as: 
1. Croghan and colleagues gave subjects six weeks of therapy whereas Blondal and 
colleagues provided subjects with five months of patches and a year of nasal spray; 
2. Croghan’s trial was conducted in a nonspecialized outpatient clinical setting rather than 
a specialized academic setting.   
Table 2.3.  Abstinence outcomes of Blondal and colleagues’ trial of the combination 
nicotine nasal spray and nicotine patch therapy. 
Months Patch and nicotine spray Patch and placebo spray  
 % Proportion % Proportion OR, 95%CI, p-value 
6 31.4 37/118 16.0 19/119 2.40, 1.27-4.50, 0.005 
12 27.1 32/118 10.9 13/119 3.03, 1.50-6.14, 0.001 
72 16.2 19/117 8.5 10/118 2.09, 0.93-4.72, 0.08 
 
There are theoretical arguments both for and against combination therapy.  One argument is 
that the combination of slow plus rapid-delivery NRT reaps the advantages of both 
pharmacokinetic profiles.  Use of rapid-acting NRT would quench urges to smoke shortly 
after their onset before abstinent smokers lose their resolve; be more rewarding which may 
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motivate abstinent smokers to use NRT often enough to prevent under-dosing; provide rapid-
feedback to enable users to titrate their dose to achieve an optimal therapeutic index; and 
unlike slower-acting NRT would extinguish episodic urges that develop in response to 
smoking cues and situational contexts.(131, 225, 226)  Use of nicotine patches as well as a 
rapid-acting NRT, ensures a high nicotine blood concentration is maintained even if people 
forget to use the rapid-acting NRT as frequently as prescribed. 
There is an equally plausible argument that the combination of slow plus rapid-delivery NRT 
could be undesirable.  Slow delivery of nicotine from patches may lead to desensitisation of 
nAChRs, rendering them less responsive to nicotine from a rapid nicotine delivery device.  
Empirical evidence, from clinical trials, is required to determine which of the two potential 
biological mechanisms has the greater effect in vivo.  Further research is justified because the 
lower end of the Credible Index in the recent Cochrane review was close to showing no effect 
on abstinence for combination therapy (1.08). 
An informal search of Medline was conducted to identify trials that assessed the effect on 
abstinence of nicotine patch combination therapy cf. nicotine patch monotherapy, using the 
search term ((Patch$ adj3 nicotine) or (Transdermal adj3 nicotine)) and (combination.mp or 
DRUG THERAPY, COMBINATION/).  ADJx is an Ovid operator which searches for 
publications in which the words either side of the operator, occur within x number of words of 
each other.  The rationale for this search term was that nicotine patches are referred to in the 
literature sometimes as nicotine patches, and sometimes as transdermal nicotine, also, the 
word nicotine does not always immediately precede the words patch or transdermal, hence the 
use of the adj3 term will capture more of the desired publications; the latter part of the search 
term aims to detect only instances when nicotine patches are used in combination therapy, by 
requiring either the presence of the keyword “combination” or the subjects category “Drug 
Therapy, Combination”.  The use of a $ (wildcard) symbol at the end of the term patch 
ensured it would detect both the singular and plural of patch. 
This search strategy identified 117 reports published before subjects began to be recruited to 
the ZAP trial in 2010.  These 117 reports were scored for inclusion/exclusion, using a 
standardised scoring sheet.  For inclusion, a publication must report a trial that: 
1. was an RCT; 
2. gave one treatment group nicotine patches plus at least one other chemical-based 
treatment (not solely a behavioural intervention) and a comparator treatment group 
received nicotine patch therapy without the additional active therapy; 
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3. reported abstinence outcomes, not solely intermediary outcomes (such as smoking 
reduction, or cancer biomarkers); 
4. was in English. 
Twenty-one publications met these criteria and were included in the review (Table 2.4, page 
54).  Details of the study designs, outcome measures, and abstinence outcomes were extracted 
from the publications that met the criteria for inclusion in this review (Table 2.4)).   
The most common drug to be used in combination with patches was bupropion, which was 
tested in six trials, followed by nicotine lozenges in three trials, each of the following 
combinations with patches were tested by two trials per combination: mecamylamine, 
naltrexone, nasal spray,, and each of the following combinations with patches were tested by 
one trial per combination: citric acid inhaler, nicotine gum, inhalator, nortriptyline, 
paroxetine, rimonabant, and selegiline.  Two trials tested the effect of nicotine patches plus 
more than one drug therapy, one trial tested the combination of nicotine patch, nicotine 
inhalator and bupropion; another trial tested nicotine patch plus nicotine gum, bupropion and 
Cognitive Behavioural Therapy.   
A meta-analysis of these twenty-one trials was performed, using the rmeta package of the R 
language, which demonstrated that nicotine patch combination therapy significantly increased 
long-term abstinence rates by one-and-a-half times (29.06% cf. 19.06%; 95%CI:7.54%—
12.47%, OR=1.52, p=2x10-15, Figure 2.4, page 56 ).  To reduce the potential effects of 
heterogeneity between the trials, meta-analyses were performed on trials that were grouped 
according to the drug that had been added to nicotine patch therapy.  When the bupropion plus 
patch trials were submitted to meta-analysis, the combination had higher abstinence rates cf. 
patch monotherapy or patch plus placebo (OR=1.87, p=1x10-7).  Meta-analysis of the trials of 
NRT plus patch found that these combinations significantly increased abstinence cf. patch 
without NRT (OR=1.33, p=0.0006), and the test for heterogeneity calculated Χ2=5.03, 





Table 2.4 Literature review and meta-analysis of trials of combination nicotine patch therapy cf. monotherapy. 
Trial first Author 
Trial title 
(first few word) 
Other treatment 
added to patch 














OR p value † 
George TP A placebo-controlled 
trial of bupropion  
bupropion placebo plus patch uncertain 26 weeks‡ 4 29 0 29 NA 0.0382 
Killen JD Randomized clinical 
trial of the efficacy 
bupropion combined  
bupropion 
nicotine patch plus 
placebo 
7-day PP CO verified 26 weeks‡ 16 103 21 108 0.80 0.4553 






? Continuous abstinence 6 months‡ 12 95 2 138 8.72 0.0004 





7-day PP  6 months ‡ 95 245 52 244 1.82 3x10-5 






7-day PP  26 weeks ‡ 22 63 12 64 1.86 0.0396 
Westman EC Airway sensory 
replacement  




10 weeks ‡ 8 41 4 59 2.88 0.0540 
Rose JE Nicotine-
mecamylamine  




26 weeks ‡ 8 20 4 20 2.00 0.1675 
Rose JE Mecamylamine 
combined  




26 weeks ‡ 9 24 3 24 3.00 0.0455 
O'Malley SS A controlled trial of 
naltrexone 
augmentation  




6 weeks 53 103 36 93 1.33 0.0735 
Krishnan-Sarin S Naltrexone and 
nicotine patch  
naltrexone nicotine patch + 
placebo 
Continuous abstinence  4 weeks 9 16 5 16 1.80 0.1540 
Wong GY A randomized trial of 
naltrexone  
naltrexone nicotine patch + 
placebo 
Continuous abstinence  24 weeks 9 26 8 25 1.08 0.8430 
Croghan GA Comparison of 
nicotine patch alone  
nasal spray A. nicotine patch 
monotherapy; B. 
nasal spray  
7-day PP CO verified 6 months ‡ 42 462 36 459 1.16 0.4965 
Blondal T Nicotine nasal spray 
with nicotine  
nasal spray nicotine patch + 
placebo 
Continuous not a puff, 
CO verified 
6 months ‡ 37 118 19 119 1.96 0.0053 
Evins AE A 12-week double-
blind, placebo-
controlled study of  
nicotine gum, CBT, 
bupropion 
nicotine gum, CBT, 
nicotine patch Continuous CO verified  3 months 5 25 2 26 2.60 0.2017 
Smith SS Comparative 
effectiveness of 5 
smoking  
nicotine lozenge nicotine patch mono-
therapy 
7-day PP not 
biochemically verified 
24 weeks 75 279 50 282 1.52 0.0092 
Piper ME A randomized 
placebo-controlled 
clinical trial of  
nicotine lozenge nicotine patch mono-
therapy 7-day PP 6 months ‡ 104 267 90 262 1.13 0.2723 
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Trial first Author 
Trial title 
(first few word) 
Other treatment 
added to patch 














OR p value † 
Cooney NL Smoking cessation 
during alcohol 
treatment 
nicotine gum nicotine patch plus 
placebo 
Prolonged not smoked 
on 7 consecutive days or 
2 consecutive weeks 
6 months ‡ 9 45 6 51 1.70 0.2674 
Prochaska 
A randomized trial of 
nortriptyline 
combined  
nortriptyline nicotine patch plus 
placebo 
Prolonged 6 month 
“abstinence” 1, 
biochemically verified 
6 months ‡ 18 79 8 79 2.25 0.0319 
Killen JD Nicotine patch and  paroxetine nicotine patch alone 7-day PP, CO verified 6 months ‡ 27 75 22 74 1.21 0.4153 
Rigotti NA A randomized 
controlled trial of 
adding the nicotine 
patch. 
rimonabant rimonabant plus 
placebo patch 7-day PP not 
biochemically verified 
24 weeks 156 369 104 366 1.49 6x10-5 
Biberman R A randomized 
controlled trial of 
oral. 
selegiline nicotine patch plus 
placebo Continuous 26 weeks 14 56 6 53 2.21 0.0652 
   
All trials 732 2540 490 2591 1.52 2x10-16 
   Trials of Bupropion combinations 149 535 87 583 1.87 1x10-7 
   Trials of NRT combinations 267 1171 201 1173 1.33 0.0006 







Figure 2.4 Forrest Plot of trials that compared nicotine patch monotherapy to nicotine 
patch combined with other NRT published prior to mouthspray study 
 
2.2.2.1.7 Duration of therapy 
Two Cochrane Reviews concluded that extending the duration of nicotine patch therapy did 
not significantly increase abstinence.(27, 212)  This lack of an effect may be because of poor 
adherence to using patches for the full duration of treatment.(227)   
2.2.2.2 Novel therapies 
In recent decades there have been efforts to develop novel nicotine delivery methods, that 
avoid the harmful components of tobacco smoke, and which are more rewarding than 
conventional NRT.  Such nicotine delivery methods include  
1. rapid dissolution nicotine lozenges and nicotine films; 
2. nicotine mouthsprays such as Zonnic and the very similar Nicorette QuickMist;  
3. electronic cigarettes;  
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4. Igor Gonda’s AERx Essence inhaler that uses bespoke air-classifier technology but 
was never commercialised,(228)  
5. the pMDI inhaler nicotine free-base formulation developed by Myrna Dolovich and 
colleagues which was utilized in this dissertation to measure its pharmacokinetics, 
tolerability, and effect on urges to smoke compared to smoking a cigarette,(229)  
6. the pMDI formulation developed by David Lechuga-Ballesteros, Mei-Chang Kuo and 
colleagues,(230) which used organic acids to reduce the pH of nicotine, and was tested 
in the INHALE clinical trial within this dissertation.   
7. The nicotine pyruvate inhaler investigated by Jed Rose, which uses air-classifier 
technology to utilise the user’s breath to suck nicotine free-base vapour into pyruvic 
acid vapor, thereby forming a respirable nicotine pyruvate vapour.(231) 
8. A nicotine free-base inhaler called Voke which is manufactured by British American 
Tobacco and contains nicotine free-base, ethanol, menthol, propylene glycol and 
saccharin.(232)   
Of these products, electronic cigarettes have had the most widespread influence on smokers, 
hence electronic cigarettes are the only novel product discussed below. 
2.2.2.2.1 Electronic cigarettes 
This sub-chapter briefly describes electronic cigarettes, but does not go into detail because 
they are not manufactured to a pharmaceutical grade, whereas the focus of this dissertation 
was on medicinal nicotine delivery.  Electronic cigarettes (e-cigs) use energy from a battery to 
heat a metal coil, thereby causing liquid nicotine and excipients to volatilise into a mixture of 
gas and small droplets, which are capable of being inhaled.(233)  E-cigs were initially 
developed in secret by Philip Morris in the 1990s,(234) then in 2003 Hon Lik independently 
invented the design of an e-cig and since then e-cigs have spread globally.(235)  E-cig 
technology has rapidly evolved to the point that the safety and efficacy profiles of first-
generation devices are likely to differ greatly from third-generation devices and more modern 
devices which heat the e-cig liquid to higher temperatures which may degrade their chemical 
contents.(236) 
Two meta-analyses of placebo-controlled RCTs found that nicotine e-cigs significantly 
increased abstinence rates.(237, 238)  However, a population survey, found that the rate of 
quitting smoking was the same for people who had, and those who had not, tried e-cigs.(235)  
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Although the long-term safety of e-cigs is unknown, they are likely to be many orders of 
magnitude safer than smoking.(239)  However, newer generation e-cig have much more 
powerful batteries and heat the e-cig liquid to higher temperatures, and as a result, may have 
much higher levels of toxicants in their vapour than older types of e-cigs.(240) 
The pros and cons of the pMDI compared to e-cigs will be discussed further in the pMDI 
chapters of this dissertation (Chapters Nine to Twelve). 
In conclusion, new nicotine delivery devices have been developed with the aim of improving 
quit rates and acting as better substitutes for smoking.  Electronic cigarettes have arguably had 
wide appeal among smokers and have assisted many to quit however, they have several 
disadvantages, not least of which is their unknown long-term safety, and new alternative 
products are required. 
2.3 Methodological considerations 
The scientific method was developed to maximise the likelihood of uncovering the truth, and 
minimising potential sources of error and bias, by deriving all conclusions from observation, 
from empirical evidence, which is patent to all, and indeed is reliably repeatable by all.  In the 
two large RCTs within this dissertation, in order to maximise the validity of the results, 
particular attention was paid to the integrity of the blind, use of credible placebos for the 
control groups, measurement of potential confounding variables and statistical adjustment of 
the results by the effects of those confounders and effect-modifiers.(241)  A variable may 
confound the estimate of the effect an intervention has on an outcome, if the variable is 
correlated with both the outcome and the receipt of the intervention.   
2.3.1 The role of blinding 
Issues related to blinding of treatment allocation in general are outlined below, then these 
issues are discussed in relation to NRT trials.  This is followed by a description of six NRT 
trials that observed unmasking and the issues they raised.  Subsequently, a trial that 
manipulated subjects’ beliefs about their treatment assignments is reported.  This sub-chapter 
concludes with a description of methods that have been suggested to prevent failure of the 
blind and to avoid bias when the mask no longer conceals subjects’ assignments. 
2.3.1.1 The purpose of blinding 
Blinding of subjects, research staff, and statisticians, to subjects’ treatment assignments, and 
the mechanism by which subjects are assigned to treatment, is vital to minimise bias, such as 
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selection bias, performance bias, detection bias, attrition bias, expectancy bias and response 
bias.(242, 243)  Selection bias occurs when the process of choosing who will, and who will 
not, be enrolled into a trial, leads to enrolment of subjects who collectively are not 
representative of the population being studied, and also occurs when the process by which 
subjects are assigned to treatment is not random and consequently baseline confounders are 
not randomly distributed between treatment groups.  Detection bias may occur if the method 
by which outcomes are measured is systematically different between treatment groups.  
Attrition bias may occur if subjects who drop out of a trial are systematically different from 
those who remain in the trial and if the reasons for drop-outs are significantly different 
between treatment groups.  Expectancy bias may occur if the anticipations that researchers or 
subjects have about the outcome, have an influence on that outcome and differ between 
treatment assignments.  Response bias refers to the inaccuracies that occur when subjects 
report outcomes that are inaccurate or untrue, and if the extent to which this occurs differs 
between treatment assignments.    
Bias from inadequate allocation concealment can have a considerable effect on the estimate of 
the treatment effect, with a meta-analysis finding that unblinded trials had on average a 
statistically significant thirty percent more favourable estimation of treatment effect than trials 
with adequate allocation concealment.(242)  The use of a placebo in the control group, rather 
than not giving that group an intervention, may help to maintain the blind of subjects and 
research staff. 
Blinding of subjects may help to protect the power of the placebo effect.  If subjects know 
they are in the placebo group, or are aware they are using a therapy that may be ineffective or 
less effective, then their expectancy of treatment success may be lowered, and they may be 
unlikely to gain a beneficial placebo effect – if anything, they may become despondent and 
worse off than if they had received no treatment (a nocebo effect).   
2.3.1.2 Appropriate placebo to maintain blinding 
A placebo may be considered to be effective if it inspires the majority of people who take it, 
to think that it is the active treatment.  This requires the placebo to be sufficiently 
“believable”, in other words, its appearance and sensory effects should make it seem like it 
could be an active therapy.  A sufficiently “believable” placebo may ensure that the control 
group has similar expectancies as the active group, and therefore are likely to experience the 
same placebo effect that subjects in the active group experience.(244)  If the placebo effect 
has the same effect on the outcomes, in both the active and control groups, then the placebo 
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effect will be removed from analyses that compare the outcomes between the two groups, 
whereas, if the placebo effect was stronger in one group compared to the other, the placebo 
effect will remain and contaminate the estimation of the effectiveness the active intervention 
relative to the control intervention.   
Use of a “believable” placebo may also help to minimise response bias, in which subjects 
report what they think will please researchers because, if subjects are blind to their treatment 
assignment, then the types of response subjects think will please researchers, is likely to be 
similar in all treatment groups.  Not only does the placebo need to be “believable”, the 
placebo must have an identical appearance as the active treatment in order to maintain the 
integrity of the blind of research staff. 
2.3.1.3 Causes of unblinding and method to determine if unblinding led to bias 
There are a number of aspects of trial design and conduct which can potentially cause 
unwitting unblinding of subjects and researchers, and although there are methods to mitigate 
this, it has been argued that, particularly in trials in which the therapeutic and/or side-effects 
of the active and/or placebo treatments are observable to the subjects and/or researchers, it 
may not be possible to conduct a truly blind trial, and the effect that unmasking the treatment 
assignment has on the treatment outcome, should be accounted for and adjusted for in the 
analysis.(245)  For instance, simply being aware of which side-effects a subject suffered has 
been sufficient to unmask research staff.(246)  Hughes and Krahn argued that subjects must 
be asked what they think their treatment assignment is, and if subjects’ guesses of their 
treatment assignments are more accurate than would be expected by chance, it is essential to 
determine if this had led to bias of the treatment outcome.(245)  Hughes and Krahn suggest 
that whether or not unmasking led to bias, can be determined by measuring the difference in 
the magnitude of the treatment effect in three groups of subjects: subjects who correctly 
guessed their treatment assignment; subjects who incorrectly guessed their treatment 
assignments; and subjects who were unsure of their treatment assignment; if the magnitude is 
the same in all three subgroups there is no bias.   
2.3.1.4 Unblinding in NRT and smoking cessation trials 
Trials of NRT and other smoking cessation therapies, such as bupropion, are particularly 
prone to failure of allocation concealment because the treatment effects of nicotine (and 
bupropion), and the symptoms of the nicotine withdrawal syndrome, are clearly felt by 
subjects, also, some subjects are familiar with the side-effects of these medications, either 
from prior personal experience, the public reputation of the medications, or reading the 
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study’s information sheet.  Moreover, research staff may clearly observe subjects’ affective 
responses to the NRT/placebo, and their visible and audible side-effects, which may give 
strong clues as to the treatment allocation.  Indeed, a review of seventy-three double-blind, 
placebo-controlled clinical trials of NRT found that only seventeen (17/73, 23%) studies 
assessed blind integrity, and of those seventeen studies, twelve reported that the odds of 
participants correctly guessing their drug assignment were better than chance, and the three 
trials that had adjusted their estimation of the effect of the active intervention on abstinence 
by the blind/un-blind status of subjects, found that the adjustment did not alter the size of the 
treatment effect.(247)   
I found six NRT trials that observed unmasking, one of which led to bias,(248) two which did 
not lead to bias,(249, 250) three that observed unmasking and did not report if this led to bias 
in the assessment of the treatment effect (there are only two citations for these three trials 
because two trials were reported in the same publication).(42, 251)     
2.3.1.5 Methods to avoid unmasking and to avoid bias from unmasking 
A variety of methods have been suggested to avoid unmasking of subjects and research staff.  
The possibility has been raised of using an intervention in the control group that mimics the 
side-effects of the active drug, such as giving the control group the same drug given to the 
active group, but at a dose low enough to be less effective yet high enough to produce side-
effects similar to those known to be caused by the drug given to the active groups and which 
were disclosed to subjects as part of informed consent.(246, 247, 253, 254)  A further method 
to reduce the likelihood that subjects will be unmasked, is to add irrelevant symptoms (that 
are not side-effects of the treatments given to either treatment group, some of which are 
commonly experienced by healthy people in everyday life, and some which are rarely 
experienced) to the list of side-effects in the informed consent form, and to the list of side-
effects that subjects are asked to rate their experience of throughout the trial, so that subjects 
in the active group are not more likely to think they are in the active group simply because 
they have suffered many of the side-effects that they are asked to rate, and so that subjects in 
the placebo group do not think they are on placebo simply because they have suffered none of 
the side-effects that they are asked to rate.(254)  
2.3.1.6 Accounting for unblinding 
As was mentioned above, Hughes recommended that subjects should be asked what treatment 
they think they received, to check whether the integrity of the blind had been maintained, 
which can be accomplished by assessing if subjects’ guesses were significantly more likely to 
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be correct than incorrect.(245)  Hughes also recommended that the potential for unblinding to 
bias the estimate of the size of the treatment effect, should be assessed by determining if the 
magnitude of the treatment effect differed between subjects who correctly guessed their 
treatment assignment compared to those who were truly blind because they guessed 
unsure.(245) 
2.3.1.7 Conclusion 
In summary, unblinding can still occur and can bias estimates of the treatment effect, despite 
keeping the treatment allocation secret from subjects and research staff, and regardless of 
whether a placebo is given to the control group.  The methods used to maintain blinding in the 
trials upon which this dissertation is based, and the analyses of whether unblinding occurred 
and whether it biased the estimates of the treatment effect, are outlined below in the chapters 
on each trial.   
2.3.2 Appropriate comparator treatment for the control group 
As has been mentioned above, the treatment that the control group receives, needs to be 
capable of being perceived as being a genuinely effective treatment, rather than an obviously 
sham intervention, in order for it to provide subjects in the control group with a similar 
placebo effect and similar expectancies, to what the active group experience and also, to 
ensure that the rate of loss-to-follow-up, withdrawal of consent, and poor treatment 
adherence, caused by subjects’ beliefs that the intervention is ineffective, are similar between 
active and control groups.  
Treatment adherence can have a substantial impact on the efficacy of the treatment, and given 
that perceived lack of efficacy may play a substantial role in subjects not taking a treatment as 
often as required or, for as long a duration of time as required, it is likely that a placebo which 
is readily perceived as inert would not be taken as often as required, and this poor treatment 
adherence may bias the estimate of the treatment effect.(243, 255)     
The placebo treatments used in the trials upon which this dissertation is based, were designed 
to look identical to their equivalent active treatments and to have sensory and adverse effects 
that matched those of the active treatments as closely as possible.  This was perhaps most 
thoroughly achieved in the ZAP trial, in which capsaicin was added to the placebo 
mouthspray, along with the same menthol flavouring as was in the active treatment, in order 
to match the burn of nicotine and the menthol flavour of the active mouthspray.  Indeed, 
capsaicin produces similar sensory effects to cigarette smoking, and reduces smokers’ urges 
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to smoke.(256)  Although it was not possible to add a similar irritant as capsaicin, to the 
placebo pMDI, because of safety concerns, nonetheless, the placebo pMDIs looked exactly 
the same as the active pMDIs, and had sufficient menthol to mildly irritate the oropharynx.  
Hence the placebo treatments were likely to engender similar placebo effects, and 
expectancies of efficacy, as the active treatments.   
In both the mouthspray and pMDI RCTs, subjects in both treatment groups were given active 
transdermal nicotine which may have alleviated some of their nicotine withdrawal symptoms 
and this may have assisted subjects in the placebo groups to believe that they had been 
assigned to the active condition.  Subjects in the trials upon which this dissertation is based 
were asked to rate the sensory and psychological effects of the treatments they received and to 
guess their treatment assignment, which was taken into account in the analyses of the 
treatment effects for both trials. 
The comparator intervention, in both the mouthspray and pMDI RCTs, was active patch plus 
placebo which, but for the placebo, is monotherapy.  The active rapid-acting NRTs plus patch 
combination therapies in INHALE and ZAP, were therefore effectively being compared to a 
monotherapy, despite a substantial body of research having demonstrated that for many 
NRTs, combination therapy is more effective than monotherapy.  However, the only way to 
compare the active combination therapy to a placebo combination therapy, while maintaining 
blinding by giving subjects in both groups therapies that looked the same, would be to give 
the control group a placebo version of the active rapid-acting NRT (inhaler or mouthspray), 
give active NRT (should this be a lozenge, or gum?) plus active patch to the control group so 
that this group gets combination therapy;, and give the active group the active 
inhaler/mouthspray, active patch, and an active or placebo version of the second NRT given 
to the control group in addition to the nicotine patch.  In the end, the simplest option was 
chosen, in an effort to maximise subjects’ adherence to the treatments.   
2.3.3 Analysis of the results: statistical considerations 
Generalised Linear Models (GLM) were used to determine if associations between variables 
were of a causal nature.  For the binary outcome of abstinent/not-abstinent, a particular type 
of GLM was used, known as logistic regression or as binomial GLM.  After fitting a GLM to 
the data, it is necessary to check that the GLM meets the assumptions of the mathematics 
underlying GLM.(257)  The assumptions of GLM are: 




2. The dependent variable does not need to be normally distributed, but it often 
assumes a distribution from the exponential family (for instance binomial, Poisson, 
multinomial, normal). 
3. GLM does not assume a linear relationship between the dependent variable and the 
independent variables, but it does assume a linear relationship between the 
transformed response in terms of the link function (which in the case of GLM is 
the logit) and the explanatory variables; for example, for binary logistic regression 
logit(π)=β0+βX. 
4. Independent variables are allowed to be the power terms or some other nonlinear 
transformations of the original independent variables. 
5. The homogeneity of variance does not need to be satisfied. In fact, it is not even 
possible in many cases given the model structure, and overdispersion may be 
present (overdispersion refers to when the observed variance is larger than what 
the model assumes).  
6. Errors need to be independent but are not required to be normally distributed. 
7. GLM uses maximum likelihood estimation (MLE) rather than ordinary least 
squares (OLS) to estimate the parameters, and thus relies on large-sample 
approximations. 
8. Goodness-of-fit measures rely on sufficiently large samples, where a commonly 
used rule is that not more than twenty percent of the expected cells counts are less 
than five. 
Typically, clinical trials of NRT, use the simple unadjusted chi-squared test, to determine if 
abstinence rates differed significantly between treatment groups.  This gives the simplest 
estimate of the treatment effect, which can be compared to analyses that adjust the estimate of 
the treatment effect by various variables, in the hope that this will reduce bias and not 
introduce it.   
Missing abstinence outcome data must be imputed in order to include subjects with missing 
data in analyses and avoid bias (unless their data are imputed, they will be left out of the 
analysis, and the subjects whose data are not missing and who therefore remain in the analysis 
may not be a random sample of the subjects who were randomised to treatment at their 
commencement of the study).  This is outlined in detail under the heading “Intention-to-treat 
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versus per-protocol” below.  The effect of various methods of imputation was tested in 
analyses of the RCTs in this dissertation.  
In this dissertation exact p-values are reported rather than whether they were below thresholds 
such as p<0.01.  The rationale for this is that many analyses were conducted, and in order to 
adjust for multiple comparisons with Bonferroni correction, it is helpful to know the exact p-
value.  For instance, if the p-values are reported as p<0.001; then if one wishes to accept as 
significant, only comparisons with p<0.05/10=0.005 (Bonferroni correction for ten 
comparisons), then one will potentially reject as insignificant all comparisons whose 
significance was p≥0.001, including comparisons whose significance is 0.001≤p<0.005. 
This dissertation focusses on determining whether the results of statistical tests are 
statistically significant, by whether their p-values are below the threshold of 0.05 and uses 
Bonferroni correction to account for multiple comparisons.  There has been controversy about 
these approaches, which led the American Statistical Association (ASA) to publish a 
statement that gives guidance on the use and interpretation of p-values.  The statement was 
authored by Wasserstein and Lazar and was published below an editorial also written by 
Wasserstein and Lazar.(258)  The editorial begins by raising the issue that many people use 
the cut-off of p<0.05 for statistical significance simply because that is the standard approach, 
without understanding the statistical arguments that underlie this method.  The editorial cites 
four articles published in the popular press and in blogs, that claim there are many flaws with 
null hypothesis testing, two by Siegfried,(259, 260) and the other two by Cummings(261) and 
Leek(262)  Also cited, is a paper by Nuzzo published in Nature.(263)  The issues of the 
misuse and misunderstanding of p-values and the need for scientific endeavours to be 
reproducible are raised in the editorial.   
The controversy about the use and interpretation of p-values was evident in the fact that it 
took many months for the expert group convened by the ASA, to reach consensus about the 
wording of the ASA Statement.  The Wasserstein and Lazar editorial mentions the issue of 
how to handle multiple comparisons and cites Gelman’s and Loken’s 2014 article in 
American Scientist in this regard.(264)  The editorial goes on to state that the authors of the 
statement considered Johnson’s claim in his 2013 paper(265) that a p-value that is close to 
0.05 offers only weak evidence that the null hypothesis should be rejected.  The editorial 
makes note of the article by Greenland and colleagues which is a guide to misinterpretations 
of statistical tests of significance.(266).  The ASA statement, gives a non-technical definition 
of what a p-value is, and states that scientific conclusions should not be based solely on 
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whether a p-value crosses a specific threshold but, rather, many contextual elements should 
also be considered in conjunction with the p-value, such as study design.   
The ASA statement also points out that the size of the p-value is not always correlated with 
the effect size nor its human significance, hence even though a test has a very small p-value, 
its OR may be close to unity.  The aforementioned paper by Nuzzo(263) refers to a study 
whose conclusions had a significance of p=0.01 but which had a significance of p=0.59 when 
the trial was reproduced, Nuzzo traces the development of the p-value by Fisher in the 1920s, 
and concludes that whether a p-value is below a threshold, is but one measure of statistical 
significance and other factors must be taken into account alongside the p-value.  Nuzzo, 
Cumming and Gelman argue that it is necessary to accompany p-values with the OR and 
95%CI in order to give additional information about the statistical significance and effect size.  
Clearly, there are limitations to the certainty that a small p-value can provide, and other 
considerations must be taken into account, but p-values continue to play an important role in 
determining statistical significance.(266) 
There has been substantial debate about how to control for multiple comparisons and whether 
they are best corrected by the convention method known as Bonferroni adjustment.  If the 
decision, about whether a test is significant, is based on whether the p-value is below a certain 
level (known as the alpha, which is the probability of making a type I error [incorrectly 
rejecting the null hypothesis]); then, if multiple tests have been conducted, each test having 
the probability of a type I error, then, if alpha is set to the traditional value of 0.05, after 
twenty tests, one test is likely to have a p-value that is <0.05 by chance.  This led to the 
technique of Bonferroni correction, in which alpha is set at 0.05 and divided by the number of 
comparisons, thereby getting smaller in proportion to the number of comparisons, setting an 
increasingly stringent requirement that p-values must meet in order to be considered 
statistically significant.  This creates a problem for research that investigates the association 
of genetic markers and disease, which test such a large number of associations, that the alpha 
set by Bonferroni comparisons would be so small that it is possible that a real association may 
be deemed as not statistically significant.  This led to Bayesian approaches to handle multiple 
comparisons, such as a method reported by Jon Wakefield(267) which was discussed in an 
editorial by Sander Greenland.(268)  Greenland points out that Bonferroni adjustment 
focusses on avoiding falsely rejecting the null hypotheses at the expense of potentially 
incorrectly accepting the null hypothesis, while Bayesian approaches focus on avoiding the 
incorrect acceptance of the null hypothesis.   
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The conservative method of Bonferroni adjustment has been used in this dissertation, with the 
understanding that the potential for this to lead to incorrectly deciding that associations are 
not statistically significant, is best addressed by further research that focusses on those 
associations and is sufficiently powered to adjudicate on their statistical significance, by use 
of the new data gained from the new trial, rather than Bayesian techniques. 
2.3.3.1 Definitions of Abstinence  
A variety of definitions of abstinence have been promulgated.  The reason why the definition 
of abstinence is not self-evident, is that addiction to smoking tobacco is a chronic relapsing 
disease, and relapse could occur at any time during or after treatment, yet it is not practicable 
to follow subjects up indefinitely to determine their final abstinence status.  Furthermore, only 
a small minority of subjects will completely abstain from smoking and the effect size of 
smoking cessation treatments are not large, so big sample sizes are required to find 
statistically significant effects between therapeutic modalities if strict definitions of 
abstinence are used which few people can achieve; for example, to detect a doubling of 
abstinence rates from forty percent to eighty percent with an alpha of five percent and power 
of eighty percent with an uncorrected chi-square test requires twenty-two subjects in each 
treatment group; whereas to detect a doubling of abstinence from five percent to ten percent 
requires a sample of 435 subjects in each group under the same conditions.  Hence, by using 
less strict definitions of abstinence, that a greater proportion of subjects will be able to satisfy, 
it is possible to save time and resources by enrolling fewer subjects but still retaining 
adequate statistical power.   
Since there is no safe level of smoking,(269, 270) the goal of treatments is to aid smokers to 
become completely smoke-free, so ideally there would be evidence that the definition of 
abstinence used in trials is highly predictive of long-term complete abstinence.  In response to 
the aforementioned issues, several definitions of abstinence have been formulated.   
In 2003, a working party of the Society for Research on Nicotine and Tobacco (SRNT), led 
by John Hughes, published recommendations for the abstinence outcomes that trials of 
smoking cessation therapies should report.(68)  It was recommended that trials should report 
multiple measures of smoking abstinence; and that:  
• The primary outcome should be prolonged abstinence after an initial grace period in 
which lapses to smoking a few cigarettes early on do not count as a failure. 
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• Point prevalence abstinence (not smoked even a puff during a period of seven days 
measured at regular time-points such as at one and three months after the target quit 
date) should be reported as secondary outcomes.  Point prevalence definitions should 
consider smoking even a puff the same as having smoked a whole cigarette. 
• Subjects should be counted as failures if they smoke on seven or more consecutive 
days or smoke in two consecutive weeks.  Hughes and colleagues stated that his 
working party did not recommend the use of the criterion that subjects must not have 
smoked even a puff of a cigarette at any time after the target quit date in order to be 
counted as abstinent because, that is overly stringent since it counts as failures long-
term abstainers who have had a single slip.   
• Hughes and colleagues stated that terms like ‘prolonged abstinence’, and especially 
‘continuous abstinence’, have often been assumed to refer to absolutely no smoking.  
In contrast, these terms should only be used to indicate that the definition of relapse or 
failure has not been met. 
• Survival analyses should be reported to more fully describe the failures. 
• Continued use of NRT should not count as a failure, but the use of any tobacco, even 
if it is not in the form of a cigarette, should be counted as a failure. 
• A Lapse is defined as smoking a few cigarettes. 
• A Relapse is defined as a return to regular smoking (that is, having smoked on seven 
consecutive days or in two consecutive weeks). 
• A grace period is a period immediately after the treatment or scheduled quit date, in 
which smoking is not counted as a failure. 
• A grace period of two weeks should be used, depending on the nature of the treatment. 
• Failure is defined as an outcome other than the goal of the treatment. 
• Prolonged abstinence is defined as not meeting the definition of failure between the 
end of the grace period and the follow-up. 
• Continuous abstinence is defined as not meeting the definition of failure between the 
target quit date and the follow-up.   
• The term ‘sustained abstinence’ should not be used. 
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• Aid-to-cessation trials should follow subjects for six to twelve months after the target 
quit date, which should include at least three months after the end of treatment. 
• Proof-of-concept trials may provide only three months of treatment and stop follow-up 
at the end of treatment. 
In 2005 the Russell Standard was published to overcome a perceived lack of clarity in the 
2003 SRNT guidelines, and to limit the range of confusing abstinence outcomes reported in 
trials that were included in Cochrane Reviews.(271)  There are six components of the Russell 
Standard: 
1. Duration 
a. Two duration options: RS6: six-months of smoking status follow-up, or RS12: 
twelve-months of smoking status follow-up.    
b. Abstinence can be timed from the designated quit date, or can allow a 
predefined grace period.  Because it can be difficult to collect follow-up data 
on the exact date that they are scheduled to be collected (for example if 
subjects do not attend a follow-up visit on time), it is allowable to collect data 
up to four weeks after they were supposed to be collected, but not before they 
was supposed to be collected. 
c. Once subjects have met the failure definition they can be censored without 
regard to the final follow-up. 
2. Abstinence 
a. A subject is classified as abstinent if he or she has not smoked more than five 
cigarettes from the start of the abstinence period till the final follow-up, and if 
there is biochemical verification of no recent smoking. 
3. Biochemical verification 
a. At final follow-up, if the abstinence has not been biochemically verified, then 
the person should be counted as a failure. 
b. If exhaled carbon monoxide (CO) is nine (ppm) or less this indicates 
abstinence, even if the reason it is higher is because one of the allowable 




a. All randomised subjects should be included in the denominator for calculating 
abstinence rates except where LTFU is unavoidable because: 1. the subject 
died; or 2. the subject moved to an untraceable address. Subjects who decline 
to attend are counted as failures. 
5. Protocol violators should be classified in their original treatment group and included in 
the analyses. 
6. Follow-up should be conducted by staff members who are blind to the subjects’ 
treatment assignment. 
In 2009, Aveyard and colleagues published an abstinence outcome, termed ‘floating 
prolonged abstinence’, which is sufficiently flexible to capture the effects of cessation-
induction trials.(272)  These trials enrol subjects who are not willing to set a target quit date in 
the near future but, are willing to take therapy and be open to the possibility that they might 
set a target quit date in the longer term.  Floating prolonged abstinence allows the start of the 
abstinence period to occur at any time in the follow-up period, but necessitates a sufficiently 
long duration of follow-up to allow ideally at least six months of abstinence to be observed. 
Although I was unable to locate any criticisms of the Russell Standard in the published peer-
reviewed literature, it is his view that the Russell Standard has several important limitations 
compared to the SRNT definitions.  By focussing on the exact number of cigarettes smoked, 
rather than the regularity of smoking, it is not possible to biochemically validate abstinence in 
someone who claims not to have smoked more than five cigarettes but smoked one cigarette 
just prior to their follow-up clinic visit, and it is less suited to measuring outcomes for non-
daily smokers.  It seems unfair to allow for up to five cigarettes to be smoked, but then require 
that none of those five cigarettes should be smoked in the eight hours prior to follow-up when 
exhaled CO will be measured.   
The Russell Standard of abstinence also seems to be a heterogenous outcome because, in 
order to be classified as abstinent, a regular smoker of twenty CPD must reduce his or her 
smoking, between the end of a two-week grace period and final six month follow-up, by at 
least 99.86% from 3,640 cigarettes to a maximum of five cigarettes; while a regular smoker of 
one cigarettes per week must only reduce his or her smoking by at least 19.23% from twenty-
six to five cigarettes.  A further potential downside to the Russell Standard is that subjects 
may possibly find it easier to remember broad general outcomes like whether they had 
smoked every day for seven days in a row cf. the exact specific number of cigarettes they had 
smoked between one follow-up and the next, a period of time that may be as long as three 
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months.  For example, it is possible that a smoker may find it easier to remember how often 
they became intoxicated with alcohol and smoked, than to remember how many cigarettes 
they smoked while they were intoxicated with alcohol. 
Taking into account the simplicity of the SRNT abstinence definitions, the ease with which 
subjects may recall whether they have met the definitions, and the scope the SRNT definitions 
leave for subjects to lapse but redeem themselves, Professor Julian Crane and I, decided to use 
the SRNT definitions of abstinence in the trials upon which this dissertation is based.  The 
Russell Standard has subsequently superseded the SRNT abstinence definition and is the one 
used in research conducted after the Russell Standard was published by West and colleagues 
in 2005. 
2.3.3.2 Intention-to-treat versus per-protocol 
Intention-to-treat analysis (ITT) includes data from all subjects who were randomised to 
treatment, and analyses subjects in the original group to which they were randomised, 
regardless of all other considerations, such as protocol violations.  Examples of protocol 
violations include, subjects who use the treatment for a group to which they were not 
assigned; failure to provide subjects with the full course of treatment; subject non-adherence 
(failure of subjects to use the treatment correctly, or use it often enough, or failure to use any 
of the treatment at all); enrolment of subjects who did not meet the inclusion criteria; subjects 
who withdraw from the study or who were lost-to-follow-up.  Including protocol violators in 
the analyses ensures that the reasons for the protocol violation do not confound the analyses. 
There are some instances when it may be justified to modify the intention-to-treat approach.  
For example in time-to-event trials it may be justifiable to censor subjects and not follow 
them up after they have experienced the primary outcome (such as having met the definition 
of failure of prolonged abstinence), however this provides an ITT analysis only for the 
primary outcome, not for the secondary outcomes that are measured towards the end of the 
trial follow-up (such as point prevalence abstinence and rates of adverse events in the seven 
days prior to final follow-up).(273)   
The principal advantage of ITT analysis is that it preserves randomisation, whereas per-
protocol analysis breaks the randomised nature of a RCT.  ITT is a conservative approach 
because it biases the estimate of treatment effect towards the null hypothesis, whiles per-
protocol analyses may bias the findings towards or away from the null. 
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Intention-to-treat analysis is essential to guide clinical decision-making.  Health professionals 
need to know how effective and safe an intervention is likely to be, for all the patients who 
are prescribed the intervention, which requires analysis of trial results to be based on the 
outcomes of all subjects who were randomised to an intervention.  However, health 
professionals and their patients may also be interested in knowing how effective an 
intervention is, when it is used correctly, which requires a per-protocol analysis that excludes 
subjects for a variety of reasons, such as failure to use more than half the doses of treatment 
provided, or taking the treatment to which they were not assigned. 
Per-protocol analyses are susceptible to bias because they exclude a subgroup of subjects who 
had been randomised to treatment.  If the factors that led to the protocol violation were 
systematically different between treatment groups (such as severity of adverse effects), then 
those factors may confound the estimation of the effect of the trial intervention on the 
outcome.  By retaining all subjects in the analysis, in the treatment to which they were 
originally assigned, ITT ensures that the treatment effect is not confounded by covariates 
associated with protocol violations.  The statistical power of per-protocol analyses is not as 
high as the statistical power of ITT analyses, because exclusion of protocol violators reduces 
the sample size. 
Wright and colleagues demonstrated that ITT analysis is less susceptible to bias from protocol 
violations compared to other forms of analysis.(274)  They achieved this by creating a series 
of hypothetical data sets that contained common protocol violations (loss-to-follow-up, and 
switching treatment assignments), which they analysed by a variety of methods: 1. including 
all subjects in the treatment group to which they were originally randomised (ITT analysis); 2. 
including only subjects who completed the study and analysing them in the group that 
accorded with the treatment they had received at the end of the study (as-treated analysis); and 
3. including only subjects who had used their assigned treatment correctly (adherers-only 
analysis).  Despite the face-validity of the latter two approaches to data analysis, they were 
more prone to bias than use of ITT. 
McMahon argued that analyses that only include subjects who complied with taking the 
investigational drug, and exclude data from non-adherent subjects, (termed “on-treatment 
analyses”), are at best, speculative hypothesis-generating exercises, because they may be 
biased by the exclusion of subjects on the basis of factors that are related to compliance and 
which are possibly related to the study outcomes; this makes it difficult to interpret the results 
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of these analyses, and therefore they should be restricted to the ‘discussion’ section of 
publications and not reported in the ‘results’ section.(275)   
ITT analyses require assumptions to be made, and may require the use of complex statistical 
techniques, which are discussed directly below.  The benefits that ITT analyses have, in terms 
of reducing bias, must be balanced against the plausibility of the assumptions that ITT 
analyses make.   
2.3.3.3 Methods to analyse data with missing values 
In order to undertake an ITT analysis when some data are missing, it is necessary to account 
for the missing data, to enable all randomised subjects to be included in the analyses.   
The statistical methods used to handle missing values would ideally take into account the 
mechanism responsible for the values being missing, and the relationship between the missing 
values and non-missing values.(274)  From a statistical point of view, there are three 
categories of missing values: 
1. Missing Completely at Random (MCAR): the values of a variable that are missing, 
are a random subset of the values of that variable; the propensity for a data point to be 
missing is completely random and not correlated with any other variable or with 
whether or not any other variables are missing. 
2. Missing at Random (MAR): the values of a variable that are missing are a random 
subset of the values of that variable but the absence of those values (missingness) is 
correlated with another variable.  The propensity for a data point to be missing is not 
related to the missing data, but it is related to some of the observed data. 
3. Not Missing at Random (NMAR): the values of a variable that are missing are not a 
random subset of the values of that variable, and the absence of those values 
(missingness) may be correlated with another variable. 
The statistical methods for dealing with missing data that are missing completely at random or 
that are missing at random, are based on trustworthy well established statistical knowledge 
about the properties of random numbers; however, for data that are not missing at random, the 
mechanism by which the data were missing, may have had an influence on the trial outcome, 
and are therefore referred to as nonignorable missing data.(276)  Analyses of nonignorable 
missing data and protocol violations must model the potential reasons for why the data were 
missing, and the predictors of protocol violation, using methods that are robust to data that are 
NMAR, such as Maximum Likelihood estimation that simultaneously models the reasons for 
74 
 
missing data and the associations of interest; methods of imputation (e.g. imputing the mean 
value, last observation carried forward, multiple imputation); random effects models; 
Bayesian methods; weighting the analysis to allow for the missing data; however, these 
analyses should be repeated in sensitivity analyses, testing a range of different assumptions 
about the reasons for missingness.(274, 276-278)  Not all Bayesian methods are suitable for 
the NMAR pattern of missingness; for example, Markov Chain Monte Carlo methods 
presume that data are missing arbitrarily.(279) 
The traditional approach to analyse missing abstinence outcomes in smoking cessation trials, 
is to count all missing abstinence outcomes as not abstinent, regardless of all other 
considerations.(271)  This approach is referred to as ‘penalised imputation’ and has the 
advantage of allowing outcomes from all randomised subjects to be included in the analysis.   
There is conflicting evidence about the validity of the assumption that subjects whose 
abstinence outcomes are missing due to loss-to-follow-up are not abstinent.  Some evidence 
suggests that penalised imputation is justified, such as a study of three Quitlines in the United 
States in which subjects who required six contact attempts to record their outcomes were used 
as a proxy for non-respondents; abstinence rates in subjects who required six attempts to 
collect their data were between four and thirteen percentage points lower than those who 
required only one contact.(280)  Also, in a nicotine patch trial, all smokers who were 
telephoned after missing their follow-up clinic visits, reported that they had relapsed to 
smoking.(281)  However, evidence from the Swedish Quitline found that the abstinence rate 
estimated with penalised imputation of missing data from a postal survey, was lower than the 
abstinence rate calculated when outcome data for people who had not returned their postal 
survey were gained by a subsequent telephone call, however this could be tainted by social 
desirability bias as people may have been embarrassed to admit in a telephone conversation 
that they had relapsed.(282) 
Penalised imputation has been criticized because it is only statistically appropriate to impute 
missing values, if they are missing completely at random (MCAR) or missing at random 
(MAR), yet there are several mechanisms, for why subjects become lost-to-follow-up and do 
not report their outcomes, that are not random, and which may not be randomly distributed 
between treatment groups, such as embarrassment or disillusionment among subjects who fail 
to be abstinent; or, the view that the trial can no longer offer a worthwhile benefit to subjects 
who have been unable to quit; or, subjects who have achieved their aim of quitting smoking 
feeling that they no longer need any further help from participating in the trial.(272)   
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A wide range of statistical techniques have been developed to avoid the potential bias of 
penalised imputation and per protocol analysis, such as complex multiple imputation 
methods, that impute missing outcomes based on the outcomes of subjects whose data were 
not missing, and whose baseline pre-randomisation characteristics were similar to those of 
subjects whose data were missing, and the use of selection models, and techniques that can 
model the effect of time and repeated measures over time such as Generalized Estimating 
Equations (GEE) and Generalized Linear Mixed Models (GLMM).(283, 284)   
The ‘selection model’ method, uses GLM to identify characteristics that predict missingness, 
and uses the extent to which each subject possess those characteristics, to calculate the 
propensity for each subject to have missing data based on those predictors.  These propensity 
scores are then included, as an independent variable, in the logistic regression used to estimate 
the treatment effect, in order to adjust that estimate by the reasons for missing data.(284)   
Multiple Imputation (MI) uses Bayesian methods to calculate plausible values for the missing 
data and calculate the uncertainty around those plausible values.(278)  Multiple imputation 
methods have been used to analyse outcomes in a number of smoking cessation trials, such as 
a trial of varenicline.(285)  However, MI has limitations (such as the assumption that data are 
MAR or MCAR), and not all statistical software programmes yield unbiased estimates even 
when data are MAR or MCAR.(286)  
Maximum Likelihood (ML) imputation chooses values for the estimates (the coefficients for 
each of the independent variables in the linear model) that are most likely to be true, based on 
the data that have been observed and their relationship with the likelihood of data being 
missing.(276)  Maximum Likelihood (ML) imputation has statistical properties that are 
superior to those of Multiple Imputation (MI), for example, MI produces different results each 
time it is run because it randomly selects the values to impute, whereas ML always produces 
the same results whenever it is run.(276) 
The effect of different methods to impute missing outcome data, on the degree to which a 
trial’s outcomes are biased, has been investigated empirically.  A study of twenty-two NRT 
trials found that penalised imputation produced similar relative risks of abstinence compared 
to complete case analysis, however when simulated data (data created by an algorithm, not 
derived from trial subjects) were added to the analysis, penalised imputation produced 
95%CIs beyond those of complete case analysis, whereas two different methods of multiple 
imputation did not;, and the direction of the bias from penalised imputation of simulated data 
increased abstinence rates in favour of the group with the lowest proportion of missing data 
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(which is typically the active group in NRT trials).(287)  Although penalised imputation 
might be considered more accurate than complete case analysis, because the imputation of 
data that is missing from complete case analysis gives penalised imputation a larger sample of 
data, , penalised imputation can lead to imprecision and wider confidence intervals depending 
on the amount of missing data and its ratio between groups.  Further doubt about the validity 
of penalised imputation was raised in another study of simulated data, which also showed that 
under some conditions, depending on whether the proportion of missing abstinence data 
differs between treatment groups, penalised imputation can overestimate the active treatment 
effect.(288)    
Penalised imputation does not necessarily always lead to bias, sometimes it provides similar 
estimates to those calculated by multiple imputation, such as in a trial of pro-active smoking 
cessation treatment versus usual care, where penalised imputation found 17.8% of 
intervention participants quit compared with 8.1% in the control group (OR=2.5; 
95%CI:1.5—4.0; p<0.001), and multiple imputation found quit rates of 26.8% and 12.4% in 
active and control groups respectively (OR=2.6; 95%CI:1.7—3.9; p<0.001).(289)  Further 
evidence that the various methods of imputation may produce similar results was seen in a re-
analysis of abstinence data from two clinical trials, which used a range of imputation methods 
(penalised imputation, last observation carried forward, and multiple imputation), and found 
that estimates of the treatment effect were very similar between imputation methods, except 
when extreme assumptions were made about the cause of missingness and the distribution of 
missing data between treatment groups.(290)  
Although penalised imputation is the most commonly used method to handle missing data, 
and may produce similar results to modern statistical techniques, it can cause bias and 
therefore it has been suggested that outcomes from both penalised imputation and modern 
methods of handling missing data, should be presented in publications of trial results.  The 
effect of different methods to handle missing abstinence outcomes, was explored in the 
analysis of the two RCTs on which this dissertation is based. 
In the analyses of the two large RCTs, reported here, missing abstinence outcomes were 
imputed by a range of methods, unless otherwise stated penalised imputation was used for 
missing abstinence outcomes.  Outcomes for which it is not possible to impute a value for 
non-responders (such as CEQ and side-effect severity scores) were calculated by comparing 
all available data between groups (complete-case analysis).   
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The most accuracy is not gained by the method of imputing missing values, but rather by 
avoiding loss to follow-up and preventing data from being missing.  A few trials have 
investigated the efficacy of methods to reduce subject attrition in addiction trials, such as 
financial incentives which were found to be ineffective in an internet trial of reduction of 
alcohol consumption,(291), and identification or factors associated with attrition in smoking 
cessation trials.(292)  In the INHALE and ZAP trials attempts were made to avoid subject 
attrition by asking for the contact details of someone subjects knew who lived at a different 
address to them, whose contact details were unlikely to change at the same time as the 
subject’s contact details change.  This never yielded useful information when subjects had 
become lost to follow-up. 
2.3.3.4 Adjustment of treatment effect 
On occasion it may be desirable to adjust analyses of the outcomes of trials, however to do so, 
may create bias and error.  These issues are discussed in the following paragraphs. 
2.3.3.4.1 Reasons for why adjustment may be desirable 
To protect the validity of a trial’s outcomes, it is sometimes useful to adjust the analyses of 
the outcomes of trials in certain circumstances, such as to take account of variables that were 
correlated with both the treatment assignment and the treatment outcome, and therefore could 
potentially confound the relationship between the treatment and the outcome.  Sometimes it is 
desirable to adjust the analysis if there has been a clustering effect due to recruitment of 
subjects from sources such as primary care practices, which can lead to a cluster effect if 
patient characteristics and the care they receive or the treatment outcomes are differentially 
distributed between the primary care practices or trial sites from which subjects were 
recruited.(293)   
2.3.3.4.2 Assumptions of adjusted analyses 
The issues relating to adjusting trial data in these circumstances are discussed by Friedman 
and colleagues in chapter seventeen “Issues in Data Analysis” of their textbook 
“Fundamentals of Clinical Trials.”(294)  In their textbook, Friedman and colleagues point out 
that analyses that include a covariate in order to adjust the estimate of the effect of the 
intervention on an outcome, by the effect that the covariate has on that outcome, make a 
number of assumptions, including: 
1. that the coefficient for the degree to which the covariate influences the dependent 
variable is the same in both treatment groups; 
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2. the covariates are linear; 
3. the covariates are normally distributed; 
and that, conducting an adjusted analysis that breaks these assumptions, can itself lead to bias. 
2.3.3.4.3 Adjustment by post-randomisation variables 
Friedman and colleagues argue that any variables that are measured after initiation of 
treatment will potentially have been affected by the treatment (except for demographic 
variables such as gender and age) and because the treatment is different in the two groups, the 
treatment in one group may have a different effect on that variable cf. the treatment in the 
other group.  Adjusting for such a variable can therefore bias the estimate of the treatment 
effect, particularly if it excludes subjects from the analysis in a manner that differs between 
groups due to differential missingness of the variable being adjusted for between groups.  
Friedman and colleagues argue that any observation that is measured after the initiation of 
treatment should be treated as a dependent variable, and not be included as a predictive 
(independent) variable in the analysis.  Treatment adherence is an example of a post-
randomisation covariate. 
Adjusting the estimate of treatment effect for compliance, or stratifying according to 
compliance, is likely to introduce bias unless the proportion of noncompliance, and the 
treatment outcomes after the discontinuation of treatment, are similar between groups,(295) 
and if the reasons why subjects did not comply with taking the active drug are the same as the 
reasons why the control subjects did not take the control drug.(274)  There are many instances 
where the reasons for non-compliance could be different between active and placebo groups, 
such as: tolerability of the drug, or perceived lack of efficacy.(274, 296)  However bias can be 
minimised by including in the analysis an outcome for all people whose data are missing as a 
result of non-compliance, either by imputing the final outcome for them or by including an 
extra variable which records the reason for why the data are missing (such as, “withdrawn 
because of severe adverse effects”, or “withdrawn because of lack of effect”.(296)  
Adjustment of the treatment effect by the values of a variable, will exclude subjects from the 
analysis whose values for that variable are missing, and therefore this analysis will no longer 
be an intention -to-treat analysis and may lead to bias.(297)   
There are examples in the literature where researchers have adjusted the estimate of the 
treatment effect in order to avoid bias, even though this can in itself lead to bias.  Firstly, a 
systematic literature review revealed that the publications of trials that report use of modified 
79 
 
intention-to-treat analyses (ITT) has become more common, and the majority of publications 
that used modified ITT analyses favoured the active treatment or the authors’ 
assumptions.(298)  In 56% of trials, the deviations from ITT related to the treatment received, 
41% to a post-baseline assessment, 25% to a target condition, and five percent to follow-up, 
while post-randomisation exclusions occurred in 80% of trials.  Secondly, the potential need 
to adjust for post-randomisation baseline differences is common, since another systematic 
review of randomised controlled trials published in four major journals, found that seventeen 
of the fifty reviewed publications declared that there was at least one significant difference 
between treatment groups in subjects’ baseline characteristics after randomisation, and in a 
third of trials, the estimation of the treatment effect had been adjusted by those differences 
(299)    
Due to the issues mentioned above, the European Agency for the Evaluation of Medicinal 
Products recommends that factors that may be affected by treatment allocation, such as 
duration of treatment, level of compliance, or use of rescue medication, should not be adjusted 
for in the analysis of the primary outcome, because adjusting for a factor that may be affected 
by the treatment, either by direct or indirect causation, may exaggerate or obscure the 
treatment effect.(300) 
Adjustment of the estimate of the treatment effect must be done with great caution, and the 
results of adjusted analyses must be compared to simple unadjusted estimates.  In this 
dissertation, analyses of the primary outcomes were unadjusted, but for secondary outcomes 
that were speculative hypothesis-generating exercises, the estimation of the treatment effect 
was adjusted by pre- and post-randomisation variables. 
2.3.3.5 Statistical methods used in this dissertation. 
The Mann-Whitney test was used to calculate the statistical significance of differences 
between ordinal data that were not normally distributed and do not potentially range from 
negative infinity to positive infinity, such as data from Likert scales.  The statistical 
significance between count data, such as abstinence rates, were calculated using Fisher’s chi-
squared test without Yates continuity correction. 
2.3.3.5.1 Logistic regression 
Logistic regression involves writing a mathematical equation which will calculate a best 
approximation of the outcome for all subjects in a data set, based on characteristics of those 
subjects and the treatment they received.  It takes the form y = β0 + β1x1 + β2x2 + . . . βixi 
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where y is the dependent variable (such as the primary outcome of a trial), x1-xi are the 
variables that predict the value of y (the independent variables, also known as the covariates) 
and β1-i are the coefficients.   
The textbook by Hosmer and Lemeshow gives the background and methodology for logistic 
regression.(301)  Logistic regression is a type of linear regression, in which the dependent 
variable is dichotomous rather than a continuous variable with values from -∞ to +∞.  The 
anti-log (eβi) of a coefficient of a covariate gives the odds ratio (OR) for the effect of that 
covariate on y.  The OR is a useful way of summarising the degree to which a covariate 
influences the value of the dependent variable: the OR for x shows that for every increase in 
one unit of the covariate x, the dependent variable y will change by the value of the OR for x.  
The coefficient for each covariate, is adjusted by its covariance with the other covariates in 
the model and the extent to which the covariates cause the value of the dependent variable to 
change independent of the effects of the other covariates.  Therefore, the coefficient of a 
covariate represents the size of the unique effect that covariate has on y, distinct from the 
effects of the other covariates in the model.   
It is important to carefully decide which covariates to include in a logistic regression , and 
which to leave out, because the addition of extra covariates will increase the error in the 
model (because there will be an error term for each covariate) which can lead to a total error 
term for the model that is unacceptably large.  Also, each addition of an extra covariate 
increases the degrees of freedom by one, thereby potentially increasing the p-value for the 
model and reducing its statistical significance.  However, if one only includes in a 
multivariate linear regression those terms which were statistically significant in univariate 
regression, this has the disadvantage that it will miss out covariates, that significantly modify 
the effect of other covariates on the outcome (effect modification) but, do not modify the 
dependent variable in univariate regression.   
In order to include all potential confounders in a multivariate GLM, it is recommended that 
first, all covariates that have a p-value of <0.25 in univariate regression be included in the 
multivariate model, and once this is done, the coefficients should be examined and covariates 
which were not significant (at p<0.05) in univariate regression, which remain non-significant 
in the multivariate logistic regression, should be removed from the multivariate model one at 
a time.  If their removal causes a twenty percent or greater change in the OR of a covariate or, 
causes a covariate to lose it statistical significance, the removed variable should be returned to 
the model.  In addition, factors which are thought to be clinically relevant, or whose role in 
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determining the outcome is under investigation, should also be included in the multivariate 
logistic regression even if they are not significant in univariate regression.(301)   
The quality of a logistic regression can be judged by how well the model fits the data, in other 
words, the degree to which the predicted values of y for each subject match the actual values 
of y in the dataset, which is measured by the error term.  One global measure of the size of the 
difference between the predicted values and the observed values (goodness-of-fit) is called the 
Root Mean Square Error (RMSE), with smaller values indicating a closer fit between the 
predicted values (the values fitted by the model) and the observed values.  Alternative 
measures of goodness-of-fit include the Pearson’s chi-squared statistic and deviance; Hosmer-
Lemeshow test; and the R2 statistic, Root Mean Square Error of Approximation (RMSEA), 
and Standardized Root Mean Square Residual (SRMR).  Other measures of a model’s quality, 
which can be used to compare one model to another, include the Likelihood Ratio, Wald 
statistic, Analysis of Variance (ANOVA), and the Akaike information criterion (AIC). 
The goodness-of-fit of GLM in this dissertation was measured by the Hosmer and Lemeshow 
Goodness of Fit test (using the hoslem.test() function in the ResourceSelection package in R).  
If the result of this test is not statistically significant, this indicated that there is no evidence of 
ill-fit in the GLM’s estimation of the data.  
2.4 Psychological Batteries  
Psychological Batteries are composed of a series of questions which aim to index a mental or 
emotional construct, such as mood, which is an internal state and not able to be directly 
observed except by people experiencing their own mental state.  Typically, a battery asks 
people to rate on a Likert scale the extent to which they agree or disagree with a range of 
statements or the degree to which they experienced a particular emotion state.  Likert scales 
have a set number of ratings which increase in intensity, such as a seven-point scale from ‘not 
at all true of me’ to ‘extremely true of me’.  Psychological batteries may use Visual Analogue 
Scales (VAS), which measure subjects’ agreement or disagreement with the statements, on a 
continuum between two points and is measured in millimetres. 
One way to judge the merits of a psychological battery, is to conduct a factor analysis of 
people’s answers to the battery’s questions.  Factor analysis is a statistical technique that 
assesses whether the variation and covariation between the answers that people have given to 
each item (question) in the battery, suggests that this variation and covariation is caused by 
the variation and covariation of unseen characteristics called latent variables.(302)  For 
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instance, factor analysis of Intelligence Quotient (IQ) tests suggests that variation in people’s 
scores for the items of IQ tests, is caused by variation in latent variables (also referred to as 
latent factors) such as “verbal fluency”, and “three-dimensional thinking”. 
A great many psychological batteries have been developed to measure and explore the 
symptoms and affective states caused by tobacco smoking and its withdrawal syndrome. 
Those that were used in the trials upon which this dissertation is based, are described below. 
2.4.1 Brief-Wisconsin Inventory of Smoking Dependence Motives 
The brief-Wisconsin Inventory of Smoking Dependence Motives (WISDM-37) indexes 
smokers’ reasons for smoking.  It consists of thirty-seven statements (items), that smokers 
rate their level of agreement with, on seven-point Likert scales.  Factor analyses of data from 
smokers in the USA suggested that WISDM-37 has an eleven factor structure (affiliative 
attachment, automaticity, loss of control, cognitive enhancement, craving, cue 
exposure/associative processes, social/environmental goads, taste, tolerance, weight control, 
affective enhancement) with four pairs of freely correlated error covariances.(44)  In addition 
to the eleven factors, two synthetic scales (the Primary Dependence Motives (PDM) scale and 
the Secondary Dependence Motives (SDM) scale) and a total score can be calculated, 
although published confirmatory factor analyses do not support the existence of higher-order 
factors such as the SDM, PDM and Total scores.  The PDM scale indexes heavy smoking that 
is not discriminated on contextual cues, that occurs with little conscious control, and is 
characterized by frequent, strong, and annoying craving; it is the mean of four WISDM 
subscales: Automaticity, Loss of Control, Craving, and Tolerance.  The SDM scale is the 
mean of the remaining subscales that are not part of the PDM scale. The tolerance and PDM 
subscales were predictive of six-month abstinence in two trials in the USA.(44)  
Social/Environmental Goads indexes the potency of social stimuli or social contexts in 
increasing smoking motivation.  It is the mean of three items, an example of one item is 
“Most of the people I spend time with are smokers”. 
Confirmatory Factor Analysis (CFA) is a multivariate statistical method that tests whether the 
correlations and covariances between the observed variables supports a particular factor 
structure proposed to explain those covariances and correlations.  I conducted a CFA of the 
WISDM-37, using the Lavaan package of the R language, confirmed the proposed factor 
structure of WISDM-37 had acceptable fit indices with the data from the ZAP trial.  The 
WISDM-37 was used in the ZAP trial to more thoroughly explore the reasons for why people 
smoke and find it difficult to quit, beyond what is explained by nicotine dependence. 
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2.4.2 Fagerström Test for Nicotine Dependence 
The Fagerström Test for Nicotine Dependence (FTND) is a series of six questions which are 
rated on a variety of scales, some of which allow for only a dichotomous yes/no response.  It 
measures addiction to nicotine and focusses principally on tolerance and withdrawal 
discomfort, the total score is the outcome that is commonly reported, which can range from 
zero to ten, with higher scores indicating higher dependence.(303)  Exploratory Factor 
Analysis (EFA) is a multivariate statistical method that reveals the underlying structure of 
variables.  It is used to uncover the theoretical constructs that are responsible for the 
correlations and covariance between the observed variables.  Several Exploratory Factor 
Analyses (EFA) have suggested that the FTND has two correlated factors with a crossloading 
of one item onto both factors.  The first factor contains questions/items involving morning 
smoking and has been interpreted as assessing the degree of urgency to restore nicotine levels 
to a given threshold after overnight abstinence. The second factor, which contains items 
relating to daytime smoking patterns, has been interpreted as a measure of the persistence 
with which nicotine levels are maintained at a given threshold during waking hours.(304)  A 
Confirmatory Factor Analysis (CFA) by me confirmed the proposed factor structure and 
found the data collected for this dissertation had excellent goodness of fit indices with this 
factor structure in both the ZAP and INHALE trials. 
2.4.3 Modified Cigarette Evaluation Questionnaire  
The Modified Cigarette Evaluation Questionnaire (mCEQ) is a set of twelve questions about 
the sensory and psychological qualities of smoking a cigarette (for instance, “Was smoking 
satisfying?”; “Did cigarettes taste good?”; “Did smoking calm you down?”) which are rated 
on seven-point Likert scales.  Cappelleri’s and colleagues’ EFA suggested the mCEQ had 
three factors composed of multiple items (Psychological Reward, Satisfaction, Aversion), and 
two factors, each composed of a single item (Enjoyment of Respiratory Sensations, Craving 
Reduction).(305)  The mCEQ was used in this dissertation to rate the sensory and 
psychological effects of the mouthsprays and inhalers.  For the ZAP trial the mCEQ scales 
were slightly reworded to rate the oral rather than respiratory effects of the mouthspray (for 
example “did you enjoy the sensations in your throat and chest?” was changed to “did you 
enjoy the sensations in your mouth and throat?”), and a new item was added to measure the 
craving reduction that occurred within fifteen minutes, in addition to the mCEQ item that 
indexed immediate craving reduction, because nicotine does not immediately reach the brain 
after Zonnic is used.  Furthermore, the references to smoking and cigarettes were reworded to 
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refer to the inhaler/mouthspray.  The altered questionnaires were not piloted or validated prior 
to use. 
2.4.4 Brief Questionnaire of Smoking Urges  
The Brief Questionnaire of Smoking Urges (brief-QSU) is composed of ten items, rated on 
seven-point Likert scales (for example, “I have a desire for a cigarette right now”; “Nothing 
would be better than smoking a cigarette right now”).  A factor analysis suggested the brief-
QSU has two factors plus a higher order factor, the publication of this factor analysis also 
reported that the total score (average of all ten items) had excellent reliability.(306)  Despite 
the two factor structure, it is the total score that is often reported in trials that used this scale, 
and this was the approach taken in this dissertation.  A CFA by me confirmed the proposed 
factor structure and found the data collected for this dissertation had excellent goodness of fit 
indices with this factor structure. 
2.4.5 Minnesota Nicotine Withdrawal Scale 
The Minnesota Nicotine Withdrawal Scale (MNWS) measures urge to smoke, depressed 
mood, irritability, anxiety, difficulty concentrating, restlessness, increased appetite, and sleep.  
The MNWS is made of nine items, rated on five-point Likert scales from 0 “not at all” to 4 
“extreme”.  It is one of the most commonly used measures of nicotine withdrawal, and 
measures all the symptoms of withdrawal recommended by a panel of experts.(307)  It has 
been suggested that it has five factors, two factors (insomnia and negative affect) consist of 
more than one item, while the other three factors have only one item each, however the CFA 
performed by Cappelleri and colleagues only included the two factors that consisted of 
multiple items and did not include the factors that consisted of a sole item.(126)  
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3 Nicotine mouthspray and nicotine patch double-blind 
randomised placebo-controlled trial 
3.1 Introduction 
This chapter presents the background and rationale of an RCT of a nicotine mouthspray 
combined with nicotine patch.  The findings of the trial are given, followed by detailed 
examinations of issues involved in the analyses of the results.  These issues include how to 
handle missing abstinence data and imputation; predictors of abstinence; unblinding; and the 
roles of Māori ethnicity and enrolment at a Māori community trial site.   
Rapid delivery of nicotine to the brain is essential for the release of rewarding 
neurotransmitters in the brain,(32) yet nicotine replacement therapies that are currently 
licensed as smoking cessation pharmacotherapies deliver nicotine to the brain much more 
slowly than cigarette smoking, which has led smoking cessation experts to call for the 
development of more rapid nicotine delivery systems as alternatives to smoking.(12, 57)  
Although the oral route is not as ideal as the inhaled route for the rapid delivery of nicotine to 
the brain,(61) it is better suited for this purpose than the transdermal route which has a very 
slow delivery, and the nasal route which despite providing rapid delivery of nicotine is very 
aversive.(163, 308)   
In order to increase the speed with which medicinal nicotine is delivered to the brain, a 
number of oral nicotine delivery devices have been developed, including:  
1. conventional NRTs (gum, lozenges, mouthsprays)(27), 
2. rapidly dissolving nicotine films,(309) 
3. oral tobacco (such as snus(310-312)) and dissolvable tobacco.(313))   
Compared to these products, nicotine mouthsprays have several advantages:  
1. no time is lost waiting for nicotine to be released from the NRT because the nicotine is 
already in solution;  
2. mouthsprays are convenient and acceptable to use in a wide range of cultures and 
contexts, which is not necessarily true of chewing gum nor chewing tobacco.(314)   
Two nicotine mouthspray formulations are currently available: Zonnic (Niconovum AB) and 
Nicorette (Johnson & Johnson).  Zonnic was developed by Niconovum as an alternative to 
Nicorette, it is very similar to Nicorette but is sufficiently different from Nicorette for the 
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company that purchased Zonnic from Niconovum (Reynolds American Inc.) to successfully 
defend a lawsuit claiming infringement of copyright brought against them by Johnson & 
Johnson.(315)  The principal difference between the two brands of mouthsprays is in the way 
they deliver their contents to the oral cavity.  Nicorette sprays its formulation into the mouth 
without any attempt to localise where the spray lands, whereas Zonnic uses a tube to direct the 
spray towards the cheek, thereby reducing its irritating effects by limiting the surface area that 
contacts the spray and avoiding contact with receptors at the back of the throat that mediate 
cough and aversion.  This also means that a higher concentration of Zonnic is deposited in the 
cheek, than the concentration of Nicorette that deposits in any single area of the mouth, so 
that a higher concentration gradient and consequently a higher driving force for absorption is 
achieved with Zonnic cf. Nicorette.  Prior to the conduct of the trial upon which this 
dissertation is based, no large clinical efficacy trial had been conducted to determine the 
potential of Zonnic to aid long-term smoking cessation.   
The first trial of Zonnic to be published was a small (n=100) trial of an earlier formulation of 
Zonnic than the one used in this trial.  In the first trial, subjects were given Zonnic 
(1mg/spray), 2mg nicotine oral inhaler, and 2mg nicotine gum to use ad libitum for a week 
before being randomised to use one of those products for the next three months (mouthspray 
n=50; gum n=25 and inhaler n=25).(316)  At the end of the first week, more subjects 
preferred Zonnic (n=54/100), despite it having a higher incidence of side-effects.  There were 
no significant differences in abstinence rates between the products at any of the six time-point 
that abstinence was measured throughout a year of follow-up after randomisation.  Bolliger 
and colleagues recommended that Zonnic’s nicotine dose be halved to improve its tolerability.  
In order to improve Zonnic’s tolerability, while maintaining its efficacy, Niconovum reduced 
Zonnic’s ethanol content by two-thirds but maintained the same dose of nicotine (personal 
communication from Anders Axelsson, Niconovum’s pharmaceutical chemist).   
The new formulation of Zonnic, with its lower ethanol content, was studied in a small (n=47), 
short-term cross-over trial, which tested the tolerability and reduction of withdrawal 
symptoms with this newer version of Zonnic mouthspray (1mg/spray), compared to Zonnic 
lozenge (2.5mg), Nicorette nicotine gum (4mg), and placebo lozenge.(317)  In that trial each 
product was used for eight hours on four separate days after overnight abstinence from 
smoking.  Zonnic mouthspray relieved craving faster than placebo lozenge and Nicorette 
gum, with significant reductions in craving within five minutes of use.  Eleven of the subjects 
also participated in a comparative pharmacokinetic study (of two sprays of 1mg/spray Zonnic 
mouthspray (two sprays is considered one dose), one 2.5mg Zonnic nicotine lozenge, and one 
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piece of 4mg Nicorette nicotine gum), which demonstrated that two sprays of Zonnic 
produced a mean (median) maximum plasma concentration (Cmax) of 14.5ng/ml (11.0), and 
time to maximum plasma concentration (Tmax) of 10.0 (5.2) minutes, Table 3.1.(317)  One 
dose of Zonnic mouthspray (2mg) produced a higher Cmax and Area Under the Curve (AUC) 
and shorter Tmax than the gum and; although the mouthspray had a lower Cmax and AUC than 
the lozenge, the mouthspray had a shorter Tmax.(317)    
Two trials of Nicorette mouthspray have been published.  A pharmacokinetic study (n=45) of 
two sprays of 1mg/spray Nicorette mouthspray, demonstrated a mean (SD) Cmax of 5.3 (2.1) 
ng/ml, and median Tmax of 12.5 minutes,(208) which is 5.31/10.0*100=53.10% the Cmax of 
Zonnic, and took (12.5-14.5)*100/14.5=-13.79% less time to reach this Cmax.  The author of 
this dissertation was unable to find any head-to-head trials of Zonnic mouthspray compared to 
Nicorette mouthspray, hence their pharmacokinetic profiles can only be compared using data 
from different trials.  Such comparisons may be tainted by confounding due to the trials being 
composed of different subjects, and having been performed among different populations and 
at different trial sites.  A randomised placebo-controlled trial of three months of Nicorette 
mouthspray (n= 479) observed significantly higher prolonged and seven-day point-prevalence 
abstinence rates for active Nicorette mouthspray compared to placebo at all time-points, 
except at week twenty-four when it was reported as p=0.055 for prolonged abstinence 
(however, when I used the reported values to replicate the chi-squared test, the outcome at 
week twenty-four was p=0.7347), the twelve-month prolonged abstinence was significantly 
higher in the active vs. placebo groups at 13.8% vs. 5.6%, RR 2.48, OR 2.71, p=0.007).(33)  
Nicotine substitution (absorbing nicotine from NRT instead of cigarettes) was low in this trial, 
and the authors suggested that this could be increased by scheduling the use of the spray or by 
concomitant use of nicotine patches.  As stated earlier, a search of the literature conducted by 
the author of this dissertation, revealed that no-one has published the results of a trial that 
followed this advice.   
As mentioned in the introduction to this dissertation, its author designed several simple Likert 
scales that were used in the mouthspray plus nicotine patch trial, to measure smokers’ desire 
and determination to quit and/or reduce their smoking, and their degree of self-efficacy to forgo 
the pleasure of smoking and handle stressful events without smoking.  Also, I designed simple 
scales to index factors that may potentially have confounding, or modifying, effects on the 
estimate of the extent to which the active mouthspray was responsible for the difference in 
abstinence rates between the active and control conditions.  These factors included whether 
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Table 3.1.  Comparative Pharmacokinetics of Zonnic mouthspray, lozenge, and Nicorette gum (317) 

















n 10 10 10 9 9 9 11 11 11 
Mean 30.3 10.8 411 45.8 7.8 310 14.5 10.0 343 
SD 14.9 3.8 174 14.7 4.6 215 11.0 5.2 107 
95%CI 21.1, 39.5 8.4, 13.1 303, 518 36.2, 55.4 4.8, 10.8 169, 450 8.0, 21.0 6.9, 13.0 280, 406 






subjects lived with other smokers, the number of smokers that they spend time with on a 
typical day, the number of personal acquaintances they knew who have quit smoking, and 
whether subjects had previously tried to quit smoking or used NRT before.  The rationale for 
these questions was that the social pressure from other smokers may hinder subjects from 
quitting, and on the other hand, having had quitting behaviour modelled to them, may 
improve their self-efficacy and also help motivate them to quit.  Having made previous quit 
attempts may have given subjects more experience with quitting which may help in their 
current attempt, or it may be a sign that they have a more dependent personality and a greater 
physical nicotine dependence (the type of nAChR subtypes they have, how quickly they 
become desensitized) which may make it harder for them to quit.  These scales, that were 
created by me, were not piloted or validated, nor were their psychometric properties tested 
prior to their use in the Zonnic plus patch trial for this dissertation. 
In conclusion, prior to the design of this trial, there had been only one RCT of a nicotine 
mouthspray for smoking cessation, specifically, a trial of Nicorette mouthspray, and there had 
been no studies of Zonnic mouthspray for smoking cessation; and no trials of the specific 
combination of a nicotine mouthspray plus nicotine patch. 
3.2 Methods 
This trial and its protocol were registered with the Australasian Clinical Trial Registry 
ACTRN12609000482268. 
3.2.1 Setting and participants 
The trial was conducted at the University of Otago in Wellington and Christchurch, as well as 
Kōkiri Marae health services in Lower Hutt and Porirua (ACTRN126090004822680).  One 
thousand four hundred twenty-three subjects were randomised to treatment.  Smokers were 
enrolled if they smoked nine or more cigarettes per day (CPD), had a Fagerström Test of 
Nicotine Dependence (FTND) score of three or more (303); and were eighteen to seventy 
years old.  Smokers were ineligible if they took psychoactive medications or illicit drugs; 
drank more than twenty-eight standard units of alcohol per week; had hyperthyroidism, 
diabetes, renal or hepatic disease; in the past three months had unstable angina, myocardial 
infarct, or stroke; or were female and using inadequate contraception or were breastfeeding.  
Ethical and regulatory approval were gained from the Central Regional Ethics Committee and 
the Standing Committee on Therapeutic Trials, respectively, and all subjects provided written, 
signed, informed consent. 
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3.2.2 Subject recruitment 
Subjects were recruited through media release, posters on buses and in cafes, the trial’s 
internet site, and through medical practices.  Potential subjects could access the trial to be 
screened for eligibility via the trial website, by email, and by telephone. 
3.2.3 Randomization, allocation concealment and blinding 
Subjects were randomised by computer after being screened, attending their baseline visit and 
giving informed consent.  Subjects were assigned unique product codes by the computer, 
which masked their treatment assignment.  Active and placebo Zonnic bottles looked identical 
and were labelled with the unique product codes (RAN0001 to RAN1600) by an external 
company who kept the key to the codes in a sealed tamper-evident envelope until the end of 
the trial, the product codes were imported as a comma separated values file into the computer 
program so it could randomly assign subjects, store their assignment in a manner that was not 
visible, and display product codes that aligned with their assignment so staff could dispense 
the products and remain masked.  Placebo Zonnic contained the same menthol flavour as 
active Zonnic, and had sufficient capsaicin added to match the burning sensation from the 
nicotine in the active product.   
3.2.4 Intervention 
Both treatment groups received five months of active Habitrol nicotine patches to be worn 
twenty-four hours per day, 21mg/patch for the first eighteen weeks, then 14mg followed by 
7mg in the final four weeks.  The active and control groups received six months of active and 
placebo Zonnic respectively, to use ad libitum when they felt the urge to smoke.  Subjects 
received brief counselling and Appreciative Inquiry,(318) at all contact times performed by 
Dr Caldwell and the research assistants who were trained in these techniques by Dr Brent 
Caldwell.  The content of the brief counselling and Appreciative Inquiry was titrated and 
tailored to each subject’s personal needs.  Appreciative Inquiry involves asking the subject to 
talk about times when they have done things well, such as when they resisted the urge to 
smoke, and emphasises the positive rather than a person’s failings.  Zonnic was a nicotine 
mouthspray made by Niconovum AB in Sweden. 
3.2.5 Procedures and schedule of visits 
Subjects were screened by telephone and invited to attend a baseline visit.  At the baseline 
visit, informed consent was obtained and subjects were randomly assigned to active and 
control conditions.  Subjects answered questionnaires, and were given the patches and 
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mouthspray to use, and rate their opinion of them.  All subjects were encouraged to start using 
the Zonnic and patches from the date of their baseline visit, and immediately reduce their 
smoking by at least a quarter and continue to reduce it by a quarter each week over the next 
three weeks then quit smoking.  Subjects were asked to record their use of the mouthspray and 
amount they smoked on diary cards during the period of smoking reduction.  Subjects were 
followed-up by telephone a day after their target quit date, and nine months later, and by four 
clinic visits (one, three, six and twelve months after the target quit date).   
3.2.6 Outcome measures 
The primary outcome was prolonged six-months abstinence after a grace period of four weeks 
after the target quit date, biochemically verified by exhaled carbon monoxide of less than ten 
ppm at all clinic visits.  Abstinence was defined as not smoking on seven consecutive days 
after the grace period.(68)  Secondary outcomes included seven-day point prevalence at each 
follow-up contact, amount of Zonnic used, reduction in smoking, reduction in urges to smoke 
and withdrawal symptoms, and the sensory and adverse effects of Zonnic.  Urges were 
measured by the brief-Questionnaire of Smoking Urges (QSU).(306)  Withdrawal over the 
past twenty-four hours was measured by the Minnesota Nicotine Withdrawal Scale 
(MNWS).(126)  Characteristics of the mouthspray were measured with the modified Cigarette 
Evaluation Questionnaire (CEQ).(305)  Ten potential side-effects were measured on ad hoc 
Likert scales from 0: ‘Not at all’; to 4: ‘Extreme’.   
The outcomes recorded at baseline were: age, gender, ethnicity, home address, QSU, mCEQ 
to measure the qualifies of the mouthspray, brief-Wisconsin Inventory of Smoking 
Dependence Motives, ad hoc questions measuring motivation to reduce and to quit smoking. 
The outcome measures recorded at baseline and all follow up time-points were all performed 
by either Dr Brent Caldwell, Professor Julian Crane or, one of the Research Assistants.  As 
much as possible, the same staff member conducted all the follow-ups for each subject so that 
subjects had continuity of care. 
3.2.7 Sample size 
The aim was to recruit 1,600 subjects to have 80% power to detect a difference in twelve-
month quit rates of 23.8% and 18.0% in the active and placebo group respectively at the 0.05 
level of significance.  This calculation was based on the mouthspray being 1.32 times more 
effective the quit rate in the control group which was assumed to be equal to 18% which was 




Analysis was undertaken using R version 3.4.0.(319)  Prior to conducting any inferential 
statistical analyses, the data were plotted, and summaries of the data (mean, median, 
interquartile range, range) were examined to look for outliers, non-linear relationships, and 
potential data-entry errors.   
Details of the statistical methods are given in ‘Chapter 2.3 Methodological considerations’ on 
page 63.  Specifically, abstinence was measured by the chi-squared test without Yates 
continuity correction.  The statistical significance of tests between ordinal data was calculated 
using the Mann-Whitney test.  Unless otherwise stated, missing abstinence outcomes were 
imputed as not-abstinent and missing eCO were counted as not biochemically verified. 
Initially statistical analyses of predictors of abstinence were conducted on cleaned raw data.  
After the identification of collinearity in GLM predicting abstinence, the independent 
variables were centred and scaled prior to use in multivariate GLM, in order to ensure that all 
independent variables were measured on the same scale and to avoid collinearity between 
main effects and interaction terms and collinearity arising from correlation between 
independent variables.(320, 321)  Further methods were required to account for collinearity, 
which are described below.   
3.2.8.1 Statistical methods for identifying predictors of abstinence 
The extent to which variables were responsible for the odds that subjects would attain 
prolonged six- and twelve-months abstinence was investigated in a step-wise fashion.  First, 
one univariate GLM was run per potentially predictive variable, then bivariate models 
explored the effects of the variables on each other’s capacity to predict the odds of achieving 
prolonged abstinence, and the potential for collinearity and multicollinearity were explored in 
bivariate models and multivariate models, respectively.  Multicollinearity is caused by the 
similarity of the effects of more than two independent variables on the dependent variable.  
Bivariate models were run prior to multivariate models in order to identify which variables 
were responsible for changes in the values and statistical significance of the ORs of other 
variables when they were adjusted by each other.  The bivariate models were constructed in 
three groups:  
1. the first contained only potential predictors of abstinence that had been measured at 
baseline, prior to randomisation; 
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2. the second contained pre-randomisation potential predictors of abstinence and 
adjusted them by treatment assignment; 
3. the third group of GLM had post-randomisation variables as their independent 
variables, such as subjects’ reactions to the mouthsprays and patches.   
The purpose of the first group of GLMs was to reveal which of the characteristics that are 
measurable before smokers embark on an attempt to quit, and before they start taking any 
smoking cessation therapy, are important in predicting the outcomes of their quit attempts.  
The results of these GLMs may be used by smoking cessation workers to identify which of 
their patients are less likely to succeed, and allow those patients to be offered more intensive 
and more frequent assistance, as soon as they embark on an attempt to quit, prior to them 
experiencing a lapse and the detrimental effects that a lapse may have (such as the Abstinence 
Violation Effect).(322)    
The second group of GLMs aimed to determine the effect of active versus placebo 
mouthspray on abstinence, taking into account pre-randomisation predictors of successful 
quitting.  The third batch of bivariate models included post-randomisation variables, in order 
to discover which characteristics of smokers and their attempts to quit, predict their prolonged 
abstinence, so smoking cessation workers can identify which of their patients need more 
assistance after they commence treatment, before they relapse. 
Statistical analyses that aimed to identify the predictors of abstinence, and how much those 
predictors exerted their effects on abstinence independently of each other, and how much their 
effects were similar, encountered the statistical issue of collinearity, which is discussed below. 
As stated previously, when more than one predictive variable is included as an independent 
variable in a GLM, there is a risk that two or more of the independent variables will have such 
a similar effect on the dependent variable that, the effects of these independent variables on 
the dependent variable are indistinguishable, which can lead to inflation of the error variances 
in the model, and this may cause the p-values for one or other, or both, of the two independent 
variables to become erroneously insignificant, and may cause the size of the odds ratios of 
those variables to be incorrect.(323)   
A common cause of collinearity is a high degree of correlation between the independent 
variables in a model.  However, correlation is not the only cause of collinearity, and due to the 
variability of the interplay between the potential causes of multicollinearity, there may be no 
accurate hard-and-fast rules-of-thumb or cut-off values for each of the potential causes, to 
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serve as guides to identify and avoid collinearity in all cases.  Despite this, some rules-of-
thumb are commonly used, and were followed in these analyses. 
The causes of collinearity include:  
1. a high degree of correlation between predictive variables,  
2. the magnitude of the effects of the independent variables on the dependent variable,  
3. the magnitude of the error variance,  
4. the variance of the independent variables,  
5. the amount of data, and  
6. the number of variables in the model.   
Hence, it may not be possible to completely avoid multicollinearity by simply measuring the 
size of the correlations between variables and only including variables in the GLM that are 
not highly correlated.  Nonetheless, extremely highly correlated variables are likely to cause 
collinearity, and also break the fundamental assumption of linear regression, that independent 
variables are not correlated and are truly independent of each other.  Correlation can arise if 
there is mathematical coupling between variables, which occurs if one variable directly or 
indirectly contains the whole or part of another variable (such as including scales from 
psychological batteries that are composed of the sum of other scales in the battery (for 
instance, the inclusion of both WISDM’s Tolerance scores and WISDM’s PDM scores as 
independent variables in a GLM, because the PDM scores are composed of the Tolerance 
scores summed with other scores).(323)   
Two methods to identify if collinearity has occurred, are to calculate the Variance Inflation 
Factor (VIF),(323, 324) or to calculate the Condition Index.(323)  The VIF has an advantage 
over simply looking at the correlations between two variables, because it simultaneously 
evaluates the correlation between a variable and all the other variables in the model.  The ‘vif’ 
function in the R language produces a single VIF score for each predictor in the model.  
Convention states that, if the VIF is equal to unity, there is no multicollinearity among the 
independent variable; but, if the VIF is greater than unity collinearity/multicollinearity may 
have occurred.  A commonly used rule-of-thumb, for which I could find no published 
justification, is to treat VIF scores that are greater than ten as an indication that the regression 
coefficients in the model are poorly estimated due to multicollinearity.     
95 
 
In addition to VIF, there are other methods of detecting collinearity and multicollinearity, 
such as the Condition Index.(323)  A Condition Index of thirty or higher has been proposed to 
indicate the need to investigate the possibility that collinearity has occurred.(325) 
Signs that one should be alert to, in order to know that it is necessary to check whether 
collinearity or multicollinearity has occurred and potentially biased the estimates, include 
observing any one of the following events after the addition of a new covariate to a model:  
1. a change of more than twenty percent in the size of the estimate of a variable that was 
already in the model after a new variable is added; 
2. a change of more than twenty percent in the size of the estimate of a variable after it is 
added to a model, compared to the size of its estimate in a univariate model; 
3. a change in the sign (positive or negative) of the estimate of a variable that was 
already in the model or the variable that had just been added to the model; 
4. a variable that is theoretically or biologically likely to be an important predictor, and 
which had been a statistically significant predictor, becomes non-significant after the 
addition of a new covariate, and the new covariate that had been significant in 
univariate regression also becomes non-significant once it enters the model.  The loss 
of significance of both the newly added covariate and an existing covariate, rather than 
only one variable losing its significance, suggests that collinearity has occurred rather 
than statistical adjustment. 
Several methods to overcome multicollinearity are available (323): 
1. Remove variables that are highly correlated. 
2. Centring and scaling the values of the variables that are also in an interaction term 
because this will reduce the correlation between the main effects of those variables 
and their interactive effects.  A variable is centred by subtracting the mean for that 
variable from each of the subjects’ values for that variable.  Scaling involves dividing 
the centred variables by the standard deviation of the variable.   
3. Centring and scaling regression models that contain polynomial terms (variables that 
have been squared, cubed, or raised to the power of four).     
4. Conduct a Principal Component Analysis (PCA) of the variables in the model and 
perform the original logistic regression that was plagued with collinearity, on the PCA 
scores of the Principal Components instead of using the raw data.  Principal 
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Component Analysis involves the transformation of data into variables (called 
components) that are linearly uncorrelated, the first variable (component) has the 
largest variance which represents the greatest amount of variability in the original data 
as possible, within the constraint that each principal component is orthogonal to the 
preceding components.  Component scores are orthogonal to each other and therefore 
less likely to be correlated.  Principal Component regression has been used by 
researches when there are a large number of correlated predictive variables which need 
to be reduced into components in order for linear regression to be accomplished, and 
has been employed in a range of research fields, such as, a study of the sensory 
properties of cigarettes,(326) predictors of infertility,(327) and gene expression in 
response to chronic nicotine exposure.(328) 
5. Adding a ridge (a small numerical constant to each of the explanatory variables in the 
model). 
Multicollinearity is not the only cause of variables that had been significant predictors in 
univariate regressions, losing this significance when they are combined in a multivariate 
model.  Other potential causes include: 
1. Loss of degrees of freedom: addition of more parameters from a given dataset, to the 
independent variables in a GLM, causes a reduction in precision, that leads to higher p-
values. 
2. Misspecified models: The underlying theory for t-statistics/p-values requires that the 
model be correctly specified.  In a univariate model, given that there is only one 
predictor, the chance is high that the univariate model may suffer from omitted variable 
bias. Hence, as more variables are added to the model, especially if they are highly 
predictive of the outcome, a variable that was a significant predictor in univariate 
regressions may lose its significance.  This is an example of statistical adjustment. 
In addition to the bias that may occur due to collinearity and multicollinearity, adjustment of 
the estimation of the effect of active treatment by post-randomisation covariates can also lead 
to bias.(329)  Furthermore, conducting post-stratification analyses based on post-
randomisation characteristics, may lead to bias (post-stratification is a method for adjusting 
the sampling weights, usually to account for under-represented groups in the population who 
are therefore under-represented in the sample).(330)  In this dissertation, some analyses were 
conducted which adjusted the effect of treatment assignment by post-randomisation events in 
order to generate hypotheses.  The justification for this approach is outlined below.  Despite 
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the dangers to validity from the use of adjustment by post-randomisation events, this 
technique is commonly used to gain further information and cast light on the mechanisms of 
the treatment effect,(331) for instance: 
1. White and colleagues used methods of analysis, to more accurately measure the 
difference in the treatment outcomes, between two treatments in an RCT, in which 
subjects in one group used more ‘rescue-therapy’ because of a worsening of their 
symptoms, compared to subjects in the other treatment group.(332)  The use of rescue 
medications is not randomised, and tends to obscure the inferiority of the drug in one 
treatment arm compared to the other, because subjects taking the less effective 
treatment can ameliorate their symptoms by use of rescue medication.  Simply using a 
per-protocol analysis that excludes data from subjects who used rescue medication 
would likely result in bias because subjects who used rescue-medication are likely to 
be very different from the other subjects in the trial.  White and colleagues proposed 
methods based on ranks or multilevel models to enable post-randomisation events 
such as the use of rescue-medication, to be taken into account when measuring the 
relative efficacy of two treatments.  Rank-based methods are non-parametric and 
assume that rescued patients have particularly unfavourable underlying outcomes. The 
multilevel regression model relates a patient’s outcome to allocated treatment and 
rescue status at each follow-up time-point, and requires correct modelling of all 
prognostic factors that predict starting rescue medication, and of the covariance 
between outcomes measured at different times (multilevel regression allows data that 
are repeatedly collected at each follow-up to be analysed in the same regression even 
though they are correlated).  White and colleagues outline how sensitivity analyses can 
be used over a range of possible models for the effect of rescue medication. 
2. Researchers have adjusted the estimate of the treatment effect by the level of patient 
compliance with taking the study medication.  Efron and Feldman discuss the issue of 
adjusting for treatment compliance in a placebo-controlled trial of a cholesterol-
lowering drug, in which there was a strong positive correlation between compliance 
and lower cholesterol levels in the active group, and a similar but not as strong effect 
in the placebo group.(333) 
3. Lin and colleagues adjusted the estimate of the treatment effect by a post-
randomisation biomarker, to evaluate whether this biomarker was able to act as a 
surrogate endpoint for the outcome of interest (the clinical endpoint).(334) 
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4. Rochon argues that it is not uncommon to adjust the estimate of the treatment effect by 
a post-randomisation variable in order to explore the therapeutic mechanism of the 
intervention, however such analyses should be treated as speculative and should only 
be used as an exploratory exercise to develop hypotheses for future research to test in 
RCTs.(335) 
3.3 Results 
Results are reported here and also in the Appendix B, the numbering of tables and figures that 
appear in Appendix B are prefaced with a capital B.  
3.3.1 Subjects 
Subjects were recruited between March 2010 and August 2011, the last subject completed in 
May 2012. A total of 1423 subjects were randomised. The flow of subjects through the study 
is illustrated in Figure 3.1, page 99.  Subjects in the two treatment groups were similar in their 
demographics and nicotine dependence at baseline, but the control group had slightly more 
prior attempts to quit smoking (Table 3.2, page 100).     
3.3.2 Abstinence 
The combination of active Zonnic and active nicotine patch yielded significantly higher 
prolonged and point-prevalence abstinence rates compared to placebo plus active nicotine 
patch, by all three definitions of prolonged abstinence (not smoked on seven consecutive 
days, not smoked on two consecutive weeks, not smoked even a puff in the past seven days), 
up to six months after the target quit date but, by nine- and twelve-months, only the first of 
these three measures of prolonged abstinence definitions was statistically significantly higher 
in the active group, (Table 3.3, page 101)).  Prolonged twelve-months abstinence (not smoked 
on seven consecutive days from end of grace period to twelve-months post-target-quit-date) 
was 10.1% (72/716) in the active group compared to 7.1% (50/707) in the control group, OR 
1.47 (95%CI:1.01—2.12), which was just within the p<0.050 level of significance.  
Adjustment for the single baseline characteristic that was significantly different between 
groups (number of prior quit attempts) did not materially alter the unadjusted values, and the 
number of prior quit attempts was not a significant predictor of abstinence.  Prolonged 
abstinence rates for the other two definitions of abstinence were similar to those shown in 































2408 people contacted the study 
Screened n=2286 
Attended baseline visit n=1425 
Ineligible n=374 




Withdrew consent n=1 
Placebo n=707; † n=54; ‡ n=11 
1
st




 Quit Phone n=178; †n=11; ₰n=76; ‡n=1 2nd Quit Phone n=193; †n=22; ₰n=81; ‡n=3 
1 month visit n=395; †n=53; ₰n=116; ‡n=4 1 month visit n = 341; †n=44;₰n=116; ‡n=6 
3 month visit n=228; †n=25; ₰n=47; ‡n=5 3 month visit n=186; †n=17; ₰n=48; ‡n=4 
6 month visit n = 154; †n=8; ₰n=18; ‡ n=3 6 month visit n = 123; †n=4; ₰n=20; ‡ n=3 
9 month phone n=131; †n=9; ₰n=22 9 month phone n=101; †n=4; ₰n=14 
12 month visit n = 104 12 month visit n = 86 
Active n=716; † n=49; ‡ n=8 
Not screened and LTFU n=122 
† Attended this visit/phone-call but LTFU after this stage; ₰ not abstinent at this stage and 




Table 3.2 Subject characteristics at Baseline. Median, mean, (interquartile range) 
Item  Active (n=716) Placebo (n=707) p 
Age (years) 47.0, 45.6 (38.0 to 53.0) 46.0, 45.3 (37.0 to 54.0) 0.67 
Female (%), 52.3 55.0 0.34 
European (%) 71.2 70.0 0.55 
Māori (%) 14.4 16.1 0.43 
CPD 20.0, 20.0 (15.0 to 25.0) 20.0, 20.0 (15.0 to 25.0) 0.92 
FTND 6.0, 6.1 (5.0 to 7.0) 6.0, 6.1 (5.0 to 7.0) 0.82 
eCO 5.0, 4.7 (4.0 to 6.0) 5.0, 4.7 (4.0 to 6.0) 0.47 
Age started smoking daily  15.0, 16.2 (14.0 to 17.0) 16.0, 16.2 (14.0 to 18.0) 0.30 
Live with other smoker(s), % 44.7 42.8 0.50. 
Number of smokers spend time with on typical day0: none; 1: 1-2; 2: 3-
5; 4: 6-10; 7: >10 
1.0, 1.4 (1.0 to 2.0) 1.0, 1.4 (1.0 to 2.0) 0.95 
Number of people know personally who quit smoking. n=1,415. 0: none; 
1: 1-2; 2: 3-5; 4: 6-10; 7: >10 
2.0, 2.1 (1.0 to 3.0) 2.0, 2.1 (1.0 to 3.0) 0.70. 
% who talked to professional about smoking cessation  72.6 72.9 0.90 
% who have a history of addiction to a drug other than smoking 14.9 16.4 0.49 
% have prior quit attempt 95.1 94.2 0.52 
% used NRT before 79.8 81.6 0.45 
Number of previous quit attempts 3.0, 4.5 (2.0 to 5.0) 3.0, 4.9 (2.0 to 5.0) 0.03 
Duration of most recent quit attempt (days), n=1323 21, 177 (4 to 84) 21, 247 (3 to 84) 0.18 
† n=number of subjects who provided data for this outcome.   
CPD average number of cigarettes smoked per day 
FTND Fagerström Test for Nicotine Dependence 




Table 3.3 Abstinence outcomes (not smoked on seven consecutive days)  
 





Unadjusted OR of active cf. 
control treatment predicting not 








OR 95%CI p 
1 34.4 24.6 1.60 1.27 to 2.02 6x10-5 
6 16.2 11.9 1.43 1.06 to 1.94 0.019 
9 13.5 10.7 1.30 0.95 to 1.80 0.107 
12 11.6 9.1 1.32 0.94 to 1.86 0.116 
6 months 
prolonged 
15.5 10.6 1.55 1.13 to 2.12 0.006 
9 months 
prolonged 
11.9 8.6 1.43 1.01 to 2.02 0.045 
12 months 
prolonged 
10.1 7.1 1.47 1.01 to 2.15 0.045 
† abstinence (not smoked on seven consecutive days) reported at follow-ups, missing 
outcomes imputed as not abstinent.  Outcomes reported at 1 month cover the period 
from the target quit date to 1 month later; outcomes at subsequent follow-ups cover the 
period of time from previous follow-up to the day of the follow-up in the table 
 
3.3.3 Biochemical Verification 
The majority of subjects who reported they were abstinent attended their follow-up visits and 
provided an eCO sample (Table 3.4, page 102).   Table 3.4 displays the number of subjects 
who claimed not to have smoked in the past seven days (which can be biochemically verified, 
unlike the claim not to have smoked on seven consecutive days or in two consecutive weeks 
which cannot be biochemically verified because the claim could be true even if eCO indicates 
smoking occurred within the past eight hours).  Approximately ten percent of subjects who 
claimed not to have smoked even a puff, had missing CO outcomes, and the number of 
missing CO samples did not differ significantly between treatment groups (Table 3.4).  
Subjects who failed to meet the primary definition for abstinence (not smoked on seven 
consecutive days) were given the option of withdrawing from the trial, which many chose to 
do, and hence would not have provided further eCO samples.  
3.3.4 Adverse effects 
Subjects in the active group reported significantly more severe adverse effects compared to 
the control group throughout the entire duration of the trial (Table B1, p355).  Adverse effects 
were predominantly upper gastrointestinal symptoms, and although more severe for the active 
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Table 3.4 Patterns and numbers of missing CO measurements, amongst subjects who reported how many puffs they smoked in the past 
seven days 
 
Active Group Control Group 
 
1 month 3 month 6 month 12 month 1 month 3 month 6 month 12 month 
Number who provided CO 324 200 127 91 279 159 102 74 
Number of missing CO values 392 516 589 625 428 548 605 633 
Number who missed CO but reported 
their abstinence 
61 27 25 12 47 27 20 12 
Number who missed CO and missed 
reporting their abstinence 
331 502 564 613 381 531 585 621 
Number who reported smoking not a 
puff and CO was missing  
18 15 17 6 6 10 8 6 
Total number who reported smoking 
not a puff 
168 144 106 77 121 96 77 66 
Missing CO and reported smoking not 
a puff as a % of those who reported 
smoking not a puff 
10.7 10.4 16.0 7.8 5.0 10.4 10.4 9.1 
Missing CO values as a % of 
randomised 
54.7 72.1 82.3 87.3 60.5 77.5 85.6 89.5 
Missing CO and abstinent at previous 
visit 
na 46 41 27 na 33 25 15 
p value for number who were missing 
CO in active compared to control 
groups 




Table 3.5.  Cigarette Evaluation Questionnaire scores for active and placebo mouthsprays  
 Active n= 716 
Median, mean (IQR) 
Placebo n = 707 
Median, mean (IQR) 
p value 
Baseline 
Satisfaction 12.0, 11.8 (8.0—15.0) 12.0, 12.4 (9.0—16.0) 0.006 
Satisfying 4.0, 4.2 (3.0—5.0) 4.0, 4.2 (3.0—5.0) 0.74 
Taste good 4.0, 3.9 (2.0—5.0) 4.0, 4.2 (3.0—6.0) 0.0008 
Enjoy 4.0, 3.7 (2.0—5.0) 4.0, 4.0 (3.0—5.0) 9x10-5 
Psychological reward 9.0, 10.9 (5.0—15.0) 8.0, 10.6 (5.0—14.0) 0.18 
Enjoyment of mouth and throat sensations 3.0, 2.9 (1.0—4.0) 3.0, 3.2 (1.0—5.0) 0.0009 
Craving reduction – immediate 3.0, 2.9 (1.0—4.0) 2.0, 2.5 (1.0—4.0) 8x10-5 
Craving reduction – within 15 minutes 4.0, 3.6 (2.0—5.0) 3.0, 3.3 (1.0—5.0) 0.002 
Aversion 2.0, 2.8 (2.0—3.0) 2.0, 2.3 (2.0—2.0) 2x10-11 
One Month after target quit date 
Satisfaction 10.0, 10.1 (6.0—14.0) 10.0, 10.5 (6.0—14.0) 0.38 
Satisfying n=655 4.0, 4.2 (3.0—6.0) 4.0, 4.0 (3.0—5.8) 0.07 
Taste good n=657 2.0, 2.8 (1.0—4.0) 3.0, 3.1 (1.0—5.0) 0.07 
Enjoy n=656 3.0, 3.1 (1.0—4.0) 3.0, 3.4 (2.0—5.0) 0.01 
Psychological reward 12.0, 13.2 (8.0—17.0) 11.0, 12.6 (7.0—17.0) 0.17 
Enjoyment of mouth and throat sensations 1.0, 2.2 (1.0—3.0) 1.0, 2.4 (1.0—4.0) 0.06 
Craving reduction – immediate 4.0, 4.0 (2.0—6.0) 4.0, 3.7 (2.0—5.0) 0.05 
Craving reduction – within 15 minutes 5.0, 5.1 (4.0—7.0) 5.0, 4.6 (3.0—6.0) 0.0007 
Aversion 2.0, 3.0 (2.0—4.0) 2.0, 2.4 (2.0—2.0) 0.0001 
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 Active n= 716 
Median, mean (IQR) 
Placebo n = 707 
Median, mean (IQR) 
p value 
Three Months after target quit date 
Satisfaction  10.0, 10.2 (6.0—14.0) 10.5, 10.9 (7.0—15.0) 0.24 
Satisfying  4.0, 4.1 (3.0—6.0) 4.0, 4.0 (3.0—5.8) 0.50 
Taste good  2.0, 2.9 (1.0—4.0) 3.0, 3.3 (1.0—5.0) 0.03 
Enjoy 3.0, 3.2 (1.0—4.0) 4.0, 3.6 (1.3—5.0) 0.10 
Psychological reward 12.0, 12.4 (8.0—17.0) 12.0, 13.0 (8.0—17.0) 0.71 
Enjoyment of mouth and throat sensations 1.0, 2.3 (1.0—3.0) 2.0, 2.7 (1.0—4.0) 0.049 
Craving reduction – immediate 4.0, 4.1 (2.0—6.0) 4.0, 3.7 (2.0—5.0) 0.03 
Craving reduction – within 15 minutes 5.0, 5.1 (4.0—7.0) 5.0, 4.6 (3.5—6.0) 0.003 
Aversion 2.0, 2.7 (2.0—2.0) 2.0, 2.3 (2.0—2.0) 0.005 
Individual items were rated on a scale from 1=not at all; 2=very little; 3=a little; 4=moderately; 5=a lot; 6=quite a lot; 7=extremely. 
Some outcomes are the sum of several items: 
• Satisfaction is the sum to three items (satisfying, taste good, enjoy) scores range from 3 (not at all) to 21 (extremely) 
• Psychological Reward is the sum of five items (calm down, more awake, less irritable, help concentrate, reduce hunger) score range from 5 to 35 
• Aversion is the sum of two questions (dizzy, nauseous) score 2 to 14 





versus placebo mouthspray, were generally mild and self-limiting.  By the six-month visit 
four of the ten side-effects that were measured, which had been significantly more severe in 
the active cf. control group at an earlier time-point, were no longer significantly more severe  
in one group compared to the other (cough, excess saliva, hurt throat, “other”); by the twelve-
month visit, the only significant differences in the severity of side-effects between groups, 
were hiccough and burping, which were significantly more severe in the active group.  
Adverse effects of patches were generally mild, with at least half of subjects experiencing 
mild itch early in the trial (Table B2, page 357). 
3.3.5 Sensory effects of the mouthspray 
Subjects’ perceptions of their first sprays of Zonnic, were measured at the baseline visit on the 
CEQ (Table 3.5, page 103).  Neither active nor placebo mouthsprays were particularly 
strongly liked when they were first used.   
Four CEQ scales and two of three items that make up the Satisfaction scale of the CEQ were 
significantly different between groups (at the level of p<0.05/9=0.0056 (Bonferroni correction 
for the nine comparisons (six scales plus three items) in Table 3.5).  Two of these significant 
differences favoured the active mouthspray (the active group reported higher ‘Immediate 
craving reduction’, and higher ‘Craving reduction within fifteen minutes’), while the 
remaining four significant differences favoured the placebo mouthspray (the control group 
reported higher Taste Good, Enjoy the mouthspray, Enjoyment of mouth and throat 
sensations, and lower Aversion).  At one- and three-months after subjects target quit dates, the 
active mouthspray continued to have significantly higher scores for ‘Craving Reduction 
within fifteen minutes’ and ‘Aversion’ cf. placebo mouthspray.  Beyond three months there 
were no significant differences in CEQ scores between groups, after Bonferroni correction for 
nine comparisons, hence data recorded after three months are not displayed in Table 3.5).  
3.3.6 Use of mouthspray and patches 
The amount of mouthspray and patches that subjects used was similar between active and 
control groups at all time-points, after Bonferroni correction for the six time-points when 
treatment adherence was measured, Table 3.6, page 106.  Subjects used relatively little of the 
spray, and used much less than the maximum dose of thirty sprays per day, despite being 
encouraged to use it whenever they had an urge to smoke and at the times of day when they 
would have previously routinely had a cigarette.  Most subjects stopped using Zonnic before 
they attended the six-months visit (Table 3.6).  At six months median daily use, amongst 
subjects still using their mouthspray, was three to four sprays per day.  Table 3.6 on page 106  
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Table 3.6 Amount of Zonnic and nicotine patches used (median, mean, IQR, number who answered, p-value 
 Quit phone 1 month 3 month 6 month 9 month 12 month 





2 to 4 
637 
4.0, 3.1 




1 to 4 
365 
3.0, 2.6 




0 to 4 
222 
1.0, 1.8 




0 to 3 
145 
1.0, 1.4 




1 to 3 
128 
1.0, 1.7 




0 to 2 
101 
0, 0.58 








1 to 6 
633 
2.0, 3.5 




1 to 5 
379 
3.0, 3.0 




0 to 3 
223 
1.0, 1.6 




1 to 4 
84 
2.0, 2.3 




0 to 2 
89 
0, 0.7 




0 to 2 
101 
0, 0.6 






†  †  1.0, 1.9 
0 to 3 
378 
1.0, 2.0 




0 to 3 
222 
1, 1.3 




0 to 9.5 
138 
0, 6.4 




†  †  0, 0.3 
0 to 0 
100 
0, 0.3 







3 to 4 
645 
4.0, 3.2 




3 to 4 
352 
4.0, 3.2 




2 to 4 
219 
4.0, 2.8 




0 to 4 
120 
3.0, 2.2 




1 to 1 
130 
1.0, 1.5 




0 to 0† 
84 
0, 0.3† 
0 to 0† 
64 
p=0.69 
Values in this table are median, mean, IQR, n, p. 
How often use ZONNIC recorded on a Likert scale: 0: ‘Never; 1: ‘Hardly ever’; 2: ‘Some days’; 3: ‘Most days’; 4: ‘Every day’ 
Average daily sprays of ZONNIC recorded on a Likert scale: 0: none, 1: 1-2, 2: 3-4, 3: 5-6, 4: 7-8, 5: 9-15; 6: >15 
How many sprays past 7 day recorded on a Likert scale: 0: none, 1: 1-20, 2: 21-30, 3: 31-40, 4: 41-50, 5: 51-60; 6: >60 
How many sprays past 7 days recorded on a Likert scale: 0: none, 1: 1-20, 2: 21-30, 3: 31-40, 4: 41-50, 5: 51-60; 6: >60 
How often use Patch. recorded on a Likert scale: 0: ‘Never; 1: ‘Hardly ever’ 2: ‘Some days’; 3: ‘Most days’; 4: ‘Every day’ 
† this outcome was not recorded at this time-point 




demonstrates that a few subjects continued to use Zonnic after six months.  Subjects who 
liked Zonnic were given generous supplies to make sure they had enough even if they 
misplaced their mouthspray.  Many subjects reported that the Zonnic was peppery and 
unpleasant, and that this discouraged them from using it more often.  However, the majority 
of subjects did not suffer severe adverse sensory effects, for instance, the median and mean 
severity of ‘hurt mouth’ at baseline was 0 and 0.2 respectively for both active and placebo 
(0=‘Not at all’; 1=‘Slight’).   
Nicotine patch use was more consistent than the use of mouthspray, with the median use to 
five months being on most days.  Patches were liked by more than half of subjects, with the 
median score of “like” for their opinion of patches in both treatment groups at the day after 
the target quit date phone-call (Table 3.7).  
Table 3.7.  Results of the phone-call a day after the target quit date (raw data) 
 Active  











How well subjects felt they were doing 
with their quit attempt. 1 = ‘Not at all’; 2 = 
‘Slight’ 3 = ‘Moderate’; 4 = ‘Quite a bit’; 5 = ‘Extreme’ 
4.0, 3.7 
(3.0 – 4.0) 
4.0, 3.8 
(4.0 – 4.0 
0.0680 
Frequency of patch. 1 = ‘Never; 2 = ‘Hardly 
ever’ 3 = ‘Sometimes’; 4 = ‘Most days/nights’; 5 = 
‘Every day/night’. n= 1,274 
5.0, 4.4 
(4.0 – 5.0) 
5.0, 4.2 
(4.0 – 5.0) 
0.0395 
Frequency of patch at night. 1 = ‘Never; 2 = 
‘Hardly ever’ 3 = ‘Sometimes’; 4 = ‘Most nights’; 5 = 
‘Every night’. n=674 
4.0, 3.2 
(1.0 – 5.0) 
3.0, 3.1 
(1.0 – 5.0) 
0.4012 
Severity of side-effects of Patches. 1 = 
‘Not at all’; 2 = ‘Slight’ 3 = ‘Moderate’; 4 = ‘Quite a bit’; 5 
= ‘Extreme’ 
2.0, 2.2 




Like Patches. 1 = ‘Strongly dislike’; 2 = ‘Dislike’; 
3= ‘Neutral’; 4 = ‘Like’; 5 = ‘Strongly like’ 
4.0, 3.6 
(3.0 – 4.0) 
4.0, 3.5 
(3.0 – 4.0) 
0.1475 
Frequency of Zonnic. 1 = ‘Never; 2 = ‘Hardly 
ever’ 3 = ‘Sometimes’; 4 = ‘Most days/nights’; 5 = 
‘Every day/night’ 
5.0, 3.0 
(3.0 – 5.0) 
5.0, 4.1 
(3.0 – 5.0) 
0.9151 
Sprays of Zonnic per day. 0: 0; 1: 1-2; 3: 3-5; 
4: 6-10; 5:>10 
3.0,3.3 
(2.0 – 4.0) 
3.0, 3.3 
(2.0 – 4.0) 
0.2036 
Severity of side-effects of Zonnic. 1 = ‘Not 
at all’; 2 = ‘Slight’ 3 = ‘Moderate’; 4 = ‘Quite a bit’; 5 = 
‘Extreme’ 
2.0, 2.1 
(1.0 – 3.0) 
1.0, 1.7 
(1.0 – 2.0) 
2x10-8 
Like Zonnic. 1 = ‘Not at all’; 2 = ‘Slight’ 3 = 
‘Moderate’; 4 = ‘Quite a bit’; 5 = ‘Extreme’ 
3.0, 2.7 
(2.0 – 4.0) 
3.0, 2.7 
(2.0 – 4.0) 
0.4143 
How well coping with urges. 1 = ‘Not at all’; 
2 = ‘Slight’ 3 = ‘Moderate’; 4 = ‘Quite a bit’; 5 = 
‘Extreme’ 
4.0, 3.6 
(3.0 – 4.0) 
4.0, 3.4 




 Active  











How well coping with withdrawal. 1 = ‘Not 
at all’; 2 = ‘Slight’ 3 = ‘Moderate’; 4 = ‘Quite a bit’; 5 = 
‘Extreme’  
4.0, 3.7 
(3.0 – 5.0) 
4.0, 3.6 
(3.0 – 4.0) 
0.0054 
Quit status.  1: ‘Not quit, overdue to quit’, 2: ‘Has 
quit but quit late’, 3: ‘Has quit, quit on time’’, 4: ‘Has 
quit, quit early’. 
3.0, 2.6 
(1.0 – 4.0) 
2.0, 2.3 
(1.0 – 4.0) 
0.0085 
How confident will quit/stay quit. 1 = ‘Not at 
all’; 2 = ‘Slight’ 3 = ‘Moderate’; 4 = ‘Quite a bit’; 5 = 
‘Extreme’ 
4.0, 3.9 
(3.0 – 5.0) 
4.0, 3.9 
(3.0 – 5.0) 
0.4116 
Intend to continue. 1 = ‘Not at all’; 2 = ‘Slight’ 3 
= ‘Moderate’; 4 = ‘Quite a bit’; 5 = ‘Extreme’ 
5.0, 4.3 
(4.0 – 5.0) 
5.0, 4.3 
(4.0 – 5.0) 
0.2897 
The statistical significance of the comparisons of values between groups was measured 
using the Mann-Whitney test. 
 
For every one unit increase in subjects’ liking of patches score a day after the quit phone-call, 
their odds of achieving prolonged not smoked on seven consecutive days increased by 
OR=1.45 (Table 3.8).  How often subjects wore the patches, reported at the quit phone-call, 
significantly increased the odds of prolonged six-months not smoked on seven consecutive 
days in univariate regression of centred and scaled data by OR=2.30, (Table 3.8).  Subjects 
with a greater liking of patches, also reported using patches more often (ρ=0.47, 
95%CI:0.42—0.51, p=2x10-16).  The majority of subjects had no side-effects from nicotine 
patches, except at one month after the target quit date when the median scores for ‘red marks 
on the skin’ and ‘itch’ were both one in both treatment groups, and at three months after the 
target quit date when the median score for itch was one in both groups (0=‘Not at all’; 
1=‘Slight’), at no time was the severity of patch side-effects more severe in one group 
compared to the other after Bonferroni correction. 
Table 3.8.  Outcomes from a day after target quit date phone-call (data were centred 
and scaled, each row is a separate univariate model, the dependent variable in the 
models was six months prolonged not smoked on seven consecutive days 
abstinence); these analyses were per protocol; missing values were ignored. 
 
OR 95%CI p 
Severity of side effects of mouthspray 0.78 0.64—0.94 0.0100 
Severity of side effects of patches 0.85 0.72—1.01 0.0767 
How well subjects think they are coping 
with withdrawal symptoms 
1.21 1.03—1.44 0.0266 
Opinion of mouthspray score 1.44 1.19—1.75 0.0002* 




OR 95%CI p 
How many sprays of mouthspray used per 
occasion 
1.50 1.27—1.78 3x10-6* 
How often mouthspray used per day 1.53 1.27—1.88 2x10-5* 
How often Patch worn at night 1.62 1.27—2.09 0.0002* 
How well subjects think they are coping 
with urges to smoke 
2.05 1.67—2.55 2x10-11* 
How well subjects think they are coping 
with quitting 
2.09 1.69—2.63 7x10-11* 
How confident subjects think they are that 
they are going to quit/remain quit 
2.19 1.75—2.78 3x10-11* 
Intend to continue to try to quit / to remain 
quit 
2.28 1.71—3.20 3x10-7* 
How often patches were worn 2.30 1.74—3.21 1x10-7* 
Quit status: not quit/ quit late/ quit on time/ 
quit early 
3.53 2.71—4.74 7x10-19* 
* p<0.05/14=0.00357 
The statistical significance of the comparisons of values between groups was measured using the 
Mann-Whitney test. 
 
The potential for subjects’ demographics and characteristics of their smoking habits recorded 
prior to randomisation, as well as their initial reactions to the mouthspray at baseline, plus, 
how much they reported liking the mouthspray at the quit phone-call, to predict how many 
sprays of Zonnic they used per occasion of using it, at the time of the phone-call a day after 
their target quit date, was investigated by bivariate GLMs, with the number of sprays of 
Zonnic used per occasion, as the dependent variable, and treatment assignment plus a variable 
measured at baseline or, the quit phone-call, as the independent variables (Table 3.9, page 
110).  These GLM were conducted in three groups, one group contained sixteen baseline 
variables measured prior to randomisation as independent variables, another group was 
composed of six baseline variables measured after randomisation as independent variables, 
while the third group contained one variable measured at the target quit phone-call as an 
independent variable.   
Three subject characteristics recorded before randomisation were significant predictors of the 
number of sprays of mouthspray used per occasion at the quit-phone-call, after Bonferroni 
correction for sixteen comparisons.  Two of these variables predicted greater use of Zonnic 
(male gender, and ‘average number of cigarettes smoked per day’).  The third variable, 
enrolment at a Māori community trial site, significantly predicted lower use of Zonnic (but 
being of Māori ethnicity was not significantly predictive, Table 3.9).  Two other variables   
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Table 3.9. Baseline and quit phone-call predictors of number of sprays used per 
occasion Zonnic was used at the quit phone-call.  Each row in this table reports the 
outcome of one bivariate GLM (one unique GLM per row), with the variable in the 
“variable” column and treatment assignment as the two independent variables. 
Variable OR 95%CI p 
Pre-randomisation 
Male Gender 1.19 1.12—1.25 1x10-9 ‡ 
Baseline average number of cigarettes 
smoked per day (CPD) 
1.13 1.07—1.19 3x10-5 ‡ 
Enrolled at Māori community trial site 0.80 0.76—0.84 7x10-16 ‡ 
Number of smokers spend time with on 
typical day 
1.06 1.01—1.12 0.0299 † 
WISDM Social/environmental Goads 0.94 0.89—1.00 0.0385 † 
Age started smoking daily 1.05 0.99—1.11 0.1012 
Age 1.05 0.99—1.11 0.1117 
Years of smoking 1.03 0.98—1.09 0.2805 
Baseline FTND 1.03 0.97—1.09 0.2976 
WISDM Taste 1.02 0.97—1.08 0.4195 
Number of personal acquaintances who 
have quit 
1.02 0.97—1.08 0.4634 
Number of previous quit attempts 1.01 0.95—1.07 0.7878 
NZDep2006 0.99 0.94—1.05 0.8385 
Previously used NRT 0.99 0.93—1.04 0.6481 
Live with other smoker(s) 0.96 0.91—1.02 0.1632 
Māori ethnicity 0.96 0.90—1.01 0.1351 
Post-randomisation experience of Zonnic at baseline 
CEQ Enjoy 1.23 1.17—1.30 9x10-14 ‡ 
CEQ Enjoyable respiratory sensations 1.19 1.13—1.26 3x10-10 ‡ 
Zonnic hurt mouth score 0.92 0.87—0.97 0.0038 † 
Zonnic hurt throat score 0.93 0.88—0.98 0.0083 † 
Nausea after using Zonnic 0.99 0.93—1.04 0.6084 
Zonnic relieved urge to smoke within 15 
minutes 
1.05 0.98—1.12 0.1858 
Post-randomisation experience of Zonnic reported at quit phone-call 
Opinion of Zonnic score (how much liked 
Zonnic) 
1.80 1.69—1.92 8x10-67 ‡ 
† p<0.05 




were significant predictors at the level of (0.05/16)<p<0.05, both relating to social aspects of 
smoking, one decreasing while the other increasing Zonnic use (Number of smokers spend 
time with on typical day, and WISDM Social/environmental Goads, respectively).  FTND did 
not predict the amount of Zonnic used, nor did age, age started smoking daily, and the number 
of years between first starting to smoke and current age.  How enjoyable subjects’ first 
experience of Zonnic was at the baseline visit, and the intensity of mouth and throat irritation 
reported at baseline, significantly predicted Zonnic use at the phone-call a day after the target 
quit date, after Bonferroni correction (ORs 1.23, 0.92, and 0.93, respectively).  Subjects’ with 
a more favourable opinion of Zonnic at the day after target quit date phone-call, had used 
almost twice the amount of Zonnic as those who did not like Zonnic. 
Although there was no significant difference in the number of sprays of mouthspray used per 
occasion it was used between Māori and non-Māori (Table 3.9), Māori used Zonnic on 
significantly fewer days than non-Māori between baseline and the quit phone-call (median of 
‘most days’ cf. ‘every day’, p=0.0002). There were no significant ethnic differences in side-
effects at baseline nor the quit phone-call.  For the sample as a whole, with all ethnicities 
combined, the side-effect of hurt mouth at baseline, was significantly negatively correlated 
with the number of sprays of Zonnic used each time Zonnic was used ρ=-0.08 95%CI -0.14–-
0.03, p=0.004. 
Greater use of mouthspray was significantly associated, after Bonferroni correction for ten 
comparisons, with not having smoked on seven consecutive days at the next follow-up at the 
target quit phone-call when the two treatment groups were combined and in the control group, 
but not the active group (Table 3.10, page 113).  The only other times when greater use of 
mouthspray was followed by this abstinence outcome was, in the active group at nine months, 
and the control group at one month post target quit-date.  Reverse-causation was avoided by 
recording use of Zonnic before abstinence was measured.  In these calculations, bias due to 
missing abstinence outcomes was avoided by penalised imputation of missing abstinence 
outcomes; however, the use of Zonnic was what was reported by subjects, with no imputation. 
Not only did the number of sprays taken per occasion when mouthspray was used prior to the 
target quit date phone-call, significantly predict immediately subsequent abstinence, it also 
significantly predicted six- and twelve-months prolonged abstinence, whether only complete 
data on the use of mouthspray were used (per-protocol analysis) or, missing data on the 
amount of Zonnic used were imputed using a range of assumptions about the values of 
missing data (Table 3.13, page 122).  At the quit call, 592/637 (93%) and 576/619 (93%) 
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reported having used their mouthspray after the baseline visit, in the active and control 
groups, respectively.  The OR, adjusted for treatment assignment, for use of mouthspray, and 
achieving twelve-months prolonged abstinence was 1.41 (95%CI:1.20—1.68, p<0.0001).  
However, this estimate of the effect of the amount of Zonnic used, on abstinence, may be 
biased because it is a post-randomisation effect and is on the causal pathway between 
treatment and abstinence.   
 
In an effort to limit bias from missing data, in estimating the impact of the amount of Zonnic 
use on prolonged twelve-months abstinence, missing data were imputed with a range of 
values (none, median, first quartile and third quartile).  In these models with imputed values, 
which all included treatment assignment as an independent predictor, the OR for use of 
Zonnic varied from the lowest value of 1.38 (95%CI 1.17, 1.64) when missing data were 
imputed with the third quartile, to the highest value of 1.47 (95%CI 1.26, 1.72) when missing 
data were imputed with the first quartile, while the OR when median use was imputed was 
1.46 (95%CI 1.24 to 1.74).   
3.3.7 Urges to smoke and withdrawal symptoms 
Compared to baseline, urges to smoke reduced significantly in both treatment groups at all 
time-points throughout the trial, with subjects in the active group experiencing significantly 
greater reductions in total urge scores compared to the control group, after Bonferroni 
correction for comparisons at four time-points (p<0.0125), at six months (Table 3.11).   
Nicotine withdrawal scores significantly reduced in both treatment groups at three, six, and 
twelve months compared to the scores at the one-month visit, for most of the five scales of the 
MNWS (Table B3, page 359), nicotine withdrawal was not measured at baseline in the 
mouthspray trial.  There were no significant differences in withdrawal scores between groups 
after Bonferroni correction for five scales of the MNWS) (Table B3).  There were no 
statistically significant interactions between treatment assignment and the scores of any of the 
five scales of the MNWS at any follow-up time-point, in predicting prolonged six months not 
smoked on seven consecutive days, revealing that the deleterious effects of MNWS scores on 
abstinence were the same in both treatment groups. 
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Table 3.10  Average number of sprays of active or placebo Zonnic used per day, and abstinence at the subsequent follow-up time-point, 


























3.18 2.85 0.0213 2.97 3.08 0.5686 3.31 2.62 0.0002 
Three 
month 
Six month 1.54 1.83 0.0940 1.31 1.88 0.0422 1.70 1.78 0.6449 




4.36 6.98 0.0065 2.53 10.00 0.0042 5.98 7.50 0.2598 
Bonferroni correction for five comparisons (effect of Average daily Zonnic use at Quit call, and 1, 3, 6, 9 and 12 month abstinence respectively) = 
0.05/5 = 0.01  
Bonferroni correction for ten comparisons (effect of Average daily Zonnic use at Quit call, and 1, 3, 6, 9 and 12 month abstinence respectively, in the 





Table 3.11. Brief-Questionnaire of Smoking Urges (complete-case analysis). Median change in total QSU score compared to baseline 
score. Negative numbers indicate a reduction in urge 
Time-point One month Three month Six month Twelve month 
 Active Placebo Active Placebo Active Placebo Active Placebo 
Change in total score -8 -6 -8 -6 -8 -4 -8 -6 
n 342 296 214 179 139 115 96 79 
p-value intra-group 2x10-16 2x10-16 2x10-16 2x10-16 2x10-16 2x10-16 2x10-16 2x10-16 





3.4 Intention to treat and missing data 
To determine if missing abstinence outcomes were Missing Completely At Random, Missing 
At Random, or Not Missing At Random, it is necessary to test whether the missingness is 
related to any of the observed variables.    
Whether the prolonged not smoked on seven consecutive days outcome was missing or not, 
was significantly correlated with variables recorded during the trial (Table F1 in Appendix F, 
page 440).  These variables included pre-randomisation baseline variables such as: 
1. subject characteristics,  
2. how motivated subjects were to reduce smoking,  
3. smokers’ motives for smoking,  
4. the trial site location where subjects chose to enrol;  
and post-randomisation baseline variables such as: 
1. side-effects of the mouthspray, and  
2. ratings of mouthspray on the CEQ. 
Given that a large number of variables were tested to see if they were correlated with 
missingness, it is necessary to adjust the level of significance to account for multiple 
comparisons.  Bonferroni adjustment must be used rather than Holm-Bonferroni adjustment 
because I had no a priori hypotheses about which order to use in making Holm-Bonferroni 
adjustments (no a priori decision about which variable would be the most statistically 
significant, which variable would be second-most significant, and so on).  Sixty-one variables 
were tested for their capacity to predict missingness at six time-points, resulting in 366 
comparisons, Bonferroni correction requires that significance be set to p<0.000136612.  The 
correlations of thirty-five variables with missingness were significant after Bonferroni 
adjustment for 366 comparisons (Table F1 in Appendix F, page 440), many of which were 
also correlated with abstinence status among subjects whose abstinence outcomes were not 
missing.  Therefore, missing abstinence data were Missing Not at Random.   
One variable was significantly predictive of missingness at the target quit phone-call after 
Bonferroni correction for 366 comparisons: 
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1. Greater baseline ‘determination to reduce smoking’ was significantly correlated with 
abstinence outcomes not being missing. 
Three variables were significantly predictive of missingness at every follow-up time-point 
except the target quit date phone-call:  
1. younger age,  
2. higher baseline FTND scores,  
3. enrolling at a non-University, community trial site. 
Two variables were significantly predictive of missingness at every follow-up time-point 
except the target quit date phone-call and twelve-months follow-up, after Bonferroni 
correction for 366 comparisons:  
1. Māori ethnicity; 
2. Higher Social/Environmental Goads scores 
Age started smoking daily, and higher WISDM Tolerance scores, were significantly 
predictive of missingness after Bonferroni correction for 366 comparisons, at two time-points.  
Greater NZDep2006 scores were significantly predictive of missingness after Bonferroni 
correction for 366 comparisons, at three-time-points. 
Four variables were significantly predictive of missingness after Bonferroni correction for 366 
comparisons at one time-point:  
1. “Number of smokers spend time with on typical day” predicted missingness a month 
after the target quit date. 
2. Higher CEQ-Satisfaction scores at baseline were significantly correlated with not 
having missing abstinence outcomes at three months. 
3. Higher CEQ-Enjoy Respiratory Sensations scores at baseline were significantly 
correlated with not having missing abstinence outcomes at three months. 
4. Greater determination at baseline, to reduce smoking, was significantly correlated 
with less chance of missing abstinence outcomes at the target quit-date. 
Several methods of handling missing abstinence data were used, which were compared in a 
sensitivity analysis.  The outcome of prolonged six months not smoked on seven consecutive 
days was used for these analyses.  The methods used were: complete case analysis, penalised 
imputation, and multivariate imputation performed by the mice package in the R language.   
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The results for active treatment assignment predicting six months prolonged not smoked on 
seven consecutive days with penalised imputation was OR=1.55, 95%CI:1.13—2.12, 
p=0.006.  The same analysis using complete-case analysis found that active treatment 
increased abstinence by OR=1.63 95%CI:1.05—2.55, p=0.029, but this analysis excluded 978 
observations due to missingness (978/1423, 68.73% of randomised subjects). 
3.4.1 Selection Model 
The selection model approach to accounting for missing outcomes is based on creating a score 
of subjects’ propensities to have missing values.  Three months was the time-point chosen to 
measure the propensity to have missing data because this was the midway point in the trial.  
Eight variables significantly predicted missing abstinence outcomes three months after the 
target quit date:  
1. Age 
2. Enrolled at Maori community trial site 
3. WISDM Tolerance 
4. NZDep2006 
5. Māori ethnicity 
6. CEQ psychological reward 
7. CEQ enjoy respiratory sensations 
8. Previously tried to quit 
Of these eight variables, two also significantly predicted prolonged six-months abstinence 
1. Age 
2. Enrolled at Maori community trial site 
When age and enrolment at a community versus university trial site were used in a selection 
model to create scores for all subjects’ odds of having missing abstinence outcomes, and these 
scores were included with active treatment in a logistic regression predicting six-months 
prolonged abstinence, the effect of active treatment was OR=1.55, 95%:1.13—2.14, 
p=0.0067.  When all eight variables that were predictive of missingness were used to calculate 
a score for each subjects’ likelihood of having missing abstinence outcomes three months 
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after their target quit dates, the effect of active treatment on six-months prolonged not smoked 
on seven consecutive days abstinence was OR=1.60, 95%CI: 1.15—2.24, p=5x10-13. 
3.4.2 Multivariate imputation with the mice package 
The mice package in the R language uses multivariate imputation to impute incomplete 
multivariate data by chained equations.  An advantage of the mice package for handling 
missing data in this trial, is that mice is capable of imputing missing values that are Missing 
Not At Random (MNAR).(336) 
Mice was used to impute missing six-months prolonged not smoked on seven consecutive 
days abstinence outcomes, based on the values of as wide a range of variables as possible that 
were related to the likelihood of missingness and abstinence, in order to increase the accuracy 
of the imputed values.  Multiple imputation only avoids bias, if enough variables are included 
in the imputation model that are predictive of missing values.(278)  The missing abstinence 
outcomes were imputed based on the following variables: Treatment assignment, Age, 
baseline CPD, Māori ethnicity, NZDep2006, average number of standard drinks of alcohol 
drunk per week at baseline, age started smoking daily, history of addiction (binary yes/no had 
addiction to substances other than smoking tobacco in the past), Live with other smoker(s) 
(binary yes/no), number of other smokers spend time with per day on a typical day, personally 
know a smoker who has quit smoking (binary yes/no), baseline Desire to Reduce Smoking, 
baseline Determined to Reduce Smoking, baseline Prepared to forgo the pleasure of smoking, 
baseline Prepared to handle stress without smoking, baseline WISDM-37 Automaticity, 
WISDM-37 Loss of control, WISDM-37 Craving, WISDM-37 Cue exposure, WISDM-37 
Social/Environmental Goads, WISDM-37 Tolerance, WISDM-37 Weight control, WISDM-
37 Total, Trial site at university location (binary yes/no), baseline CEQ (modified Cigarette 
Evaluation Questionnaire) Satisfaction, baseline CEQ Psychological Reward, baseline CEQ 
Enjoy Respiratory Sensations, baseline Hiccough Side-effect, baseline Hurt Mouth Side-
effect.  These data were converted into a matrix and used by mice to impute missing data 
values. 
Mice identified that there were 1,307 missing data patterns in the aforementioned matrix.  
Seven of the most common missing patterns are listed below, from most common to less 
common: 




2. 245 subjects had no missing data. 
3. 164 subjects were missing six-months prolonged not smoked on seven consecutive 
days and history of addiction. 
4. Fifty-nine subjects were only missing history of addiction. 
5. Ten subjects were missing six-months prolonged not smoked on seven consecutive 
days and age started smoking daily. 
6. Six subjects were missing six-months prolonged not smoked on seven consecutive 
days, history of addiction, and age started smoking daily. 
7. Five subjects were missing six-months prolonged not smoked on seven consecutive 
days and the number of smokers they spend time with on a typical day. 
After fifty iterations of data imputation, the pooled results showed that in a univariate model 
of active treatment assignment predicting six months prolonged not smoked on seven 
consecutive days, the effect of active treatment was OR=1.43, 95%CI 1.15-1.79, p=0.0013.  
The estimates of the effect of active treatment attained from the four methods of imputation 
used in these analyses, were not significantly different from each other because the ORs for 
each method of imputation were within the 95%CI estimated by the other methods of 
imputation.    
Table 3.12 (page 120) displays the estimates of active treatment on six months prolonged not 
smoked on seven consecutive days provided by the different methods used to handle missing 
abstinence values.  The highest estimate of abstinence was found with complete case analysis, 
which is consistent with the argument that this method was most likely to bias the estimate 
towards being higher, because subjects who were abstinent may be more likely to report their 
abstinence status than those who were not abstinent.  Notably, complete case (per protocol) 
analysis included the lowest number of subjects compared to the other analyses, which leaves 
scope for bias with this method because it excludes many subjects.   
Penalised imputation produced the second highest estimate of the effect of active treatment 
and used data from all subjects.  However, failure to be abstinent is not the only reason why 
subjects would not have reported their abstinence outcomes, other reasons that are unrelated 
to abstinence status exist (such as being too busy or having changed contact details thereby 
not receiving reminders to attend), so it is potentially unreasonable to impute all missing 
outcomes as non-abstinent.  However, in order for this to bias the estimate of treatment effect, 
the reasons for missingness that are related to abstinence would have to be differentially 
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present across the two treatment groups (for example if the treatment in one group caused a 
side-effect which made it more difficult for subjects in that treatment group to respond to 
researchers’ attempts of contact them to record their abstinence outcomes).  The results of the 
multiple imputations from the mice package are the least likely to be biased because mice 
included data from all subjects, used Bayesian techniques to ensure that the uncertainty 
around the effects of all the variables in the model were incorporated into the estimate of the 
effect of active treatment, and it estimate had the narrowest 95%CI.(278)    
Table 3.12. Estimates of active treatment predicting prolonged not smoked on seven 
consecutive days by different methods of handling missing abstinence outcomes 




Complete case 1.63 1.05-2.55 0.029 351 
Penalised Imputation 1.55 1.13-2.12 0.006 1423 
Selection Model 1.60 1.15-2.24 5x10-13 1423 
Multiple Imputation 1.43 1.15-1.79 0.001 1423 
 
3.5 Predictors of abstinence 
The following paragraphs report the results of analyses of whether or not the values of 
variables, recorded at a variety of time-points, were predictive of prolonged abstinence.  
These analyses encountered methodological dilemmas due to collinearity, for which several 
methods were used to account for collinearity, which are reported below.   
At the beginning of the conduct of the statistical analysis, analyses were performed on the raw 
data after it had been data-cleaned.  Some of the bivariate regressions suggested that 
collinearity was likely to have occurred because, there were instances where two variables, 
that had been highly statistically significant predictors of abstinence when they were each in 
univariate models, both became insignificant when they were both entered together into a 
bivariate model predicting abstinence.  Hence, the analyses were re-run, using data that had 
been centred and scaled.   
Centring and scaling the data improved variables’ Condition Index scores and Variance 
Inflation Factor scores but, failed to remove all suspicion that collinearity had occurred, hence 
Principal Component Analysis (PCA) of the data was conducted, and logistic regressions 
were calculated based on the PCA component scores.   
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Techniques to identify if collinearity had occurred, failed in this trial.  For instance, the cut-
off of ten for VIF failed to detect collinearity in this trial: when Tolerance and PDM, which 
were both highly significantly predictive of abstinence in univariate models, were included in 
the same model, neither was a significant predictor anymore.  This is likely due to collinearity 
because they were very highly statistically significantly correlated with each other ρ=0.13, 
95%CI 0.08–0.18, p=6x10-7, albeit the correlation was very weak.  Yet, the VIF for these 
variables were smaller than ten (3.26 and 2.49, respectively). 
Not all of the analyses using these three approaches to missing data were patently tainted by 
collinearity and hence the results of these analyses are presented below. 
3.5.1 Raw data 
The analyses in this section of the dissertation were based on raw data which had been 
cleaned by deleting data whose values were implausible or contradictory and were therefore 
likely to be data-entry errors.   
3.5.1.1 Univariate regressions 
Table 3.13, page 122, displays the univariate influence of seventy-eight variables, that had the 
greatest effects on the odds that subjects would achieve abstinence, including variables that 
were recorded pre- and post-randomisation, Bonferroni correction for seventy-eight 
comparisons would require p<0.0006.  Thirty-six of these variables were measured prior to 
randomisation, Bonferroni correction for thirty-six comparisons would require 
p<0.05/36=0.00139.   
The variable measured prior to randomisation, which had the most disadvantageous effect on 
prolonged six-months not smoked on seven consecutive days was Māori ethnicity (OR=0.39, 
p=0.001), closely followed by enrolling at a Māori community trial site (OR=0.39, p=0.002), 
the next most detrimental variables were having previously used NRT (OR=0.59, p=0.004), 
and scores of the Social/Environmental Goads scale of the brief-WISDM psychological 
battery (OR=0.78; p=4x10-8).  The pre-randomisation variables that were most highly 
predictive of increased odds of prolonged six-months not smoked on seven consecutive days 
abstinence, were ‘currently aged 50 years or older’ (OR=2.10, p=3x10-6), ‘started smoking 
daily aged sixteen years or older’ (OR=1.58, p=0.004), “how prepared subjects’ felt they were 
to handle stress without smoking” (OR=1.23, p=0.02), and ‘number of personal acquaintances 
who have quit’ (OR=1.20, p=0.005).  
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Table 3.13.  Univariate predictors of prolonged six and twelve months not smoked on seven consecutive days 
  Prolonged six months abstinence Prolonged twelve months 
abstinence 
# Univariate Predictor OR 95%CI p OR 95%CI p 
Pre-randomisation predictors 
1 NZDep2006 (A measure of socioeconomic deprivation, 
rated from 1 to 10 with 10 being the most deprived) 
0.93 0.88–0.98 0.0098 0.92 0.86–0.98 0.0149 
2 Male gender 1.17 0.86–1.59 0.33 1.09 0.75–1.58 0.65 
3 Number of previous quit attempts1 1.01 0.99–1.02 0.15 1.00 0.97–1.02 0.930 
4 Māori ethnicity 0.39 0.21–0.67 0.001 0.48 0.23–0.89 0.03 
5 Enrolled at Māori community trial site 0.39 0.23–0.62 0.0002 
 ۞ 
0.37 0.18–0.66 0.002 
6 Current Age (years) 1.04 1.02–1.05 1x10-6 
 ۞ 
1.04 1.03–1.06 7x10-7 
֍ 
7 Currently aged ≥50 years 2.10 1.54–2.87 3x10-6 
 ۞ 
2.59 1.78–3.80  9x10-7 
֍ 
8 Started smoking daily aged 16 years or older 1.58 1.16–2.17 0.004 1.80 1.23–2.66 0.003 
9 Age started daily smoking 1.06 1.02–1.10 0.0008 1.07 1.03–1.12 0.0003 
֍ 
10 Baseline FTND 0.86 0.79–0.94 0.0008 0.90 0.81–1.00 0.04 
11 Baseline eCO 0.88 0.78–0.99 0.0394 0.91 0.79–1.01 0.23 
12 Number smokers that subjects spend time with on typical 
day 
0.87 0.74–1.01 0.07 0.81 0.67–0.98 0.03 
13 Previously used NRT (yes cf. no) 0.59 0.42–0.85 0.0040 0.58 0.38–0.89 0.01 
14 Number of personal acquaintances who have quit 1.20 1.06–1.36 0.005 1.28 1.10–1.50 0.002 
15 Do you live with other smokers? Yes/no 0.71 0.51–0.98 0.04 0.62 0.41–0.91 0.017 
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  Prolonged six months abstinence Prolonged twelve months 
abstinence 
# Univariate Predictor OR 95%CI p OR 95%CI p 
16 How prepared did subjects’ feel they were to handle stress 
without smoking (recorded at baseline) 
1.23 1.04–1.45 0.02 1.20 0.98–1.47 0.08 
17 How prepared did subjects’ feel they were to forgo the 
pleasure of smoking 
1.12 0.96—1.32 0.16 1.15 0.95—1.41 0.15 
18 How much subjects desired to reduce their smoking 0.89 0.76—1.04 0.13 0.82 0.68—0.98 0.0272 
19 How determined subjects were to reduce their smoking 0.91 0.78—1.06 0.22 0.86 0.71—1.03 0.09 
20 How much subjects desired to quit smoking 1.08 0.92—1.27 0.35 1.05 0.87—1.28 0.59 
21 How determined subjects were to reduce their smoking 1.05 0.90—1.23 0.55 1.04 0.87—1.27 0.65 
22 Affiliative Attachment† 0.97 0.90–1.06 0.53 0.98 0.89–1.08 0.70 
23 Automaticity † 0.90 0.83–0.99 0.02 0.89 0.80–0.99 0.03 
24 Loss of control † 0.90 0.81–1.01 0.07 0.90 0.79–1.04 0.14 
25 Cognitive enhancement † 1.01 0.93–1.10 0.77 1.01 0.92–1.12 0.81 
26 Craving † 0.92 0.82–1.03 0.14 0.89 0.78–1.03 0.10 
27 Cue exposure/Associative Processes † 0.95 0.85–1.05 0.31 0.91 0.81–1.04 0.16 
28 Social/environmental goads † 0.78 0.71–0.85 4x10-8 
 ۞ 
0.76 0.68–0.85 2x10-6 
֍ 
29 Taste † 1.04 0.95–1.14 0.44 1.00 0.90–1.11 0.97 
30 Tolerance † 0.79 0.71–0.88 1x10-5 
 ۞ 
0.81 0.71–0.92 0.007 
31 Weight control † 1.07 0.99–1.17 0.10 1.05 0.94–1.16 0.38 
32 Affective enhancement † 0.94 0.86–1.03 0.20 0.94 0.84–1.05 0.26 
33 Total WISDM score † 0.98 0.97–1.00 0.027 0.98 0.96–1.00 0.03 
34 Primary Dependence Motives (PDM) †  0.81 0.71–0.92 0.002 0.80 0.68–0.94 0.007 
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  Prolonged six months abstinence Prolonged twelve months 
abstinence 
# Univariate Predictor OR 95%CI p OR 95%CI p 
35 Secondary Dependence Motives (SDM) † 0.91 0.79–1.06 0.23 0.87 0.73–1.04 0.13 
36 QSU Baseline 1.00 0.98–1.01 0.5719 0.99 0.98–1.01 0.35 
Post-randomisation predictors 
1 Active mouthspray 1.55 1.13–2.12 0.0064 1.47 1.01–2.15 0.0454 
2 How confident did subjects feel they were going to quit / 
going to stay quit recorded a day after the target quit date* 
2.06 1.68–2.57 3x10-11 
 ۞ 
1.73 1.38–2.21 6x10-6 
֍ 
3 Had quit by target quit date follow-up phone-call*  9.65 6.21–15.61 4x10-22 
 ۞ 
7.51 4.48–13.31 3x10-13 
֍ 
4 How strongly subjects intend to continue to quit smoking at 
target quit date phone-call? *   
2.12 1.63–2.88 3x10-7 
 ۞ 
2.55 1.76–3.99 6x10-6 
֍ 
5 At the one-month post target quit date, of subjects who 
attended this visit, the subject reported amount smoked for 
all of the first 14 days after baseline (cf. subjects who 
attended the visit but did not record CPD for all fourteen 
days of first fortnight) * 
3.83 2.60–5.77 3x10-11 
 ۞ 
3.75 2.36–6.20 7x10-8 
֍ 
6 At the one-month post target quit date, reported smoking on 
average more than 50% fewer cigarettes per day than at 
baseline during the first fortnight after baseline.* 
1.58 1.06–2.40 0.03 1.31 0.83–2.09 0.26 
7 How confident did subjects feel they were going to stay quit 
after the nine-month phone-call? * 
NA NA NA 2.97 2.11–4.44 1x10-8 
8 How well subjects felt they were coping with withdrawal 
symptoms at the nine-month phone-call* 
NA NA NA 1.63 1.28–2.14 0.0001 
9 How strongly did subjects intend to continue to be abstinent 
from smoking recorded at nine-month phone-call? *  
NA NA NA 7.38 3.38–19.99 9x10-6 
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  Prolonged six months abstinence Prolonged twelve months 
abstinence 
# Univariate Predictor OR 95%CI p OR 95%CI p 
10 Number of sprays taken per occasion when mouthspray 
was used reported 24 hours after target quit date (per 
protocol, missing data were ignored) * 
1.39 1.21–1.59 3x10-6 
 ۞ 
1.40 1.19–1.66 6x10-5 
֍ 
11 Number of sprays per occasion mouthspray was used 
reported 24 hours after target quit date (missing imputed as 
none) * 
1.44 1.28–1.62 3x10-9 
 ۞ 
1.43 1.24–1.65 1x10-6 
֍ 
12 Number of sprays per occasion mouthspray was used 
reported 24 hours after target quit date (missing imputed as 
1st quartile) * 
1.46 1.28–1.67 1x10-8 
 ۞ 
1.46 1.25–1.71 2x10-6 
֍ 
13 Number of sprays taken per occasion when mouthspray 
was used reported 24 hours after target quit date (missing 
data were imputed with median value) * 
1.44 1.26–1.66 3x10-7 
 ۞ 
1.45 1.23–1.72 1x10-5 
֍ 
14 Number of sprays per occasion mouthspray was used 
reported 24 hours after target quit date (missing imputed as 
3rd quartile) * 
1.34 1.17–1.55 4x10-5 
 ۞ 
1.37 1.16–1.63 3x10-4 
֍ 
15 Number of sprays per occasion mouthspray was used 
reported 24 hours after target quit date (missing imputed as 
the maximum recorded (10 sprays) * 
1.21 1.07–1.37 0.0034 1.23 1.06–1.44 0.0072 
16 How well subjects felt they were coping with urges to smoke 
a day after the target quit date * 
1.93 1.60–2.36 2x10-11 
 ۞ 
1.85 1.48–2.34 2x10-7 
֍ 
17 How well subjects felt they were coping with withdrawal 
symptoms a day after the target quit date * 
1.19 1.02–1.39 0.0266 1.19 0.99–1.44 0.0701 
18 How well subjects felt they were coping with urges to smoke 
at the nine-month phone-call * 
NA NA NA 2.36 1.81–3.24 6x10-9 
19 QSU 1 month* 0.97 0.94–1.00 0.0371 0.96 0.92–0.99 0.0220 
20 QSU 3 month* 0.89 0.85–0.93 5x10-7 
 ۞ 




  Prolonged six months abstinence Prolonged twelve months 
abstinence 
# Univariate Predictor OR 95%CI p OR 95%CI p 
21 QSU 6 month* 0.87 0.82–0.91 7x10-7 
 ۞ 
0.86 0.79–0.91 2x10-5 
֍ 
22 QSU 12 month* NA NA NA 0.88 0.81–0.94 0.0014 
 MNWS subscale scores       
 One month       
23 Craving* 0.55 0.46–0.66 5x10-11 
 ۞ 
0.60 0.49–0.73 6x10-7 
֍ 
24 Restlessness* 0.93 0.79–1.09 0.3559 0.99 0.82–1.18 0.9171 
25 Appetite* 1.17 1.02–1.34 0.0281 1.16 0.99–1.35 0.0709 
26 Negative affect* 0.91 0.86–0.97 0.0046 0.89 0.82–0.96 0.0040 
27 Insomnia* 0.89 0.81–0.97 0.0082 0.87 0.78–0.97 0.0141 
 Three month       
28 Craving* 0.49 0.40–0.60 2x10-11 
 ۞ 
0.55 0.44–0.69 2x10-7 
֍ 
29 Restlessness* 0.82 0.67–0.99 0.0424 0.85 0.68–1.04 0.1308 
30 Appetite* 1.13 0.96–1.34 0.1405 1.02 1.00–1.43 0.0453 
31 Negative affect* 0.86 0.80–0.93 0.0002 
 ۞ 
0.87 0.79–0.95 0.0024 




  Prolonged six months 
abstinence 
Prolonged twelve months 
abstinence 
# Univariate Predictor OR 95%CI p OR 95%CI p 
 Six month       
33 Craving* 0.30 0.22–0.41 7x10-15 
 ۞ 
0.41 0.31–0.54 1x10-9 
֍ 
34 Restlessness* 0.63 0.47–0.82 0.0009 0.61 0.44–0.81 0.0013 
35 Appetite* 1.32 1.01–1.77 0.05 1.11 0.88–1.41 0.3711 
36 Negative affect* 0.84 0.76–0.93 0.0008 0.85 0.76–0.94 0.0030 
37 Insomnia* 0.85 0.73–0.98 0.0286 0.83 0.71–0.97 0.0219 
 Twelve month       
38 Craving* N/A N/A N/A 0.41 0.28–0.57 6x10-7 
֍ 
39 Restlessness* N/A N/A N/A 0.71 0.46–1.08 0.1036 
40 Appetite* N/A N/A N/A 1.49 1.02–2.30 0.0514 
41 Negative affect* N/A N/A N/A 0.94 0.80–1.12 0.50209 
42 Insomnia* N/A N/A N/A 0.88 0.70-1.12 0.2957 
1 There was a significant difference between treatment groups for this variable at baseline despite randomisation. 
† subscale of the brief-WISDM 
* post-randomisation variable 
۞ p < 0.000396825 (Bonferroni correction for 126 comparisons (63 comparisons with both prolonged six and twelve months)  
֍ p < 0.000367647 correct for (Bonferroni correction for 136 comparisons (63 comparisons with both prolonged six and twelve months, plus ten comparisons only 
with prolonged twelve months abstinence) 
eCO = expired carbon monoxide 




The variable, recorded after randomisation, with a particularly consistent effect on abstinence 
after Bonferroni correction was MNWS-Craving, for which, at every follow-up timepoint, 
higher scores significantly predicted lower abstinence at six and twelve months (Table 3.13, 
page 122).  After Bonferroni correction, QSU scores recorded at three- and six-months 
predicted abstinence at six- and twelve-months after subjects’ target quit dates. 
For the outcome of prolonged six months not smoked on seven consecutive days, twenty-one 
variables were predictive in univariate GLMs after Bonferroni correction for 126 comparisons 
(63 variables that were assessed for predicting both six- and twelve-months prolonged 
abstinence), Table 3.13, page 122.  
In univariate regression, active cf. control treatment increased six months prolonged not 
smoked on seven consecutive days by OR=1.55, 95%CI:1.13—2.12, p=0.006.  Many 
variables influenced the odds that subjects would achieve abstinence, in addition to whether 
subjects had received active or placebo mouthspray, such as subjects’ ages and their FTND 
scores (Table 3.13, page 122).   
Of the twenty-one variables that were statistically significant predictors of abstinence in 
univariate GLMs after Bonferroni correction for 126 comparisons, nine predicted a reduced 
chance of prolonged six months abstinence: 
1. three variables that were measured prior to randomisation:  
a. enrolled at Māori community trial site; and  
b. the scores of two brief-WISDM sub-scales: Social/Environmental Goads and 
Tolerance; and  
2. six variables measured after randomisation:  
a. MNWS Craving score at one, three, and six months post-target quit date 
(MNWS was not recorded at baseline),  
b. MNWS Negative Affect score at three months post-target quit date,  
c. brief-QSU total score at one- and three-months post-target quit date. 
Twelve variables predicted an increased chance of attaining of prolonged six months 
abstinence, the variables with the largest beneficial effect included: 
1. one pre-randomisation variables: ‘being 50 years old or older’ (OR=2.10). 
2. eleven variables recorded post-randomisation: 
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a. having quit on or before the target quit date (OR=9.7);  
b. having attended the one-month post-target quit date visit and fully completed 
the record of CPD for the first fortnight of the trial, compared to attending the 
one month visit and not fully completing the diary card of CPD for the first 
fortnight of the trial, (OR=3.8); 
c. strongly wanting to continue trying to quit or remain abstinent and continue to 
participate in the trial, recorded the day after the target quit date (OR=2.1),  
d. being highly confident that one will quit/stay abstinent, measured a day after 
the target quit date (OR=2.1),  
e. how well subjects were coping with their urges to smoke reported a day after 
the target quit date (OR=1.9), and  
f. how much Zonnic subjects reported using a day after the target quit date by all 
five of the methods of dealing with missing data.   
For the outcome of prolonged twelve months not smoked on seven consecutive days (Table 
3.13, page 122), twenty-four variables were predictive at the p<0.00037 level of significance 
(Bonferroni correction for 136 comparisons), of which seven predicted a reduced chance of 
abstinence, and seventeen predicted an increased chance of abstinence, all twenty-four of 
these variables were post-randomisation events.  Of these twenty-four significant variables, 
the variables with the smallest ORs were the Craving subscale scores of the MNWS recorded 
at one, three, six and twelve months post-target quit date (OR=0.60, 0.55, 0.41, 0.41, 
respectively); while the variables with the largest OR were, having quit on or before the target 
quit date, intending to continue being abstinent reported at the nine-month phone-call, 
recording the amount smoked every day of the first fortnight of the trial, how confident 
subjects were that they would continue to remain abstinent reported at the nine-month phone-
call, aged fifty or older at baseline, how strongly subjects intended to stay quit/continue to try 
to quit at the quit phone-call, and how well subjects felt they were coping with urges to smoke 
at nine-months phone-call (ORs for the first four of these variables were 7.51, 7.38, 3.75, 
2.97).   
Thirteen scales were invented as part of this dissertation, to index potential factors that may 
influence subjects’ chances of achieving and maintaining abstinence (Table 3.13, page 122), 
the variables recorded after randomisation are marked with an asterisk: 
1. number of personal acquaintances who have quit 
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2. do you live with other smokers? Yes/no 
3. number smokers that subjects spend time with on typical day 
4. how prepared did subjects feel they were to handle stress without smoking  
5. how prepared were subjects to forgo the pleasure of smoking 
6. how much subjects desired to reduce their smoking 
7. now determined subjects were to reduce their smoking 
8. how much subjects desired to quit smoking 
9. how determined subjects were to quit smoking 
10. previously used NRT (yes cf. no). 
11. how well subjects felt they were coping with urges to smoke on target quit date and 
nine-month phone-call* 
12. how well subjects felt they were coping with withdrawal symptoms on target quit date 
and nine-month phone-call* 
13. how strongly subjects intended to continue to try to quit/remain abstinent, recorded 
after quit phone-call a day after the target quit date, and at the nine-month phone-call* 
The effects of these thirteen variables on prolonged six- and twelve-months abstinence (not 
smoked on seven consecutive days) were measured in univariate models (Table 3.13, page 
122).  Bonferroni correction for thirteen comparisons would require p<0.05/13=0.0038.  Of 
these thirteen variables, “Previously used NRT” had the most negative effect on both six- and 
twelve-month prolonged abstinence (OR=0.58 and 0.59, respectively) however although this 
was significant at p<0.05 for both outcomes, they were not significant after Bonferroni 
correction.  The variable with the next most negative effect on six- and twelve-months 
prolonged abstinence was “live with other smoker(s)” (OR=0.71 and OR=0.62, respectively), 
which were significant at p<0.05 but not after Bonferroni correction.  Of the thirteen 
variables, the four with the biggest effect of increasing abstinence, were recorded at the nine-
month phone-call and related to how well subjects felt they were coping with withdrawal 
symptoms, and urges to smoke; how confident subjects felt they were going to stay quit, and 
how strongly subjects intended to continue to be abstinent from smoking (the ORs ranged 




3.5.1.2 Bivariate regressions and exploration of potential for collinearity 
Bivariate models of 467 pairs of variables that potentially predicted six months prolonged 
abstinence were run, and their VIF scores and Condition Indices were calculated to determine 
if collinearity had occurred.  Table 3.14, page 132, displays the most extreme results of these 
analyses, together with the results of the corresponding univariate GLM for each variable in the 
bivariate GLMs, along with the Pearson’s correlation coefficient, Condition Index and VIF 
score for each pair of variables in the bivariate models.  These results demonstrate that the OR 
for some variables changed dramatically in bivariate compared to univariate regressions, 
(ranging from, a thirty-six percent decrease, to an eighty-nine percent increase).  These changes 
in ORs may be due to one variable “legitimately” adjusting the value of another variable 
because one variable was the true cause of the outcome while the other was a confounder; or, 
may be due to collinearity.   
Amongst the most extreme changes in ORs in bivariate regressions compared to univariate 
regressions, the VIF was always below ten, however in many cases the Condition Index was 
thirty or higher.  Frequently, the pairs of variables that had high Condition Indices were pairs 
in which one variable was mathematically related to the other variable, a phenomenon 
referred to as mathematical coupling (as was the case for the highest Condition Index of 666 
for ‘WISDM Total' scores when in a bivariate model with ‘WISDM SDM’ scores as the other 
predictive variable).  However, not all large Condition Indices were for pairs of variables in 
which mathematical coupling could be responsible for the large Condition Indices.  For 
instance, age (expressed in years) had a Condition Index of 205 when it was adjusted by 
whether or not the subject lived with another smoker (which itself had a Condition Index of 
88), notably the correlation coefficient between these pairs of variables was very small 
(ρ=-0.10), indicating that these variables are unlikely to be mathematically related and their 
correlation was negligible.   
A high correlation was not a prerequisite for a high Correlation Index, for instance, Māori 
ethnicity and Age had only a weak correlation of -0.27, but these variables had Condition 
Indices of 128 and 195, respectively, when they were entered as independent variables in a 
bivariate model predicting six months prolonged abstinence.   
Although the size of the correlation between variable is not the only factor that may lead to 
collinearity in logistic regressions, it can play an important role, hence a correlation matrix of 
predictor variables was constructed.  This correlation matrix showed that the most highly 
correlated variables were the estimates of all six methods of handling missing data on the use  
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Table 3.14.  Bivariate regression to determine the effects of two variables on prolonged six months not smoked on seven consecutive days, adjusted by each other (note these models used raw data 
and some were subject to multicollinearity) 











































Decreases in OR displaying the largest to smaller decreases 
-36.27 Aged≥50 2.10 1.54 2.87 3x10-6 1.34 0.79 2.26 0.28 105 Age -1.04 1.04 1.02 1.05 1x10-6 1.02 1.00 1.05 0.04 283 0.85 2.8 
-21.66 Start≥16 1.58 1.16 2.17 0.004 1.24 0.82 1.86 0.31 38 Age start -1.48 1.06 1.02 1.10 0.0008 1.04 1.00 1.09 0.06 84 0.65 1.7 
-18.01 Start≥16 1.58 1.16 2.17 0.004 1.30 0.94 1.79 0.12 11 Social 0.31 0.79 0.72 0.86 3x10-6 0.79 0.72 0.86 4x10-7 6 -0.15 1.0 
-16.85 Aged ≥50 2.10 1.54 2.87 3x10-6 1.74 1.27 2.40 0.0007 11 Social 1.59 0.79 0.72 0.86 3x10-6 0.80 0.73 0.87 1x10-6 6 -0.20 1.0 
-13.21 PDM†† 0.81 0.71 0.92 0.002 0.70 0.55 0.89 0.003 7 
Loss of 
control†† 
28.44 0.90 0.81 1.01 0.07 1.16 0.95 1.42 0.15 35 0.85 3.1 
-13.10 SDM 0.87 0.73 1.04 0.13 0.79 0.66 0.94 0.008 3 
Weight 
control 
9.45 1.07 0.99 1.17 0.10 1.17 1.06 1.30 0.002 8 0.37 1.5 













0.06 1.01 0.99 1.02 0.15 1.01 1.00 1.03 0.14 8 0.21 1.0 
-11.66 SDM 0.91 0.79 1.06 0.23 0.80 0.66 0.98 0.03 4 Cognitive 9.99 1.01 0.93 1.10 0.77 0.80 0.66 0.98 0.03 15 0.76 1.9 
-9.92 Start≥16 1.58 1.16 2.17 0.004 2.03 1.48 2.78 1x10-5 10 Tolerance 1.99 0.79 0.71 0.88 1x10-5 0.79 0.71 0.88 2x10-5 25 -0.05 1.0 
Increases in estimate of OR displaying the increases from largest to smaller 
89.28 SDM 0.91 0.79 1.06 0.23 1.72 1.14 2.62 0.0105 45 
WISDM 
total 























0.90 0.81 1.01 0.07 1.16 0.95 1.42 0.15 35 PDM†† -13.21 0.81 0.71 0.92 0.002 0.70 0.55 0.89 0.003 7 0.85 3.1 
27.00 PDM 0.81 0.71 0.92 0.002 1.02 0.83 1.27 0.8190 7 Tolerance -1.09 0.79 0.71 0.88 1x10-5 0.78 0.66 0.92 0.0033 30 0.70 2.5 
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0.39 0.23 0.62 0.00021 0.46 0.27 0.75 0.0031 10 Social 0.64 0.79 0.72 0.86 3x10-6 0.79 0.72 0.87 5x10-7 8 0.06 1.0 
19.03 SDM 0.91 0.79 1.06 0.23 1.08 0.92 1.27 0.33 4 Social -2.10 0.79 0.72 0.86 3x10-6 0.77 0.70 0.85 2x10-7 9 0.15 1.2 




0.90 0.81 1.01 0.07 1.05 0.92 1.20 0.50 37 Tolerance -2.06 0.79 0.71 0.88 1x10-5 0.77 0.68 0.88 6x10-5 9 0.53 1.4 
13.50 Affective 0.94 0.86 1.03 0.20 1.07 0.92 1.24 0.3849 45 
WISDM 
Total 
-0.74 0.98 0.97 1.00 0.027 0.98 0.95 1.00 0.0345 239 0.72 2.3 
12.23 Māori 0.39 0.21 0.67 0.0015 0.44 0.23 0.75 0.0055 128 Age -0.10 1.04 1.02 1.05 1x10-6 1.03 1.02 1.05 3x10-6 195 -0.27 1.0 
12.13 Māori 0.39 0.21 0.67 0.0015 0.43 0.23 0.76 0.0060 17 NZDep 2.08 0.92 0.86 0.98 0.0149 0.95 0.90 1.00 0.0741 13 0.19 1.0 
 
CoI 1st Condition Index for first variable   
CoI 2nd Condition Index for second variable 
† the VIF scores for the first and second variables were equal in these bivariate regressions. 
Social = WISDM Social/Environmental Goads  
Start≥16 = Started smoking aged ≥16 years 
Age start = Age started smoking daily 
Cognitive = WISDM Cognitive enhancement 





of Zonnic recorded at the target quit date phone-call, which were perfectly correlated (ρ=1).  
One pair of variables had a correlation coefficient of 0.90<ρ<1.00 (WISDM’s SDM score and 
WISDM’s total score).   
Seven pairs of variables had a correlation coefficient of 0.80≤ρ<0.90: 
1. Age in years and the age category of 50 years of age or more;  
2. WISDM’s PDM and WISDM’s Loss of Control;  
3. WISDM’s PDM and WISDM’s Craving;  
4. WISDM’s PDM and WISDM’s total;  
5. WISDM’s Craving and WISDM’s total score;  
6. WISDM’s Affective and WISDM’s SDM;  
7. WISDM’s Affective and WISDM’s total. 
Six pairs of variables had a correlation coefficient of 0.70≤ρ<0.80: 
1. WISDM’s Total score with WISDM’s Affiliative Attachment; 
2. WISDM’s Total score with Loss of Control; 
3. WISDM’s Total score with Cognitive Enhancement; 
4. WISDM’s Cognitive Enhancement with WISDM’s Affective; 
5. WISDM’s Cognitive Enhancement with WISDM’s SDM; 
6. WISDM’s Cognitive Enhancement with WISDM’s Total score. 
Seventeen pairs of variables had a correlation coefficient of 0.60≤ρ<0.70: 
1. How well subjects though they were coping with their urges to smoke at the nine-
month phone-call and the degree to which they intended to continue to try to quit/stay 
quit and continue participating in the trial at the nine-month phone-call; 
2. Age started smoking daily (in years) and the categorical variable ‘started to smoke 
daily aged sixteen or older’; 
3. Brief-QSU total score at the one month visit and the brief-QSU total score at the six-
month visit; 
4. MNWS Negative Affect at three month visit and MNWS Craving at three-month visit; 
5. MNWS Negative Affect at three months and MNWS Negative Affect at one month; 
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6. MNWS Negative Affect at three months and MNWS Restlessness at three months; 
7. WISDM Affiliative Attachment and WISDM Affective; 
8. WISDM Affiliative Attachment and WISDM PDM; 
9. WISDM Affiliative Attachment and WISDM SDM; 
10. WISDM Total and WISDM Automaticity; 
11. WISDM Craving and WISDM Loss of Control; 
12. WISDM Craving and WISDM Cognitive Enhancement; 
13. WISDM Craving and WISDM Affective; 
14. WISDM Craving and WISDM SDM; 
15. WISDM PDM and WISDM Tolerance; 
16. WISDM PDM and WISDM Affective; 
17. WISDM PDM and WISDM SDM. 
Many of the large correlations between variables, were the result of mathematical coupling, 
for example the PDM synthetic scale is composed of the Tolerance score added to the scores 
of several other WISDM scales, furthermore the total score is the sum of the scores of all the 
WISDM scale.  Failure to use appropriate statistical methods to handle correlated predictive 
variables can lead to erroneous estimates of their effects on the dependent variable.(301) 
Given how common collinearity was in the bivariate models, as indicated by the Condition 
Index, methods were investigated to overcome or avoid collinearity and multicollinearity, 
starting with centring and scaling the variables.  The results of these analyses are presented in 
the next sub-chapters of this dissertation (Chapter 3.5.2, page 142).   
Not all analyses of the raw data were patently affected by collinearity, and offer useful 
insights into the relationships between variables, some of which are reported here, after which 
analyses that employed centred and scaled data are reported.  Correlation tests and Mann-
Whitney tests, were calculated, to explore potentially causal relationships amongst the raw 
data in the bivariate regressions.   
Subjects who had previously used NRT were older (median age forty-seven versus forty-five, 
p=0.0038), which may be expected to increase their likelihood of abstinence.  However, 
subjects who had previously used NRT, smoked more cigarettes per day at baseline, which 
was a predictor of lower prolonged six months abstinence (p=0.02).  Having previously used 
136 
 
NRT was not associated with FTND, socio-economic deprivation, the amount of Zonnic used 
reported a day after the target quit date, Māori ethnicity, nor the choice to enrol at a Māori 
community trial site. 
Subjects who were older had a persistent increased likelihood of maintaining six- and twelve-
months prolonged abstinence.  Variables that were associated with increased abstinence, were 
more common among older subjects.  Older subjects were more likely to know more people 
who have quit (p=0.0012), started smoking daily at the age of sixteen or older (p=0.0110),, 
and were less likely to be socio-economically deprived (median five cf. six, p=0.0119), less 
likely to live with other smokers (p=2x10-5), less likely to be Māori (p=0.0063) and less likely 
to enrol at a Māori community trial site (p=0.0035).  Age was not associated with baseline 
FTND. 
In univariate models, baseline FTND and baseline eCO were significantly associated with 
prolonged six months not smoked on seven consecutive days abstinence but, although FTND 
was significantly (p=0.04) associated with prolonged twelve months not smoked on seven 
consecutive days, eCO was not.  The correlation between FTND and eCO was calculated, to 
determine if subjects with higher nicotine dependence had a higher eCO, which might be 
expected to be the case if more highly nicotine dependent people smoked more and had a puff 
typography that promoted absorption of more CO (stronger draw of air through the cigarette, 
a longer breath-hold), an extremely small but statistically significant correlation was found 
(ρ=0.11, 95%CI 0.06–0.16, p=3x10-5).   
In univariate models, three scales of the brief-WISDM were significantly predictive of six- 
and twelve-months prolonged abstinence at p<0.0038: Social/Environmental Goads, 
Tolerance and PDM.  In order to avoid collinearity, the correlations between these three 
variables was calculated (PDM is the sum of Tolerance and three other subscales).  
Social/Environmental Goads was negligibly but highly statistically significantly correlated 
with Tolerance ρ=0.15, 95%CI 0.10–0.20, p=3x10-8, and with PDM (ρ=0.13, 95%CI 0.08–
0.18, p=6x10-7.  Tolerance was very strongly positively correlated with PDM (ρ=0.77, 95%CI 
0.74–0.79, p<2x10-16. 
Subjects who reported coping better with their urges to smoke a day after their target quit 
date, also reported using more sprays of Zonnic (ρ=0.25, 95%CI 0.20–0.30, p<2x10-16).  This 
correlation between coping with urges and use of more sprays of Zonnic, was highly 
statistically significant, but only a weak, positive relationship.   
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In order to determine if this correlation was strong enough to lead to collinearity and thereby 
mask the effects of these correlated variables on prolonged abstinence, three sets of GLM 
were run, one set of GLMs consisted of a univariate GLM for each of the variables ‘how well 
subjects felt they were coping with urges to smoke a day after the target quit date’, and ‘how 
many sprays of Zonnic they were using’ at that time; the second set of GLM consisted of one 
bivariate GLM with both the aforementioned variables as its independent variables, while the 
third set of GLMs contained the same independent variables as the first set, but also included 
treatment assignment (Table 3.15, page 138).  One group of GLMs had prolonged six-month 
abstinence as the dependent variable, while the other set of GLMs had prolonged twelve 
months abstinence as the dependent variable.  These models demonstrated that both ‘how well 
coping with urges’ and ‘how many sprays of Zonnic used on average’ remained statistically 
significant predictors of prolonged six and twelve months abstinence after their effects on 
abstinence were adjusted by each other in bivariate GLM, and also remained statistically 
significant when treatment assignment was added as an independent variables, which suggests 
that the estimates of effects of these variables on abstinence had not been masked by 
collinearity, and that each of these three variables had an independent effect on abstinence.  
When an interaction term was added between ‘how many sprays of Zonnic were used on 
average reported a day after the target quit date’, and treatment assignment, the interaction 
term was not significant, which indicates that use of more sprays of mouthspray resulted in 
the same increased chance of attaining abstinence in the placebo group as the active group.   
3.5.1.3 Urges to Smoke and Withdrawal symptoms 
Urges to smoke and withdrawal symptoms are thought to play a pivotal role in maintaining 
smokers’ addiction to tobacco smoking and prompting relapse after attempts to desist from 
smoking.  Therefore, the role played by subjects’ scores on two psychological batteries that 
measure urges to smoke and the intensity of withdrawal symptoms were calculated. 
The role that subjects’ urges to smoke played in subjects’ ability to quit and maintain their 
prolonged abstinence was explored in univariate regressions, and bivariate regressions that 
adjusted for treatment assignment.  The brief-QSU was administered at baseline, and the one, 
three, six, and twelve months follow-ups.  Univariate regressions of the role of QSU total 
score showed that early after the target quit date, the intensity of subjects’ urges to smoke had 
a mildly deleterious effect on prolonged six- and twelve-months abstinence and this effect 
became more pronounced for urge measured three- and six-months after subjects target quit 
dates (Table 3.16).  Bonferroni correction for comparing QSU scores recorded at five time-
points for two abstinence outcomes would require p<0.05/(5*2)=0.005, a threshold met by  
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Table 3.15 Uni-variate, bi-variate and tri-variate models of ‘How well subjects felt they were coping with urges a day after target quit date’ 
and ‘How many sprays of Zonnic taken on average reported one day after quit date’ (note some of these models may have been subject 
to multicollinearity). 
 Prolonged six month not smoked on seven 
consecutive days 
Prolonged twelve months not 
smoked on seven consecutive days 
  OR 95%CI p OR 95%CI p 
Uni-variate GLM 
 How well coping with urges 1.93 1.60–2.36 2x10-11 1.85 1.48–2.34 2x10-7 
 Number of sprays of Zonnic taken on average 1.39 1.21–1.59 3x10-6 1.40 1.19–1.66 6x10-5 
Bi-variate GLM  
 How well coping with urges 1.88 1.54–2.31 1x10-9 1.79 1.42–2.30 2x10-6 
 Number of sprays of Zonnic taken on average  1.25 1.09–1.45 0.0020 1.28 1.08–1.53 0.0056 
Tri-variate GLM 
 How well coping with urges 1.85 1.52–2.28 3x10-9 1.77 1.39–2.27 5x10-6 
 Number of sprays of Zonnic taken on average  1.26 1.09–1.46 0.0017 1.28 1.08–1.53 0.0051 







QSU total scores at three and six months as predictors of prolonged six- and twelve-months 
abstinence, and by QSU scores at twelve months as a predictor of prolonged twelve months 
abstinence.  QSU scores early in subjects’ participation in the trial had less of an effect on 
lowering prolonged abstinence and were less statistically significant than QSU scores 
measured later on. 
Table 3.16.  Brief-QSU total scores at baseline, one, three, six and twelve months as 
univariate predictors of prolonged six and twelve month not smoked on seven 
consecutive days (Each row reports results from two separate GLM, each predicting 
one of the two durations of prolonged abstinence). 
 Prolonged six months Prolonged twelve months 
Brief-QSU total 
score 
OR 95%CI p OR 95%CI p 
QSU Baseline 1.00 0.98–1.01 0.5719 0.99 0.98–1.01 0.35 
QSU 1 month 0.97 0.94–1.00 0.0371 0.96 0.92–0.99 0.0220 
QSU 3 month 0.89 0.85–0.93 5x10-7 0.89 0.84–0.94 6x10-5 
QSU 6 month 0.87 0.82–0.91 7x10-7 0.86 0.79–0.91 2x10-5 
QSU 12 month NA NA NA 0.88 0.81–0.94 0.0014 
NA = not applicable 
 
In order to assess what role active treatment had in potentially ameliorating urges to smoke 
and their erosion of abstinence, bivariate regressions were run which included both treatment 
assignment and QSU total scores for each of the time-points when the QSU was recorded.  
Great care must be taken when examining the effects of a post-randomisation event (such as 
QSU score measured after baseline) together with an assessment of the effect of active 
treatment on abstinence (Table 3.17, page 140).  A further threat to the validity of these 
analyses is that they ignore data that were missing due to subjects being lost-to-follow-up and 
not reporting their QSU scores, which may bias the conclusions of these analyses. 
After Bonferroni correction and adjustment by treatment assignment, QSU total scores 
recorded three- and six-months post target quit date were significantly predictive of prolonged 
six-months abstinence but, QSU-total scores recorded prior to three-months after subjects’ 
target quit dates were not significantly predictive of abstinence (Table 3.17).  By three months 
the effect of QSU total scores on prolonged six- and twelve- months abstinence was highly 
statistically significant, yet treatment assignment in these models was not.   
At three months, the effect of QSU total scores on prolonged six months abstinence was not 
statistically more detrimental to abstinence in the control group cf. the active group because 




the active group (OR=0.84, 95%CI 0.76–0.91, p=0.00037, cf. OR=0.91. 95%CI 0.86–0.96, 
p=0.0005, in the control and active groups respectively, and a GLM with an interaction term 
showed no significant interaction between treatment assignment and QSU-total scores at three 
Table 3.17.  Bivariate models of QSU total scores measured at each follow-up, 
adjusted by treatment assignment, as predictors of six and twelve months prolonged 
not smoked on seven consecutive days.  Each row is a separate GLM. 
 
QSU total score Active mouthspray 
 Time OR 95%CI p OR 95%CI p 
Prolonged six months not smoked on seven consecutive days 
Baseline  1.00 0.98—1.01 0.5679 1.55 1.13—2.13 0.0064 
1 month 0.96 0.92—0.99 0.0248 1.26 0.84—1.89 0.2686 
3 months 0.89 0.85—0.93 5x10-7 1.31 0.87—2.00 0.2011 
6 months 0.87 0.82—0.92 1x10-6 1.79 1.01—3.21 0.0475 
Prolonged twelve months not smoked on seven consecutive days 
Baseline  0.99 0.98—1.01 0.3511 1.46 1.01—2.15 0.0484 
1 month 0.96 0.92—0.99 0.0248 1.26 0.84—1.89 0.2686 
3 months 0.89 0.84—0.94 6x10-5 1.30 0.84—2.04 0.2435 
6 months 0.86 0.79—0.92 3x10-5 1.30 0.77—2.20 0.3332 
12 months 0.88 0.81—0.94 0.0011 1.71 0.89—3.33 0.1101 
 
months in predicting prolonged six months abstinence, indicating that a one unit increase in 
QSU scores had the same effect on abstinence in the active group as in the control group.  
Three months after subjects’ target quit dates, the QSU-total scores were not significantly 
different between treatment groups.   
Three months after subjects’ target quit dates, in both treatment groups, QSU-total scores 
were significantly lower among subjects who had not smoked on seven consecutive days 
since the one-month follow-up cf. those who had (in the active group 10.00, 12.48 (10.00—
13.00) cf. 17.00, 20.33 (10.75—25.25), p=1x10-8; in the control group 10.00, 11.86 (10.00—
12.00) cf. 14.00, 18.85 (11.00—23.00), p=8x10-9).  The rates of not smoking on seven 
consecutive days between the one- and three-months follow-ups were 177/716 (24.72%) and 
120/707 (16.97%) in the active and control groups, respectively, p=0.0003.  The correlation 
between, not having smoked on seven consecutive days from the one-month to three-month 
follow-ups, and QSU-total scores at three-months after subjects’ target quit dates, was 
stronger and much more statistically significant than the correlation between, not having 




treatment assignment (ρ=-0.43, 95%CI:-0.50 to -0.34, p=2x10-16 cf. ρ=0.10, 95%CI:0.04 to 
0.15, p=0.0003).  There were no statistically significant correlations between treatment 
assignment and QSU-total scores at one-, three-, or six-months post target quit dates. 
The role played by subjects’ withdrawal symptoms in achieving and maintain abstinence was 
investigated with univariate regressions of MNWS scores, and bivariate regressions that 
adjusted for treatment assignment and the interaction between MNWS scores and treatment 
assignment.  Subjects completed the MNWS at the one, three, six, and twelve months follow-
ups (Bonferroni adjustment for five MNWS scales, measured at four time-points, and 
assessing the effect on both six- and twelve-months prolonged abstinence, would require 
p<0.05/(5*4*2)=0.00125.  Table 3.13, page 122, displays the results of per protocol univariate 
regressions of the effects of the scores of each MNWS subscale administered throughout the 
trial, on intention-to-treat (penalised imputation) prolonged six- and twelve-months 
abstinence.  The scales that met the strictest Bonferroni correction were:  
1. ‘Craving’ scores at all time-points for both prolonged six- and twelve-months 
abstinence;  
2. ‘Restlessness’ at six months for prolonged six months abstinence; 
3. ‘Negative affect’ at three and six months for prolonged six months abstinence.   
‘Appetite’ and ‘Insomnia’ scores were not significant after Bonferroni correction for either 
prolonged six- nor twelve-months abstinence, at any time-point. 
Higher ‘Craving’ scores had a large and sustained negative effect on abstinence, ranging from 
an OR as low as 0.30 at six months for predicting prolonged six-months abstinence, to as high 
as 0.60 at one month as a predictor of prolonged twelve-months abstinence.  The only other 
scale of the MNWS to have a highly significant effect on abstinence (p<0.00125) at more than 
one time-point was ‘Negative Affect’ at three and six months for predicting prolonged six 
months abstinence.   
The ‘Craving’ and ‘Negative affect’ scales were strongly positively correlated with each 
other, at three and six months (ρ=0.41, 95%CI 0.33–0.49, p=2x10-16, and ρ=0.43, 95%CI 
0.32–0.52, p=10x10-12, respectively).  Not only would any GLM that included both ‘Craving’ 
and ‘Negative affect’ potentially be at risk of collinearity due to the strong correlation 
between these scales, it may pose the risk of bias because it would exclude the majority of 
subjects who were randomised because, for instance, only 395 subjects rated both their 
‘Negative affect’ and ‘Craving’ at the three months follow-up (395/1423 (27.76%) of 




‘Negative affect’ scores in the active compared to control groups, at three nor six months 
follow-ups, the very time-points when ‘Craving’ and ‘Negative affect’ were significantly 
predictive of abstinence.   
Furthermore, a GLM with prolonged six months abstinence as the dependent variable, and 
both treatment and ‘Craving’ at six months as independent variables, calculated that active 
mouthspray was not a significant predictor of abstinence, but ‘Craving’ was OR=0.30, 95%CI 
0.22–0.40, p=1x10-14.  A GLM calculated that there was no significant interaction between 
the effects of treatment and ‘Craving’ on prolonged six months abstinence, indicating that 
active treatment did not ameliorate the effect of higher ‘Craving’ scores on abstinence. 
In an attempt to avoid collinearity, the data were centred and scaled prior to analysis, the 
results of which are reported in the following sub-section. 
3.5.2 Centred and scaled data 
As a first step towards avoiding multicollinearity, the variables that were potentially 
predictive of abstinence were centred and scaled, and then entered into bivariate regressions 
of every unique pairing of variables that may potentially predict abstinence.  Despite the use 
of centring and scaling, five bivariate models showed signs suggestive of collinearity, 
however the rest of the bivariate models did not, and they provide robust tests of theoretically 
interesting and clinically important relationships. 
To confirm that centring and scaling the data had removed the problem of collinearity, the 
Condition Index and VIF were calculated for each pair of variables in the bivariate GLMs.  
The median, mean, (IQR), Range of the Condition Indices from all the bivariate GLMs was 
1.0; 1.1; (IQR 1.0—1.1); Range 0.2—6.5.  The values for VIF were 1.35; 1.86; (IQR=1.00—
2.43); Range=1.00—8.00; with twenty-two instances where the VIF was greater than unity 
and ten where it was greater than two.  While the values of the Condition Indices were well 
below the cut-off of thirty, suggesting that none of the bivariate models suffered from 
collinearity and that centring and scaling the variables had been sufficient to avoid 
collinearity, the values of the VIF were greater than unity in twenty-two occasions, which is 
suggestive of collinearity.  Many of the pairs of centred and scaled variables were strongly 
correlated, which violates the assumptions of GLM that the predictive variables are 
independent of each other.   
The correlation coefficients of the centred and scaled variables had a median of 0.03; 




variables had the highest correlation coefficients in the range 0.80≤ρ<0.90 (WISDM’s PDM 
and WISDM’s Loss of Control ρ=0.82; and WISDM’s PDM and WISDM’s Total score 
ρ=0.80).  The majority of the high correlations were due to mathematical coupling, which can 
be avoided by not including variables in a GLM that are composed of the sum of other 
variables in that GLM.   
The results of the bivariate models of centred and scaled data were analysed to identify 
variables that acted as important adjustors of the effects of other variables;, and to detect 
potential collinearity.  This was accomplished by calculating the change in the value of the 
OR for each variable when it was adjusted by each of the other variables, compared to the 
value of the OR in univariate regression; and also, by noting if a variable became statistically 
significant or lost its statistical significance, when it was adjusted by another variable.   
3.5.2.1 Bivariate regressions of pre-randomisation variables 
Of the 466 bivariate logistic regressions of unique pairs of pre-randomisation variables, in 108 
regressions both independent variables had been significant at p<0.05 in univariate 
regressions and remained so in bivariate regressions; in 42 regressions in which both 
independent variables had a significance of p<0.05 in univariate models, one variable 
remained significant at p<0.05 but the other variable did not when the two variables were both 
entered as independent variables in bivariate regressions, and in five regressions for which 
both independent variables had a significance of p<0.05 in univariate models, neither variable 
retained this level of significant in bivariate models which suggests that collinearity had 
occurred (Table B4, page 361, displays the largest positive and negative changes in OR 
between univariate and bivariate logistic regressions for 110 bivariate GLM).   
The 108 regressions in which both the independent variables remained significant, 
demonstrate that 108 pairs of variables were predictive of abstinence independent of each 
other; the forty-two regressions in which one variable retained its significance while the other 
did not, suggests that forty-two variables no longer significantly influenced abstinence when 
their effects were adjusted by the effects of another variable, while the five regressions in 
which both variables lost the significance that they had had in univariate regressions, is 
suggestive of collinearity.  In the following paragraphs, the largest positive and negative 
changes in the ORs for variables when they were in bivariate compared to univariate logistic 
regressions are reported, followed by the results of the forty-two pairs of variables in which 




univariate models, then finally, the results of the five models that showed evidence of 
collinearity are reported.    
For the majority of the variables in the bivariate models, the values of their OR changed very 
little when they were adjusted by the other variables in bivariate models compared to 
univariate models, however the OR changed dramatically for some variables, the changes in 
ORs across all the bivariate models had a median of 0.66%; IQR -1.29%—3.51%; 
range -45.07%—103.04%; mean 5.94% SD 23.40% (Table B4, page 361).  Seven variables’ 
ORs changed by ≥90%, when they were adjusted within bivariate models compared to 
univariate models.  All of the thirty largest decreases in ORs in bivariate regressions were for 
the variable of age dichotomised at the median age (Aged ≥50 years), whose OR reduced 
from 2.12 by 35—-40% depending on which other variable was in the model, however, being 
the median age or older remained a statistically significant predictor of higher abstinence in 
all but one of the thirty models (the model in which the largest reduction in the OR for older 
age occurred, when the dichotomised age category was adjusted by Age as a continuous 
variable (these two variables are mathematically related, and had a correlation of 0.79, hence 
this bivariate model is likely to be subject to collinearity)).   
The other 29/30 models, in which the OR for the categorical age variable reduced, but 
remained statistically significant, demonstrate that older age alone, was not the only 
characteristic that protected people from failing to achieve and maintain abstinence but, 
rather, other characteristics also affected the likelihood of achieving and maintaining 
abstinence which either shared the same causal mechanism by which the older age category 
improved abstinence or, outweighed the effect of older age to some extent, such as how 
prepared subjects reported they were at baseline to handle stressful events without smoking; 
or subjects’ level of socio-economic deprivation which, when it was taken into account, 
reduced the protective effect of being fifty years or older by a third, while the effect of being 
fifty years or older reduced the deleterious effect of socio-economic deprivation by 1.6% 
bringing its OR closer to unity from 0.81 to 0.82 (Table B4, page 361).   
The next largest reductions in a variable’s OR for achieving prolonged six-months abstinence, 
in bivariate compared to univariate regressions, were all for “Started smoking daily aged 
sixteen or older”, whose positive impact on abstinence reduced by -17.86% to -29.57%, 
depending on which other variable was in the model (only eleven of these results are 
displayed in Table B4, as this table displays only the largest changes, in the interests of 




in twenty-eight bivariate models but, lost its significance when adjusted by “Age started 
smoking daily (years)”, and “WISDM Social/Environmental Goads”, in the former case this 
loss of significance is likely due to mathematical coupling, indeed the correlation between 
“age started smoking” and age started smoking dichotomised at sixteen years of age was 0.68.  
(The rationale for creating the dichotomised variable was to determine if older age per se 
when starting smoking was the key ingredient of the effect on abstinence or, if it was smoking 
prior to the former legal age of sixteen years of age for purchasing cigarettes that mattered (in 
New Zealand the minimum age was fifteen years from 1903 to 1988, and sixteen years from 
1988 to 1998).)  In the latter case, the correlation between “Started smoking daily aged ≥16 
years old” and Social/Environmental Goads was -0.20; 95%CI:-0.25 to -0.15, p=1x10-13, a 
weak negative correlation but highly statistically significant. 
All sixty of the largest increases in a variable’s OR for predicting six-months prolonged not 
smoked on seven consecutive days, in bivariate compared to univariate regressions, were for 
the variables “Māori ethnicity” and “Enrolled at a Māori Community Trial Site”, with the 
largest increase in OR being 103.04% for Māori ethnicity when it was adjusted by subjects’ 
WISDM Social/Environmental Goads scores.  The seven next largest increases were for either 
Māori ethnicity or ‘enrolled in Māori community trial site’ when these variables had been 
adjusted by each other and by; age; NZDep2006; and age started smoking daily  The results 
of these analyses demonstrate that the lower abstinence rates amongst Māori and people who 
enrolled at Māori community trial sites were at least partially caused by socio-economic and 
other demographic characteristics, such as socio-economic deprivation, and cultural factor 
such as social and environmental norms.  These issues will be reported and discussed in more 
detail in the following chapters titled “Role of Ethnicity”, and “Role of Māori community trial 
site”.  After the sixtieth increase in a variable’s OR in bivariate cf. univariate models of 
72.05%, the next largest increases were much smaller at 51.93%, then 40.78% after which the 
rate of increases slowed and remained in the late thirties before falling further.  Similarly, 
after the fiftieth decrease in ORs, subsequent decreases were much smaller. 
In the forty-two bivariate regressions in which both independent variables had a significance 
of p<0.05 in univariate models, but only one variable retained this significance in bivariate 
regressions; the percent change in the ORs of variables in bivariate compared to univariate for 
the variables that remained significant in bivariate regression was median, mean (IQR, range) 
1.05; 4.02; (-2.26—2.94; -33.01—91.16); while the percent change in ORs for the variables 
that became insignificant in bivariate regression was 4.44; 6.55, (2.41—12.44; -45.07—33.47; 




OR for variables that lost their significance in bivariate regressions was statistically 
significantly higher than the percent change in OR for variables that retained their 
significance in bivariate models (p=3x10-5), demonstrating that variables for which the value 
of their OR was more stable in bivariate regressions compared to univariate regressions, also 
had more stable statistical significance and exerted a larger change on the OR of the other 
variable that they had been paired with in bivariate regressions and this large change in the 
other variable’s OR caused that other variable to lose its significance.     
In 13/42 of the models which one independent variable lost its significance while the other 
independent variable retained its significance in bivariate compared to univariate regressions, 
the change in OR in bivariate compared to univariate regression, was less than five percent for 
both independent variables in the bivariate models (Table B5, page 374).  The fact that a less 
than five percent change in the ORs of two independent variables, in bivariate compared to 
univariate models, was sufficient for one of those variables to lose its statistical significance, 
may have been the result of the variables that lost their significance in bivariate models 
having had a statistical significance in univariate regression that was not much lower than 
0.05.  For instance, the significance in univariate regressions was 0.02≤p<0.05 for four 
variables that lost their significance in bivariate regressions, one of these variables (‘Live with 
other smoker(s)’) was the variable that lost its significance in six of the thirteen bivariate 
models in which the ORs for both variables in the bivariate models changed by less than five 
percent in bivariate compared to univariate regressions.  
There were some changes in significance in bivariate regressions that demonstrated 
theoretically interesting adjustments.  For instance, when WISDM’s Tolerance scores were 
included in a bivariate model with baseline FTND, Tolerance caused a 23.14% increase in the 
OR for FTND, bringing it closer to unity and causing it to lose its significance, while 
Tolerance retained its significance (Table B5, page 374).   
In five of the bivariate models, that used centred and scaled data, the statistical significance of 
both variables in the bivariate models were insignificant at the level of p<0.05 whereas the 
variables had this level of significance in univariate models, which is suggestive of 
collinearity, although the Condition Indices and VIF scores were not always high, albeit three 
of the five pairs of variables had high correlation coefficients - yet other pairs of variables had 
higher correlations but exhibited no suggestion of collinearity).  The VIF and Condition Index 
scores for variables in the five bivariate models in which both variables lost their statistical 




indicative of the likelihood of collinearity. Hence, although centring and scaling the variables 
improved the Condition Index, it did not remove the collinearity.   
In order to explore the extent to which the effect that variables, of particular theoretical 
interest (such as FTND), had on prolonged abstinence and the degree to which this effect was 
altered by the effects of other variables, univariate and bivariate models were created to see if 
the OR for one of the two independent variables changed by more than ±five percent in 
bivariate compared to univariate models.  In five models the OR for FTND changed by less 
than five percent and retained a statistical significance of p<0.05, while the OR of the other 
variable changed by more than five percent and remained significant at p<0.05 (when the 
other independent variable was:  
1.  ‘aged fifty or older’;   
2. ‘Started smoking aged sixteen or older’;   
3. Māori ethnicity;   
4. ‘enrolled at a Māori community trial site’;   
5. ‘previously used NRT’.   
In three models the OR for FTND changed by less than or equal to five percent and retained a 
statistical significance of p<0.05, while the OR of the other variable changed by more than 
five percent and lost its significant at p<0.05: 
1. baseline exhaled CO;   
2. WISDM-Automaticity; 
3. WISDM-total. 
In six models the OR for FTND changed by less than five percent and retained a statistical 
significance of p<0.05, while the OR of other variable changed by more than five percent and 
remained statistically insignificant; the other variables in these six models were: WISDM’s 
Loss of Control; WISDM-Craving; male gender; baseline QSU total; WISDM-SDM; and 
WISDM-Affective. 
In one model the OR for FTND changed by more than five percent and lost its statistical 
significance, while the OR of other variable changed by less than five percent and remained 
significant at p<0.05: 
1. As was reported earlier, when FTND was entered into a bivariate model with WISDM 




and four percent for Tolerance) and the p-value for FTND became >0.05 while 
Tolerance remained significant. 
In one model the OR for FTND and the other variable changed by more than five percent and 
both variables lost their statistical significance: 
1. FTND adjusted by WISDM’s PDM.  These variables had a correlation of 0.51 
however, their Condition Indices were only 1.7 and 1.0, respectively, and the VIF 
score was 1.34.  This suggests that collinearity occurred when both PDM and FTND 
were included in the same model, despite the model’s low Condition Index and low 
(albeit greater than one) VIF.   
Having explored the effects of combining centred and scaled variables in bivariate models, 
the effects of combining more than two variables was assessed, by building multivariate 
models following the model building advice of Hosmer and colleagues.(257)  One 
multivariate model was constructed for four groups of variables, the results of which are 
reported below, the four groups of multivariate models were: 
1. pre-randomisation variables; 
2. pre-randomisation variables plus treatment assignment; 
3. post-randomisation variables recorded at baseline and; 
4. post-randomisation variables recorded after baseline.   
3.5.2.2 Multivariate regression of pre-randomisation variables measured at 
baseline  
A multivariate logistic regression of pre-randomisation variables was constructed, following 
the method recommended by Hosmer and colleagues(257), the details of which are outlined in 
Appendix E on page 429.  These analyses determined the final main effects model of pre-
randomisation predictors (Table 3.18). 
Table 3.18.  Multivariate model (the main effects model) of pre-randomisation 
predictors of six months prolonged not smoked on seven consecutive days, with 
eight independent variables.  The variables are ordered from most, to least, 
statistically significant. 
  OR 95%CI p 
(Intercept) 0.18 0.12—0.26 5x10-17 
WISDM Social/environmental Goads 0.67 0.55—0.82 8x10-5 
Aged ≥50 years 1.80 1.27—2.55 0.0009 




  OR 95%CI p 
WISDM Weight control 1.28 1.09—1.52 0.0032 
Previously used NRT 0.55 0.37—0.84 0.0046 
Enrolled at Māori Community trial site 0.48 0.27—0.81 0.0095 
How prepared to handle stress without smoking 1.20 1.01—1.45 0.0457 
Number of previous quit attempts 1.11 0.96—1.26 0.1262 
 
In the final model, seven variables predicted six-months prolonged not smoked on seven 
consecutive days, with a significance of p<0.05 (Table 3.18).  Bonferroni adjustment for the 
twenty-four centred and scaled variables recorded prior to randomisation that had a 
significance of p<0.25 in univariate regressions would require p<0.00208, a condition met by 
three variables: 
1. WISDM Social/environmental Goads;  
2. Aged ≥50 years;  
3. WISDM Tolerance. 
 ‘WISDM Social/environmental Goads’ and ‘WISDM Tolerance’ decreased the odds of 
prolonged six-months abstinence by almost half, just under a third and by a quarter, 
respectively, while Aged ≥50 years increased it by almost double and slightly more than one-
and-a-quarter, respectively. 
Comparison of the magnitude of ORs and p-values of the independent variables in the final 
model of pre-randomisation variables predicting six-months prolonged abstinence, to the ORs 
and p-values in univariate models demonstrate the change in the effects of variables when 
they are adjusted by the effects that other variables have on abstinence, compared to 
univariate analyses.  The percent change in the values of the ORs had a median of 2.77%, 
IQR:-2.06%—7.51%, Range:-29.74%—14.79%, mean (SD) 0.21% (13.53%).  The largest 
reduction of almost a third, was for the effects of being aged fifty or older, making it less 
protective of abstinence, the second largest reduction was for ‘previously used NRT’ which 
became insignificantly four percent more detrimental to abstinence.  The largest increase in 
OR was for ‘WISDM Weight-control’ which became 14.79% more predictive of abstinence, 
while the second largest increase was in the OR for ‘Enrolled at a Māori community trial site’ 
whose effect of lowering abstinence was mitigated by 9.75%.  None of these changes in the 
values of variable’s OR were statistically significant, since the OR estimated by univariate 




adjustment in the multivariate model, one variable (WISDM Weight-control) became 
significance at p<0.00625 (Bonferroni correction for eight comparisons), a significance it had 
not had in univariate regression.  Two variables lost their significance at the level of 
p<0.00625 but retained it at p<0.05 in the multivariate compared to univariate regressions 
(‘Previously used NRT’, and ‘Prepared to handle stressful events without smoking’.   
3.5.2.3 Multivariate regression of pre-randomisation variables measured at 
baseline adjusted by treatment assignment 
When the multivariate logistic regression of the final model of pre-randomisation variables 
predicting six-months prolonged abstinence, was adjusted by treatment assignment, there was 
very little change in the magnitude of the ORs of the pre-randomisation variables (Table 
3.19).   
Table 3.19.  Results of final model of centred and scaled variables measured prior to 
randomisation, as predictors of six months prolonged not smoked on seven 
consecutive days, adjusted by treatment assignment, and the effect this adjustment 
had on the estimates of the effects of pre-randomisation variables (% change in OR).  
Variables are displayed in order from most to least statistically significant.  
 OR 95%CI p 
% change 
OR֍ 
Intercept 0.14 0.09—0.22 1x10-16 ‡ -22.22 
WISDM Social/environmental 
Goads 
0.68 0.55—0.82 9x10-5‡ 1.49 
Aged 50 or older 1.82 1.28—2.58 0.0008‡ 1.11 
WISDM Tolerance 0.76 0.65—0.90 0.0010‡ 0 
WISDM Weight control 1.29 1.09—1.52 0.0032‡ 0.78 
Previously used NRT 0.56 0.38—0.86 0.0064† 1.82 
Active mouthspray 1.60 1.13—2.27 0.0079†  
Enrolled at Maori community 
trial site 
0.48 0.27—0.82 0.0097† 0† 
How Prepared to handle stress 
without smoking 
1.19 1.00—1.44 0.0588 -0.83 
Number of prior quit attempts 1.11 0.96—1.27 0.1262 0 
֍ change cf. multivariate model which is not adjusted by treatment assignment 
† p<0.05 (seven variables met this criterion). 
‡ p<(0.05/12) i.e. p<0.004167 (four variables met this criterion). 
 
3.5.2.4 Post-randomisation events recorded at baseline 
Post-randomisation events that occurred at baseline, shortly after subjects first used the 




develop a test that could identify people immediately after they have commenced smoking 
cessation treatment, who are at greater risk of lapsing, based on signs and symptoms that 
occur very early after they start treatment, and who therefore require extra assistance or, 
further tailoring of their treatment to meet their individual needs.  The baseline post-
randomisation events that were recorded, included outcomes such as subjects’ reactions to the 
mouthsprays and patches, in terms of their sensory qualities, effects on the urge to smoke, and 
adverse-effects.  
Below, the distribution of baseline ratings of the sensory qualities of the active and placebo 
mouthsprays, measured on the CEQ, is described (Table 3.20), followed by an assessment of 
whether these outcomes influenced the likelihood of subjects achieving prolonged abstinence 
(Table 3.21, page 152).   
Table 3.20.  Values of centred and scaled CEQ subscales recorded at baseline, in 
each treatment group. The values are centred and scaled and therefore do not have 
the same ordinal scale as the raw data.  Rows are displayed from most to least 
statistically significant. 
 



































0.30 0.10 -0.76 0.83 -0.23 -0.09 -1.29 0.83 
0.001
87 





-0.28 0.02 -0.92 0.68 -0.44 -0.03 -0.92 0.52 
0.177
44 
Qu. = Quartile 
 
The scores of all but the Psychological Reward scale were significantly different between 
treatment groups after Bonferroni correction for comparisons between the six CEQ scales 
(p<0.05/6=0.00833), two of which were favourable to the active mouthspray (immediate 
craving reduction, craving reduction within fifteen minutes), and two may be perceived as 




Neither active nor placebo mouthsprays were awarded particularly favourable ratings by the 
majority of subjects, for instance, the median raw scores for items ‘Satisfying’, ‘Taste good’, 
and ‘Enjoy’ were all four, on a scale from 1=’not at all’; 2=’very little’; 3=’a little’; 
4=’moderately’; 5=’a lot’; 6=’quite a lot’; 7=’extremely’; and the median score for 
‘Enjoyment of mouth and throat sensations’ in both groups was three, indicating the 
sensations were “a little” enjoyable. 
Two scales of the CEQ were predictive in univariate regressions of prolonged six months not 
smoked on seven consecutive days at p<0.050 (Satisfaction, and ‘Enjoy respiratory 
sensations’), none were predictive after Bonferroni adjustment (Table 3.21).   
Table 3.21.  The effect of Cigarette Evaluation Questionnaire scores, measuring the 
qualities of the mouthsprays at baseline after randomisation, centred and scaled, on 
prolonged six-months abstinence.†   
 OR Lwr95%CI Uppr95%CI p 
Satisfaction 1.20 1.02 1.40 0.025 
Enjoy respiratory sensations 1.17 1.00 1.36 0.048 
Aversion 1.07 0.92 1.23 0.333 
Psychological reward 1.07 0.92 1.25 0.351 
Craving reduction immediate 0.96 0.82 1.12 0.638 
Craving reduction within 
15min 
1.00 0.82 1.21 0.964 
† Each row displays the results of a separate univariate regression of scores of a CEQ 
sub-scale as a predictor of prolonged six months abstinence 
 
When the effects of CEQ scores on abstinence were adjusted by treatment assignment, in one 
bivariate logistic regression per CEQ scale, there was little change in the magnitude of the 
ORs for the CEQ scales and no change in which were significant at p<0.05; while although 
the OR for treatment assignment reduced by approximately a quarter when it was adjusted by 
the CEQ scale scores, it was always within the 95%CI for the univariate effect of active 
mouthspray on abstinence (Table 3.22, page 153).  The reduction of the beneficial effect 
estimated by GLM that contain a post-randomisation variable as an independent variable, 
along with treatment assignment, suggests that the post-randomisation variable explains part 
of the mechanism by which active treatment improved abstinence.  For example, the OR for 
the effect of active treatment on prolonged abstinence reduced by -17.98 percent when it was 
adjusted by CEQ-Satisfaction scores, a variable which increased the odds of abstinence by 
OR=1.2 and was significant both in univariate regression, and after adjustment by treatment 




Table 3.22. Effect on prolonged six months not smoked on seven consecutive days in bivariate regressions adjusted by treatment 
compared to the univariate effects of CEQ sub-scales 
 CEQ Active mouthspray % change in 
OR of CEQ 
sub-scale 
% change in 
OR of Active 
mouthspray CEQ sub-scale OR 95%CI p OR 95%CI p 
Satisfaction univariate 1.20 1.02—1.40 0.025      
Satisfaction bivariate 1.22 1.04—1.42 0.0146 1.27 1.09—1.49 0.0029 1.37 -17.98 
Psychological reward univariate 1.07 0.92—1.25 0.351      
Psychological reward bivariate 1.07 0.92—1.24 0.3849 1.24 1.06—1.45 0.0071 -0.06 -19.96 
Aversion univariate 1.07 0.92—1.23 0.333      
Aversion bivariate 1.04 0.89—1.19 0.6415 1.23 1.05—1.45 0.0108 -3.26 -20.59 
Enjoy mouth/respiratory sensations univariate 1.17 1.00—1.36 0.048      
Enjoy mouth/respiratory sensations bivariate 1.19 1.02—1.39 0.0257 1.26 1.08—1.48 0.0038 1.71 -18.54 
Craving reduction immediate univariate 0.96 0.82—1.12 0.638      
Craving reduction immediate bivariate 0.94 0.80—1.10 0.4654 1.25 1.07—1.46 0.0056 -1.77 -19.39 
Craving reduction within15min univariate 1.00 0.82—1.21 0.964      
Craving reduction within15min bivariate 0.98 0.80—1.20 0.8691 1.14 0.93—1.39 0.2081 -1.66 -26.66 






mediated by the sensory and psychological effects indexed by CEQ-Satisfaction.  The brief-
QSU was not re-administered at baseline.    
Adverse events recorded at the baseline visit after randomisation are displayed in Table B1 in 
Appendix B, page 355.  Univariate logistic regressions were used to determine if the severity 
of adverse events influenced the odds of achieving prolonged six-months not smoked on 
seven consecutive days.  The severity of none of the adverse effects of the mouthsprays 
recorded at baseline after randomisation significantly (p<0.05) predicted prolonged six-
months not smoked on seven consecutive days in univariate regressions.  The severity of red 
marks left on the skin by patches during the baseline visit was the only adverse-effect of 
patches to significantly predict prolonged not smoked on seven consecutive days (OR=0.20; 
95%CI:0.03—0.58, p=0.0195).  
Many of the variables measured at baseline after randomisation, after having been scaled and 
centred, were highly correlated, therefore it was not possible to conduct multivariate 
regressions using the scaled and centred data, and satisfy the requirement for the independent 
variables to be uncorrelated, without first transforming the data, which was accomplished by 
principal component analysis, the results of which are reported in a subsequent section of this 
dissertation (Chapter 3.5.3).  For instance, the CEQ item ‘taste good’ had a correlation of 0.75 
with the CEQ scale ‘did you enjoy the mouthspray?’. 
3.5.2.5 Post-randomisation events recorded a day after the target quit date 
It was hypothesised that data collected by telephone interview a day after the target quit date 
(three weeks after baseline), would be useful for predicting abstinence, considering that by 
that time subjects would have had three weeks’ experience of the mouthspray, patches, and 
smoking reduction and; be the time-point at which a tool to identify people who are at greater 
risk of relapse would be most clinically useful, because:  
1. studies have demonstrated that the relapse curve after smoking cessation is initially very 
steep, with the majority of people relapsing very early after their attempt to quit (9, 142, 
337); 
2. the quit phone-call was the earliest time subjects were contacted after their baseline 
visit; hence, it is the follow-up time-point with the least missing data caused by drop-
outs and non-adherence.  
This was accomplished by ‘purposeful selection’(257) of variables to incorporate in two 




multicollinearity, and excluding very highly correlated variables, and variables that are 
mathematically coupled, while following the advice of Hosmer and colleagues by starting the 
process of choosing variables to include in the model by looking at variables that had a 
significance of p<0.25 in univariate models, and variables that played a role in adjusting the 
estimates of the effects of other variables.(257)  The details of the model building process are 
given in Appendix E. 
Table 3.7, page 107, displays subjects’ unscaled and uncentred responses to the quit phone-
call questions in the active compared to control treatment groups, which use the same scale as 
the Likert scales that match each question.  A table of the scaled and centred responses is not 
presented here, because the values of subjects’ scores are scaled therefore, they do not line up 
with the Likert scales for these data (such as “0=not at all”).  Fourteen outcomes were 
measured during this phone-call, requiring a Bonferroni correction of 0.05/14=0.0036.  The 
only outcome that met this level of significance was the higher severity of side-effects with 
active mouthspray compared to placebo mouthspray.  The role played by these fourteen 
outcomes in modifying the odds of subjects achieving prolonged abstinence was explored by 
univariate then bivariate and multivariate GLMs after having centred and scaled the data in an 
attempt to avoid collinearity.  The details of this process are given in Appendix E. 
In preparation for construction of a multivariate model of outcomes collected during the day 
after target quit-date phone-call, the correlations of the fourteen variables with each other 
were measured, and univariate models were constructed to identify centred and scaled 
variables that predicted abstinence with a significance of p<0.25.  The results of these 
bivariate regressions are displayed in Table 3.8 on page 108.  The correlations between 
centred and scaled variables recorded at the quit phone-call had a median and mean of 0.23 
and 0.18, respectively, IQR:-0.02 to 0.33; range:-0.41 to 0.65.   
In the fourteen univariate models, all potential predictors were significant at p<0.25 (the cut-
off for entry into a multivariate model); while eleven were significant at p<0.0036, which is 
the Bonferroni correction for fourteen comparisons (Table 3.8, page 108).  In these univariate 
models, missing values of the independent variables (such as how often mouthspray and 
patches were used, and the severity of side-effects) were ignored and not imputed, while 
missing abstinence outcomes were treated with penalised imputation.  All bar three variables 
were significantly predictive of abstinence after Bonferroni correction (‘Severity of side 
effects of mouthspray’, ‘Severity of side-effects of patches’, and ‘How well coping with 




the fourteen variables, that predicted a lower chance of abstinence (significantly for adverse 
effects of mouthspray (p=0.0100), and non-significantly for adverse effects of patches 
(p=0.0767)), the remaining variables were positively associated with abstinence.   
Of the variables measured a day after subjects’ target quit dates, the variable that caused the 
biggest increase in the odds of achieving six-months prolonged abstinence, in univariate 
regressions, was whether or not subjects had quit early, compared to quit on-time or, quit late 
or, had not yet quit, which increased the odds of abstinence three-and-a-half times (Table 3.8, 
page 108). How often patches were worn, increased the odds of abstinence by almost two-
and-a-third.  Four variables increased abstinence by between two to two-and-a-quarter times: 
1. how strongly subjects intended to continue to try to quit (if they had not yet done so) or 
continue to remain abstinent (if they had already quit); 
2. self-report of how confident subjects were that they would quit (if they had not yet), or 
would remain quit (if they had already quit); 
3. self-report of how well subjects felt they were coping with attempting to quit and;  
4. how well they thought they were coping with urges to smoke. 
Some of the predictors of abstinence recorded at the phone-call a day after the target quit date 
were highly correlated despite the variables having been centred and scaled, which may lead 
to multicollinearity if they are entered into the same GLM (Table B7, page 379).  Twenty-
seven correlations were more than a weak positive or negative relationship (ρ>+0.29 or 
ρ<-0.29).  The largest correlation of 0.65 was between ‘How often mouthspray used per day’ 
and ‘How many sprays of mouthspray used per occasion’.  The next largest correlation of 
0.59 was between ‘How well subjects thought they are coping with urges to smoke’ and ‘Quit 
status: not quit/ quit late/ quit on time/ quit early’.   
There was no correlation between number of sprays used per occasion Zonnic was used 
reported at the target quit phone-call and treatment assignment (ρ=0.04, 95%CI:-0.02—0.09, 
p=0.21). When these variables were entered into a bivariate model, both remained 
significantly predictive of six-months prolonged not smoked on seven consecutive days 
(OR=1.52; 95%CI:1.28—1.81, p=2x10-6, and OR=1.62; 95%CI:1.17—2.26, p=0.0036, 
respectively).  When an interaction term was added between these two independent variables, 
the interaction was not significant, indicating that the use of more sprays per occasion it was 




In order to use information from these fourteen variables in a logistic regression predicting 
abstinence, without the problem of their correlations, the variables were combined by 
summing them all except for the scores of adverse effects of patches and adverse effects of 
mouthspray, which were both subtracted from the summed scores, to create a total score.  
When this total score was entered into a univariate GLM predicting prolonged six months not 
smoked on seven consecutive days, the total scored had an OR of 1.17, 95%CI: 1.10—1.26, 
p=8x10-6.  Subjects who scored more than or equal to the median total score were statistically 
significantly almost six times as likely to attain prolonged six-months not smoked on seven 
consecutive days abstinence than subjects who scored less than the median (Table 3.23). 
Table 3.23.  Prolonged six months not smoked on seven consecutive days among 
subjects who scored less than the median total score of the fourteen variables 
recorded at the quit phone-call cf. subjects who scored greater or equal to the 
median. 




Abstinent 34 8 
Not abstinent 101 127 
OR total scores within median split 34/101=0.34 8/127=0.06 
OR total scores ≥median split cf. total scores <median 
split  
0.06/0.34=0.18  
OR total scores <median split cf. total scores ≥median 
split  
0.34/0.06=5.67  
Χ2=17.622, df = 1, p=3x10-5 
 
Given the potential for collinearity due to large correlations and the potential loss of 
heterogeneity by summing the scores of several outcomes, and that I could find no clear 
indication of which variables could be ignored and left out of a multivariate GLM, in order to 
remove the potential for high correlations to cause multicollinearity, a principal component 
analysis was conducted of the predictive variables to derive component scores that are not 
highly correlated, which would be suitable to use in multivariate regression.  The results of 
this multivariate PCA are reported in the next section of this dissertation. 
3.5.3 Principal Component Analysis 
Principal Component Analysis transforms data, that often contain correlated values, into new 
uncorrelated values known as principal components, whose values are not correlated.  The 
first component calculated by PCA explains the greatest amount of variance among the 




amount of the remaining variance under the constraint that its values are orthogonal to the 
previously calculated components. 
Three PCAs were performed on: 
1. pre-randomisation variables measured at baseline; 
2. post-randomisation data collected at baseline; 
3. post-randomisation data recorded at the phone-call a day after the target-quit date. 
3.5.3.1 Pre-randomisation variables measured at baseline 
PCA was performed on twenty-six pre-randomisation variables that predicted prolonged six-
months abstinence at the p<0.25 level of significance in univariate regressions (such as, 
demographics, ethnicity, smoking behaviour, and WISDM scores). 
The loadings of the twenty-six pre-randomisation variables onto the components of the PCA, 
where the magnitudes of the loadings were ≤-0.10 or ≥0.10 are displayed in Table E2 in 
Table 3.24.  Univariate GLM of centred and scaled Component scores of pre-
randomisation variables as predictors of six months prolonged not smoked on seven 
consecutive days, displaying the components that were significant at p<0.25.  Rows 
are ordered from smallest to largest p-value.  Each row is a separate univariate GLM. 
Component OR Lwr95%CI Upr95%CI p 
5 0.68 0.57 0.81 2x10-5 
2 1.44 1.20 1.73 8x10-5 
4 1.33 1.11 1.60 2x10-3 
15 0.78 0.65 0.93 6x10-3 
1 1.26 1.06 1.50 0.0080 
11 1.19 1.00 1.41 0.0448 
14 1.16 0.97 1.38 0.1080 
3 1.15 0.96 1.37 0.1231 
23 1.13 0.95 1.35 0.1600 
17 1.13 0.95 1.34 0.1670 
9 0.91 0.79 1.07 0.2049 
 
Appendix E, page 434.  Component loadings are the correlation coefficient between the raw 
variables and the component.  The square of a component loading is the percent of the 




The component scores for each of the twenty-six components in the PCA were scaled and 
centred and entered as the independent variable in twenty-six univariate GLMs predicting six 
months prolonged not smoked on seven consecutive days, of which eleven were significant at 
p<0.25, and six were significant at p<0.05 (Table 3.24, page 158).  The largest correlation 
coefficient between the eleven scaled and centred component scores that predicted prolonged 
six-months not smoked on seven consecutive days, with a significance of p<0.25, was 
5x10-15, confirming that the component scores were uncorrelated with each other.   
The steps of the model-building method of Hosmer and colleagues were followed, as outlined 
in Appendix E (page 429), which led to the development of the final mode (Table.3.25, page 
159)). 
Table 3.26, page 160,  displays the loading pattern of pre-randomisation variables onto the 
components in the final PCA model which significantly predicted abstinence in the final 
multivariate model, the loadings that were between -0.10 and +0.10 were deleted from this 
table to make it easier to read, and the patterns easier to discern, which is a commonly used 
approach, (Table E2 (page 434) displays the all loadings for all components).   
Table 3.25  Final multivariate model of pre-randomisation variables as predictors of 
prolonged six months not smoked on seven consecutive days (each row reports the 
outcome from a single GLM).  The rows are ordered from most to least statistically 
significant.   
Component OR 95%CI p  
Intercept 0.12 0.10—0.15 4x10-92 * 
5 0.67 0.56—0.81 3x10-5 * 
2 1.49 1.23—1.81 4x10-5 * 
4 1.35 1.13—1.63 0.0012 * 
15 0.77 0.64—0.93 0.0057  
1 1.27 1.07—1.52 0.0074  
* p<0.001923 (p<0.05/26)  
 
The loading pattern of the components that significantly predicted six-months prolonged not 
smoked on seven consecutive days after Bonferroni correction (Components 2, 4, and 5), 
showed that the largest loadings on Component2, whose scores predicted a greater odds of 
abstinence, were two equal negative loadings for ‘Desire to reduce smoking’ and ‘Determined 
to reduce smoking’, a negative loading of slightly smaller magnitude for ‘WISDM 
Social/environmental goads’, followed by a negative loading for ‘Enrolled at Māori 



















Live with other 
smoker(s) 
How prepared 
to handle stress 
without smoking 
How prepared 
to forgo the 
pleasure of 
smoking 
2 -0.32  -0.24 0.20 -0.20   
4 0.10  -0.36  -0.28   









eCO Age (years) Māori ethnicity 
2 -0.40 -0.40 -0.22   0.26 -0.26 
4 0.50 0.50 -0.22   0.16  
5 0.10   0.24 0.10    
 














2  0.19  0.18  -0.36  
4      -0.38  







WISDM PDM WISDM SDM WISDM total 
  
2   0.12    
  
4       
  






ethnicity’ and one positive for ‘Age’.  The biggest loadings onto Component4, whose scores 
predict a greater chance of abstinence, were large positive loadings of ‘Desire to reduce 
smoking’ equal with ‘Determined to reduce smoking’, followed by negative loadings 
‘WISDM Social/environmental goads’, ‘Number of smokers spend time with on typical day’, 
‘Live with other smoker(s)’, and NZDep2006.  The loadings of greatest magnitude on 
Componen5, whose scores predict a lower odds of abstinence, were a negative loading for 
‘How prepared to handle stress without smoking’, followed by a negative loading for ‘How 
prepared to forgo the pleasure of smoking’, then a negative loading for ‘WISDM Weight 
control’, a positive loading for FTND, a positive loading for ‘Previously used NRT’, and a 
positive loading for ‘WISDM Tolerance’. 
Component2 may be interpreted as representing disinterest in reducing smoking, not having 
social and situational motives for smoking, not choosing to participate at a Māori community 
trial site, not being of Māori ethnicity, but being of older age.  Component4 represents the 
impetus to reduce smoking counterbalanced by having social and environmental motives for 
smoking and the number of smokers that one socialises with on a very regular basis and 
whether there is another smoker in one’s household, along with socio-economic deprivation; 
while Component5 is the fusion of not being prepared to deal with stress or forgo the pleasure 
of smoking or handle weight gain after quitting smoking, having a higher nicotine dependence 
and WISDM-tolerance motives for smoking, and having previously been treated with NRT. 
A screening tool was developed, based on the final model and the PCA upon which it was 
based, that could be used as a simple pen and paper plus simple hand-held calculator tool 
(avoiding complex calculations that are involved in statistical analyses, such as logarithms 
and anti-logarithms) to identify smokers who are at higher risk of relapse, before they 
commence NRT and before they attempt to quit, so their treatment may be better tailored to 
their needs, and they can be offered extra assistance as early as possible, before they 
experience their first lapse, well before they relapse, and before they suffer the consequences 
of the Abstinence Violation Effect.  The scoring tool was created by multiplying the variables 
that had the three largest positive or negative loadings onto Component2 by their loading onto 
that component, and summing the results of those multiplications ((‘Desire to Reduce 
Smoking’*-0.40) + (‘Determined to Reduce Smoking’*-0.40) + (‘WISDM 
Social/environmental Goads’*-0.36)).   
The scores of the pre-randomisation scoring tool had a median, mean (IQR) of -3.48, -3.10, 




seven consecutive days regressed on the pre-randomisation scoring tool scores, calculated that 
higher scores predicted higher odds of abstinence, of OR=1.20, 95%CI:1.09—1.33, p=0.0003.  
Subjects who scored equal or greater than the third quartile of the scores, were 2.39 
(95%CI:1.52—3.85, p=0.0002) times more likely to attain prolonged six-months not smoked 
on seven consecutive days abstinence, than subjects who scored equal or lower than the first 
quartile.   
The ability of the pre-randomisation screening tool to predict abstinence prior to subjects 
being randomised, and before they commenced their treatment, was compared to that of their 
FTND scores that were also measured prior to randomisation.  The correlation between the 
pre-randomisation screening tool scores and FTND scores was negligible albeit statistically 
significant, ρ=-0.09, 95%CI:-0.14 to -0.04, p=0.0007, suggesting collinearity due to 
correlation is unlikely.  When both the pre-randomisation screening tool scores and baseline 
FTND scores were entered as independent variables into a bivariate logistic regression 
predicting prolonged six-months not smoked on seven consecutive days, the magnitudes of 
their ORs were within the 95%CIs of the ORs in univariate models, and both variables 
remained significant (OR=1.19, 95%CI:1.07—1.31, p=0.00078 for the pre-randomisation 
screening tool, and OR=0.87, 95%CI:0.79—0.95; p=0.00227 for FTND).  FTND scores for 
779 subjects were equal to or less than the median FTND score, and who could therefore be 
considered to have a lower nicotine dependence and a higher chance of quitting. Of these 779 
subjects, 360 had pre-randomisation screening tool scores that were less than the median 
value of those scores, suggesting that they had a lower chance of quitting; thus predictions 
based on the scores on the pre-randomisation screening tool contradict the predictions based 
on subjects’ FTND scores 360/779=46.21% of the time. 
Having established that the scores of Components2,4, and 5 of the PCA of variables recorded 
prior to randomisation, were significant predictors of abstinence in multivariate regression 
after Bonferroni correction for twenty-six comparisons, the effects of active compared to 
placebo mouthspray on abstinence, over and above the effects of pre-randomisation subject 
characteristics, were examined by adding treatment assignment to the multivariate model of 
pre-randomisation predictors of abstinence, and by assessing the subsequent changes in the 
ORs for treatment and the pre-randomisation variables in this model cf. univariate models.  
The values of the ORs and the statistical significance or the independent variables in the 
multivariate model of pre-randomisation variables plus treatment assignment; compared to, 
the values in the multivariate model of pre-randomisation variables without treatment 




little, both for the changes in the ORs for pre-randomisation variables (mean=0.43%, 
median=0.22%, IQR:0.18%—0.73%), and the change in OR of active treatment assignment 
(-4.08%).   
3.5.3.2 Post-randomisation events recorded at baseline 
When twenty-nine components were calculated from data collected at baseline after 
randomisation, and twenty-nine univariate logistic regressions of these components’ scores 
were performed, only component4’s scores predicted prolonged six months not smoked on 
seven consecutive days at p<0.05 (OR=1.39, 95%CI: 1.08—1.77, p=0.00868).  Bonferroni 
correction for twenty-nine comparisons would require p<0.00172.  The scores of seven 
components were significant at p<0.25 in these univariate regressions (Components1, 3, 4, 13, 
23, 27, and 29).  
When the scores of all components that were significant at p<0.25 in univariate regressions 
were entered into a multivariate model, no variable that had previously not been significant at 
p<0.05 became so, and none of the variables’ ORs changed by more than twenty percent, the 
only variable that remained significant at p<0.05 was component4.  Removal of all variables 
whose significance was not less than five percent, one at a time, did not result in a change of 
more than twenty percent in the ORs of the remaining variables in the model. 
Component4’s largest positive and negative loadings were 0.95 for ‘CEQ Reduce hunger’, 
0.16 for ‘CEQ less irritable’, 0.15 for ‘CEQ feel more awake’, 0.15 for ‘CEQ helped 
concentrate’, 0.13 for ‘CEQ calmed you down’, 0.12 for ‘CEQ relieved urge to smoke within 
15 minutes’, and 0.10 for ‘CEQ immediately relieved the urge to smoke’.   
To create a simple screening tool to identify people, who are less likely to achieve abstinence, 
based on events that occur shortly after people first use their mouthspray, the scores of the six 
items with the largest loadings on Component4 were multiplied by their loading on 
Component4, and these six products were summed.  This scale was not significantly 
predictive of prolonged six-months not smoked on seven consecutive days, at alpha=0.05, 
when all subjects were analysed together (OR=1.06; 95%CI:0.95—1.16; p=0.29), nor when 
the active and control groups were analysed separately.  
3.5.3.3 Post-randomisation events recorded a day after the target quit date 
Post-randomisation events recorded at the day after target quit date phone-call were analysed 




based on their early experiences of attempting to quit.  PCA was used to create a set of 
uncorrelated predictors of abstinence, from data collected a day after the target quit date.   
PCA requires that there be no missing data, however, at the quit phone-call, only 270 subjects 
had complete data for the fourteen variables that were collected at this timepoint and may 
potentially predict abstinence.  Therefore, only the variables that had the most complete data 
were retained for PCA.  Thus, eleven variables, which contained complete data from 1,009 
subjects, were submitted to PCA, consisting of eleven, seven-point Likert scales, rating: 
1. how well subjects felt they were coping with their quit-attempt;  
2. how well subjects thought they were coping with urges to smoking;  
3. how well subjects they were coping with withdrawal symptoms;  
4. how confident subjects were that they were going to quit/remain abstinent;  
5. how strongly subjects intended to continue trying to quit/remain quit;  
6. six scales that recorded how often the patches and mouthspray were used, their side-
effects, and subjects like/dislike of the patches and mouthspray.   
Of the eleven components of this PCA, the scores for Components 1 and 5 were significant in 
univariate regressions after Bonferroni adjustment for eleven comparisons, while four were 
significant at the level of p<0.25 recommended by Hosmer for initial inclusion in a 
multivariate model (Table 3.27).  The correlations between the component scores that 
predicted abstinence with a significance of p<0.25 in univariate regressions were negligible, 
mean=3𝑥10−16; SD=2x10-15; median=-2x10-16; IQR:-1x10-15—9x10-16; Range:-3x10-15—
2x10-15, which suggests that correlation is unlikely to lead to multicollinearity.   
Table 3.27 Principal Component Scores of quit date predictors of prolonged not 
smoked on seven consecutive days, each row is a separate univariate GLM 
Component Number OR 95%CI p 
1 0.54 0.46—0.63 2x10-13 ‡ 
2 1.04 0.89—1.21 0.6180 
3 1.05 0.89—1.24 0.5547 
4 1.06 0.88—1.29 0.5418 
5 0.72 0.58—0.89 0.0022 ‡ 
6 1.29 1.04—1.60 0.0202 † 
7 1.03 0.80—1.33 0.8305 
8 0.73 0.55—0.98 0.0333 † 
9 1.17 0.87—1.57 0.2829 




Component Number OR 95%CI p 
11 1.09 0.78—1.53 0.6343 
‡ p<0.05/11; † 0.05/11<p<0.25 
 
The four components that were significant at p<0.25 in univariate regressions, were included 
as independent variables in a multivariate model of six months prolonged not smoked on 
seven consecutive days.  The sizes of the ORs, p-values, and width of the 95%CIs as a 
proportion of the upper 95%CIs, for the four components changed only minimally when they 
were adjusted by each other in the multivariate compared to univariate models. 
A further GLM was run in which the components that were insignificant in multivariate 
regression had been removed, in order to see if the estimates of the two remaining 
components changed by more than twenty percent or, if they became statistical insignificance.  
Removal of the two insignificant component scores caused, at most, a -7.53% change in the 
OR of one of the remaining independent variables in the GLM (Component 5), and caused the 
statistical significance of both component1 and component5 to become greater, which 
justifies the removal of the nonsignificant scores (Table 3.28, page 166).   
The independent variables of the GLM, containing only the scores of Component1 and 
Component5 as independent variables, were not strongly correlated, (ρ=0.13, 95%CI:0.07—
0.19, p=3x10-5), the magnitude of the correlation indicates no relationship or a negligible 
relationship (+0.01≤ρ≤+0.19), albeit a highly statistically significant relationship.  The model 
fit the data well: the null deviance was 845, and residual deviance was 751, hence the model 
reduced the deviance; the goodness of fit was evaluated by the Hosmer and Lemeshow 
Goodness of Fit test, which calculated Χ2 of 7.10 on 8 degrees of freedom, p=0.53; indicating 
failure to find evidence of poor fit; there were no correlations between the errors and trial 
locations.  The GLM, containing only the scores of Component1 and Component5 as 
independent variables, met all the requirements that a model must meet in order to be used for 
inferential analyses.  The scores for Component1 halved the odds of prolonged six months 
abstinence, while the scores of Component5 almost reduced the chance of achieving 
abstinence by half (Table 3.28).   
The loading pattern of these two components (Table 3.29) demonstrated that seven variables 
loaded negatively onto Component1, the most extreme of which was -0.41 for ‘How well 





Table 3.28. The effect on estimates of scores of Components 1 and 5, in a multivariate model with and without scores of Components 6 
and 8 
 
Multivariate, each row is from the same GLM Multivariate, without Components 6 or 8 
Component 
Number 
OR 2.5%CI 97.5%CI p  OR 2.50% 97.50% p  
1 0.52 0.43 0.61 9x10-14  0.50 0.42 0.60 1x10-14  
5 0.62 0.47 0.80 0.00029  0.57 0.44 0.74 2x10-5  
6 1.34 1.00 1.80 0.05052  
    
 
8 0.76 0.53 1.07 0.11507  
     
 
Multivariate, without Components 6 or 8 cf. Multivariate with them 




OR Change in p value 
       
1 -2.98 Smaller 
       
5 -7.53 Smaller 






Table 3.29. Loading of variables onto the two statistically significant Components of PCA of 
data collected a day after the target quit date. 
Variable Comp.1 Comp.5 
How well subjects think they are coping with quitting -0.31  
How often patches were worn -0.30  
Opinion of Patches Score (how much subjects liked patches)   
How often mouthspray used per day -0.32  
How many sprays of mouthspray used per occasion   
Opinion of mouthspray score   
Severity of side effects of patches   
How well subjects think they are coping with urges to smoke -0.41  
How well subjects think they are coping with withdrawal 
symptoms 
-0.34 0.70 
How confident subjects are that they will/remain quit -0.34 -0.47 
Intend to continue to try to quit / to remain quit -0.32 -0.42 
Note this table displays only the loadings that were less than -0.30 or greater than 0.30, which is 
a conventional approach, and assists in making the table easier to read, and makes the patterns 
more readily discernible. 
 
the traditional cut-off of ±0.30 for loadings to be considered to be of any consequence (Table 
3.29, displays loadings of magnitude <-0.30 and >0.30).   
Given that higher scores of both Component1 and Component5 predicted lower abstinence, 
higher values of variables that had negative loadings onto those components, would predict 
greater abstinence.  Notably, ‘How often patches were worn, reported at the quit phone-call, 
had a loading of -0.30 on Component1 and ‘How often subjects wore the patches’, reported at 
the quit phone-call, significantly increased the odds of prolonged six-months not smoked on 
seven consecutive days in univariate regression (OR=2.30, 95%CI:1.74—3.21, p=1x10-7).  
Also, how many sprays of mouthspray used per occasion it was used loaded by -0.32 on 
Component1, and predicted higher abstinence in univariate regression.  The kinds of variables 
that loaded onto Component1 suggest that higher scores (which predict a lower chance of 
abstinence) would be achieved by smokers who think they are coping less well with urges to 
smoke, and less well with withdrawal symptoms, and who are less confident that they will 
remain quit, and use the mouthspray and patches less often.   
Whereas, the loading pattern of Component5 suggest it appears to measure confidence and 




they were coping with withdrawal symptoms, which was offset by two smaller negative 
loadings for how confident subjects were that they will quit/remain quit, and how strongly 
they intended to continue to attempt to quit/remain quit.  Thus, higher Component5 scores and 
a lower odds of prolonged abstinence is predicted by higher self-rated coping with withdrawal 
symptoms, lower confidence a day after the target quit date that one will quit and a lesser 
resolve to continue to abstain from smoking. 
In order to construct simple tools, that do not require PCA, and that may be used a day after 
the target quit date, to rate peoples’ likelihood of attaining prolonged abstinence, which can 
be used by people trying to quit and their clinicians, to identify the need for further assistance 
or a change in the therapy being used, two simple scoring systems were created, one by 
multiplying subjects’ scores for the variables that loaded onto Component1 by their loading 
on Component1, and summing these products to create a total score; and the other tool used 
the same method using Component5 scores.  The variables for the Simplified Component1 
scores were: 
(‘how well coping with quitting’*-0.31)+ 
(How often wear patch*-0.30)+ 
(How often use mouthspray *-0.32)+ 
(How well are you coping with urges to smoke*-0.41)+ 
(How are you coping with withdrawal symptoms*-0.34)+ 
(How confident going to quit/remain abstinent*-0.34)+ 
(Strength of intention to continue to try to quit/remain quit*-0.32).   
The variables for the Simplified Component5 scores were (the two negative loadings for the 
second and third variables that loaded onto Component5 were changed to be positive rather 
than negative): 
(How well are you coping with withdrawal symptoms?)*0.70)+ 
(How confident are you that you will quit / stay quit?)*0.47)+ 
(How strongly do you intend to try to quit / stay quit*0.42) 
The total Simple Component1 and Simple Component5 score were entered as independent 
variables into two univariate GLMs, which showed that an increase of one unit of Simple 




while higher Simple Component5 scores increased the odds of abstinence by one-and-three-
quarters (Table 3.30).   
Subjects who scored in the highest quartile of scores on the Simple Component1 scale, had an 
OR of achieving prolonged six months not smoked on seven consecutive days of 0.04, and 
were a tenth as likely to achieve abstinence compared to subjects who scored in the lowest 
quartile of these scores (Table 3.31).   
Table 3.30.  Simplified versions of Components 1 and 5 from PCA of a day after 
target quit date phone-call responses, as univariate predictors of prolonged six 
months not smoked on seven consecutive days† 
 OR 95%%CI p 
Simple Component 1 0.45 0.36—0.55 2x10-13 
Simple Component 5 1.74 1.42—2.17 2x10-7 
† each row is the result of a separate univariate GLM.  These are per protocol analyses and 
exclude subjects with missing data from the phone-call, 1,009 subjects had complete data 
and were included in these analyses. 
 
Table 3.31.  Abstinence rates for each quartile of the simplified score based on 













OR cf. <= 
1st Quartile 
<= 1st Quartile 72 184 0.39 28.13 1.00 
> 1st Quartile & 
<= Median 
46 211 0.22 17.90 0.56 
> Median & <= 
3rd Quartile 
21 223 0.09 8.61 0.23 
> 3rd Quartile 10 242 0.04 3.97 0.10 
Totals 149 860 0.17 58.61 0.44 
Mann-Whitney tests calculated that there was no statistically significant difference between 
treatment groups in the ranking of subjects’ scores for the simple component1 scoring tool, 
suggesting that the abstinence rates of subjects in both treatment groups, suffered equally 
from the effects of higher scores on this scale.  This was confirmed by running bivariate 
GLMs for this scale, with treatment assignment as the other independent variable (Table 
3.32), followed by adding an interaction term between the scale and treatment assignment, 
which showed the interaction term was not statistically significant.  Once the effect of the 
simplified Component1 scores on abstinence was taken into account, the effect-size of active 
treatment assignment diminished by -14.34% and was no longer a significant predictor of 




statistical significance of the interaction term between treatment assignment and simplified 
Component1 scores, confirms that the simplified Component1 scores had the same deleterious 
effect on abstinence in the active compared to control groups.  These analyses demonstrate 
that active mouthspray did not ameliorate the effects of Component 1 scores on abstinence. 
Active treatment had a non-significantly lesser effect on increasing prolonged six-months 
abstinence among subjects whose Simplified Component1 scores were greater than the 
median cf. subjects whose scores were less than the median (OR, 95%CI, p 1.32, 0.80—2.20, 
0.28 cf. 1.72, 0.98—3.10, 0.06, respectively). 
Table 3.32.  Bivariate GLMs of Simple scores based on Component1 and on 
Component5 of the PCA of quit phone-call and Treatment assignment predicting 
prolonged six months not smoked on seven consecutive days. 
Independent variable OR 95%CI p % change * 
Univariate     
Simplified Component 1 scores 0.45 0.36—0.55 2x10-13  
Simplified Component 5 scores 1.74 1.42—2.17 2x10-7  
Active treatment 1.55 1.13–2.12 0.0064  
Bivariate Component 1 and Treatment 
Simplified Component 1 scores 0.46 0.37—0.56 4x10-13 1.14 
Active treatment 1.32 0.92—1.92 0.13 -14.34 
Bivariate Component 5 and Treatment 
Simplified Component 5 1.73 1.41—2.15 3x10-7 -0.98 
Active treatment 1.38 0.97—1.99 0.0761 -10.70 
* % change in OR multivariate cf. univariate 
 
When the scores of the simplified component5 scale were entered into a bivariate logistic 
regression with treatment assignment, the values of the ORs for simplified component5 and 
active treatment, altered, compared to their values in univariate regressions by -0.98% 
and -10.70%, respectively, and active treatment lost its statistical significance, while the 
significance of simplified component5 scores changed little (Table 3.32, page 170).  When an 
interaction terms was added between simplified component5 scores and active treatment 




3.6 Adequacy of the blind and effect of unblinding on treatment 
effect 
Six- and twelve-months after subjects’ target quit dates, subjects were asked what treatment 
group they thought they had been assigned to.  By the time subjects were asked to guess their 
treatment assignments, the majority of subjects had either withdrawn consent, been lost-to-
follow-up, or been censored because they had smoked more than the primary definition for 
failure.  The characteristics of those who remained in the study at six and twelve months after 
the target quit date were significantly different from those who had dropped out by that stage 
(Table F1 in Appendix F, page 440), and therefore an analysis of the effect of the adequacy of 
the blind on abstinence may not generalise to the entire sample even after adjusting the 
analysis for factors that predicted drop-outs.  For instance, as was reported earlier, at every 
follow-up time-point except the target quit date phone-call, compared to subjects who 
reported their abstinence, subjects whose abstinence outcomes were missing, were 
significantly younger, had higher FTND scores, and more often enrolled at a non-University 
(community) trial site. 
At six months, 105 subjects reported their treatment guesses, thirty-nine thought they were on 
active treatment, twenty-two thought they were taking placebo, while forty-four were unsure.  
Of the sixty-one subjects who guessed they were on active or placebo treatment, forty were 
correct, while twenty-one were incorrect, which is better than would be expected by chance, 
(the probability of guessing correctly compared to incorrectly was 0.66, 95%CI 0.52–0.77, 
p=0.02), which indicates that the blind had failed amongst the subjects who continued to 
participate in the trial.   
By twelve months, 166 subjects reported what treatment they thought they had been assigned 
to, seventy-seven thought they were on active treatment, twenty-two thought they had 
received placebo, while sixty-seven were unsure.  Of these guesses, sixty-seven were correct, 
and thirty-two incorrect, which clearly is better than would be expected by chance 
(p=0.00056), and evidence of failure of the blind.   
3.6.1 Predictors of unblinding 
Seven potential predictors of subjects correctly guessing their treatment assignment at six and 
twelve months were investigated: 
1. actual treatment assignment; 




3. having a baseline FTND that was greater than the median FTND,  
4. scoring greater than the median score at baseline on the CEQ aversion scale,  
5. scoring greater than the median score at baseline on the CEQ craving reduction within 
fifteen minutes,  
6. hurt mouth score greater than zero at baseline,  
7. hiccough score greater than zero anytime from baseline to six-month follow-up.   
The number of variables that were tested for their potential to predict subjects correctly 
guessing their treatment assignment was limited to seven in order to avoid incorrectly finding 
a significant association due to making multiple comparisons.   
For guesses of treatment assignment at six and twelve months, GLMs were constructed to test 
the potential for these seven candidate predictive variables to predict three outcomes: 
1. correctly guessing the treatment assignment compared to being incorrect (subjects 
who were unsure were excluded),  
2. correctly guessing compares to being unsure (subjects who were incorrect were 
excluded),  
3. correctly guessing the treatment assignment compared to being either unsure or 
incorrect 
For guesses of treatment assignment at six months, of the seven potential predictors listed 
above, the only variable that significantly predicted any of the three outcomes in the 
paragraph above, was subjects’ actual treatment assignments, whose statistical significance 
ranged from as little as p<0.04999 to p=0.018, which would not remain significant after 
Bonferroni correct..  Significantly more subjects guessed correctly cf. incorrectly and; 
correctly cf. incorrectly or being unsure, but not correctly cf. unsure (at p<0.050), at six- and 
twelve-months follow-up (Table 3.33).  At six and twelve months, significantly more subjects 
guessed they were on active treatment in the active cf. control groups (Table 3.33). 
To detect potential predictors of unblinding at twelve months, GLM tested the same seven 
potential predictors of unblinding that were tested at six months (listed on page 172), which 
demonstrated that the significant predictors of all three types of unblind (listed on page 172) 
were: treatment assignment and baseline FTND; while having the side-effect of hiccoughing 





Table 3.33. Association between actual treatment assignment and treatment 
assignment guess (guessed active, placebo, or unsure. 
 Actual treatment assignment 














Unsure 18 26 44 34 33 67 
Correct 25 15 40 52 15 67 
Incorrect 7 14 21 7 25 32 
p correct cf. 
incorrect 
(25+15) cf. (7+14) 
p=0.020 
 
(52+15) cf. (7+25) 
p=0.0006 
 










p correct cf. unsure 
(25+15) cf. (18+26) 
p=0.7436 
 
















 p=0.00933  p=0.00546  
p number who 
answered the 
question 
p=0.490  p=0.028  
 
At twelve months, treatment assignment predicted all three of the types of unblinding listed 
above at OR=12.38, 95%CI 4.69–36.48, p=1x10-6; OR=3.36, 95%CI 1.62–7.26, p=0.0015; 
and OR=4.90, 95%CI 2.48–10.1, p=8x10-6, respectively.  Baseline FTND, treated as a 
continuous variable, significantly predicted all of the above three types of unblinding at 
twelve months at OR=1.31, 95%CI 1.03–1.70, p=0.03; OR=1.25, 95%CI 1.02–1.54, p=0.035; 
and OR=1.27, 95%CI 1.06–1.54, p=0.01, respectively.  At twelve months, for the first and 
third of the three types of unblinding listed above, having experienced the side-effect of 
hiccoughs at any time between baseline and six months was significantly predictive at 
OR=9.96, 95%CI 2.52–46.62, p=0.0017; and OR=2.01; 95%CI:0.67—6.34; p=0.2166, 
OR=3.24, 95%CI 1.22–9.40, p=0.022, respectively.  Being older than the median age; scoring 
greater than the median CEQ aversion score at baseline; and scoring greater than the median 
for craving reduction within fifteen minutes, were not predictive of any of the three outcomes 




3.6.2 Effect of unmasking on abstinence 
Hughes and Krahn recommended that analyses of smoking cessation trials should assess 
whether, failure of the blind of treatment assignments, biased the estimate of the effect of 
active treatment on abstinence, by assessing if the treatment effect was similar between 
people who guessed correctly, incorrectly, and unsure.(245)   
Amongst the 105 subjects who reported their guess of what treatment assignment they had 
been given six months after their target quit dates, there were no significant differences in 
prolonged six months abstinence rates between people who were correct, incorrect, or unsure 
in their guess about their treatment assignment at six months (Table 3.34). 
Table 3.34: Effect of treatment arm guess on prolonged six months abstinence 
 Abstinent Not abstinent 
Total rows 
 
n/N % n/N % 
Unsure 26/105 24.76 18/105 17.14 44/105 
Correct 26/105 24.76 14/105 13.33 40/105 
Incorrect 12/105 11.43 9/105 8.57 21/105 
Total columns 64/105 60.95 41/105 39.05 105/105 
Chi-squared statistic = 0.47, df = 2, p = 0.79 
 
At six months, there was not a significant interaction between the correctness of subjects 
guesses of their treatment assignments, and their actual treatment assignments, when 
predicting prolonged six months abstinence.     
The OR for active cf. control treatment predicting the odds of prolonged six-months 
abstinence was not significantly different between subjects who guessed their treatment 
assignment correctly six-months after their target quit dates cf. those who guessed their 
treatment assignments incorrectly, and cf. subjects who were unsure after Bonferroni 
correction for comparisons between the three types of guesses (p<0.05/3=0.0167) (Table 3.35, 
page 175).   
Twelve months after subjects’ target quit dates, prolonged twelve months not smoked on 
seven consecutive days abstinence rates were not significantly different between subjects who 
at twelve months correctly guessed, incorrectly guessed, and subjects who were unsure of, 
their treatment assignment (Table 3.36, page 175).  There was no significant univariate effect 
of subjects’ perceived treatment assignments on abstinence, and also, no univariate effect on 




Table 3.35 Effect of active treatment on prolonged six-months not smoked on seven 
consecutive days among subjects whose guesses of their treatment assignment, six 
months after their target quit date, were correct/incorrect/unsure. 
Guess of treatment 
assignment 
Effect of active treatment on abstinence 
Guess  OR Lwr95%CI Upr95%CI p 
Correct 0.97 0.71 1.33 0.8683 
Incorrect 1.54 1.00 2.36 0.0662 
Unsure 0.86 0.64 1.16 0.3187 
Six months after subjects’ target quit dates, rates of prolonged six-months 
abstinence, were not significantly different between subjects who, at that time, 
guessed their treatment assignment correctly, incorrectly, and unsure, in the active 
group (16/25, 64.00%, 6/7, 85.71%, 9/18, 50.00%, p=0.24, respectively, nor in the 
control group (17/26, 65.38%, 10/15, 66.67%, 6/14, 42.86%, respectively, 
p=0.3157. 
OR correct cf. OR incorrect p=0.0885; OR correct cf. OR unsure p=0.5853; OR 
Incorrect cf. OR unsure p=0.0288 
 
interaction term was added to a model with prolonged twelve-month abstinence as the 
dependent variable, and the independent variables of subjects’ actual, and perceived treatment 
assignments, the interaction was not statistically significant. 
Twelve-months after subjects’ target quit date, there was no difference in treatment effect 
between subjects who, at that time, guessed their treatment assignment correctly, incorrectly 
and unsure (Table 3.37, page 176). 
Table 3.36 The effect of the correctness of treatment guess at the twelve-month 
follow-up on prolonged twelve-month not smoked on seven consecutive days 
abstinence 
 Veracity of treatment guess 
 
Unsure Correct Incorrect 
Abstinent 40 46 19 
Not abstinent 27 21 13 
Totals 67 67 32 
% abstinent within treatment guess 59.70 68.66 59.38 





Table 3.37 Effect of active treatment on prolonged twelve-months not smoked on 
seven consecutive days among subjects whose guesses of their treatment 
assignment, six months after their target quit date, were correct/incorrect/unsure 
 OR Upr95%CI Lwr95%CI p 
Correct 1.12 0.85 1.46 0.4197 
Incorrect 1.17 0.77 1.78 0.4787 
Unsure 1.18 0.93 1.49 0.1836 
 
In univariate logistic regressions, whether subjects guessed, that they had been assigned to 
active, placebo, or were unsure, six-month or twelve-months after their target quit dates, was 
not predictive of six-months and twelve-months prolonged abstinence, respectively. 
The analyses of blinding demonstrated that significantly more subjects correctly guessed their 
treatment assignment compared to those who incorrectly guessed their treatment assignment 
at six and twelve months.  At six and twelve months the effect of active treatment on 
abstinence was not significantly different in those who correctly guessed their treatment 
assignment compared to those who did not, and compared to those who were unsure.  
Therefore, although the blind integrity was broken at both six and twelve months, this did not 
bias the estimate of treatment effect at either timepoint. 
3.7 Role of Māori ethnicity 
Of the 1,423 subjects who were randomised, the ethnicity of 1,415 was recorded.  Māori was 
the second-biggest ethnic group, with 216 (15%) subjects who reported their ethnicity, 
reporting that they were Māori.  Non-Māori numbered 1,199, of whom 997 identified as 
European/Pākehā New Zealanders.  Of twenty-nine subject characteristics measured before 
randomisation at baseline, five were significantly different between Māori and non-Māori 
after Bonferroni correction, p<0.05/29=0.00172 (Table 3.38, page 177): 
1. Māori started smoking at a younger age, 
2. Māori had greater desire to reduce their smoking and, 
3. a greater determination to reduce their smoking,  
4. higher WISDM Social/Environmental Goads scores, and  
5. lower WISDM Taste scores. 
Māori and non-Māori had similar ages, age started smoking daily, number of cigarettes 
smoked per day, FTND scores, NZDep2006 scores, and desire and determination to quit 




Table 3.38.  Baseline subject characteristics Māori cf. non-Māori (median, mean) 
 Māori  Non-Māori p 
Age 44, 43 47, 46 0.45 
Baseline FTND 6, 6 6, 6 0.47 
Number of cigarettes smoked per 
day 
20, 19 20, 20 0.11 
Number of previous quit attempts 3.0, 5.1 3.0, 4.6 0.81 
NZDep2006 8, 7 5, 5 0.10 
Age started smoking daily 14, 15 16, 16 2x10-11 * 







Number smokers spend time with 
on typical day 
2, 2 1, 1 0.78 
Number personal acquaintances 
who have quit 
2, 2 2, 2 0.94 
How prepared to handle stress 
without smoking  
3.0, 2.9 3.0, 2.7 0.0290 
How prepared to forgo the 
pleasure of smoking 
3.0, 3.2 3.0, 3.1 0.0055 
Desire to quit smoking 4.0, 3.4 3.0, 3.3 0.0419 
Determined to quit smoking 4.0, 3.5 4.0, 3.4 0.0163 
Desire to reduce smoking 3.0, 2.8 3.0, 2.3 5x10-5 * 
Determined to reduce smoking 3.0, 2.8 3.0, 2.3 6x10-6 * 
Previously used NRT Yes=169, no=46 Yes=964, no=227 0.48 
WISDM Affiliative -0.33, -0.29 0, -0.11 0.19 
WISDM Automaticity 1.50, 1.08 1.50, 1.16 0.40 
WISDM Loss of Control 1.38, 1.17 1.75, 1.43 0.023 
WISDM Cognitive Enhancement -0.67, -0.36 0.33, 0.04 0.0053 
WISDM Craving 1.00, 1.00 1.25, 1.17 0.11 
WISDM Cue-exposure 0.33, 0.48 0.67, 0.58 0.18 
WISDM Social/Environmental 
Goads 
0.33, 0.34 -1.00, -0.79 5x10-15 * 
WISDM Taste 0.00, -0.13  0.33, 0.28 0.0011 * 
WISDM Tolerance 2.00, 1.55 1.50, 1.36 0.0258 
WISDM Weight Control 1.67, -1.09 -1.67, -1.13 0.55 
WISDM Affective Enhancement 0.33, 0.43 0.67, 0.47 0.72 
WISDM PDM 1.34, 1.21 1.44, 1.28 0.51 






Māori ethnicity, when considered in isolation, was a significant predictor of lower abstinence 
at all time-points after baseline, with the unadjusted odds of Māori attaining six months 
prolonged abstinence compared to non-Māori being 0.39 (Table 3.13, page 122).  Māori 
consistently had lower abstinence rates than non-Māori, regardless of treatment assignment, 
with Māori assigned to take active mouthspray having lower abstinence than non-Māori using 
active mouthspray, and fewer Māori in the control group attaining abstinence than their non-
Māori counterparts in the control group; also, Māori had lower abstinence rates at all time-
points after adjusting for treatment assignment and subjects’ number of prior quit attempts 
subjects (Table 3.39, page 180).  There was no significant interaction between Māori ethnicity 
and treatment assignment, which shows that active treatment increased abstinence cf. placebo 
treatment just as much for Māori as it did for non-Māori. 
In an attempt to identify why Māori ethnicity appeared to predispose people to low rates of 
abstinence, and to determine if Māori ethnicity was merely a confounder of the relationship 
between some other variable and abstinence, bivariate GLM of centred and scaled data were 
constructed, with Māori ethnicity as one of the independent variables, and the other 
independent variable being from one of three groups of variables.  The three groups of 
variables were: 
1. baseline characteristics that played a role in the achievement of abstinence and had a 
differentially prevalence or severity among Māori cf. non-Māori, such as variables 
listed in Table 3.38 (on page 177); for instance, higher WISDM Social/Environmental 
Goads scores, starting smoking daily at a younger age, and living with other smokers;  
2. baseline characteristics that were not significantly different between Māori and non-
Māori subjects but, were associated with abstinence in this trial such as current age; 
and, 
3. differential post-randomisation behaviour amongst Māori, such as Māori subjects’ 
lower use of Zonnic.   
Table 3.40, page 181, displays the results of the analyses of bivariate models that contain 
Māori ethnicity as one of the predictor variables.  It demonstrates that in bivariate compared 
to univariate models, the percent change in the OR for Māori ethnicity was median=5.83, 
mean=9.16, IQR:1.67—12.69, range:-4.02—32.59.  While the percent change in the OR for 
the covariates in these models was median=0.59, mean=2.12, IQR:-1.62—3.81, 
range:-19.25—23.47.  None of the changes in OR for Māori ethnicity in bivariate cf. 




The biggest increase in the OR for Māori ethnicity, of almost a third, occurred when it was 
adjusted by WISDM Social/Environmental Goads scores, whose OR increased by two 
percent.  The increased OR for Māori of OR=0.51, when it was adjusted by WISDM 
Social/Environmental Goads scores was not a statistically significant increase, because 0.51 is 
within the 95%CI for the univariate effect of centred and scaled variable for Māori ethnicity.  
The largest decrease in the OR for Māori was four percent when adjusted by ‘live with other 
smoker(s)’ and was not statistically significant. 
The percentage changes in values of the covariates by which Māori ethnicity was adjusted, in 
these bivariate regressions cf. univariate regressions were median=0.59, mean=2.12, 
IQR:-1.62—3.81, range:-19.25—23.47.  The largest increase was for ‘Enrolled in Māori 
community trial site’ and the largest decrease was for active treatment.  The univariate effect 
of ‘Enrolled in Māori community trial site’ (centred and scaled) was OR=0.39, 95%CI:0.23—
0.62, p=0.0002; since the adjusted OR of 0.59 is within the 95%CI for the univariate effects, 
the change was not statistically significant.  The adjusted OR for treatment assignment, was 
within the 95%CI for the univariate effect of treatment assignment (1.13—2.12), and hence it 
was not significant.  The correlation between Māori ethnicity and ‘enrolled at Māori 
community trial site’, when these variables were scaled and centred, was ρ=0.35, 
95%CI:0.31—0.40, p=2x10-6. As a result of the large correlations between the twenty 
variables that were associated with Māori ethnicity, multivariate regressions were performed 
on the component scores of two PCAs.  One PCA calculated the principal components of all 
variables recorded prior to randomisation, which were different between Māori and non-
Māori, with a significance of p<0.25; the other PCA was performed on variables collected 
after randomisation that were significantly different between Māori and non-Māori with a 
significance of p<0.25.  Logistic regressions were performed on the scores of components of 
these PCAs to determine their effects on prolonged abstinence, with and without adjustment 
by treatments assignment. 
Twenty variables recorded prior to randomisation were different between Māori and non-
Māori with a significance of p<0.25 (Table 3.38, page 177).  The PCA scores of each of these 
variables, plus a variable indicating if subjects were Māori and a variable indicating the trial 
site they attended, were entered as the independent variables into twenty univariate logistic 
regressions.  The results of these univariate regression showed that, of the scores of the nine 
components that were significant at p<0.25, only the scores of Component4 were significant 




Table 3.39.  Effect of Māori ethnicity on not smoked on seven consecutive days since the previous follow-up abstinence at 1, 3, 6, 9, and 
12 months after target quit date (not smoked on seven consecutive days), adjusted by treatment assignment, and number of previous 
quit attempts (the number of previous quit attempts was significantly different between treatment groups after randomisation). 
 1 month 3 months 6 months 9 months 12 months 
 OR p OR p OR p OR p OR p 
Active mouthspray 1.63 7x10-5 1.58 9x10-4 1.49 0.01 1.36 0.08 1.33 0.12 
Number of previous quit attempts 1.00 0.40 1.01 0.32 1.01 0.15 1.00 0.75 1.00 0.96 
Māori ethnicity 0.59 0.005 0.51 0.003 0.36 0.001 0.40 0.005 0.42 0.01 
Univariate logistic regression of Māori ethnicity predicting prolonged six-months not smoked on seven consecutive days: OR: 0.39, 95%CI 0.21—0.67, 
p=0.0015.  When adjusted by subjects’ number of previous quit attempts (because that was statistically significantly different between treatment assignments at 
baseline despite randomisation) and treatment assignment, the odds for Māori achieving prolonged six-month abstinence changed little cf. univariate regression 






Table 3.40 Bivariate logistic regressions of Māori ethnicity predicting six months prolonged not smoked on seven consecutive days.  














% Δ OR for 
Māori cf. 
univariate 
% Δ OR 
covariate cf. 
univariate 
Māori 0.50 0.26 0.88 0.0243 
Enrolled in Māori 
community trial site 
0.48 0.27 0.78 0.0054 28.72 23.47 
Māori 0.44 0.23 0.75 0.0055 Age 1.48 1.26 1.75 3x10-6 12.23 -1.15 
Māori 0.42 0.22 0.73 0.0037 
Started smoking daily 
aged ≥16 
1.48 1.08 2.04 0.0165 2.04 0.14 
Maori 0.42 0.22 0.73 0.0042 
Age started daily 
smoking 
1.23 1.07 1.42 4x10-3 8.35 -2.79 
Māori 0.37 0.19 0.65 0.0014 
Live with other 
smoker(s) 
0.85 0.72 1.00 0.0490 -4.02 0.72 
Māori 0.51 0.27 0.90 0.0284 
WISDM Social/enviro 
Goads 
0.62 0.51 0.74 2x10-7 32.59 1.55 
Māori 0.39 0.21 0.68 0.0017 Treatment 1.25 1.07 1.47 0.0062 1.02 -19.25 
Māori 0.40 0.21 0.69 0.0020 
Desire to Reduce 
Smoking 
0.92 0.79 1.08 0.3002 2.36 3.57 
Maori 0.40 0.21 0.69 0.0022 
Determined to Reduce 
Smoking 
0.95 0.81 1.11 0.5146 3.31 4.55 
Māori 0.39 0.21 0.68 0.0017 WISDM Taste 1.05 0.89 1.23 0.5734 0.99 -1.53 
Māori 0.39 0.20 0.70 0.0030 
How many sprays of 
Zonnic per occasion 
1.51 1.27 1.80 4x10-6 1.89 0.46 
Māori 0.44 0.23 0.78 0.0091 
Number occasions of 
Zonnic per day 





As a prelude to multivariate regressions of the nine component scores that were predictive of 
prolonged six-months abstinence with a significance of p<0.25, the correlations between these 
scaled and centred component scores were calculated and were all found to be zero.  The 
percent change in values of the ORs in multivariate cf. univariate regression was minimal 
(median, mean, (IQR), -0.04, 0.21, (-0.42—0.64),, and no variable gained or lost its statistical 
significance at the threshold of p<0.05. 
Table 3.41.  Univariate and multivariate logistic regressions of prolonged six-months 
abstinence, predicted by the component scores of a PCA of variables whose values 
were significantly different between Māori and non-Māori subjects at p<0.25.  Results 
of regressions that were significant at p<0.25 are displayed from most to least 
statistically significant.  One univariate regression was performed for each of the 
component scores. 
Component # OR 2.5%CI 97.5%CI p 
Univariate 
4 0.68 0.57 0.80 9x10-6 
2 1.30 1.10 1.54 0.0028 
5 0.78 0.65 0.92 0.0040 
3 0.83 0.71 0.98 0.0287 
15 0.86 0.73 1.02 0.0809 
1 1.14 0.97 1.34 0.1186 
10 1.11 0.94 1.31 0.2104 
13 0.91 0.77 1.07 0.2385 
14 0.91 0.77 1.07 0.2452 
Multivariate 
(Intercept) 0.12 0.10 0.15 2x10-103 
4 0.65 0.54 0.78 3x10-6 
2 1.35 1.12 1.63 0.0016 
5 0.78 0.65 0.92 0.0048 
3 0.81 0.68 0.96 0.0160 
15 0.85 0.72 1.01 0.0736 
1 1.12 0.95 1.33 0.1693 
10 1.10 0.93 1.32 0.2690 
13 0.90 0.75 1.08 0.2684 
14 0.89 0.75 1.06 0.2004 
 
The multivariate GLM was refined following the method of Hosmer and colleagues, leading 
to the final model which contained three statistically significant variables (Table 3.42, page 




Table 3.42 Final model of pre-randomisation variables that were significantly different 
at p<0.25 between Māori and non-Māori 
 OR 2.5%CI 97.5%CI p 
(Intercept) 0.13 0.11 0.16 2x10-107 
Component4 score 0.67 0.56 0.79 6x10-6 
Component5 score 0.76 0.64 0.91 0.0028 
Component3 score 0.81 0.68 0.96 0.0173 
 
The model with only Components4,5 and 3 as independent variables, met most of the 
assumptions of GLM.  However, there was a weakly statistically significant correlation that 
was very weakly negative between the residuals of this logistic regression and “Enrolment at 
a Māori community trial site” of -0.06, (95%CI: -0.12 to -0.008), p=0.02561).  This 
correlation suggests that there is a missing variable that was not measured, and if it were to 
have been added to the model, the fit of the model would be improved and the values of the 
residual error would be smaller.(339)  There was not a significant correlation between the 
residuals and Māori ethnicity.  The Hosmer and Lemeshow goodness of fit (GOF) test was 
insignificant (p=0.69) indicating that there was no evidence that the model did not fit the data, 
hence this may be considered to be the final mode. 
The loading pattern of the three component scores in the final model, reveals what the three 
components represent (Table 3.43)). 
Table 3.43.  Loading pattern of the PCA of pre-randomisation variables significantly 
different between Māori and non-Māori at p<0.25. 
Component3 Componet4 Component 5 
Variable Loading Variable Loading Variable Loading 

























Desire to quit 
smoking 
-0.37 
Live with other 
smoker(s) 
0.38 WISDM Taste -0.30 
Prepared to forgo 
the Pleasure of 
smoking 
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Variable Loading Variable Loading Variable Loading 








Desire to quit 
smoking 
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Maori ethnicity 0.13 
Prepared to forgo 
the Pleasure of 
smoking 
-0.14 



























-0.11 na na na na 
na = not applicable, no more variables loaded less than -0.10 or greater than 0.10 
 
Of the three component scores, Component4 had the biggest and most highly significant 
effect on abstinence (Table 3.42, page 183), reducing it by just under a third.  The highest 
loadings onto Component4 were a positive loading for WISDM Social/ environmental goads, 
negative loadings for both the desire and determination to reduce smoking, and a positive 
loading for living with other smoker(s).  The scores of Component5 had the next most 
detrimental effect on abstinence, reducing it by a quarter.  Component5’s loadings of greatest 
magnitude were positive loadings for baseline cigarettes smoked per day and WISDM 
Tolerance scores.  The highest loadings onto Component3, which reduced the odds of 
abstinence by a fifth, were positive loadings for the desire and determination to reduce 
smoking, thus higher scores for these variables reduced abstinence, in the context of the 
values of the other variables that load onto this component.   
Māori ethnicity loaded by >0.10 and <-0.10 onto Component3 and Component4 but not 
Component5.  The largest loading for Māori ethnicity was 0.25 on Component4, its loading 
on Component3 was close to the 0.10 cut-off for being considered to be of negligible 
consequence.  Enrolment at a Māori community trial site loaded by >0.10 and <-0.10 onto 





After treatment assignment was added to the final multivariate model, the values of the ORs 
of the independent variables in the final model changed by less than one percent, the value of 
the OR of the intercept reduced by seventeen percent, and the value of the OR for active 
treatment reduced by eight percent and its p-value increased (OR=1.42; 95%CI:1.02—2.00; 
p=0.0402).  The p-values for the independent variables in the final model changed by less 
than fifteen percent and there was no change in which variables’ p-values were less than five 
percent.   
Table 3.44.  How often mouthspray was used, reported at the day after target quit 
date phone-call.  Per-protocol analysis, n=1256.  Coding: 0=‘Never; 1=‘Hardly ever’; 
2=‘Sometimes’; 3=‘Most days’; 4=‘Every day’ 
 All ethnicities Māori Non-Māori 
 
Active Placebo Active Placebo Active Placebo 
Median 4.00 4.00 3.00 3.00 4.00 4.00 
Mean 3.03 3.05 2.62 2.69 3.09 3.12 
1st Qu. 2.00 2.00 1.00 1.00 2.00 2.00 
3rd Qu. 4.00 4.00 4.00 4.00 4.00 4.00 
n 637 619 87 92 547 522 
p active cf. 
placebo 
0.92 0.79 0.87 
p 
Active non-Māori cf. Active Māori p=0.005  
Placebo non-Māori cf. Placebo Māori p=0.01  
 
3.7.1 Quit-call predictors 
At the target quit phone-call, Māori reported using active and placebo Zonnic on significantly 
fewer days than non-Māori (Table 3.44, page 185).   
Although Māori used their mouthspray less often than non-Māori, Māori in both treatment 
groups used similar numbers of sprays per occasion that they used the mouthspray, compared 
to non-Māori (Table 3.45). 
Table 3.45.  How many sprays of mouthspray used per occasion, reported at the 
phone-call a day after the target quit date.  0: 0; 1: 1-2; 3: 3-5; 4: 6-10; 5:>10 
 All ethnicities Māori Non-Māori 
 
Active Placebo Active Placebo Active Placebo 
Median 2.00 2.00 2.00 2.00 2.00 2.00 
Mean 2.30 2.30 2.14 2.22 2.29 2.38 




 All ethnicities Māori Non-Māori 
 
Active Placebo Active Placebo Active Placebo 
3rd Qu. 3.00 3.00 3.00 4.00 3.00 3.00 
 n 633 617 85 96 545 516 
p-value active cf. 
placebo  
0.20 0.68 0.21 
p-value cf. 
ethnicities 
Active non-Māori cf. Active Māori 
p=0.42 
Placebo non-Māori cf. Placebo 
Māori p=0.48 
 
The results of multivariate regressions (of the effects on abstinence of: being Māori; the 
number of sprays of Zonnic used per occasion; how often Zonnic was used reported at the 
quit phone-call; enrolling at a Māori community trial site); are reported in the next section of 
this dissertation that examined the role of enrolment at Māori community trial site, in the 
chance that subjects will achieve prolonged abstinence. 
3.8 Role of Māori community trial sites 
There were two Māori community trial sites, (one at Kōkiri Marae in Seaview, and one at 
Kōkiri Marae’s health service in Porirua); and two university trial sites (at the University of 
Otago in Wellington and in Christchurch).  Of the randomised subjects who reported their 
ethnicity and enrolled in the Māori community trial sites, 146/284 (51.41%) were 
European/Pākehā, 115/284 (40.49%) Māori, and 11/284 (3.87%) Pacific people.  At the 
university trial sites, 851/1131 (75.24%) were European/Pākehā, 101/1131 (8.93%) Māori, 
and 20/1131 (1.77%) Pacific people.  Subjects who chose to enrol at a Māori community trial 
site had significantly lower odds of six- and twelve-months prolonged abstinence compared to 
those who enrolled at a university trial site (OR 0.39 and 0.37, respectively, Table 3.13, page 
122).   
In an attempt to elucidate potential causes of this inequality in abstinence rates, the 
differences in pre-randomisation subjects’ characteristics, between university and Māori 
community trial sites were measured, and their effects on abstinence were calculated.  Then, 
the effects on abstinence of the pre-randomisation variables was adjusted by treatment 
assignment, followed by an exploration of the role post-randomisation events had in causing 
the discrepant abstinence rates between trial sites. 
At baseline, subjects who chose to enrol at Māori community trial sites were significantly 




differences being higher incidences in the community trial sites of characteristics that were 
associated with lower abstinence (Table 3.46).  Of the thirty-five variables whose values at 
baseline were compared between community and university trial sites, ten were significantly  
Table 3.46.  Baseline differences between University trial sites and Māori community 
trial sites  




 Median Mean Median Mean p 
Age 47 46 45 44 0.0081 
FTND 6.0 6.0 6.5 6.4 0.0012 † 
Cigarettes per day 20.0 20.0 20.0 20.0 0.29 
Number of prior quit 
attempts 
3.0 4.9 3.0 4.1 0.04 
eCO 5.0 4.9 5.0 4.7 0.54 
NZDep2006 5.0 5.1 7.0 6.5 3x10-13 † 
Age started smoking daily 16.0 16.4 15.0 15.1 4x10-8 † 
Started smoking aged 16 
or older 
591/1120 53 106/282 38 7x10-6 † 
Duration of most recent 
quit attempt (days) 
21 235 21 113 0.50 
Live with other smoker(s) 
(1 yes, 0 no) 
0 0.42 0 0.50 0.02 
Number of smokers spend 
time with on a typical day 
1.0 1.4 1.0 1.5 0.02 
Personally know a smoker 
who has quit 
2.0 2.2 2.0 2.0 0.02 
Desire to quit 3.0 3.3 4.0 3.4 0.03 
Determined to quit 4.0 3.4 4.0 3.5 0.02 
Desire to reduce 3.0 2.1 4.0 3.3 2x10-16 † 
Determined to reduce 3.0 2.1 4.0 3.3 2x10-16 † 
Prepared to forgo pleasure 
of smoking 
3.0 3.1 3.0 3.2 0.002 
Prepared to handle stress 
without smoking 
3.0 2.7 3.0 2.9 0.003 
How long since you last 
smoked (min) 
45 90 60 235 8x10-9 † 
WISDM Affiliative 4.0 3.9 3.7 3.8 0.4353 
WISDM Automaticity 5.5 5.2 5.5 5.0 0.0465 
WISDM Loss of Control 5.8 5.5 5.3 5.2 0.0006† 
WISDM Cognitive 
Enhancement 








 Median Mean Median Mean p 
WISDM Craving 5.3 5.2 5.0 5.0 0.0573 




3.0 3.2 4.0 4.0 4x10-9† 
WISDM Taste 4.3 4.3 4.0 4.1 0.0540 
WISDM Tolerance 5.5 5.4 5.8 5.5 0.2521 
WISDM Weight Control 2.3 2.9 2.3 2.9 0.5326 
WISDM Affective 
Enhancement 
4.7 4.5 4.7 4.4 0.7589 
WISDM PDM 5.4 5.3 5.3 5.2 0.0713 
WISDM SDM 3.9 3.9 4.0 3.9 0.9583 
WISDM Total 48.8 48.5 48.0 48.1 0.3899 
 n % n % p-value 
Previously used NRT 235/285 82.5 908/1131 80.3 0.46 
Māori ethnicity 103/1154 8.9 117/287 40.8 2x10-16 † 
NZDep2006 1 (least deprived) to 10 (most deprived 
† significant after Bonferroni correction for 35 comparisons p<0.05/35=0.00143 
 
different between the two types of trial sites after Bonferroni correction (p<0.05/35=0.00143): 
subjects at the Māori community trial sites  
1. had higher FTND scores; 
2. experienced greater socio-economic deprivation; 
3. were younger when they started smoking daily; 
4. more often started smoking before they were sixteen years old; 
5. had a greater desire to reduce their smoking; 
6. had a greater determination to reduce smoking (but, were not significantly different 
(p<0.00143) in their desire or determination to quit smoking); 
7. a longer time had elapsed since they had last smoked; 
8. had lower WISDM Loss of Control scores; had higher WISDM Social/Environmental 
Goads scores; 
9. and were more likely to be of Māori ethnicity (forty-one percent cf. nine percent). 
A bivariate logistic regression of prolonged six-months not smoked on seven consecutive 




an interaction term between these two independent variables, calculated that the interaction 
was not significant, meaning that the ratio of efficacy of active cf. control treatment was the 
same in Māori community trial sites as in university trial sites. 
As the first step in conducting a multivariate regression of the effects of, the differences in 
values of variables between the two types of trial sites, on prolonged six-months abstinence, 
the correlations were calculated between the variables that were eligible for entry into a 
multivariate model because their values differed between the two types of trial sites with a 
significance of p<0.25.  Twenty-four variables were eligible, to which a variable was added 
that indicated whether subjects had enrolled in a Māori community trial site, giving a total of 
twenty-five variables to be analysed.   The correlations between the centred and scaled 
variables that were eligible, ranged from -0.30 (between age and WISDM 
Social/Environmental Goads) to 0.91 (between ‘desire to reduce smoking’ and ‘determination 
to reduce smoking’.  In order to include information from as many of these variables as 
possible, without breaking the premise of GLM, that the independent variables are 
uncorrelated, and to reduce the likelihood of multicollinearity, a principal component analysis 
(PCA) of the variables was performed, to create twenty-five component scores that were 
uncorrelated and could be used as independent variables in a logistic regression.   
Univariate linear regressions of subjects’ prolonged six-months not smoked on seven 
consecutive days abstinence, regressed on their scores on these twenty-five component, 
showed that the scores of eleven component predicted prolonged abstinence with a 
significance of p<0.25, of which components 1, 2, 4 and 6 were significant at p<0.05 (Table 
3.47).  
Table 3.47.  Univariate logistic regressions of the scaled and centred component 
scores predicting prolonged six-months abstinence.  Components were from PCA of 
variables recorded before randomisation which had different values among subjects 
who enrolled at a Māori community trial site cf. subjects who enrolled at a university 
trial site, with a significance of p<0.25.  Each row is a separate GLM and rows are 
ordered from most to least statistically significant.  Component scores whose 
significance was p≥0.25 are not displayed, 25 components were extracted, all of 
which were entered into univariate GLMs. 
Component # OR 2.50%CI 97.50%CI p 
2 0.66 0.55 0.79 9x10-6 
1 1.27 1.08 1.51 0.0044 
6 1.32 1.05 1.67 0.0177 
4 0.82 0.69 0.97 0.0239 




Component # OR 2.50%CI 97.50%CI p 
8 1.14 0.99 1.31 0.0560 
12 1.14 0.96 1.35 0.1380 
3 0.88 0.74 1.05 0.1573 
11 1.12 0.94 1.33 0.2006 
14 0.90 0.76 1.07 0.2313 
21 0.90 0.76 1.07 0.2443 
 
Multivariate regressions were performed to determine if enrolling at a Māori community trial 
site remained a significant predictor of lower abstinence, after all the measured differences 
between Māori community and university trial sites were taken into account simultaneously 
(Table 3.48).  The percent change in ORs for the component scores in multivariate cf. 
univariate regression was median=0.71, mean=0.58, IQR:0.21—2.22, range:7.56—6.87.  One 
variable (Component20) changed from having a significance of p>0.05 in univariate 
regression to p<0.05 in multivariate regression.  There were no other changes in which 
variables were statistically significant in univariate cf. multivariate regression.   
Table 3.48 Multivariate logistic regressions of prolonged six-months abstinence 
predicted by the scaled and centred component scores of variables recorded before 
randomisation which had significantly different values among subjects who enrolled 
at a Māori community trial site cf. subjects who enrolled at a university trial site, at the 
level of p<0.25.  Each row is a result from the same GLM and rows are ordered from 
most to least statistically significant.  Component scores whose significance was 
p>0.25 are not displayed 
Component # OR 2.50%CI 97.50%CI p 
(Intercept) 0.12 0.10 0.15 2x10-91 
2 0.61 0.50 0.75 3x10-6 
1 1.31 1.10 1.55 0.0028 
6 1.41 1.09 1.86 0.0111 
4 0.82 0.68 0.99 0.0364 
20 1.21 1.01 1.46 0.0389 
12 1.17 0.98 1.41 0.0820 
8 1.14 0.97 1.32 0.0861 
14 0.88 0.73 1.05 0.1573 
11 1.13 0.94 1.35 0.1933 
3 0.89 0.74 1.07 0.2170 





The multivariate model was refined by removing independent variables that had a 
significance of p>0.05, one variable at a time, removing the least statistically significant 
variable first, and measuring the change in the values of the ORs of the remaining variables, 
and checking that there was no loss of statistical significance of the variables, and re-entering 
a variable if its removal resulted in a greater than twenty-percent change in the OR of a 
variables in the model or if a variable became statistically insignificant.  This process led to 
the removal of all component scores that were not significant predictors at p<0.05 (Table 
3.49).  All component scores that had a significance of p>0.25 in univariate regressions were 
then added, one at a time, and removed after confirming that none of the ORs of the other 
independent variables changed by more than twenty percent and there was no alteration of 
whether their statistical significance was below the 0.05 threshold.  
This preliminary final multivariate logistic regression, had a smaller deviance than the null 
deviance (846.65 on 1156 d.f. cf. 893.92 on 1161 d.f.).  The Hosmer Lemeshow statistic was 
insignificant (Χ2=9.92, d.f.=8, p=0.27) demonstrating lack of evidence of ill-fit.  The error 
terms were independent across geographic locations, as demonstrated by the plot of the 
residuals against trial locations and the lack of correlation of the residuals with locations.  
Hence this GLM can be considered the final model (Table 3.49). 
Table 3.49.  Final multivariate model of component scores, of pre- randomisation 
variables which had significantly different values in Māori community cf. university 
trial site, predicting prolonged six-months abstinence. 
 OR 2.5%CI 97.5%CI p 
(Intercept) 0.13 0.10 0.15 3x10-93 
2 0.62 0.50 0.75 2x10-6 
1 1.31 1.10 1.56 0.0025 
6 1.43 1.11 1.86 0.0065 
20 1.21 1.01 1.46 0.0368 
4 0.82 0.68 0.99 0.0388 
 
The loading pattern of the components in the final model are displayed in Table 3.50, page 
193, to give an indication of what the components represent.  Table 3.50 shows the largest 
loading for enrolment at a Māori community trial site, on the components whose scores 
significantly predicted prolonged six-months abstinence in multivariate regression, was 0.34 
onto Component2 whose scores reduced abstinence by a third.  Māori ethnicity loaded by 
0.28 onto Component2.  Māori ethnicity most strongly loaded by -0.33 on Component6, the 




a Māori community trial site also loaded onto Component6, having a negative loading 
of -0.27; and had a -0.14 loading onto Component4 (Component 6’s and Component4’s ORs 
for predicting prolonged abstinence were 1.43 p=0.0065and, 0.82, p=0.0388, respectively).  
Enrolment at a Māori community trial site, and Māori ethnicity, did not load by ≤-0.10 or 
≥0.10 onto any of the other components that significantly predicted abstinence at p<0.05.  
These analyses suggest that Māori ethnicity and enrolment at a Māori community trial site 
loaded with similar magnitude onto the same components and hence had a similar effect as 
each other on abstinence, and their effects on abstinence were additive, thus they both 
independently reduced the odds of abstinence.  
When treatment assignment was added as an independent variable to the final multivariate 
GLM of component scores predicting prolonged six-months abstinence, the biggest percent 
change in ORs was an 18.78% reduction in the OR of the intercept, the ORs of the 
independent variables changed by less than one percent.  The OR for active treatment reduced 
non-significantly by 5.33% to OR=1.47, 95%CI:1.10—2.10, p=0.0341 compared to its value 
in univariate regression (OR=1.55, 95%CI:1.13—2.12, p=0.0064). 
Events that occurred after the baseline visit were examined for their potential to explain the 
lower abstinence among subjects who enrolled in the Māori community trial sites.  Subjects 
enrolled at a Māori community trial site used their Zonnic on significantly fewer days than 
subjects enrolled at a university trial site (median, mean (IQR) 3.00, 2.46, (1.00—4.00) cf. 
4.00, 3.18, (2.25—4.00), p=2x10-11, on a scale of 0=Never; 1=Hardly ever; 2=Some days; 
3=Most days; 4=Every day) and; used significantly fewer sprays per occasion it was used 
(2.00, 1.74, (1.00—3.00) cf. 2.00, 2.44 (2.00—3.00), p=4x10-14 on a scale of 0=none; 1=1-2; 
2=3-5; 3=6-10; 4:>10 sprays).  The correlation between the number of days Zonnic was used 
and, the number of sprays used per occasion it was used was 0.65, 95%CI:0.62—0.68, 
p=2x10-16, therefore these variables could not both be entered into the same GLM and were 
therefore multiplied together to produce a new variable that contains information from both 
variables, which can be submitted to GLM.  This new variable had a median, mean, (IQR) of: 
• 8.00, 8.12, (4.00—12.00) in the sample as a whole;  
• 8.00, 8.02 (3.00—12.00) in the active group; 
• 8.00, 8.21 (4.00—12.00 in the control group;  
• 3.00, 2.65, (1.00—4.00) for Māori ethnicity;  
• 6.00, 5.95, (1.00—9.00) in the Māori community trial sites, and  




Table 3.50. Loadings of variables onto Components of pre-randomisation variables that were significantly different between Maori 
Community trial sites and University trial sites.   
Comp.1 Comp.2 Comp.4 Comp.6 Comp.20 
Variable Loading Variable Loading Variable Loading Variable Loading Variable Loading 
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The difference in the new variable was not statistically significant between treatment 
assignments (p=0.5192) nor among Māori cf. non-Māori (p=0.0536) but, was between the 
types of trial sites (p=5x10-13). 
In an attempt to distinguish the extent to which subjects’ odds of achieving prolonged 
abstinence were altered by each of the highly correlated variables (Māori ethnicity, Māori 
community trial site, number of days used mouthspray at the quit phone-call, and number of 
sprays used per occasion reported at the quit phone-call), a PCA of these centred and scaled 
variables was conducted, and the centred and scaled component scores from this PCA, were 
each entered as an independent variable into separate univariate GLMs predicting prolonged 
six-months abstinence (Table 3.51).  
In univariate regressions, only the scores of Component1 were significant at p<0.05, and 
would remain significant after Bonferroni correction.  Given that the scores of the other 
components did not have a significance of p<0.25, there was no need to perform a 
multivariate regression that includes them.   
Table 3.51.  Univariate logistic regressions of centred and scaled component scores 
of PCA of quit-call variables, predicting prolonged six-months abstinence.  Univariate 
each row is the results of a separate univariate GLM.  
Variable OR 2.5%CI 97.5%CI p 
Component1 1.82 1.48 2.27 4x10-8 
Component2 0.96 0.82 1.13 0.65 
Component3 0.94 0.80 1.10 0.43 
Component4 1.06 0.91 1.25 0.44 
 
The loading pattern of variables onto the components (Table 3.52), demonstrates that when 
Māori ethnicity and enrolment at a Māori community trial site both loaded with the same sign 
(positive or negative), and when both of the variables recording the use of Zonnic load onto 
the same component as each other, and both load with the opposite sign as Māori ethnicity 
and Māori community trial site, the scores of that component are a significant predictor of 
abstinence.  Higher scores of Component1 predict higher abstinence, hence, considering that 
both Māori ethnicity and Māori community trial site had negative loadings onto Component1, 
both these variables predict lower abstinence, enrolling at a Māori trial site having a one-and-
a-half times more detrimental effect on abstinence as Māori ethnicity.  The equal, and positive 




demonstrate that both frequency and amount of Zonnic used has an additive effect of 
increasing abstinence. 
Table 3.52.  Loadings of centred and scaled variables onto Component scores of the 
PCA of Māori ethnicity, enrolment at a Māori community trial site, and how often and 
how many sprays of Zonnic used reported at the quit phone call. 
 Comp.1 Comp.2 Comp.3 Comp.4 
Māori ethnicity -0.28 0.67 0.68 -0.11 
Māori community trial site -0.45 0.54 -0.71  
How often used Zonnic 0.60 0.32 -0.19 -0.71 
How many sprays of Zonnic per 
occasion of use 
0.60 0.39 -0.03 0.69 
3.9 Discussion  
A nicotine mouthspray added to a nicotine patch, significantly increased abstinence at one, 
three, and six months compared with a nicotine patch and placebo mouthspray in an intention 
to treat analysis and for all measures of abstinence.  This additional benefit was of border-line 
statistical significance after six months.  Although active mouthspray was more effective than 
placebo therapy to six months, the absolute number of smokers who achieved long-term 
abstinence was low.  Only 10.1% cf. 7.1% achieved prolonged abstinence (not smoked on 
seven consecutive days) for twelve months, in the active and control groups respectively. 
Even fewer subjects achieved unadjusted biochemically verified twelve months prolonged 
abstinence: 8.8% and 6.5% in the active and placebo groups respectively (p=0.10).  Thus, 
while the addition of a nicotine mouthspray to a nicotine patch does significantly improve 
smoking cessation, compared to a nicotine patch and placebo, particularly for the first six 
months, the benefits are not sustained.  While this is consistent with the chronic relapsing 
nature of addiction, other studies of NRT have observed superior abstinent rates for active 
NRT at twelve months, although these studies often used a placebo as the control 
intervention, whereas in this trial an active nicotine patch plus placebo mouthspray were the 
control interventions. 
3.9.1 Comparison to other nicotine mouthspray trials and trials of 
nicotine nasal spray 
A report of a placebo-controlled trial of Nicorette oral mouthspray by Tønnesen and 
colleagues, found that abstinence for active nicotine mouthspray (one mg/spray) was 
significantly higher at twelve months than placebo (13.8% vs 5.6% p=0.007).(33)  The results 




cessation rates at all time points compared to those of Tønnesen, and were not sustained 
beyond six months.  The longer duration of superiority for active therapy in Tønnesen’s trial 
may be due to his use of a shorter grace-period (a fortnight), a stricter definition of abstinence 
(absolutely no smoking) and a placebo as the control intervention, rather than an active 
treatment.  Previous combination NRT studies using fast-acting nasal preparations of nicotine 
have shown early advantages that are lost in the long-term, similar to the results of this 
trial.(224)  One study of nasal nicotine, which was made available to subjects for a year, 
showed significant improvements over patch alone to twelve months (27% vs. 11%; 
p=0.001).(67)  Further follow-up at six years, revealed insignificant differences for the 
combination versus patch alone (sixteen percent vs. nine percent; p=0.08,(67) hence a therapy 
that demonstrates superiority for twelve months can lose this superiority five years later. 
3.9.2 Possible reasons for absence of superiority for combination 
therapy after six months 
There are a number of potential reasons, in addition to lack of efficacy, for why the 
combination of an oral nicotine mouthspray and transdermal patch failed to significantly 
improve abstinence after six months in this study.  Firstly, smoking has been the subject of 
considerable and widespread community and legislative action with bans on all indoor 
smoking in public places and an escalating tobacco tax.  Many smokers able to quit have 
already done so and those that continue to smoke, arguably, are likely to be those who have 
found it most difficult to quit in the face of these public health measures.  This is supported in 
this trial by the large number of prior quit attempts (median of three) and high previous use of 
NRT (81%) reported by subjects at their baseline visit, which was considerably higher than 
what was reported by the participants in the Nicorette trial.   
This argument is known as the Hardening Hypothesis, which proposes that most smokers who 
have quit were less nicotine dependent, and therefore remaining smokers are more nicotine 
dependent than smokers were historically, an argument for which there is empirical evidence 
that supports it as well as evidence that contradicts it.(340-342)  A second potential 
explanation for why the mouthspray was not more effective was that, as Bolliger suggested in 
a pilot study of Zonnic nicotine mouthspray,(316) some smokers find the one milligram dose 
to be unpleasant.  This was also the experience of subjects in this trial, with complaints of the 
unpleasant burning peppery taste, a reduced dose/spray may improve its tolerability.  This was 
supported objectively by the ratings subjects gave of the mouthsprays on the modified CEQ 
after their initial experience of it at baseline, which predicted how much mouthspray they 




months, and more prolonged availability and use, might have helped those who relapsed after 
initial success.   
A further potential reason for why the relative efficacy of the active and placebo mouthsprays 
was not greater, was that the placebo mouthspray plus active nicotine patch was quite 
effective, due to the active transdermal delivery of nicotine in combination with the prominent 
oral sensory stimuli and the placebo effect.  Some observations were suggestive of evidence 
of the placebo effect.  For instance, in the control group there was a significant correlation 
between how often the placebo mouthspray was used at the nine months phone-call, and 
abstinence reported at the twelve months follow-up.  It may be that, due to the strong sensory 
effects of the placebo mouthspray, it was particularly effective at inducing the placebo effect, 
and thereby set a higher bar for the active combination to compete with than the placebos 
used in other trials.   
An additional reason for low abstinence rates, was that subjects’ pre-randomisation 
characteristics had a considerable deleterious effect on abstinence (consistent with the 
Hardening Hypothesis).  For instance, adjustment of the impact of active mouthspray by the 
effects of the principal component scores of pre-randomisation variables (Components 1, 2, 4, 
5, and 15), reduced the effect-size of active mouthspray by four percent from OR=1.55; 
95%CI 1.13—2.12; p=0.0064 in univariate regression, to OR=1.48, 95%CI:1.03—2.14, 
p=0.0337.  There was one statistically significant (p<0.05) interaction between the scores of 
Component1 in this model and treatment assignment, but this interaction term was only of 
modest significance (OR=0.64; 95%CI:0.44—0.91, p=0.0148) and was not significant after 
Bonferroni correction for the five interaction terms that were tested (0.05/5=0.010).  This 
suggests that the detrimental effects of the principal components of pre-randomisation 
variables on abstinence were likely to be the same in both groups.   
A further potential explanation for the absence of superiority of the active combination 
therapy, is that when the effects of active mouthspray were adjusted by the scores of the 
principal component analysis, of outcome collected during the phone-call a day after subjects’ 
target quit dates, active treatment was no longer a statistically significant predictor of 
abstinence, although adjustment of treatment effect by post-randomisation events can give 
misleading results.   
The provision of nicotine patches and nicotine mouthspray for only five and six months, 
respectively, may also explain the loss of superior abstinence rates for the active combination 




abstinence rate with nicotine nasal spray plus patch was significantly superior to placebo nasal 
spray, provided subjects with twelve months supply of nasal spray.(343) 
How often subjects wore the nicotine patches, how much they liked them, and the severity of 
red marks left on the skin caused by patches during the baseline visit, had a substantial 
bearing on abstinence, particularly the degree of red marks, which for every unit increase in 
their severity (on a five-point Likert scale from 0=‘Not at all’ to 4:=‘Extreme’), the odds of 
prolonged six-months not smoked on seven consecutive days decreased by four fifths 
(OR=0.20; 95%CI: 0.03—0.58, p=0.0195).  Likewise, how often subjects used the 
mouthspray early in the trial, predicted a greater likelihood of prolonged abstinence, in both 
the active and control conditions.   
3.9.3 Predictors of abstinence 
A number of variables recorded before and after randomisation significantly predicted 
prolonged abstinence.  The effect of frequency of use of NRT on its efficacy is not always 
measured or reported in trials of NRT, because it is a post-randomisation effect, and therefore, 
may bias the estimation of the efficacy of the active treatment in comparison to the control 
treatment.  Yet, how often a therapy is used, and whether more frequent use improves 
treatment success, is something that clinicians and patients alike are keenly interested in, and 
some trials do report this outcome.  For instance, two studies of the efficacy of smartphone 
apps observed that the more often smokers opened and used the app, the more likely they 
were to become abstinent.(344, 345) 
The number of sprays of mouthspray used each time it was used, was significantly predictive 
of prolonged six-months abstinence in both treatment groups, which may indicate that greater 
use of the sprays caused abstinence regardless of the nicotine content of those sprays; or, this 
may indicate that abstinence caused subjects to use more sprays.  Further research is required 
to develop and test new methods to increase the frequency with which smokers use NRT, 
such as making its use more rewarding by increasing the speed it delivers nicotine to the 
brain, and reducing the intensity and incidence of its adverse effects. 
The brief-WISDM Social/Environmental Goads subscale had an enduring detrimental effect 
on abstinence in this dissertation.  Few trials have tested the effect of social interventions in 
engendering and maintaining abstinence from smoking.  Gruder and colleagues found that the 
addition of social support to a televised smoking cessation program increased adherence to 




higher abstinence compared to subjects randomised to no social support.(346)  However, the 
recommendation to provide social support has been removed from United States smoking 
cessation guidelines because, a systematic review by May and West, published in 2000, found 
no evidence of its efficacy.(347)  In fact, May and West stated that the evidence suggests that, 
in the context of a smokers’ clinic, the use of buddies may be of some benefit but, there was 
insufficient evidence regarding the efficacy of the use of buddies in community interventions, 
and further research was required.(348)  Observational evidence from the Lung Health Study 
supported the hypothesis that social support would increase abstinence.(349)  That study, of 
people with mild to moderate airway obstruction, observed that at both the end of a twelve-
week group program and after one year, men but not women who were supported in quitting 
were more likely to be successful.  Clearly there is a need for the development, and robust 
testing, of the efficacy of interventions to ameliorate the effects of social and environmental 
motives for smoking on abstinence.   
Although how well subjects felt they were coping with urges to smoke, which they reported a 
day after the target quit date, on a single item Likert scale, was a significant predictor of both 
six- and twelve-months prolonged abstinence; their QSU total score at baseline was not 
predictive of either prolonged six- or twelve-months abstinence (the QSU was not 
administered a day after the target quit date), QSU total scores measured one, three and six 
months after subjects’ target quit dates, were predictive of six- and twelve-months prolonged 
abstinence.  This suggests that the urge to smoke may only predict future prolonged 
abstinence if it is measured after subjects have attempted to quit, not before they quit.  
Alternatively, this may be the result of the single item Likert scale used to measure the urge to 
smoke a day after the quit date, being a better measure of urges than the QSU administered at 
baseline, although this is unlikely, since under most conditions multi-item scales outperform 
single-item scales.(350)  
Both age and the number of the participants’ acquaintances that had successfully stopped 
smoking, were independent predictors of long-term success, although after Bonferroni 
correction, only the effect of age would remain significant, Table 3.13, page 122.  Age is 
well-known as a predictor of success in previous studies.(351)  The positive influence of 
friends who have quit is supported by evidence from the New Zealand Quitline, where 
smokers who use online blogs while trying to quit were more successful than those who did 
not, suggesting that these peer self-support mechanisms may be important for a successful 




early after the quit attempt was also a strong predictor of a successful outcome at twelve 
months.  
Not only was younger age predictive of lower abstinence, it was also predictive of loss-to-
follow-up.  The use of penalised imputation forces this association to be true, however, it is 
not possible to test if missingness always equates to relapse, unless subjects whose data were 
missing due to loss-to-follow-up could later be contacted.  It is unlikely that the causal 
direction between youth, loss-to-follow-up and abstinence will be able to be resolved without 
the development of a method to avoid or overcome failure of subjects to report their 
abstinence statuses. 
3.9.3.1 Scales designed to predict abstinence in this trial 
Eleven scales were invented as part of this dissertation by its author, to index eleven elements 
that may potentially influence subjects’ chances of achieving and maintaining abstinence, four 
of which significantly predicted prolonged six- and twelve-months not smoked on seven 
consecutive days abstinence, after Bonferroni comparison. 
In addition to the aforementioned eleven scales, that were constructed a priori, before the 
conduct of the trial; scales to predict abstinence were developed a posteriori from the 
principal component analyses.  These scales offer simple tools, that take only a short time to 
complete and score, which can readily be adopted in clinical practice to improve titration and 
tailoring of therapy to smokers’ individual needs.  The scores of several scales invented for 
this dissertation, loaded highly onto the components of Principal Component Analysis, 
indicating that they were important contributors to the variance between subjects.  For 
instance, “How prepared are you to handle stress without smoking” had loadings of -0.65 
and -0.51 on components 18 and 5, respectively; while “How prepared to forgo the pleasure 
of smoking” had a loading of 0.66 and -0.50 onto components 18 and 5, respectively.  
Although the simplified scores, based on the loadings of variables onto the components on the 
PCAs were significantly predictive of abstinence, and predicted a lower chance of abstinence 
when the FTND score predicted a higher chance, the scores based on the PCA are more 
complex to complete and involve more mathematical operations compared to the FTND, 
although it is possible that this may be overcome by technology, such as a mobile-phone app. 
The scales that were invented as part of this dissertation were all single-item scales, which are 
generally thought not to have as good psychometric properties as multi-item psychological 
batteries; however, there is qualified support for single-item measures when the underlying 




predictive validity as multi-item batteries in some instances.(354)  Indeed, the single item 
Motivation To Stop Scale, administered in the United Kingdom Smoking Toolkit study, was a 
significant predictor of abstinence, in which smokers with the highest motivation were seven 
times more likely to be abstinent than those with the lower motivation.(47) 
3.9.3.2 Missing abstinence outcomes and imputation 
A variety of methods for imputing missing abstinence outcomes were utilised in these 
analyses.  The results for active treatment assignment, as a predictor of six-months prolonged 
not smoked on seven consecutive days, was highest with complete-case analysis (OR=1.63) 
but this analysis ignored three-quarters of randomised subjects (1072/1423) who did not 
report their abstinence.  The use of selection models, that incorporate predictors of 
missingness into the estimation of the effect of active treatment on abstinence, and enable all 
randomised subjects to be included in the measurement of the effect of treatment on 
abstinence, found that active treatment had an OR of 1.60 if all significant predictors of 
abstinence were used to calculate each subject’s propensity to have missing abstinence 
outcomes, and an OR that was the same as penalised imputation if only the two variables that 
were significantly predictive of both missingness and abstinence were used to calculate the 
propensity scores (the 95%CIs were slightly different between the two methods of handling 
missing data).  Multivariate imputation with the mice package calculated the smallest 
treatment effect (OR=1.43).  All these methods of imputation were within the 95%CI of each 
other, and although complete case analysis had the largest OR, its 95%CI extended to much 
smaller abstinence rates than the other imputation methods, and it had the highest p-value.   
3.9.4 Reasons for lower abstinence among Māori and subjects who 
enrolled at a Māori community trial site 
Sub-group analyses were conducted for Māori because of their high prevalence of smoking in 
the community.  Māori had significantly lower abstinence rates, although the effect size for 
active treatment was the same for Māori and non-Māori.  Māori were less successful than 
non-Māori in quitting long term, though adjustment for baseline factors decreased this 
difference.  For instance, Māori had significantly higher WISDM Social/environment Goads 
than non-Māori.  Māori used the active spray less often and reported more severe side effects 
from the spray, than non-Māori which may have contributed to their reduced success. The low 
use of mouthspray among Māori and their lower abstinence rates in this trial is consistent with 
the lower use of conventional NRT by Māori in the community,(355) and their fifty percent 




community inequality.(356)  Lower use of NRT has also been reported in ethnic minorities in 
other countries.(357)   
The scores of three Components, from the PCA of variables that were significantly different 
between Māori and non-Māori at p<0.25, were predictive of lower abstinence in multivariate 
regression, at p<0.05; while the scores of five component, of the PCA of variables that were 
significantly different between university and Māori community trial sites, were significantly 
predictive of abstinence at p<0.05 in multivariate regression, two predicted lower abstinence 
and three higher abstinence.  The logistic regressions of these component score as predictors 
of abstinence, had significant correlation between, their error covariances, and whether 
subjects had enrolled at a Māori community trial location, which suggests that there is 
something that is involved in the relationship between these variables, which was not 
measured, and which would improve the fit of the GLMs if it had been measured and included 
in those GLM.  Further research is required to identify the mechanisms underlying the higher 
prevalence of smoking and lower abstinence rates among Māori, and to test methods to 
intervene in those mechanisms.  The analyses performed in this dissertation suggest that 
Māori ethnicity alone, and enrolment at a Māori trial site per se, may not jeopardise 
abstinence but, they typically go hand-in-hand with other characteristics that do reduce the 
odds of abstinence. 
3.9.5 Multicollinearity – need for more parsimonious explanation of 
relapse? 
Collinearity and multicollinearity were encountered in the analysis of predictors of abstinence 
in this trial.  This may be an indication that some of the outcomes recorded during the trial 
indexed the same underlying construct rather than distinct constructs, and it may mean that 
smokers relapse by fewer mechanisms, and fewer mechanisms underpin the various 
observations of smoking and quitting behaviour, than is assumed by the instruments used to 
index the mechanisms by which smokers quit and relapse in this trial.  For instance, many of 
the scores of the brief-WISDM scales were highly correlated, and their effects on abstinence 
were collinear, yet the authors of this psychological battery state that it indexes independent 
psychological constructs.   
Evidence from this trial suggests that there are at least two distinct mechanisms of relapse.  
First, is the addiction to nicotine which is measured by the FTND and Tolerance scale of 
WISDM, and which is correlated with, and not distinct from, the sensory aspects of smoking, 




of smoking  Second, is the social aspects of smoking, indexed by the Social/Environmental 
Goads subscale of the WISDM, and the social aspects of quitting, as indexed by the number 
of personal acquaintances who have quit.   
The possibility that there are but a few mechanisms by which smokers relapse after 
attempting to quit smoking, and that these processes are not well measured by traditional 
psychological batteries, can be seen in the superiority of the Tolerance scale of the brief-
WISDM over FTND scores in predicting abstinence (superior in that Tolerance had an OR 
that was furthest from unity and had a smaller p-value, cf. FTND).  Withdrawal discomfort is 
postulated to be a significant motivator of relapse, yet only one of the five sub-scales of the 
MNWS (Craving), was predictive of six- and twelve-months prolonged abstinence at all 
follow-up time-points after Bonferroni correction for the five MNWS scales measured at four 
time-points.  The observation that the Craving scale of the MNWS that had the biggest and 
most sustained detrimental effect on abstinence, and not the other scales of the MNWS, is 
consistent with the argument of this dissertation, that craving and urges for the rapid delivery 
of nicotine that are important contributors to relapse, and that the provision of more rapidly 
acting NRT may improve abstinence. 
The two techniques used to analyse data that were highly correlated and avoid 
multicollinearity, scaling and centring the data and PCA produced congruent conclusions.  
Analyses of centred and scaled data collected before randomisation found that WISDM 
Social/environmental Goads, Aged ≥50 years, WISDM Tolerance, and WISDM Weight-
control were significant pre-randomisation predictors of prolonged six-months abstinence 
after Bonferroni correction for eight comparisons, p<0.00455.  GLM of subjects’ scores from 
a PCA of pre-randomisation variables, demonstrated that after Bonferroni adjustment, 
Component2 and Component4 significantly increased the odds of prolonged six months not 
smoked on seven consecutive days, and Component5 significantly decreased it.  All four 
variables that had been found to be significant predictors of abstinence using scaled and 
centred data, loaded onto the three Components that had been found to significantly predict 
abstinence.  
Logistic regression was unable to be used to determine if Māori ethnicity and enrolment at a 
Māori community trial site had independent effects on the chances that subjects would 
achieve abstinence because, the large correlation between these variables prevented them 
from being entered as independent variables into the same GLM however, PCA showed that 




variables (Māori ethnicity -0.26, Māori community trial site -0.32), and since the scores of 
Component2 increased the odds of abstinence by almost one-and-a-half times, Māori ethnicity 
and enrolment at a Māori community trial site both decreased the odds of abstinence 
independently of each other. 
Analyses of centred and scaled data from the day after target quit-date phone-call, 
demonstrated that the biggest increase in the odds of achieving six months prolonged 
abstinence was caused by whether or not subjects had quit early, compared to quit on time or 
quit late or had not quit yet; followed by how often patches were worn; how strongly subjects 
intended to continue to try to quit (if they had not already) or continue to remain abstinent (if 
they had already quit).  The same variables from the target quit date phone-call, that GLM of 
centred and scaled variables identified as being predictive of abstinence, also had substantial 
loadings onto the components of PCA of variables collected at the target quit date phone-call.  
The loadings of variables onto the components, and whether the scores of those components 
increased or decreased the odds of abstinence, was consistent with the results of GLM of 
centred and scaled data.  Thus, it can be seen that the conclusions of the GLM of scaled and 
centred data from the quit phone-call and PCA of these data were consistent with each other.  
PCA enabled the creation of simple scales that could be used by health professionals to 
identify smokers who are more likely to fail to obtain abstinence, and who could be offered 
more intensive and more frequent assistance.  For instance, a one unit increase in subjects’ 
scores on a scaled based on the loadings of variables onto Component1 of PCA of variables 
collected at the target quit phone-call, more than halved their odds of abstinence.   
3.9.6 Limitations 
A potential criticism of the analytic approach of this dissertation is that it used a definition of 
abstinence that could not be biochemically verified, and took little account of the data on the 
expired carbon monoxide biochemical verification performed at the single clinic visit after 
baseline.  The rationale for the use of the sole criterion of ‘not smoked on seven consecutive 
days’, and not requiring biochemical verification, is that this outcome is likely to be easy for 
subjects to recall accurately (compared to the Russell Standard which requires subjects to 
remember exactly how many cigarettes they had smoked since their previous clinic visit 
(which may have been three months earlier, and they may have smoked while inebriated, 
making it potentially difficult to keep track of exactly how many cigarettes were smoked).  
The definition of abstinence used in this trial, enabled subjects who lived a long way from a 




verification.  A Cochrane systematic review of nicotine pre-loading, by Lindson and 
Aveyard,(69) identified two studies that only validated long-term, not short-term follow-up, 
and one study that did not perform any biochemical validation.  Lindson and Aveyard chose 
to include results that were not biochemically verified, based on their assumption that one 
would not expect the proportion of participants claiming abstinence, but failing validation, to 
differ between treatment groups.  This assumption was supported by the conclusion of the 
SRNT Subcommittee on Biochemical Verification (2002) that studies with limited face-to-
face contact, and where data is collected by telephone, are unlikely to benefit from 
biochemical verification because of high refusal rates.  Lindson and Aveyard state that, the 
extent that self-report inflates abstinence rates, rarely differs across conditions, and back up 
this claim with evidence from two studies that allowed comparison of validated and non-
validated quit rates, which both found that the proportion of biochemically non-validated 
participants who claimed to be abstinent did not vary significantly across conditions.   
Social desirability was shown not to bias self-reported abstinence outcomes, in a study which 
found no difference in reports of abstinence nor frequency of daily smoking, between subjects 
who were randomised to either; receive the follow-up telephone call from a staff member who 
identified herself as an assistant in the smoking cessation treatment program; or, to receive 
this telephone call from a staff member who identified herself as an employee of a firm 
conducting a market research survey of the use of various consumer products.(359)  However, 
a study of pregnant smokers found that self-report over-estimated smoking abstinence by 
twenty-five percent.(360)  Though, the subjects in that study may not be representative of the 
general population of smokers because, they may be expected to be particularly likely to 
suffer social desirability bias due to their pregnant status, which may motivate them to claim 
to be abstinent).  
Loss-to-follow-up was common, very few subjects continued to participate in the trial beyond 
a few months, and the characteristics of subjects who provided data on their use of Zonnic at 
the six-, nine-, and twelve-month visits would not be representative of the sample as a whole.  
The survival curve for abstinence is very steep, which probably explains the high and early 
rates of attrition that are typical of smoking cessation trials.  Examination of the loss to 
follow-up rates in trials included in recent Cochrane reviews reveals that some trials did not 
report their loss to follow-up rates, and many who did report loss to follow-up, reported high 
rates of attrition.  For example, a recent study of very low nicotine cigarettes in combination 
with usual Quitline care in New Zealand, published in Addiction, had a loss to follow-up at 




combined with e-cigarettes, reported that by six-months, 62/499 (50%) of subjects in the 
patches only group withdrew or were lost to follow-up cf. 161/500 (32%) in the patches plus 
nicotine e-cigarette group and 162/499 (33%) in the patches plus nicotine-free e-cigarette 
group.  In another recently published trial of specialist smoking cessation in hospitalised 
patients, the six-month loss to follow-up rates were 26% and 32% in the intervention and 
usual-care groups respectively.(361).  Therefore, the low retention rate in this trial is 
comparable to those of other studies. 
3.9.7 Conclusion 
This study has demonstrated that, amongst New Zealand smokers, the combination of a 
nicotine patch and oral nicotine spray offers short term benefit for smokers wanting to quit but 
this benefit is not sustained. This, and the overall low rate of success in this trial, suggests that 
alternative more rewarding and less aversive combination NRT treatments need to be 
developed, and that combination NRT may need to be offered for longer than six months after 
the target quit date.  Smokers who use a nicotine patch and mouthspray combination and fail 
to quit on their target quit date should immediately be offered more intensive therapy or a 






4 Background to nicotine inhalation 
This chapter provides evidence that the lung is an ideal delivery route for nicotine absorption 
because, it is the fastest route to deliver drugs to the brain, and the amount of reward that 
drugs provide is contingent on their rapid delivery to the brain.  A further advantage of the 
pulmonary route, is that it delivers a high dose of nicotine to the brain where it exerts its 
desirable effects and a much lower dose to the rest of the body where it causes adverse 
effects, hence there is less potential for adverse effects such as skin irritation, increased 
gastric acid production, burping, and indigestion which are common with oral delivery of 
nicotine.  However, there are challenges that must be overcome, in order to deliver nicotine 
via the lung, because of the involuntary protective reflexes that prevent inhalation of noxious 
chemicals, and because it is necessary for the droplets of nicotine to be of an ideal size for 
them to be absorbed in the lung.   
Three research projects relating to inhalation of nicotine were conducted prior to undertaking 
this nicotine inhaler RCT: 
1. a small pilot study of two doses of nicotine-free base pMDI;  
2. a systematic review of the literature on nicotine inhalational devices and a search of 
non-academic literature including patent applications, and  
3. a pilot study of free-base nicotine, a nicotine salt, with and without flavouring.   
The small pilot study of free-base nicotine tested the pharmacokinetics, pharmacodynamics, 
sensory effects, effects on urge to smoke, and acceptability of two doses of a nicotine free-
base pMDI.(35)  At the conclusion of the pilot study, a systematic review of the literature on 
inhaled nicotine devices (61) was conducted which identified the lack of a portable medicinal 
device for pulmonary delivery of nicotine, that was readily able to be manufactured on a 
large-scale within the budget of many socialised health systems.  Knowledge gleaned from 
the systematic literature review, the principles of chemistry; a search of patents; and 
knowledge that the pharmaceutical industry had used vanillin flavouring to mask the bitter 
taste of ipratropium bromide pMDI (Atrovent), identified that the use of nicotine salts, 
especially organic salts, may be more tolerable than nicotine free-base, and that flavouring 
with menthol or vanillin may also improve the tolerability of a nicotine pMDI.  The potential 




4.1 The pulmonary route is essential for positive reinforcement 
Cigarette smoking owes much of its addictive liability to its delivery of nicotine via the lung, 
which is the fastest route to the brain, with the speed of delivery being proportional to both 
hedonic reward and positive reinforcement.(32, 362)  When nicotine is inhaled, it is rapidly 
absorbed into the bloodstream in the lung which flows into the left atrium, into the left 
ventricle, and passes directly up the aorta, into the carotid arteries, to the brain, resulting in 
the rapid delivery of highly concentrated arterial doses of nicotine which have not yet had 
time to mix with blood in the rest of the circulatory system before these doses of nicotine 
reach the brain.  Thus, when nicotine is inhaled, its concentration in arterial blood is much 
higher than in venous blood,(36, 37) therefore the brain, where nicotine exerts its desired 
effects, receives a high dose of nicotine, whereas the rest of the body, where nicotine causes 
adverse effects, is exposed to a much lower dose. 
The introduction to this dissertation outlined the advantages of the pulmonary route for 
delivery of nicotine to the brain:  
1. Rapid delivery to the brain. 
2. Large surface area to absorb a large dose. 
3. Large buffering capacity assisting in transition of nicotine to its unprotonated form 
which rapidly crosses cell membranes. 
The speed with which nicotine is delivered to the brain plays a significant role in managing 
urges to smoke. Rapid-acting NRTs are likely to quickly extinguish the urge to smoke.(203)  
The pulmonary route would allow quitters to titrate their nicotine intake to absorb sufficient 
amounts, to extinguish their urges to smoke but, not so much that they develop adverse side-
effects,(203) since the rapidity with which nicotine is delivered to the brain and the conscious 
appreciation of its effects on the urge to smoke and its adverse effects, enables the user to 
inhale as many puffs as are required to gain the desired therapeutic effects but, also allows the 
undesirable adverse effects to be sensed early after dosing, before any further dosing occurs.  
In comparison, it takes on average an hour after applying a nicotine patch to the skin before 
nicotine passes from the patch, through the skin, to the blood vessels in the skin; hence, the 
user must wait at least an hour to judge whether the dose was sufficient to be therapeutic 
before using a higher dose if it was insufficient;, and if the dose is too high and caused 
adverse effects, the user will have to wait an hour after taking the patch off before the nicotine 
that had been absorbed into the layers of skin, passes into the bloodstream and is metabolized, 




more closely resembled those of smoking, then more people might try to quit and succeed at 
each attempt.(363)  However, fast-acting rewarding drugs are associated with the risk of 
addiction.(32, 364)  The harm associated with the risk of becoming addicted to fast-acting 
nicotine inhalers must be balanced against the harm from ongoing addiction to cigarette 
smoking.   
4.2 Inhalation of nicotine is aversive 
There are protective reflexes that prevent animals, including humans, from inhaling noxious 
substances and conscious effort is required to overcome these reflexes.  Nicotine activates pH 
sensors and C-fibre chemoreceptors in the lung, aortic arch and mediastinum, which leads to 
the interruption of inspiration and cough.(365-367)  With tachyphylaxis, tolerance develops, 
so that the severity of coughing diminishes until coughing is no longer provoked by nicotine 
inhalation.(365, 366)   
Nicotine stimulates receptors and free-nerve endings in the upper airway and mediastinum 
which causes pungent sensations (burning, stinging, irritation, tangy sharpness, prickling), 
and a momentary reflex apnoea.(365)  The extent to which people interpret these sensations as 
irritating or not, depends on whether they view the sensation as an ‘intended sensation’ or an 
‘unintended sensation’.(365)   
The irritation caused by nicotine binding to receptors at the back of the throat may be limited 
by avoiding nicotine reaching those receptors.  Potential methods to avoid nicotine from 
binding to those receptors, which are suggested by knowledge of basic science, but which 
have not been definitely proven in clinical trials, include: 
1. reducing the amount of nicotine that impacts on the throat by inhaling slowly, thus 
decreasing the momentum of the droplets of nicotine, enabling them to turn the corner 
at the back of the throat and travel within the flow of air travelling down to the lungs 
rather than continuing in a straight line to the back of the throat (momentum is equal 
to mass multiplied by the square of speed, and objects with greater momentum travel 
in a straight line and it takes more force to change their direction);  
2.  coating the nicotine in a non-aversive envelope. 
Potential methods to reduce the severity of nicotine’s aversive effects, which are suggested by 




respiratory responses to inhalation of irritating substances, but which have not been definitely 
proven in clinical trials, include: 
1. providing a distraction from the irritation by the use of strong flavouring or a counter-
irritant (particularly menthol);  
2. encouraging the user to view the irritation as desirable. 
Although limiting the impaction of nicotine on the back of the pharynx, may potentially 
reduce irritation in the throat, this will not stop the irritation caused by nicotine binding to 
airway C-fibre receptors below the larynx.(369)  For instance, cigarette smoke is aversive 
even after the upper airway has been anaesthetised.(370)  Supra-tentorial processes can 
modify the cough reflex in response to aversive peppery chemicals such as capsaicin,(369) 
which allow smokers to quickly adapt to the aversiveness of smoking. 
A greater proportion of nicotine will impact on the back of the throat, where it will cause 
irritation or “throat-impact”, if the nicotine is in its highly volatile free-base vapour 
form.(371)  The amount of nicotine that exists in its free-base form can be limited by adding 
acids.  Organic acids are particularly suited for use in hydrofluoroalkane (HFA) aerosols 
because organic acids are more soluble in HFA than inorganic acids.(230)  During the 
manufacture of cigarettes, tobacco is heated to high temperatures, a process called “toasting”, 
in order to enhance the natural sugar content of tobacco,(372) and sugars as well as organic 
acids (373) are added to tobacco, because when sugars are burned the pH of the cigarette 
smoke is lowered which makes it more tolerable to inhale.   
Menthol stimulates Transient Receptor Vanilloid ion channels in the upper airway which 
cause a cold sensation in the airway which, amongst other things, causes a momentary breath-
hold enabling more time for nicotine to be absorbed, and the cold sensation acts as a counter-
irritant to the airway irritation of nicotine, indeed menthol has been added to tobacco by 
cigarette manufacturers to reduce irritation and cough provoked by nicotine.(374) 
4.3 Technical challenges of delivering nicotine to the lung 
A wide range of devices have been designed with the aim of pulmonary delivery of nicotine, 
which are outlined in a systematic review of the literature by me in collaboration with Walton 
Sumner.(61)  The review identified that no device capable of delivering nicotine to the lung 




are used intensively and by an experienced user.  There are a variety of potential reasons for 
the failure to commercialise nicotine pulmonary-delivery devices: 
1. There are numerous physical and technically difficulties in delivering nicotine to the 
lung. 
2. A lot of money is required to manufacture nicotine delivery devices, especially 
devices that use bespoke technology for which there are no existing factories or 
machines capable of their manufacture. 
3. Pharmaceutical regulators have been reluctant to license drug delivery devices that 
have a high abuse potential.(12, 191) 
As mentioned previously, in order for nicotine to be inspired deeper than the upper airway, it 
must be in particle or droplet form because, gaseous (vapour phase) nicotine is quickly 
absorbed in the upper airway, leaving no unabsorbed nicotine to travel deeper into the lung.  
Particles/droplets must have an ideal Mass Median Aerodynamic Diameter (MMAD), 
sufficiently small to limit their momentum so they turn around the curve at back of the 
pharynx and pass down the trachea, but not so small that they fail to impinge on the lung and 
are exhaled instead of being absorbed.  Particles with a diameter of less than four µm, when 
inhaled slowly, will pass through the upper airway unhindered when inhaled orally and,(375) 
those particles that have a diameter greater than one µm will have sufficient mass to fall by 
gravity during a breath-hold of ten seconds and be deposited on and absorbed by the lung, 
rather than being exhaled.(376)  Given that nicotine and its salts are liquid at room 
temperature,(377) they would first have to be transformed into dry powders before they could 
be inhaled using a dry powder inhaler.  In their liquid state, nicotine and its salts can be 
dissolved in Hydrofluoroalkane (HFA) when a small amount of ethanol is added as a co-
solvent, and used in a pressurised metered-dose inhaler (pMDI).    
Recently developed pMDIs produce droplets with small MMAD that are within the respirable 
range,(378) and therefore are likely to deliver nicotine deep down the airway (where there is a 
greater surface area for absorption) and more closely mimic the pulmonary nicotine 
absorption from cigarette smoke.   
4.4 History of non-combustible nicotine pulmonary delivery prior to 
the design of the nicotine pMDI plus nicotine patch RCT in 2009 
In 1967 Herxheimer and colleagues used a metered dose inhaler to deliver nicotine 




similar to those caused by smoking a cigarette, although no plasma levels were 
measured.(379)   
In 1999 Andrus and colleagues reported a method for loading a pMDI with nicotine which 
produced a micro-aerosol of sufficiently small droplets to mimic the pulmonary delivery of 
nicotine by cigarette smoke but, the authors did not administer nicotine to human or animal 
subjects.(229)  As far as I am aware, prior to 2009 when this nicotine pMDI plus nicotine 
patch trial was designed, the effects of only one other nicotine inhaler on smoking cessation 
had been reported in the medical literature.  This inhaler, has been variously referred to as an 
inhalator, Nicorette/Nicotrol inhaler, or vapour inhaler.  However, the nicotine inhaled from 
that device is in the nicotine free-base form, and is absorbed via the oropharynx rather than 
the lung, hence it achieves lower Cmax, and delayed Tmax, compared to smoking cigarettes.(24)  
Electronic cigarettes, which were discussed in the main introduction to this dissertation, were 
not prominent in New Zealand in 2009 when the nicotine pMDI plus patch RCT was 
designed, and at that time it was illegal to sell nicotine-containing electronic cigarettes in New 
Zealand, although they could be legally imported from overseas for personal use. 
4.4.1 Oral inhaler 
The nicotine inhaler, referred to in the preceding paragraphs as an inhalator, was developed in 
the 1970s, it is a plastic pipe that has an adsorbent material in one end that is soaked in 
nicotine free-base and menthol.  The user sucks air through the tube, which delivers nicotine 
to the venous blood within seven minutes (203).  Positron Emission Tomography and 
comparisons of arterial and venous nicotine concentrations indicate that nicotine inhaled from 
this inhaler is mostly deposited in the oropharynx.(24).  This device produces lower blood 
nicotine concentration, and takes longer to do so than smoking does.(24)  Cough occurs in up 
to thirty percent of subjects when they first use it.(380)  An RCT of active versus placebo 
inhalator observed continuous abstinence rates at six months of 25/145 (17.24%) and 11/141 
(7.80%), p=0.0161, in the active and placebo groups, respectively.(381)  The only study that I 
was able to find, from searches of the literature, in which the inhalator was used in 
combination with nicotine patches, randomised subjects to active inhalator plus active patch 
cf. active inhalator plus placebo patch, the biochemically verified six month prolonged not 






5 A pilot study of nicotine delivery to smokers from a 
metered dose inhaler 
5.1 Introduction 
This open labelled pilot study examined the feasibility of nicotine administration via a 
standard pMDI, and compared the pharmacokinetics, pharmacodynamic effects and 
acceptability with smoking a cigarette.  
5.2 Method 
Ten subjects (seven males), who were regular daily smokers, were recruited. No subject had 
previously used therapeutic pMDIs. Exclusion criteria were: people with a history of 
cardiovascular disease or serious medical conditions, women who were breastfeeding, and 
women of childbearing age who were not using contraception. Ethical approval was obtained 
from the Central Ethics Committee.   
Metered dose inhalers containing nicotine free-base United States Pharmacopeia (USP), 
anhydrous ethanol, HFA-134a propellant, and a small quantity of levomenthol (USP) to 
improve the taste were produced by Cipla Pharmaceuticals Ltd., Mumbai, India. To make the 
100μg/puff pMDI, 20mg of nicotine free-base was dissolved in 200mg of ethanol and added 
to 10g of HFA-134a propellant. This formulation was based on that described 
previously.(229)  MMAD was measured at room temperature using the eight stage Anderson 
cascade impactor and a standard 0.4mm actuator. MMAD for the 50μg/puff inhaler was 
3.7μm, and for the 100μg/puff was 0.8μm.    
The mean nicotine content in smoke from typical cigarette brands is 1.1mg/cigarette.(382)  
Plasma nicotine was assayed by a modified method as previously described.(383)  An 
isotopically labelled nicotine (3xC13) was used as the internal standard in preference to 
diphenhydramine.  The coefficient of variation of the method at a nicotine concentration of 
20ng/mL was 0.9% for six replicates, which compares favourably with the published data for 
the method. 
The subjects attended on three days, at least four days apart and were requested to abstain 
from smoking for at least four hours prior to each study day.  Prior to starting each study day, 
a cannula was placed in a forearm vein for blood sampling.  On day one, subjects smoked one 
of their usual brands of cigarette over a five-minute period, using their own style of smoking.  




offered one or two puffs of the 50μg/puff inhaler to try, via a spacer, to familiarise them with 
the sensory effects of the inhaler.   
On day two, subjects inhaled ten puffs of 50µg/puff nicotine from a pMDI via a Volumatic 
spacer. Each puff was delivered into the spacer at thirty second intervals and the subject took 
two inhalations for each puff, therefore the total dose administered was 0.5mg.  On day three, 
subjects took the same number of inhalations from a 100µg/puff pMDI, the total dose being 
one mg. 
A Volumatic 500ml spacer was used to aid pulmonary deposition because this spacer 
improves the pulmonary deposition of asthma inhaler medication. 
Blood was taken from the cannula, and heart rate and blood pressure measured, at t=-5, 0 
minutes before the smoking/inhalation and at t=1, 3, 5, 7, 10, 15, 20, 30, 60, and 120 minutes 
after the completion of the smoking/inhalation.  For the pharmacokinetic analysis, the change 
in plasma nicotine levels from baseline was calculated (baseline was the mean of levels at 
t=-5 and t=0). 
Baseline characteristics of subjects were recorded, including smoking history and the 
Fagerström Test for Nicotine Dependence (FTND). The brief Questionnaire of Smoking 
Urges (QSU), which evaluates the desire to smoke with ten questions rated on Likert scales 
from one (strongly disagree) to seven (strongly agree), was administered at baseline and thirty 
minutes after each intervention.(306)  The brief-QSU measures a strong desire and intention 
to smoke with smoking perceived as rewarding; anticipation of relief from negative affect 
and; an urgent desire to smoke.  At the end of each study day the acceptability and likeability 
of the cigarettes and the inhalers were compared using the Cigarette Evaluation Questionnaire 
(CEQ) this is a five-point Likert scale with eleven items scored from one: not at all, to five: 
extremely.(384)  The CEQ asks subjects to rate the extent to which the cigarette they just 
smoked was satisfying, tasted good, made them dizzy, calmed them down, helped them to 
concentrate, made them feel more awake, reduced appetite, made them nauseous, decreased 
irritability, produced enjoyable sensations in the throat and chest, and immediately reduced 
craving for cigarettes. 
5.3 Results 
The mean age of the subjects was thirty-four years (range twenty-three to fifty-one years). 
Mean FTND was 3.7 (SD=2.3), indicating relatively low nicotine dependence. All ten 




the 100μg pMDI day. Mild coughing was experienced by three subjects with the 50µg inhaler 
and five subjects with the 100µg inhaler.  Severe coughing occurred in one subject with the 
100µg inhaler resulting in withdrawal from the study. 
The mean number of puffs on the cigarette day was fourteen (range eleven to eighteen).  In 
comparison to cigarettes, the pharmacokinetic profiles of the inhalers (Table 5.1, Figure 5.1), 
had lower maximum concentrations (Cmax) and took longer to reach Cmax (Tmax).  Compared to 
the 100µg inhaler, the 50µg inhaler achieved a higher Cmax, but longer Tmax, greater decay in 
nicotine levels over time and a smaller area under the curve (AUC). The bioavailability of the 
pMDI nicotine was approximately 42% when compared to the cigarette (Table 5.2).   
Table 5.1 Median maximal concentrations minus baseline levels (Cmax), concentration 
at one minute CT=1, time to maximum concentration (Tmax) and area under the 









Cmax (ng/ml) 25.9 (13.7 - 55.3) 12.5 (7.9 - 14.3) 9.4 (7.5 – 12.1) 
C T=1 25.0 (11.3 - 43.7) 4.0 (2.3 – 5.7) 6.4 (4.2 – 9.8) 
Tmax (min) 2 (1 – 5) 6 (5 – 7) 5 (3 – 7) 
AUC  1032.5 (572.8 - 1259.3) 201.5 (84 – 337) 365 (184 – 645) 
 
Table 5.2.  Bioavailability of the inhalers relative to cigarettes 
 Total Dose (mg) Median Relative Bioavailability 
(interquartile range) 
Cigarette 1.1 1 
50µg inhaler 0.5 0.429 (0.179 – 0.589) 
100µg inhaler 1.0 0.389 (0.353 – 0.563) 
 
There was greater variability between subjects, in the nicotine levels achieved by the 
cigarettes and the 50µg inhaler when compared to the 100µg inhaler (Figure 5.1, page 218). 
The pharmacodynamic effects (pulse and blood pressure) reflected the plasma level changes 
with all three preparations increasing heart rate, systolic and diastolic blood pressures (Table 
5.3, page 218).  Subjects awarded both nicotine doses substantially lower scores on the CEQ 







































































Figure 5.1 Venous nicotine pharmacokinetics.  Median maximal increase in nicotine 
concentration compared to baseline (interquartile range). 
 
Despite the larger pMDI dose causing some discomfort, both pMDI preparations were 
acceptable and reduced craving in subjects, there was little difference between the three  
Table 5.3. Median change (SD) in blood pressure (mm Hg) and heart rate (bpm) for 
the three treatment days. 






Systolic BP 17.3 (4.0) 9.5 (7.8) 7.8 (11.1) 
Time (min) 3 (10.0) 10 (9.4) 6 (9.8) 
Diastolic BP 15.0 (5.1) 11.5 (10.9) 13.5 (4.9) 
Time (min) 1 (3.1) 7 (4.3) 7 (3.5) 
HR (bpm) 16.0 (6.8) 7.5 (4.1) 9.5 (5.2) 





preparations besides the pMDIs being less pleasurable in regard to throat and chest sensations 
cf. cigarettes (Tables 5.4 and 5.5). 
Table 5.4.  Cigarette Evaluation Questionnaire (CEQ) 
CEQ item 
Cigarette 50µg 100µg 
Median Range Median Range Median Range 
Satisfying 4 3-5 3 1-4 4 1-5 
Tasted good 4 2-5 2 1-3 2 1-3 
Made me dizzy 3 1-5 2 1-5 3.5 3-5 
Calmed me down 4 1-5 3 1-5 3 1-4 
Helped me to 
concentrate 
2 1-4 3 1-4 3 1-3 
Made me feel more 
awake 
2 1-4 3 2-4 3 1-4 
Reduced my appetite 2 1-4 2.5 1-4 3 1-4 
Made me nauseous 1 1-5 1 1-3 2.5 1-4 
Made me less irritable 2 1-5 3 1-4 3 1-4 
Produced enjoyable 
sensations in the throat 
and chest 
3 1-4 1 1-2 1 1-2 
Immediately reduced my 
craving for cigarettes 
4 2-5 3 2-5) 4 2-5 
Median of individual 
total CEQ scores 
33 16-40 26 16-34 30.5 19-37 
 
Table 5.5.  Median post-QSU scores minus median pre-QSU scores (interquartile 
range) for individual items in the QSU questionnaire, and total QSU scores. 
 Cigarette 50µg 100µg 
I have a desire for a cigarette 
right now 
-1 (-2 to 0) -1 (-2.75 to -0.25) -1 (-3.25 to 0) 
Nothing would be better than 
smoking a cigarette right now 
-1 (-2 to 0) -0.5 (-1.75 to 0) -0.5 (-2 to 0) 
If it were possible, I probably 
would smoke now 
-1 (-1.5 to 1.25) -1 (-1.75 to -0.25) 
-1.5 (-2.5 
to -0.75) 
I could control things better 
right now if I could smoke 
0 (-1 to 0) 0 (-1 to 0) 0 (-1 to 0) 
All I want right now is a 
cigarette 
-1 (-2 to 0) 0 (-1.75 to 0) 0 (-2.25 to 0) 
I have an urge for a cigarette -1 (-2 to 1) -1 (-2.5 to 0) -1 (-2.25 to 0) 
A cigarette would taste good 
now 




 Cigarette 50µg 100µg 
I would do almost anything 
for a cigarette now 
-2 (-3 to 0) -0.5 (-1 to 0) -0.5 (2 to 0) 
Smoking would make me 
less depressed 
-0.5 (-1.25 to 0) -0.5 (-1 to 0.75) 0 (0 to 0.25) 
I am going to smoke as soon 
as possible 
-1 (-2 to 0) -1 (-2 to 0) -1 (-2 to 0) 










In this pilot study, a simple HFA pMDI with a large volume spacer (VolumaticTM), delivering 
nicotine at 50 and 100μg/puff, produced maximum nicotine plasma concentrations in venous 
blood that were approximately half those after smoking a cigarette and took three times as 
long to reach this maximum.  Area under the dose response curve was between twenty and 
thirty-five percent of the AUC for the cigarette day. Increases in blood pressure and heart rate 
largely reflected the plasma nicotine concentrations after smoking and from the two inhalers.   
To my knowledge, this was the first published study to show that a simple unmodified pMDI 
using standard propellants and nicotine dissolved in ethanol can rapidly provide substantial 
plasma levels of nicotine following inhalation. Peak plasma levels were higher and achieved 
more rapidly than many current forms of nicotine replacement.(385) 
In general, the inhalers were reasonably well tolerated, but initially and for the first few puffs 
especially, were associated with coughing and interruption of the smooth inspiratory flow 
required for effective inhalation from a spacer. This was more apparent for the 100μg/puff 
inhaler compared to the 50μg/puff, with one subject unable to complete the 100μg/puff study 
day because of coughing. Dose-dependent coughing and the reflex interruption of inspiration 
are the most likely explanations for the similar plasma levels obtained from the 50 and 
100μg/puff inhalers. However, all nicotine by inhalation, is aversive, and after repeated 
exposure users of the nicotine inhaler may develop tolerance to its aversiveness, just as they 
did when they first started smoking.  Tolerance to nicotine nasal spray develops after one 
week. Some degree of harshness, forms part of the sensory stimulation that smokers 
enjoy.(41)  Despite the aversiveness of the inhalers, subjects attributed similar satisfaction 




The pharmacokinetic profile of these inhalers, their swift reduction of QSU scores, and high 
CEQ scores, suggest that there was a mixture of pulmonary and oral/upper-airway absorption, 
with a rapid pulmonary component that delivered significant amounts of nicotine to the blood 
within one minute, and an oropharyngeal component with a delayed Tmax of five minutes.  
Peak arterial nicotine levels occur seven to ten seconds after each puff of a cigarette,(386) 
while peak venous levels of nicotine are reported to occur around five minutes after 
smoking,(24, 32) which are in keeping with the venous levels found in this study.  These 
venous Tmax values from smoking are similar to the venous Tmax of six minutes for the 50µg 
inhaler and five minutes for the 100µg inhaler.  The similarity of the venous Tmax of the 
inhalers and the cigarette, suggests that at least some of the nicotine from the inhalers is 
absorbed by the pulmonary route.  The fast pulmonary component of nicotine absorption from 
both inhaler doses is evident in the rapid delivery of most of the nicotine within the first 
minute after inhalation.  The amount of nicotine delivered to the venous blood one minute 
after inhalation, as a fraction of the Cmax, was 0.68 and 0.32 for the 100µg and 50µg inhalers 
respectively.  Further evidence, that nicotine from these inhalers is absorbed via the lungs, 
comes from the rapidity with which they reduced QSU scores.   
The Tmax of both doses of these nicotine inhalers were superior to published values of their 
closest comparator among the currently available medicinal inhaled NRTs, which is 
composed of a plastic tube containing a plug of nicotine and menthol in one end.  An 
intensive puffing regime of eighty deep inhalations over a twenty minute period, produces a 
Tmax of thirty minutes, mean plasma nicotine level of 7.1μg/L (7.1x10
-6ng/mL) at twenty 
minutes, and 8.1μg/L (8.1x10-6ng/mL) at both thirty and sixty minutes.(24)  This 
pharmacokinetic profile, along with a number of other findings, suggest this plastic tube 
‘inhaler’ has a primarily oral mucosal and upper airway route of absorption.(381, 387-389)   
The inhalers in this study are also faster than the fastest currently available non-inhaled NRT, 
nicotine nasal spray, which has a venous Tmax of five to ten minutes.  Other NRTs have much 
slower Tmax values, of four to ten hours for patches, and twenty-five to thirty minutes for 
nicotine gum.(11) 
The median reduction in QSU scores by the nicotine inhalers was similar to the reduction 
after cigarette smoking, with the 50µg inhaler most closely resembling the effect of smoking a 
cigarette.  The inhalers achieved these reductions in QSU scores without matching the 
pharmacokinetics of cigarettes, and must have done so as the result of other factors in addition 




subjects’ association of throat scratch with psychological reward, or the placebo effect.  
Although some amount of throat scratch is rewarding, too much of it is aversive and prevents 
deep inspiration, which may explain why the more aversive 100µg inhaler produced a smaller 
reduction in QSU scores and lower plasma nicotine levels, than the 50µg inhaler.   
Compared to cigarettes, both inhalers had substantially longer time to and lower Cmax values.  
The most likely reason is that both aerosols were more aversive than smoking with the 100µg 
inhaler being more aversive than the 50µg inhaler.  The aversity of the inhalers caused mild 
coughing in half the subjects and severe coughing in one subject, which would have led to 
reduced pulmonary absorption.  It is likely that the aversive effects of the inhalers are related 
to a complex interaction of a number of factors, such as, the concentration of nicotine, high 
pH of 10.1, large MMAD, and the presentation of nicotine to subjects’ airways without the 
corresponding sensory experiences which their personal brand of cigarettes would provide 
(such as taste, flavour, smoke).   
The use of the large standard Volumetric space would limit the use of this inhaler in everyday 
life and the pharmacokinetic profile without the use of a spacer needs to be measured in order 
to know if the inhalers can be used without a spacer. 
The subjects in this study had fairly low FTND scores and it is possible that the findings of 
this trial will not generalise to smokers with higher nicotine dependence.  Further research 
would be required to determine whether more highly nicotine dependent smokers would gain 
satisfaction and relief of their urges to smoke and withdrawal symptoms after using this 
inhaler and nicotine patch combination therapy. 
This small pilot study has shown that nicotine can be delivered to the human airway by a 
standard metered dose inhaler and that the inhaler appears to provide some relief from urges 
to smoke. Despite its aversiveness it was reasonably well accepted by the smokers in this 
study. This study was limited in its ability to provide statistically significant conclusions by 
its small sample size, and broad inclusion criteria. Further research, with a larger sample size, 
is required to disentangle the role of pH, dose, MMAD, taste, and other sensory components, 
in the facilitation of comfortable inspiration and pulmonary absorption of nicotine. Such an 
inhaler could have an important role in helping smokers to quit by rapidly removing the 





6 Cross-over trial of the acceptability and efficacy of 
nicotine free-base and nicotine lactate pressurized 
metered-dose inhaler formulations to quench smoking 
urges 
6.1 Introduction 
In order to find ways to limit the aversive effects of nicotine pMDI inhalation, the academic 
literature on nicotine inhalation devices was systematically searched,(61) informal searches of 
the internet and patent applications were conducted, and textbooks on chemistry and 
respiratory drug development were examined.(390)  Potential methods to improve the 
nicotine inhaler were identified from these sources of knowledge and their effects were tested 
in a small pilot cross-over trial. 
The aim of this cross-over study was to rapidly and inexpensively test whether potential 
methods to reduce the adverse effects of inhaling nicotine from a pMDI would be effective.  It 
was not possible to conduct a trial with a larger sample size or longer duration due to limited 
funds and limited time.  The potential methods that were tested were: 
1. Use of nicotine lactate instead of nicotine free-base.  
2. Use of flavourings (vanillin and menthol). 
3. Use of lower versus higher doses of nicotine. 
6.2 Methods 
Twelve subjects who smoked at least nine cigarettes per day with a Fagerström Test for 
Nicotine Dependence (FTND)(303) score of three or more, attended the medical school for 
one day to inhale a range of nicotine formulations.  Subjects were recruited by word of mouth 
and via the study website, primary care practices, smoking cessation services and news 
reports on radio, newspapers, television. 
A factorial design was used to test different doses, flavours, and types of nicotine.  The 
nicotine formulations were grouped according to nicotine dose (50, 100, 200, or 300µg of 
nicotine per puff).  Within each dosage, inhalers were grouped into three flavour groups 
(unflavoured, vanillin, menthol).  Within each flavour group, there were two pairs of inhalers, 
one containing nicotine free-base, the other nicotine lactate.  Inhalers were manufactured by 




Subjects took single puffs of the different formulations and rated their effects, starting with 
lower dose formulations and stepping up the dose only if they wanted to, then after 
completing single puffs from all the formulations, subjects were asked to choose which 
formulation to take up to ten puffs of, to more thoroughly assess its sensory and psychological 
effects.  Intermissions and sips of water were taken to wash out the effects of inhaling prior 
formulations.  Subjects waited until they had an urge to smoke before inhaling further puffs of 
the pMDIs. 
For each flavour and dose, whether free-base or nicotine lactate was inhaled first, was 
randomised within each flavour-group, (this order was double-blind).  The order in which 
subjects inhaled the flavour groups was constant (unflavoured first, then vanillin, and menthol 
last), to minimise contamination of flavours (the order of flavours was single-blind).   
It was presumed that the effect of the menthol flavour would last the longest, hence to 
minimise cross-over effects, menthol was always given last.  A disadvantage to this approach 
was that by the time subjects inhaled the menthol flavoured aerosols they may have developed 
tolerance to the aversive qualities of nicotine because they had already inhaled unflavoured 
and vanillin flavoured nicotine formulations and any reduced aversiveness of the menthol 
flavoured formulations could therefore have been caused by tachyphylaxis rather than 
menthol.  The aerosols were labelled with codes, rather than being labelled with their 
contents, to mask subjects and researchers. 
Subjects answered baseline questionnaires (smoking history, FTND, MNWS, brief-QSU), 
then practiced inhaling slowly and steadily from an unflavoured placebo pMDI and 
coordinating inspiration with activation of the pMDI.  Subjects inhaled all formulations 
directly from the pMDI mouthpiece and did not use a spacer.   
Subjects started at the 100µg dose, if this was not tolerable, the dose was reduced to 50µg.  At 
each dose strength, subjects took one puff of each pair of formulations (free-base and lactate) 
within each flavour-group (starting with the unflavoured pair of formulations) and commented 
on the effects of the formulation, using a form that asked about flavour, sensations, and 
enjoyment.  The form included the brief-Questionnaire of Smoking Urges (brief-QSU)(306) 
which was measured before and after each formulation had been inhaled, the modified 
Cigarette Evaluation Questionnaire (CEQ),(305), Duke Sensory Questionnaire,(256, 391) and 
ad hoc Likert scales.  The Duke Sensory Questionnaire is made up nine items, such as, puff 
liking; puff satisfaction; nicotine in puffs; similarity to own brand; and puff strength on the 




scales from 1=“not at all” to 7=“extremely”.  Subjects’ preferences between the formulations 
was measured on ad hoc Likert scales.  Side-effects (cough, hiccup, sneeze, burp) were 
recorded on a 100mm VAS and ad hoc Likert scales.  Adverse effects were also rated and 
recorded by me and another staff member. 
After inhaling the lactate and free-base formulations within the first flavour group 
(unflavoured) at the 100mcg dose (or the 50µg dose if the 100µg dose was too aversive), 
subjects repeated the procedure with the vanillin flavour at the same dose, then repeated the 
procedure with the menthol flavour of the same dose.  Subjects waited until they had an urge 
to smoke before inhaling more puffs. 
Subjects could take further single puffs if required, in order to choose which member of the 
pair (free-base/nicotine lactate) they preferred.  When subjects were confident about their 
preference between the lactate and free-base within a flavour-group, they moved to the next 
flavour-group.   
After inhaling at least one puff of all the 100µg doses (or 50µg doses if the 100µg dose was 
not tolerable), subjects chose which formulation to inhale next, at a higher or lower dose, 
depending on how tolerable the 100µg doses were.  These formulations were tested in the 
same way as the 100µg/50µg dose, except subjects only inhaled formulations they had liked 
at the lower dose, and therefore the order in which they inhaled the formulations was ad 
libertum.  Subjects ranked their preferences between formulations twice: 
1. after inhaling both nicotine formulations within a flavour-group (initial preference); 
and  
2. after inhaling all three flavour-groups at the same dose (overall single puff 
preference).   
Further single puffs of any formulations could be taken if subjects needed a head-to-head 
comparison before choosing their overall single puff preference. 
Once subjects had completed the 100µg doses, they repeated the process with the 200µg then 
the 300µg doses; however, subjects had the option to discontinue inhalation at any point and 
were not encouraged to use higher doses unless they wanted to.  Subjects only inhaled higher 
doses of the formulations they wanted to.  Once subjects decided they did not want to try any 
more single doses of the higher doses in order to decide their preferences, subjects waited 
until they had an urge to smoke, before choosing one of the formulations to inhale up to ten 




questionnaires used to record the effects of single inhalations of nicotine were used to record 
the effects of the multiple inhalations. 
Subjects were given the option of having further opportunities to have up to ten puffs of a 
formulation of their choice if they had an urge to smoke. 
Outcomes are presented according to the type of nicotine, as well as the order in which they 
were inhaled (denoted by FormulationXdose where X can be A, B, C, D, E, F indicating the 
order of inhalation.  Although this study design may lead to some cross-over effects because, 
subjects only waited until they had an urge to smoke before sampling the next formulation, 
the trial was not intended to definitively test the relative qualities of each formulation, but 
rather, to determine if any of the formulations was clearly superior or clearly unacceptably 
aversive. 
6.3 Results 
Subjects were eight men and four women; with a median age of forty-nine years (interquartile 
range (IQR) forty to fifty-one); and a median (IQR) FTND of six (four to six).  Six subjects 
usually smoked regular cigarettes, four smoked mild cigarettes, and two smoked menthol 
cigarettes. 
Subjects had quit on average 1.25 times in the past year (range zero to five), four of whom 
had quit for longer than a week.  Nine subjects had used NRT in the past year, including all 
four who quit for longer than a week.    
6.3.1 Single puff comparisons between formulations 
Table 6.1, page 227) shows the outcomes for the series of single puffs of all the formulations.  
In Table 6.1 for each dosage, the results are grouped according to flavour, and within each 
flavour group, the results for the free-base and lactic acid are displayed along with a column 
indicating whether free-base or lactic acid was taken first or second within each flavour 
group.  There were few statistically significant findings, none of which would have remained 
significant after Bonferroni correction for the number of comparisons (three flavour groups, 
three dosages, nicotine versus nicotine lactate (p<0.05/(3*3*2)=0.05/18=0.0028).  All 
formulations were well tolerated at all doses, although not all subjects chose to inhale higher 
doses of some of the formulations (particularly the unflavoured ones).  The most common 
side-effect was mild coughing.  The only other side-effect was mild hiccupping in one subject 




Table 6.1. Results of single puffs of formulations 
100µg nicotine dose 
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  Menthol Group 300µg n=10 
 Free-base n=8 Lactate n=7 FormulationE300µg n=6 FormulationF300µg n=9 
Number of puffs, median (IQR) 1 (0-1) 1 (0-1) 0.5 (0-1) 
1 
(0.75-1) 
Initially preferred highest (n) Ω 1 2 1 2 
Number coughs, median (IQR) 0 (0-0) 0 (0-2) 0 (0-0.75) 0 (0-0) 
Overall single puff preference (n)**** 1 2 0 3 
Least preferred formulation (n) 0 1 0 1 
 
All p-values for all comparisons are non-significant (p>0.05) unless shown otherwise 
A,B,C,D,E,F refer to the order in which the formulations were inhaled (alphabetical order): A,B unflavoured; C,D vanillin; E,F menthol  
† counts of those that did compared to those who did not (e.g. those who did cough compared to those that did not cough; those who did prefer the formulation 
compared to counts of those who did not prefer that same formulation; or, counts of subjects who experienced throat scratch (or cough) with that formulation compared 
to those who experienced no throat scratch (or cough) (binomial test)) 
†† compared to other pair in this group (e.g. within a flavour group lactate cf. free-base, or 2nd formulation cf. 1st formulation) (proportion test) 
‡ compared to unflavoured version of the same kind of nicotine (Mann-Whitney test), or if it is the 1st or 2nd formulation this is a comparison to the corresponding first 
or second unflavoured nicotine formulation that was inhaled respectively 
Ω this only includes the preferences of subjects who tried both types of formulations (e.g. free-base and lactate 200µg) and where therefore able to make a comparison 
* one person preferred both the free-base and lactate vanillin formulations, so only 11 people preferred one over the other. 
** two people preferred both the free-base and lactate menthol formulations, so only 10 people preferred one over the other 
*** two subjects preferred both the free-base and lactate vanillin 200µg formulations, so only 7 people preferred one over the other 
**** one person preferred all menthol formulations at all doses, regardless of whether they were the first or second to be inhaled, all equally as his first overall single 
puff preference 
¥ one subject least preferred formulation was the 100µg and 200µg doses of FormulationB (free-base) equally; one subject did not want to nominate a least preferred 
formulation because none were that bad (these subjects’ data are not counted in the table). 
α The preference data only counts subjects who tried both of the formulations being compared (otherwise they could not have a preference between them), and only 
those who preferred one over the other (not those who preferred both equally).  Numbers who preferred both equally are given in the text of the Results section. 
αα the p-values are calculated from data from those who did inhale these formulations, not the full number of subjects (calculated by the binomial test), so it is not an 
intention-to-treat sample for these p-values.   
The only side-effect of the single puffs that is shown in this table is the number of coughs, because no subjects hiccoughed, burped, or sneezed after inhaling single 





6.3.1.1 Single puffs of the 100µg formulations 
Subjects took few puffs of the formulations, ranging from an interquartile range of 1—1.2 to 
1—2.  Twice as many subjects preferred the lactate cf. free-base in the unflavoured 
comparisons; subjects were fairly evenly split between their preferences for lactate and free-
base in the vanillin comparisons; whereas one-and-a-half time more subjects preferred the 
lactate over the free-base in the menthol flavoured comparisons.  Approximately twice as 
many subjects preferred the second formulation to the first in the unfavoured and menthol 
comparisons, while the opposite was true with the vanillin comparisons.  The differences in 
the number of coughs between formulations tended to be not statistically significantly 
different or, at most, of only mild significance.  When asked to rate their overall preference 
between these formulations at the 100µg dosage, only one person had a preference, which was 
for free-base menthol, which was the first formulation they inhaled of the menthol 
formulations at this dose. 
6.3.1.2 Single puffs of the 200µg formulations 
 
More subjects chose to inhale the menthol formulations than the vanillin formulations, and 
more chose the vanillin than the unflavoured formulations.  A similar pattern was evident in 
subjects’ preferences between the 200µg formulations after they had inhaled them.  Coughing 
was not prominent with the 200µg doses.  There were more coughs with the unflavoured 
compared to flavoured formulations.  For the vanillin flavoured formulations, this was 
statistically significant with the lactate formulation but, not the free-base nicotine vanillin 
formulation, whereas with menthol flavouring both the lactate and free-base formulations 
provoked significantly fewer coughs than their unflavoured counterparts.    
6.3.1.3 Single puffs of the 300µg formulations 
Only two 300µg formulations were manufactured: menthol free-base and menthol lactate.   
Two subjects did not try any of the 300µg doses, three subjects tried both 300µg formulations 
and seven tried only one.  Seven and eight subjects chose to inhale the free-base and lactate 
formulations, respectively. 
More subjects preferred the menthol lactate and the second formulation (FormulationF300µg) 
compared to the menthol free-base and the first formulation (FormulationE300µg), respectively, 




At the 300µg dose, coughing was not prominent.  
6.3.1.4 Preferences between all formulations at the end of the series of single 
puffs (overall single puff preference) 
As their first preference (Table 6.1, page 227), all twelve subjects chose a menthol 
formulation.  The most popular dose was 200µg, while one subject preferred all doses 
equally.  Subjects were evenly split in their preferences between the free-base formulations 
versus the lactate formulations.  The second formulation that was inhaled, was more often 
preferred than the first and; at higher doses, the lactate was preferred over free-base, although 
these comparisons were not statistically significant.  The only statistically significant 
difference was the preference for the first and second menthol 200µg nicotine formulations 
that subjects inhaled, compared to the first and second unflavoured types of 200µg nicotine 
formulations they sampled. 
As their second preferences, nine subjects chose menthol, two voted vanillin, and one 
preferred the unflavoured formulations.  One subject liked all doses they inhaled (which were 
all vanillin flavoured), five and six preferred the 100µg and 200µg doses respectively; five 
and six preferred the lactate and free-base respectively.   
For their least preferred inhaler (Table 6.1), nine subjects nominated the unflavoured 
formulations (three lactate, six free-base).  The remaining two subjects chose free-base 
vanillin and lactate menthol 300µg, respectively.   
When subjects were asked which formulations they would never want to inhale again; four 
said no formulation was that bad that they would not inhale it ever again; while the other 
seven subjects nominated a wide variety of the formulations, with no pattern evident in their 
choices.   
Only two subjects required extra puffs in order to decide their adjusted overall single puff 
preference.  Both these subjects concluded that their original choice of overall single puff 
preference was indeed correct.   
6.3.2 First 10 puff experience 
All subjects chose a menthol formulation for their first ten puff trial, and no-one chose a 
100µg dose.  The formulations that subjects chose to inhale are shown in ` (Table 6.2, page 
233), along with the number of puffs they inhaled and their brief-QSU, CEQ, and Duke 




There were no significant differences in the brief-QSU scores within or between each 
formulation individually.  However, when the brief-QSU scores from all formulations were 
summed, there was a highly significant reduction in the total brief-QSU score by forty-five 
percent from a pre-inhalation score of 37 (33-46) to a post-inhalation score of 16.5 (2.8-26.8), 
p=0.0039.  This occurred one (one to three) minute after completing five (three to eight) 
puffs, for all of the formulations combined (there were no significant differences in number of 
puffs between formulations).   
6.3.3 Second 10 puff experience 
Three subjects chose to have a second trial of up to ten puffs.  Two chose menthol nicotine 
lactate (one 200µg, one 300µg); one chose vanillin free-base nicotine 100µg.  There were no 
significant differences in brief-QSU, CEQ, and Duke Sensory Questionnaire scores between 
formulations within this second trial of up to ten puffs.  Total brief-QSU scores reduced with 
borderline significance when brief-QSU scores were combined from all three formulations 
inhaled during the second ten-puff session (p=0.05).  
6.3.4 Overall final preference 
One subject preferred vanillin free-base 100µg; eleven subjects preferred a menthol 
formulation (of whom, one preferred all of them; six preferred nicotine lactate (one 100µg, 
two 200µg, three 300µg) and four preferred nicotine free-base (one 100µg, three 200µg).  
Subjects indicated a high level of agreement on a VAS that they would use the formulation 
they inhaled up to ten puffs of to quit smoking if it was available.  
6.4 Discussion 
To the my knowledge, no trials have been published that compare the tolerability of nicotine 
free-base to a nicotine salt, nor any trials of  nicotine lactate by inhalation.(61)  The key 
finding was that all formulations caused a highly significant reduction in urge to smoke.  
Another notable result was that the majority of subjects preferred a menthol formulation. Also 
significant was that the first of the vanillin 100µg formulation that were inhaled, caused less 
coughing than the first of the unflavoured 100µg formulations that were inhaled; and both the 
first and the second 100µg menthol formulations that were inhaled, caused less coughing than 
the first and second 100µg unflavoured formulations.   
While this is likely to be, at least in part, the result of tachyphylaxis causing desensitization to 
























Time from last of the single puffs 
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QSU total score reduction (QSU 












QSU reduction for all 
formulations combined 
16.50, 18.33 (2.75-26.75) p=0.0039 
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Duke Sensory Questionnaire median, mean (IQR) 
























































Side-effects n=number of subjects who experienced the side-effect; median, mean, (IQR) (millimetres on VAS) 
(intention to treat analysis).  Minimum value = 0mm; Maximum value = 100mm 
Hiccup 0 0 0 0 0 


















































































Ad hoc scales median, mean (IQR) (level of agreement rated on Likert scales from 1= not at all to 7=extremely) 




































































mm = millimetres on a 100mm Visual Analogue Scale 
Note: all subjects started at the 100µg dose when they inhaled their first puff of the series of formulations.  If they found the 100µg dose very aversive they were 
offered the 50µg dose to inhale.  This option was only taken by one subject for only one formulation. 
Prior to inhalation of up to ten puffs, the median (IQR) total brief-QSU score was 37 (33-46); which reduced by 16.5 (2.8-26.8, p<0.01) points 1 (1-3) minutes after 
completing 5 (3-8) puffs, for all of the formulations combined.  There were no significant differences in the reduction in brief-QSU scores between the different 
formulations or doses. 
Duke Puff Strength is a composite of several items.  It was created to measure overall cigarette strength (puff strength on tongue, nose, mouth and throat, windpipe, 





extent, vanillin, is able to reduce the tussive effect of nicotine.  Indeed, it is possible that the 
higher dose of menthol (0.25%) in the current trial is responsible for my subjective 
observation that subjects in this study appeared to tolerate the inhalers better than subjects in 
the earlier pilot pharmacokinetic study which used free-base nicotine and contained only “a 
trace” of menthol.(35)   
The reduced coughing with the menthol formulations may explain subjects’, statistically 
significant greater preference for the first and second kinds of menthol 200µg nicotine 
formulations they inhaled compared to the first and second unflavoured types of 200µg 
nicotine formulations they sampled.   
This pilot study demonstrated that smokers would voluntarily inhale 200µg/puff and 
300µg/puff doses of nicotine, direct from the actuator of a pMDI without use of a spacer, 
which were considerably higher doses than were used in the previous pilot pharmacokinetic 
study in which a spacer was used for all inhalations.  Standard spacers are bulky and 
impractical to carry around in daily life, hence it is a great advantage to observe that they are 
not necessary. 
The only statistically significant order effect was subjects’ greater preference for the second 
compared to first 200µg menthol formulation that they inhaled.  Four times as many subjects 
preferred the second menthol 200µg formulation they inhaled compared to the first 
(regardless of whether it contained lactate or free-base), which may be due to a carry-over 
effect of the menthol or the development of tolerance in response to the effects of nicotine in 
the first puff.   
The key limitations to this study were its small sample size, the limited amount of experience 
subjects had of each formulation, the fact that menthol was always the last flavour to be 
inhaled in the single puff comparisons, and the possibility that subjects may have been 
confused about which formulation they preferred, by inhaling up to six different formulations 
at a range of doses, over a short period of time.  Comparisons between formulations at the 
higher doses were particularly underpowered because not all subjects tried the higher doses.  
Those who did sample one of the higher doses, did not always try all of the different types of 
nicotine and flavourings at the higher dose, so the sample size for the higher doses is 
particularly small.  The small sample size did not allow a clear demonstration of the relative 
merits of nicotine lactate cf. nicotine free-base.  However, the study was only designed to 
rapidly provide an answer to whether there was a large difference in tolerability between 




This study has shown that there are a number of nicotine pMDI formulations that are tolerable 
and effective in rapidly reducing the urge to smoke, and which smokers will voluntarily 
choose to inhale.  Much larger trials would be required to detect statistically significant 





7 Combination Nicotine Metered Dose Inhaler and 
Nicotine Patch for Smoking Cessation: a randomised 
controlled trial 
7.1 Introduction 
A nicotine inhaler capable of pulmonary delivery, may be able to rival the rapid-acting 
pharmacokinetic and pharmacodynamic effects of smoking.  Smokers have been receptive to 
such new devices, as evidenced by the growing popularity of electronic cigarettes (e-
cigarettes) as an aid to quitting.(392) However, there is little available data on the efficacy of 
inhaled nicotine in subjects wishing to stop smoking.  
Pressurized metered-dose inhalers (pMDI) could offer a safe, effective, and inexpensive 
method of pulmonary nicotine delivery.(35, 379) Nicotine pMDIs are a non-proprietary 
technology that can be manufactured cheaply within the budgets of less economically 
developed countries and socio-economically deprived groups who have disproportionately 
high rates of smoking. Nicotine pMDIs can use standard technology and can therefore be 
manufactured on a large scale without delay, unlike nicotine delivery devices that use bespoke 
technologies.(61)  
Nicotine by inhalation is aversive, which is a potential obstacle to inhaled nicotine therapy. 
Inhalation of nicotine provokes cough and throat irritation, often referred to as ‘throat scratch’ 
or ‘throat impact’.(166) Although smokers quickly become tolerant to the aversive effects of 
inhaling nicotine, and these initially aversive sensory effects quickly become secondary 
reinforcers of the reward of nicotine, tolerance to the adverse effects of nicotine may be 
highly dependent on the characteristics of the method of nicotine delivery, and may not 
always generalise to other delivery devices.  Hence, smokers who are tolerant to the aversive 
and tussive effects of nicotine inhaled from their favourite brand of cigarettes may not be 
tolerant to the aversive and tussive effects of nicotine inhaled from a different brand of 
cigarettes or from a medicinal pMDI.   
Tobacco companies use a variety of methods to limit aversion to inhaling nicotine in tobacco 
products, such as adding menthol (a counter irritant) and sugar to cigarettes as well as 
levulinic acid which is thought to improve the “smoothness” (ease of inhalation and lack of 
aversive sensations and cough) of the cigarette smoke.(393)  Tobacco companies add a wide 




tobacco into mainstream smoke such as ammonia,(134, 394, 395) as well as chemicals to 
reduce harshness, such as levulinic acid.(393) 
This dissertation reports the results of a double-blind, randomised placebo-controlled clinical 
trial of a nicotine pMDI plus active nicotine patch compared to placebo pMDI plus active 
nicotine patch.  
7.1.1 Aims of the trial 
This trial was designed to test the efficacy of the nicotine pMDI in the context of the 
therapeutic approaches that clinicians are likely to use to improve abstinence: pMDI plus 
nicotine patch combination therapy, pre-cessation therapy, and minimal behavioural therapy.  
The study was designed to test three null hypotheses that nicotine from a standard pMDI, plus 
nicotine patch,  
1. is not tolerable,  
2. will not be used by smokers, and  
3. will not improve quitting success, compared to nicotine patch therapy plus 
placebo inhaler.   
7.1.2 Rationale of the trial 
Given that the pharmacokinetics of the active inhaler, used in this clinical trial, is likely to 
have amongst the most rapid pharmacokinetics of currently licensed NRTs (a comparison 
made by comparing the pharmacokinetics in published trials to that of the pilot free-base 
pMDI, rather than from a head-to-head trial), it is likely that it will have pharmacodynamic 
effects that occur shortly after its administration, and which are therefore likely to be 
attributed by subjects to inhalation from the inhalers and therefore the pharmacodynamic 
effects are likely to be neurologically paired with its sensory effects (as mentioned in the 
introduction to this dissertation, dopaminergic neurons are more likely to encode a stimulus 
with the ability to cause reward, if the time-delay between noticing the stimulus and a 
subsequent reward is very short).  Thus, it is likely that the pharmacodynamic effects of the 
inhalers may unmask subjects to their treatment assignments, which, in turn, could bias the 
estimation of the relative efficacy of the active and placebo inhalers.  For these reasons, the 
robustness of the blind, the influence of unblinding on abstinence rates, and predictors of 




The results of the small pilot study of nicotine free-base pMDIs, the systematic literature 
review, along with considerable reading about the neurology of cough and bitter tastes, led to 
the development of new formulations of the original nicotine free-base inhalers, which were 
tested among a small number of smokers (this trial was described in Chapter Eleven).   
The results of these pilot studies and reading of the literature, informed the decision to use 
nicotine lactate in this RCT, instead of nicotine free-base, initially at a 100mcg/puff dose then 
stepping up to a 200mcg/puff dose, and to use 0.25% w/w menthol as a counter-irritant in the 
active inhalers (inhalers in the pilot pharmacokinetic study only contained “a trace” of 
menthol), and a dose of 0.25% w/w and 0.50% w/w menthol in the placebo inhalers to 
provide a cooling and minty flavour to the control group (and to mimic the stepping up of the 
nicotine dose from 100µg to 200µg) in order to mask subjects in the control group to their 
treatment assignments and to assist research staff to remain masked (because the comments 
that subjects made about the flavour of the inhalers and their increase in dose would be 
similar between groups).   
7.2 Methods 
This trial and its protocol were registered with the Australasian Clinical Trials Registry 
ACTRN12609000481279. 
7.2.1 Study design and participants 
This double-blind randomised placebo-controlled, parallel group trial was conducted at the 
University of Otago in Wellington, New Zealand (ACTRN12609000481279). Subjects were 
eligible if they were eighteen to seventy years old; smoked at least nine cigarettes per day; 
had a Fagerström Test of Nicotine Dependence (FTND)(303) score of three or more; did not 
have severe hypertension (seated systolic ≥180mmHg, diastolic ≥100mmHg); had not had 
unstable angina, myocardial infarction, or stroke in the past three months unless approved to 
participate by their general practitioner; had not had serious indigestion or peptic ulcer disease 
in the past three months; had not been prescribed an inhaled corticosteroid for asthma or 
Chronic Obstructive Pulmonary Disease (COPD) in the past year unless approved to 
participate by their general practitioner. Subjects were ineligible if they currently had 
untreated or poorly controlled hyperthyroidism; unstable diabetes, or severe liver or kidney 
disease; were currently under the care of a psychiatrist; ever had a severe reaction to nicotine 
patches or sticking plaster; or were pregnant or breastfeeding or female of child bearing age 




cytochrome P450 1A2; or were currently taking a smoking cessation medicine (other than 
nicotine patches) that they were unwilling to stop using.  
The trial was advertised via the radio, newspapers, television, study website, primary care 
practices, and smoking cessation services. Subjects were initially screened for eligibility via 
the study website or telephone, and those who were eligible were invited to attend a baseline 
visit at the University of Otago in Wellington. At the baseline visit subjects’ eligibility was 
confirmed, and written informed consent was obtained. Subjects were not paid, nor were their 
study-related expenses reimbursed.   
The research protocol was approved by the Central Regional Ethics Committee 
(CEN/10/10/050) and the Standing Committee on Therapeutic Trials. 
7.2.2 Randomisation and masking 
Eligible subjects were randomised to active or placebo inhaler in a 1:1 ratio by the trial 
database according to a sequential randomisation list that was not visible to research staff or 
subjects. The database provided staff with a product code, which identified which inhaler to 
give to each subject. The product codes and inhalers for both treatment groups had the same 
appearance, both active and placebo inhalers were flavoured with menthol, and subjects’ 
treatment assignments were concealed from both subjects and staff. 
Brent Caldwell produced the randomisation numbers by creating in the R language, a vector 
the length of the number of subjects that were originally planned to recruit, this vector 
contained an equal number of 1s and 0s (representing active and control assignments, 
respectively).  This list was then randomly sampled without replacement to create a new 
vector of the same number of 0s and 1s, but the 0s and 1s were in random order.  Microsoft 
Excel was then used to create a vector of randomisation codes, RAN0001 to RAN1500.  
These randomisation numbers were matched with the corresponding list of 0s and 1s. 
Likewise the product codes were lined up with a random list of 0s and 1s.  These lists were 
entered into the Filemaker database used to enter the data as it was being collected, so the 
database could randomise subjects to their treatment assignments and product codes could be 
used by the database to make sure subjects were given the appropriate inhalers in a manner 
that maintained the double-blind.  The manufacturer was emailed a copy of the product codes 
and which treatment assignment they were.  Once the Filemaker database was made, it was 
not possible to observe what condition subjects had been assigned to nor whether the product 





Subjects from both groups received active nicotine patches for five months (Habitrol 
manufactured by Novartis), and were instructed to use Step1 (21mg/24h) for eighteen weeks, 
Step2 (14mg/24h) for two weeks, and Step3 (7mg/24h) for two weeks. Subjects whose sleep 
was disturbed were instructed to remove the patch one hour before going to bed, and subjects 
who suffered severe skin irritation were instructed to discontinue patches. Subjects used the 
inhalers for the first six months after baseline. Both active and placebo inhalers contained 
HFA134a, menthol, and anhydrous ethanol as a co-solvent to improve the solubility of 
nicotine in HFA134a. The active inhalers also contained nicotine lactate in two doses, 
100µg/puff and 200µg/puff. Subjects started with 100µg/puff and moved on to 200µg/puff 
once they had developed tolerance to the upper airway effects of the lower dose. The placebo 
inhalers contained menthol, in two doses to mimic the two doses of active inhaler (0.25% w/w 
and 0.50% w/w). The pMDIs were filled in New Zealand by Argenta Ltd under Good 
Manufacturing Practice guidelines. Subjects in both groups received minimal behavioural 
counselling (Appreciative Inquiry)(396) at all follow-ups. Subjects were instructed to use the 
inhaler when they had an urge to smoke, and to have as many puffs as required to satisfy their 
urge (maximum of ten puffs per occasion of inhaler use).  
Eligible subjects attended the clinic at baseline. After reconfirming eligibility, gaining written 
informed consent and randomisation, subjects were given a patch to put on, and were taught 
how to inhale from the inhaler optimally (slow steady inspiration and activating the pMDI 
immediately after the start of inspiration), and were encouraged to use as many puffs as was 
comfortable to gain familiarity with the inhaler and rate its effects on the modified Cigarette 
Evaluation Questionnaire (mCEQ).(305) Subjects started with 100µg nicotine or, low dose 
menthol placebo, inhaler and moved to the higher dose once they had developed tolerance to 
the upper airway effects. Subjects were given at least one canister of the low dose to use after 
the baseline visit, and sufficient higher dose inhalers to last until the one-month post target 
quit date visit. Side-effects of the inhaler and nicotine patches were recorded using Likert 
scales, (none, mild, moderate and severe), and the effect of the inhaler on smoking urges was 
measured by the change in subjects’ brief-Questionnaire of Smoking Urges (QSU) score 
pre/post inhalation.(397) Subjects’ recorded their demographic details and smoking history, 
and completed the Minnesota Nicotine Withdrawal Scale (MNWS).(126) Subjects were set a 
target quit date of four weeks after baseline, but could quit earlier if they desired.  
Subjects were given diary cards to record how much they smoked and how many puffs of the 




based on baseline number of cigarettes smoked per day (reduce smoking by a fifth 
immediately and each week thereafter and quit within twenty-eight days). Subjects were 
followed up at one week after baseline, and at one day and one, three, and six months after 
their target quit dates. All follow-up contacts were via telephone, except for one month after 
the target quit date when subjects attended the clinic. Abstinence was by self-report, with 
biochemical verification by exhaled carbon monoxide <10 parts per million (piCO 
Smokelyzer, Bedfont) at the one-month post-target-quit-date visit.(398) 
7.2.4 Outcomes 
The primary outcome was self-report of prolonged six month not smoked on seven 
consecutive days (between the end of the grace period (two weeks after target quit date) and 
six months after the target quit date).(68) Secondary outcomes were time-to-relapse, not 
smoked even a puff in the seven days prior to each follow-up from one to six months after the 
target quit date (seven-day point prevalence); not smoked even a puff since target quit date; 
MNWS, QSU and mCEQ scores; usage and side-effects of inhalers and patches. Adverse 
events were recorded by a standard questionnaire at all follow-up timepoints. 
7.2.5 Statistical Analysis 
A sample size of 502 with 1:1 randomisation between treatment groups would have eighty 
percent power, with alpha of five percent, to detect a significant difference in abstinence 
between groups of 20.0% versus 27.5%. The R language, version 3.4.0, was used for the 
analysis. Abstinence outcomes were measured by chi-squared tests without continuity 
correction, and as odds ratios calculated by unadjusted logistic regression. Kaplan-Meier 
curves were constructed to analyse time to relapse. All analyses were by intention-to-treat, 
unless otherwise stated, with all missing abstinence outcomes treated as not abstinent to avoid 
bias, unless otherwise stated.(271) A p-value of <0.05 was considered significant, with 
Bonferroni correction where appropriate. QSU scores were analysed by comparing between 
groups the total score, and the change in total score from baseline, at each follow-up time 
point. MNWS total scores and the scores for the scales of the mCEQ in each group were 
compared at each follow-up timepoint. Non-normally distributed data and ordinal data were 
analysed as median and IQR, and their significance with the Mann-Whitney test.  For 
prolonged abstinence measures, a grace period of two weeks after the target quit date was 
used, during which time smoking did not count as a failure.  The trial was not powered to 
assess the effects of the interventions on Māori cf. non-Māori however, analyses to look for 





Of 1100 smokers assessed for eligibility, 502 subjects were randomized (246 and 256 to 
active and control therapy, respectively), Figure 7.1, page 245 displays the flow of subjects 
through the trial. Subjects’ baseline characteristics are shown in Table 7.1; there were no 
significant differences between groups.  Here, tables prefaced with C appear in Appendix C, 
page 382. 






Age 45·2 (11·4) 45·0 (11·0) 
Women 122 (50%) 132 (52%) 
Ethnicity   
New Zealand Maori 27 (11%) 30 (12%) 
Non-Maori 219 (89%) 226 (88%) 
Education below university or trade 
certificate 
106 (43%) 116 (45%) 
Household income <$50K 61 (26%) 56 (23%) 
Average number of cigarettes smoked 
per day 
19·0 (6·7) 19·2 (6·5) 
Age started smoking daily 16·5 (4·2) 16·3 (3·5) 
Number of other smokers in household 0·4 (0·6) 0·6 (2·0) 
Partner smokes daily and lives in same 
house 
75 (30%) 67 (26%) 
Number of previous quit attempts 7·3 (11·5) 7·6 (12·6) 
Previously quit for >24 hours on >10 
occasions 
24 (9·8%) 30 (11·7%) 
Previously used cessation medicine or 
NRT 
211 (86%) 229 (89%) 
FTND 6·1 (1·8) 6·2 (1·6) 
FTND >5 (high dependence) 160 (65·0%) 175 (68·4%) 
 
7.3.1 Primary Outcome and measures of smoking abstinence 
Participants in the active group were twice as likely to achieve prolonged six months 
abstinence when abstinence was defined as not smoked on seven consecutive days and when 
abstinence was defined as not smoked during seven days prior to follow-ups (Table 7.2, page 








































246 active inhaler plus patch 256 placebo inhaler plus patch 
2 LTFU; 1 Withdrawn; 1 Missed 1 
week, completed 1 month 
242 Assessed at 1 week follow-up 254 Assessed at 1 week follow-up 
2 LTFU 
7 LTFU; 7 Withdrew (4 reason not 
stated, 3 inhaler side-effects) 
9 LTFU; 4 Withdrew (4 reason not 
stated) 
229 Assessed 24h after target quit date 241 Assessed 24h after target quit date 
20 LTFU; 20 Withdrew (12 reason 
not stated, 5 inhaler side-effects, 3 
inhaler ineffective) 
189 Assessed 1m after target quit date 202 Assessed 1m after target quit date 
4 LTFU; 18 Withdrew (10 reason not 
stated, 4 inhaler side-effects, 4 
inhaler ineffective) 
8 LTFU; 23 Withdrew (14 reason not 
stated, 1 inhaler side-effects, 8 
inhaler ineffective); 1 Missed 3 
month, completed 6 month 
170 Assessed 3m after target quit date 
4 LTFU; 13 Withdrew consent (9 
reason not stated, 1 inhaler side-
effects, 3 inhaler ineffective) 
154 Assessed 6m after target quit date 
21 LTFU; 18 Withdrew (9 reason not 
stated, 1 inhaler side-effects, 8 
inhaler ineffective) 
167 Assessed 3m after target quit date 
0 LTFU; 9 Withdrew consent (4 
reason not stated, 3 inhaler side-
effects, 2 inhaler ineffective) 
246 included in analysis of abstinence 256 included in analysis of abstinence 
158 Assessed 6m after target quit date 
1100 assessed for eligibility 598 excluded (184 not eligible; 91 
Declined consent; 323 Unable to enrol 




and six months later was slightly less than double (Table 7.2, page 247) but was slightly more 
than double (OR=2·44; 95%CI:1·50—4·07, p<0·001) between the one month visit and six 
months  post target quit date follow-up. For biochemically verified not smoked even a puff, 
the OR for abstinence between the one-month visit and six months later was not significant 
between groups but, was significantly more than double between the three-month visit and 
six-month post target quit date follow-up (OR=2.16; 95%CI:1.28–3.73, p=0.004).  One 
hundred twenty-four subjects claimed to have achieved prolonged six months abstinence, of 
whom 110 provided an eCO sample one month after their target quit dates and fourteen of 
whom did not.  Hence only 14/124 subjects would have been classified as not biochemically 
verified abstinent solely because they had not given a breath sample as opposed to giving a 
sample which contained ten or more ppm of CO.   
Of the 255 subjects who provided an eCO sample a month after their target quit dates, ninety-
seven had an eCO≥10ppm, and 158 had an eCO of <10ppm.  Three hundred and eighty-nine 
subjects reported whether they had smoked on seven consecutive days between the end of the 
grace period and a month after their target quit dates, of whom 188 reported having done so 
and 201 reported they had not.  Of the 201 subjects who claimed abstinence at one month 
after their target quit dates, 167 (83.08%) gave an eCO sample, 140 were <10ppm while 
twenty-seven were not.  Thus, the rate of claiming abstinence when eCO indicted subjects had 
smoked in the previous eight hours was 27/167 (16.17%), this rate was similar in the active 
and control groups (13/127 and 14/128, respectively.  In an ITT analysis of the primary 
outcome of prolonged six months not smoked on seven consecutive days, in which missing 
CO (recorded a month after subjects’ target quit dates) and abstinence outcomes were imputed 
as failures, 113 subjects claimed abstinence which was supported by CO, while 39 had 
claimed abstinence whose eCO was ≥10ppm or was missing, a rate of claiming abstinence in 
the face of a high/missing CO of 39/502 (7.77%).   
In both groups, the majority of subjects who relapsed, did so early on in the trial (Figure 7.2, 
page 248), with a similar rate of failure between groups thereafter. The rate of reporting 
abstinence when CO indicated recent smoking (≥10ppm) were similar between groups at one-
month post target quit date, suggesting that the absence of CO verification at other follow-up 
time-points is not likely to have biased the abstinence outcomes. Per-protocol abstinence 
outcomes (self-report data with no imputation) are reported in Table 7.3 (page 248), which 
demonstrates that rates of CO verified and unverified self-report prolonged abstinence were 

















Not smoked on 7 consecutive days* 
1 45·53 34·77 1·57 (1·10-2·25) 0.0139 
1†† 33.33 22.66 1.71 (1.15-2.54) 0.0080 
3 38·21 28·52 1·55 (1·07-2·26) 0.0216 
6 36·99 23·83 1·88 (1·28-2·77) 0.0013 
6 prolonged 31·71 17·97 2·12 (1·40-3·23) 0.0004 
6 prolonged†† 26.02 14.06 2.15 (1.37-3.41) 0.0031 
Not smoked in the previous 7 days 
1 34·15 20·70 1·99 (1·33-2·98) 0.0007 
1†† 27.64 16.41 1.95 (1.27-3.02) 0.003 
3 35·37 26·56 1·51 (1·03-2·22) 0.0328 
6 36·99 21·88 2·10 (1·42-3·12) 0.0002 
6 prolonged 23·98 12·11 2·29 (1·43-3·72) 0.0005 
6 prolonged†† 20.33 11.33 2.00 (1.22-3.31) 0.0057 
Not smoked even a puff 
1 22·76 16·80 1·46 (0·94-2·28) 0.0148 
1†† 18.29 13.28 1.46 (0.90-2.39) 0.1250 
3 28·05 13·28 2·55 (1·62-4·05) 4x10-5 
6 27·64 16·41 1·95 (1·27-3·02) 0.0023 
6 prolonged 15·85 8·98 1·91 (1·11-3·34) 0.0193 
6 prolonged†† 13.41 8.59 1.65 (0.94-2.95) 0.0839 
† All outcomes in the table are self-report unless otherwise stated.   
†† CO verified.  Note that CO was only measured at the one-month post-target quit date visit; 255 
subjects provided a CO sample, 127 and 128 in the active and control groups respectively, 
p=0·72.  For the outcome of not smoked in previous 7 days 68/246 (27·64%) and 42/256 
(16·41%) claimed abstinence and had CO<10ppm in the active and control groups respectively; 
while 16 (6·5%) and 11 (4·3%) subjects in the active and control groups respectively claimed 
abstinence but had CO>10ppm or did not provide a CO sample (ITT p-value 0·273). For the 
outcome of not smoked even a puff since their first smoke-free day 45/246 (18·29%) and 34/256 
(13·28%) subjects in the active and control groups respectively claimed abstinence and had 
CO<10ppm (CO verified abstinence between groups p=0·156 (intention-to-treat)); while 147/246 
and 177/256 subjects in the control and active groups respectively reported not smoking and had 
a CO>10ppm. 
* One-month abstinence was from the end of the grace period to one month after the target quit 
date.  Three months abstinence was abstinence between the one and three months after the 
target quit date.  Six months abstinence was abstinence between three and six months after the 




























l 1 256 167 0.35 0.09 0.29 0.41 
3 89 30 0.23 0.11 0.18 0.29 






 1 246 134 0.46 0.07 0.40 0.52 
3 112 25 0.35 0.09 0.30 0.42 
6 87 9 0.32 0.09 0.26 0.38 
Figure 7.2 Kaplan-Meier Not Smoked on 7 Consecutive Days 
 
Table 7.3. Prolonged six-months abstinence outcomes: self-report unverified claims 
cf. expired carbon monoxide (CO) verified claims of abstinence 
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7.3.2 Adverse events 
Treatment adverse-effects were more common with the nicotine pMDI, were predominantly 
upper respiratory tract effects of mild severity, of short duration and reduced over time in the 
active group. The most common side effects are summarized in Figure 7.3 (page 250), and all 
side effects are detailed in Table C1 in Appendix C, page 383.  Adverse events relating to 
either the inhaler or patches were reported by 245/246 (99.6%) and 247/256 (96.5%) subjects 
in the active and control groups respectively.  Adverse events relating to the inhaler were 
reported by 239/246 (97%) and 190/256 (74%) subjects in the active and control groups 
respectively.  Adverse events relating to the patches were reported by 215/246 (87%) and 
231/256 (90%) subjects in the active and control groups respectively. 
At baseline five of thirteen inhaler side-effects were significantly more common and more 
severe with the active inhalers compared to placebo inhalers (after Bonferroni correction) but, 
were of mild severity for the majority of subjects and tended to resolve (Table C1, in 
Appendix C, page 383).  The most common side-effects were mild coughing and mild throat 
scratch, which remained significantly higher in the active group one week after baseline, and 
progressively declined in prevalence in both groups thereafter. By one day after the target quit 
date 225/246 (91%) and 235/256 (92%) subjects in the active and control groups respectively 
reported on coughing since their one-week follow-up.  Just under half of subjects in the active 
group (110/225 (49%)) had not experienced any coughing, and 81/225 (36%) had experienced 
mild coughing, compared to the control group in which 199/235 (85%) of subjects had not 
coughed, and 32/235 (14%) subjects had mild coughing.  Reported throat-scratch also 
diminished during this time period, with the majority of subjects in both groups experiencing 
none, although the incidence and severity of throat-scratch was significantly higher in the 
active group. After the target quit date, the majority of subjects in both groups did not 

















Severe side-effects from the inhaler were rare, the most common severe side-effect was 
coughing reported by 13/225 (5.78%) of subjects in the active group one day after the target 
quit date. Of the twelve subjects who had severe coughing at baseline (all were in the active 
group), eleven reported their severity of coughing a week later, when only three subjects still 
suffered severe coughing. 
Difficulty breathing was the term used to characterise any adverse change in the subjective 
quality of breathing. At all time-points difficulty breathing was significantly associated with 
coughing, and most likely was caused by coughing (Table C2 in Appendix C, page 394). Four 
subjects had severe difficulty breathing at baseline all of whom also had severe coughing. 
Coughing was of very short duration. Duration of coughing was formally recorded at the one-
day post target quit date phone-call (median (IQR) 0·17 (0·08—0·50) minutes with the active 
inhaler, and 0·08 (0·08—0·50) with the placebo inhaler, p=0·90); and the one-month post 
target quit date visit (median (IQR) 0·08 (0·05—0·05) minutes with the active inhaler, and 
0·08 (0·05—0·17) with the placebo inhaler, p=0·37).  Thirteen subjects with asthma were 
enrolled with their general practitioners’ approval. Having asthma was not associated with the 
severity of difficulty breathing nor coughing. 
Although the majority of side-effects were of mild severity, a significantly greater number of 
subjects withdrew due to inhaler side-effects in the active compared to control groups (15/246 
(6·1%) vs. 3/256 (1·2%), 95%CI:1·7%—8·2%, p=0·003).  Serious adverse events were 
uncommon and not significantly different between groups (Table C4, in Appendix C, page 
396). 
Side-effects from nicotine patches were common, but predominantly mild (Table C5 page 
397). The most common side-effects were itchy skin one week after baseline, (71/239 (30%) 
and 105/254 (41%) in the active and control groups, respectively), and red skin marks one 
month after the quit date (84/178 (47%) and 83/164 (51%) in the active and control groups 
respectively). The most common severe nicotine patch side-effects, at one month after the 
target quit date was disturbed sleep/dreams (5.1% of active subjects), and at three months 
after the target quit date, was red marks on skin (5·0% of active subjects). After Bonferroni 
correction for four patch side-effects, the control group had greater severity of itchy skin at 
one-week p=0·007. 
Subjects in the active group were more likely to have reported having had a problem with the 




(15.35% cf. 6.32%, p=0.001191, Table 7.4).  Subjects at the one-week phone-call who had 
problems with their inhaler were no more or less likely to achieve prolonged six-months not 
smoked on seven consecutive days than subjects who reported having no problems. 
Table 7.4.  Number of subjects who reported having had problems with the inhaler 
one week after baseline, in the active compared to control groups. 
 Active Control 
Had problems n % n % 
Yes 37 15.35 16 6.32 
No 204 84.65 237 93.68 
Total 241  253  
p=0.001191 
 
7.3.3 Sensory and psychological effects 
7.3.3.1 Sensory qualities  
Both the active and placebo inhalers scored well on the mCEQ (Table C7 in Appendix C, 
page 404); for example, at baseline over half of subjects in both groups scored moderately or 
higher for Smoking Satisfaction.  At baseline, the active inhalers did not have significantly 
higher scores for the four positive domains of the mCEQ; whereas the placebo inhaler had 
significantly higher scores for two of the positive domains (‘Smoking Satisfaction’ and 
‘Enjoy Respiratory Sensations’) and significantly lower scores for Aversion.  One month after 
the target quit date, the active inhaler had significantly higher scores for two positive domains 
(Psychological Reward, and Craving Reduction); while the placebo inhaler had significantly 
higher scores for two positive domains (Smoking Satisfaction, Enjoyable Respiratory 
Sensations), and significantly lower scores for Aversion. By the six months phone-call, the 
active inhalers retained their significantly higher score for Craving Reduction, and the placebo 
inhaler its lower score for Aversion. 
7.3.3.2 Urge to Smoke 
There were few differences between groups in subjects’ brief Questionnaire of Smoking 
Urges (QSU) scores, the only significant differences (p<0·05) were a lower post-inhaler total 
QSU score and a larger pre/post-inhaler reduction in total QSU scores at baseline in the active 
compared to control groups; and lower total  QSU scores at the one, three and six-month 
follow-ups in the active compared to control groups (Table C8 in Appendix C, page 405). 
Although statistically significant, the differences between groups were small, ranging from 




7.3.4 Withdrawal symptoms 
Subjects in the two groups had similar nicotine withdrawal scores (MNWS scores) at all time-
points except at three and six months after the target quit date when Craving was lower in the 
active group (median 1.2, 95%CI:0.0—2.0 versus 2.0, 95%CI:0.0—2.0, p=0.009 at three 
months; and 1.2 95%CI:0.0—2.0 versus 2.0 95%CI:0.0—3.0, p=0.001 at six months, Table 
C9 in Appendix C, page 406).  
7.3.5 Treatment use 
At baseline and one week later, subjects in the active group used more puffs per day of the 
low dose, and less of the high dose compared to the control group (Table 7.5, page 255). After 
the one-week phone-call almost all subjects would have run out of low dose inhalers, 
therefore inhaler use was no longer recorded for the two doses separately. Beyond one week, 
puffs per day were similar between groups except they were higher in the control group at the 
quit phone-call (median=48, IQR:25—86 versus median=36, IQR:16—73, p=0.007) and 
higher in the active group at the six months phone-call (median=26, IQR:4—83 versus 
median=16, IQR:4—48, p=0.026).  
The percentage of days that subjects used the inhaler was similar between groups, except at 
the final follow-up when use was higher in the active group (median=67% IQR:9%—100% 
versus 34%, IQR:2—76, p=0.002). Bonferroni correction for comparisons of inhaler use at 
five time-points, and as both puffs per day, and as percent of days, would require 
p<0.05/(5*2)=0.005, a condition met only by the percentage of days that subjects used the 
inhaler at the final follow-up which, in the active group was double the percent in the control 
group. 
The number of puffs of inhaler used in the seven days before subject’s one-month post-target-
quit-date visit, was reported by 384 subjects.  The number of puffs was very weakly but 
significantly positively correlated with six-months prolonged not smoked on seven 
consecutive days (ρ=0.14, 95%CI:0.04—0.24, p=0.0052).  When the treatment groups were 
examined separately, the correlation was not significant in the control group, and was slightly  
stronger in the active group than in the combined sample (ρ=0.19, 95%CI:0.05—0.33), 
p=0.0084).  
Adherence to combination therapy was assessed by subtracting the cumulative number of 
days patches were used from the cumulative number of days inhalers were used.  The value of 




Table 7.5. Use of inhaler 
  
Active Control  
Mean Median IQR Range n Mean Median IQR Range n p 
Number of puffs at baseline visit 
100mcg active / lower menthol placebo 4.9 4 3, 6 1, 21 243 3.3 3 2, 4 1, 11 250 5x10-14 
200mcg active / higher menthol placebo 5.9 5 3, 7 0, 32 228 6.5 6 4, 8 1, 31 241 0.003 
Average number of puffs per day on days when inhalers were used 
One Week 100mcg active / lower 
menthol placebo 
9.7 0 0, 10 0, 120 228 5.6 0 0, 0 0, 196 236 3x10-7 
One Week 200mcg active / higher 
menthol placebo 
43.9 25 12, 54 0, 450 241 49.6 35 18, 64 0, 300 253 0.003 
One day after target quit date 57.3 36 16, 73 0, 400 224 73.9 48 25, 86 0, 600 235 0.007 
One month after target quit date 60.7 30 8, 80 0, 600 187 55.7 30 12, 65 0, 375 198 0.789 
Three Months after target quit date 62.2 30 12, 74 0, 600 167 45.5 24.5 9, 50 0, 385 166 0.081 
Six Months after target quit date 74.4 26 4, 83 0, 624 158 38.6 16 4, 48 0, 455 152 0.026 
Percent of days used inhaler since previous follow-up 
One week after baseline 92.8 100 100, 100 14, 100 241 93.5 100 100, 100 3, 100 254 0.401 
One day after target quit date 85.7 100 82, 100 0, 100 226 83.2 100 73, 100 0, 100 237 0.357 
One month after target quit date 76.5 100 51, 100 0, 100 185 72.5 100 50, 100 0, 100 198 0.093 
Three Months after target quit date 65.1 88.9 21, 100 0, 100 167 59.2 71.4 20, 100 0, 100 167 0.084 




After the one week quit call usage of inhaler was not recorded for each dose separately, but was for both doses combined (almost always this would have been 





dates, should be twenty-eight because, subjects were instructed to use their inhalers and 
patches for six and five months, respectively.  When the cumulative number of days, 
throughout the entire duration of subjects’ participation in the trial, that subjects reported 
using the patches was subtracted from the cumulative number of days they used the inhaler, 
the median, mean (IQR) was 19.50, 51.43, (0—100) in the trial as a whole, and there was not 
a significant difference between treatment groups.   
Use of nicotine patches was similar in both groups, with the majority of subjects in both 
groups not using patches for the full five months.  
7.3.6 Māori Ethnicity 
One hundred thirty-one Māori applied to participate in the trial, ninety were eligible and forty-
one ineligible.  Of the ninety who were eligible, fifty-seven were enrolled, and thirty-three 
were not.  For all these thirty-three subjects, research staff had made comments in the 
comments section of the baseline forms, that a reminder cellphone text message had been sent 
to them at least a day prior to their baseline appointment and that they had not attended, many 
also had comments relating to multiple attempts to reschedule the baseline visit and failure to 
attend rescheduled appointments.    
Fifty-seven (57/502; 11.35%) subjects were enrolled who identified as being of Māori 
ethnicity (Table 7.6).  There were no differences between Māori and non-Māori in their ages, 
the age they started smoking daily, their baseline FTND, their CPD at screening, the number 
of other smokers in their households, whether their life-partner smokes, whether they had 
previously used NRT or other smoking cessation medicines. 
Table 7.6.  Prolonged six months not smoked on seven consecutive days abstinence 
by ethnicity 
 Abstinent n=124 Not abstinent n=378 
 n % n % 
Asian n=6 (1.2%) 1 16.67 5 83.33 
Māori n=57 (11.35%) 12 21.05 45 78.95 
New Zealander n=94 (18.73%) 22 23.40 72 76.60 
NZ European n=288 (57.37%) 75 26.04 213 73.96 
Other n=12 (2.39%) 4 33.33 8 66.67 
Other European n=31 (6.18%) 7 22.58 24 77.42 
Pacific Peoples n=14 (2.79%) 3 21.43 11 78.57 





There were no significant differences between ethnicities in the rates of prolonged six-months 
not smoked on seven consecutive days abstinence (Table 7.6, page 256).  Given that Māori 
have a high prevalence of smoking in New Zealand (the prevalence of daily smoking amongst 
New Zealand adults in the 2006 census was 44.8% and 37.9% for Māori women and men, 
respectively, and 19.4% and 21.0% for European women and men, respectively),(399) I 
decided a priori to measure whether Māori would find the nicotine inhalers equally as 
effective as non-Māori to assist them to quit smoking after having been offered nicotine 
inhaler plus patch therapy.  A bivariate logistic regression with prolonged six months not 
smoked on seven consecutive days as the dependent variable, and the independent variables 
of Māori ethnicity, active treatment assignment, and an interaction term between these two 
independent variables, calculated that neither Māori ethnicity, nor the interaction term were 
statistically significant, indicating that the inhalers had the same effect on abstinence for 
Māori as for non-Māori. 
During the baseline visit, Māori and non-Māori used a similar number of puffs of both the 
higher and lower dose inhalers in both the active and control groups.  There were no 
statistically significant differences in the number of days Māori reported using their inhalers 
compared to non-Māori, in either treatment group, at any subsequent follow-up time-point, 
except at three months after the target quit date when, Māori reported using their inhalers a 
significant lower percentage of the days since their prior follow-up than non-Māori (median, 
mean, (IQR) 26.55, 38.79, (3.24—71.79) cf. 77.20, 62.11, (23.22—100.00), p=0.0134), 
although this would not be significant after Bonferroni correction for the five time-points 
when the days of inhaler use was reported (0.05/5=0.010). 
7.3.7 Predictors of prolonged abstinence other than treatment 
assignment 
The effects of ten pre-randomisation variables, on the chances that subjects would achieve 
prolonged six-months not smoked on seven consecutive days abstinence, were measured (age, 
gender, baseline FTND, baseline CPD, baseline MNWS and Māori ethnicity) because, the 
first five variables are known to influence the odds that smokers will be able to quit smoking, 
and Māori have a much higher prevalence of smoking cf. non-Māori in the New Zealand 
population.  Age, gender, Māori ethnicity, baseline CPD and the five scales of the MNWS at 
baseline, did not significantly predict abstinence [the values of these variables are given in the 
next paragraph], whereas baseline FTND scores were moderately statistically significant 
predictive of failure to attain prolonged abstinence (FTND scores among subjects who were 




5.88, (5.00—7.00) cf. 6.00, 6.27, (5.00—8.00), respectively, p=0.0217).  When the values of 
these ten variables were compared between abstinent and non-abstinent smokers, within each 
treatment group separately, there were no significant differences for any of the variables. 
The values of nine pre-randomisation variables were not significantly different between 
subjects who were abstinent (prolonged six months not smoked on seven consecutive days) 
cf. not abstinent.  Age among abstinent and non-abstinent smokers was mean, median (IQR) 
47.00, 45.85 (37.00—53.00) cf. 46.00, 44.85 (37.00—53.00) respectively, p=0.3419.  57/240 
(23.75%) females and 62/234 (26.50%) males achieved prolonged six months abstinence, 
p=0.4907.  Of the 57 Māori subjects, 12/57 (21.05%) attained prolonged six-months 
abstinence, while 112/445 (25.17%) non-Māori also achieved this outcome, p=0.4975.  
Baseline cigarettes smoked per day was not significantly different between subjects who 
gained six months prolonged abstinence and those who did not (17.00, 18.00 (15.00—20.00) 
cf. 20.00, 19.45 (15.00—25.00), p=0.0583.  Baseline MNWS Craving was 3.00, 2.70 (2.00—
3.00) cf. 3.00, 2.67 (2.00—3.00), among subjects who did and did not achieve prolonged six 
months abstinence, p=0.8378.  Similarly, MNWS Restlessness was 1.00, 0.86 (0—2.00) cf. 
1.00, 0.98 (0—2.00), p=0.2600.  Likewise, MNWS Increased Appetite scores were 0, 0.37 
(0—0) cf. 0, 0.34 (0—0), p=0.9294.  A similar pattern was observed for MNWS Negative 
Affect scores 0.50, 0.70 (0.25—1.00) cf. 0.50, 0.77 (0.25—1.25), p=0.2433.  So too with 
MNWS Insomnia, 0.50, 0.83 (0.00—1.50) cf. 0.50, 0.97 (0.00—1.50), p=0.1701.  
The effects of twenty-four variables, recorded post-randomisation, on the likelihood of 
subjects accomplishing prolonged six months not smoked on seven consecutive days 
abstinence, were measured (number of days subjects used their inhaler, number of puffs of 
inhaler used per day, number of puffs of inhaler used in the past seven days, cumulative 
number of days subjects used their inhalers, the scores of the five scales of the mCEQ used at 
baseline to rate the effects of the inhalers), and the five scales of the MNWS recorded one, 
three, and six month after the target quit date.  The first and second of these twenty-four 
variables were recorded at all follow-ups, while the third and fourth variables were recorded 
at all follow-ups except for one-week post baseline.   
The number of days that subjects had used their inhalers since their previous follow-up, as a 
percentage of the number of days since subjects’ last follow-up, reported a week after 
baseline, with missing data imputed as not using the inhalers, was not significantly different 
between subjects who achieved prolonged six-months not smoked on seven consecutive days 




imputation).  However, by the day after target quit date phone-call, the percentage of days that 
subjects had used their inhalers since their one-week follow-up was significantly greater 
among subjects who attained prolonged six-months abstinence cf. those who did not (median, 
mean, (IQR) 100.00%, 90.91%, (98.08%—100.00%) cf. 100.00%, 82.04%, (71.43%—
100.00), p=0.0003.  The same picture was seen a month after subjects’ target quit dates 
(100.00, 84.44, (91.86—100.00) cf. 93.20, 69.84, (43.44—100.00), p=1x10-5).  The pattern 
continued three months after subjects’ target quit dates (100.00, 72.95, (48.91—100.00) cf. 
63.00, 56.30, (10.81—100.00), p=0.00025).  The pattern was also evident six months after 
subjects’ target quit dates, albeit less statistically significant (65.93, 56.31, (8.58—100.00) cf. 
38.65, 45.07, (2.29—88.08), p=0.0221. 
Without imputation, when the percent of days that subjects used their inhalers, between the 
one week phone-call and target quit phone-call;, and their treatment assignments, were 
entered as independent variables into a logistic regression predicting their prolonged six-
months abstinence, both independent variables were significantly predictive of abstinence, 
(OR=1.02; 95%CI:1.01—1.03; p=0.0027; and OR=2.15; 95%CI:1.41—3.32; p=0.0004, 
respectively).  When an interaction term between these two independent variables was added, 
it was not statistically significant, indicating that greater use of the inhalers had the same very 
small positive effect on abstinence in both treatment groups. 
At none of the five time-points when the average number of puffs of inhaler subjects used per 
day was recorded, did the number of puffs per day differ significantly between subjects who 
did attain prolonged six-months not smoked on seven consecutive days abstinence, and those 
who did not. 
A month after subjects’ baseline visit (a day after their target quit dates), subjects who 
achieved prolonged six months not smoked on seven consecutive days abstinence, had used 
significantly more puffs of their inhalers in the past seven days than subjects who relapsed 
median, mean, (IQR) 297.0, 494.4, (140.0—590.0) cf. 217.00, 387.21, (65.25—492.50), 
p=0.0137).  This was more statistically significant a month later, when subjects who achieved 
prolonged six months abstinence had used significantly more puffs in the past seven days cf. 
those who relapsed (210.0, 461.9, (58.0—580.0) cf. 109.0, 294.3, (0—336.0), p=5x10-5).  The 
number of puffs used in the seven days prior to the three-months post-target quit date was also 
significantly higher for subjects who attained prolonged six months abstinence cf. subjects 
who relapsed (167.5, 382.9, (0—600.0) cf. 32.5, 196.4, (0—253.5), p=0.0004).  A similar, 




(3.0, 360.7, (0—266.0) cf. 0, 180.2, (0—141.5), p=0.0435).  A month after subjects’ target 
quit dates, the number of puffs of inhaler used in the past seven days, was not significantly 
different between treatment groups (median, mean (IQR) 210.0, 369.7 (70.0—500.0) cf. 
280.0, 459.8 (100.0—530.2), p=0.22, in the active and control groups, respectively). 
The cumulative days during which subjects reported they had used their inhalers during the 
entire time they participated in the trial was median, mean, (IQR) 89.0, 121.1, (28.0—222.8).  
There was no significant difference between treatment groups in the cumulative days that they 
used the inhalers (103.0, 129.3, (28.0—247.8) cf. 78.0, 113.2, (28.0—207.0), in the active and 
control groups, respectively, p=0.1057).  Subjects whose cumulative days of inhaler use was 
greater than the median of 103 days, were significantly more likely to attain prolonged six 
months not smoked on seven consecutive days abstinence, than subjects whose cumulative 
days of inhaler use was less than or equal to the median (101/245 (41.22%) cf. 23/257 
(8.95%), p=2x10-16).  Not only was this statistically significant when subjects from both 
groups were analysed together, it was also significant in each treatment group separately.  In 
the active group, subjects whose cumulative days of inhaler use was greater than 103 were 
more likely to gain prolonged six months not smoked on seven consecutive days abstinence 
than subjects whose cumulative days of inhaler use was equal to or less than the median of 
103, (66/123 (53.66%) cf. 12/123 (9.76%), p=1x10-13).  The equivalent results in the control 
group were 35/122 (28.69%) cf. 11/134 (8.21%), p=2x10-5). 
The baseline scores of only one of the five scales of the mCEQ used to rate the sensory and 
psychological effects of the pMDIs (Craving Reduction) predicted prolonged six-months not 
smoked on seven consecutive days abstinence at the p<0.05 level of significance however, 
this would not remain significant after Bonferroni correction for comparisons between the 
five scales (Table 7.7, page 262)).  Three of the five mCEQ scale scores, recorded a month 
after subjects’ target quit dates, were significantly predictive of prolonged six-months not 
smoked on seven consecutive days (Smoking Satisfaction; Psychological Reward; Craving 
Reduction) and would remain significant after Bonferroni correction (Table 7.7, page 262).   
When each scale of the MNWS was entered as an independent variable into a bivariate GLM 
with treatment assignment as the other independent variable, predicting prolonged six-months 
not smoked on seven consecutive days, the scores of none of the MNWS scales recorded at 
baseline were significant predictors of abstinence, yet treatment assignment remained a 
significant predictor of increased odds of abstinence in all those bivariate models (Table 7.8, 




abstinence at all follow-up time-points after baseline, while both restlessness and insomnia 
scores significantly predicted lower abstinence at three and six months after the target quit 
date.  Increased appetite scores were not significantly predictive of abstinence at any time 
after Bonferroni correction for five sub-scales.  In the bivariate GLMs, active treatment 
assignment significantly predicted higher abstinence at all follow-up time-points but, six 
months after the target quit date, its significance was only marginally less than 0.05, when it 
was adjusted by MNWS-Craving, unlike all other timepoints when the p-value for treatment 
assignment was much lower than 0.05.  When interaction terms were added between the 
MNWS scales and treatment assignment, the interactions terms were never statistically 
significant for any of the scales of MNWS at any of the times MNWS was measured, 
indicating that although active treatment assignment was significantly predictive of greater 
odds of abstinence, the scores of the MNWS scales that significantly lowered the odds of 
abstinence, did so to the same extent, in the active condition, as in the control group.  All the 
MNWS scales, that were significant predictors of abstinence at every time-point they were 
measured, predicted lower odds of abstinence. 
Correlation was unlikely to cause collinearity in these bivariate GLMs of MNWS scales and 
treatment assignment because, there were no significant correlations between treatment 
assignment and any of the scales of MNWS at baseline, or one month after the target quit 
date, however, three and six months after the target quit date, treatment assignment was 
statistically significantly but, very weakly, negatively correlated with MNWS Craving 
(ρ=-0.15 95%CI:-0.25 to -0.04, p=0.0076, and ρ=-0.18, 95%CI:-0.29 to -0.07), p=0.0014, 
respectively) but was not correlated with any of the four other MNWS scales. 
7.3.8 Predictors of loss to follow-up 
Subjects who guessed, at baseline, that they were probably or definitely assigned to use 
placebo inhalers, were no more, and no less, likely to become lost-to-follow-up than subjects 
who guessed they were probably or definitely assigned to use active inhalers. 
Although coughing was one of the most common adverse effects of the inhalers, particularly 
at baseline, the severity of coughing at baseline was not significantly predictive of loss-to-
follow-up.  Loss-to-follow-up was not significantly associated with gender, baseline FTND, 
scores for the five scales of the MNWS at baseline, baseline CPD, baseline CEQ scores for 







Table 7.7.  Modified Cigarette Evaluation Questionnaire scores to rate the effects of the pMDIs as predictors of prolonged six-months not 
smoked on seven consecutive days. 
 Abstinent Not Abstinent 
p 
 Median Mean 1st Qu. 3rd Qu. n Median Mean 1st Qu. 3rd Qu. n 
Baseline 
Smoking Satisfaction 4.17 4.34 3.67 5.33 124 4.00 4.22 3.33 5.25 378 0.36 
Psychological. Reward 2.20 2.53 1.60 3.00 124 2.20 2.41 1.40 3.20 378 0.53 
Aversion 1.00 1.53 1.00 2.00 124 1.00 1.47 1.00 2.00 378 0.39 
Enjoy Respiratory Sensations 3.00 3.38 2.00 4.00 124 3.00 3.30 2.00 5.00 378 0.67 
Craving Reduction 4.00 4.05 3.00 5.00 124 3.00 3.67 3.00 5.00 378 0.02 
One month after subjects’ target quit dates 
Smoking Satisfaction 4.67 4.42 3.33 5.33 121 3.67 3.78 3.00 4.67 241 0.0002 
Psychological. Reward 2.80 2.86 2.00 3.80 121 2.20 2.35 1.40 3.00 241 6x10–5 
Aversion 1.00 1.26 1.00 1.50 121 1.00 1.31 1.00 1.00 241 0.7350 
Enjoy Respiratory Sensations 2.00 2.66 1.00 4.00 121 2.00 2.55 1.00 4.00 242 0.7511 







Table 7.8 Bivariate GLM of MNWS and treatment assignment as predictors of prolonged six-months not smoked on seven consecutive 
days.  Each row is the result of a separate bivariate GLM. 
Variable MNWS Active Treatment Assignment 
 OR 95%CI p OR 95%CI p 
Baseline 
Craving 1.06 0.77—1.46 0.7133 2.11 -1.40—3.23 0.0004 
Restlessness 0.87 0.70—1.07 0.1811 2.15 -1.42—3.29 0.0003 
Increased appetite 1.02 0.78—1.31 0.8726 2.12 -1.40—3.23 0.0004 
Negative affect 0.87 0.64—1.16 0.3568 2.12 -1.40—3.24 0.0004 
Insomnia 0.88 0.73—1.06 0.1946 2.14 -1.41—3.27 0.0004 
One month after target quit date 
Craving 0.39 0.30—0.50 5x10-13 2.65 -1.62—4.39 0.0001 
Restlessness 0.81 0.64—1.00 0.0528 2.67 -1.71—4.23 2x10--5 
Increased appetite 1.30 1.06—1.60 0.0136 2.79 -1.78—4.45 1x10--5 
Negative affect 0.64 0.47—0.85 0.0026 2.69 -1.71—4.27 2x10--5 
Insomnia 0.81 0.63—1.03 0.0998 2.60 -1.66—4.12 3x10--5 
Three months after target quit date 
Craving 0.29 0.22—0.39 9x10-17 2.17 -1.26—3.77 0.0057 
Restlessness 0.43 0.30—0.59 8x10-7 2.53 -1.56—4.13 0.0002 
Increased appetite 1.07 0.85—1.34 0.5618 2.37 -1.50—3.78 0.0002 
Negative affect 0.35 0.22—0.52 2x10-6 2.58 -1.60—4.20 0.0001 
Insomnia 0.47 0.34—0.64 5x10-6 2.27 -1.41—3.69 0.0008 
Six months after target quit date 
Craving 0.28 0.20—0.37 1x10-17 1.89 -1.06—3.38 0.0316 
Restlessness 0.55 0.39—0.73 1x10-4 2.32 -1.44—3.79 0.0006 
Increased appetite 1.19 0.92—1.53 0.1771 2.47 -1.54—3.99 0.0002 
Negative affect 0.54 0.37—0.75 0.0005 2.30 -1.43—3.75 0.0007 




The percentage reduction in total QSU scores pre/post using the inhalers at baseline was 
significantly smaller among subjects who were lost-to-follow-up by the six-months post target 
quit date follow-up cf. subjects who attended their final follow-up (median, mean, 
(IQR) -30.86%, -30.98%, (-54.04% to -15.69%) cf. -38.46%, -37.38%, (-57.21% to -22.97%), 
p=0.0118)). 
A week after baseline, loss-to-follow-up was not predicted by the extent to which subjects 
reported being happy with their inhalers; how much the inhalers reduced their urges to smoke; 
the severity of the problems they had had with their inhaler; the degree of difficulty they had 
transitioning from the low to high dose inhalers. 
7.3.9 Integrity of the blind 
Both subjects and research staff were asked to guess subjects’ treatment assignments.  
Research staff only made this guess at the end of each subject’s baseline visit after the subject 
had left the room; while subjects were asked to make this guess at baseline and every follow-
up.   
To test whether unblinding had occurred, the binomial test with p=0.5 (an equal chance of 
success or failure) was used to determine if the number of subjects who guessed correct cf. 
incorrect was different from what could be expected with a simple coin-toss.  The binomial 
test is an exact test of a simple null hypothesis about the probability of success in a Bernoulli 
experiment.  The results of these analyses are summarised here and are displayed in full in 
Appendix C, pages 383-431.  Analyses showed that subjects had been unmasked at baseline 
and at all follow-up contacts, and the statistical significance of more subjects guessing 
correctly cf. incorrectly ranged from as low as: p=0.0041 to as high as p=5x10-6, for the 
treatment assignment guesses subjects made at the various time-points.  For instance, at 
baseline significantly more subjects guessed their treatment assignment correctly than 
incorrectly, the probability of being correct/incorrect was 178/305 = 0.58, 95%CI:0.53—0.64, 
p=0.0041, indicating that subjects were unmasked. 
Whether or not unblinding had biased the estimate of the primary outcome was determined by 
running a logistic regression for how much active treatment increased abstinence cf. placebo 
treatment, separately, for subjects in three categories of subjects: 
1. subjects who guessed their treatment assignments correctly,  
2. subjects who guessed incorrectly, and  




These three groups of GLMs were repeated each time subjects were asked to report their 
treatment assignment guesses.  It was not possible to test if the treatment effect was 
significantly different depending on the correctness of subjects’ treatment assignment guesses, 
by determining if an interaction term was significant between subjects’ actual treatment 
assignments and whether their guesses were correct/incorrect/unsure, because these two 
variables were highly correlated and not independent of each other. 
High correlations between independent variables breaks the assumptions of GLM hence, the 
alternative method of calculating the effect of active treatment within each type of treatment 
assignment guess was used, the results of which are displayed in Table 7.9.  There were two 
instances when the OR for active cf. control treatment were significantly different between 
subjects who guessed their treatment assignment correctly/incorrectly/unsure, at the level of 
p<0.05 but would not remain significant after Bonferroni correction for the six times that was 
measured (Table 7.9): 
1. A week after baseline, the OR for active treatment was higher for subjects who 
guessed correctly cf. unsure (p=0.049). 
2. A month after baseline, the OR for active treatment was higher for subjects who 
guessed correctly cf. unsure (p=0.025). 
Table 7.9 Active treatment assignment as predictor of prolonged six-months not 
smoked on seven consecutive days amongst subjects who, guessed their treatment 
assignment correctly cf. incorrectly cf. unsure. 
Guess Effect of active treatment on abstinence 
 OR Lwr95%CI Upr95%CI p 
 Baseline guesses of treatment assignment 
Correct 2.76 1.08 8.55 0.0499 
Incorrect 1.86 0.47 6.30 0.3374 
Unsure 1.80 0.90 3.60 0.0951 
Correct cf. Incorrect p=0.641; Correct cf. Unsure p=0.501; Incorrect cf. Unsure 
p=0.965 
 One week after baseline 
Correct 3.00 1.60 5.91 0.0009 
Incorrect 2.70 0.83 8.86 0.0951 




Guess Effect of active treatment on abstinence 
 OR Lwr95%CI Upr95%CI p 
Correct cf. Incorrect p=0.8879; Correct cf. Unsure p=0.0485; Incorrect cf. Unsure 
p=0.220 
 Day after target quit phone-call guess of treatment assignment 
Correct 2.72 1.45 5.33 0.0025 
Incorrect 1.08 0.40 2.74 0.8728 
Unsure 2.16 0.98 4.88 0.0597 
Correct cf. Incorrect p=0.119; Correct cf. Unsure p=0.437; Incorrect cf. Unsure 
p=0.278 
 One month post target quit-date guess of treatment assignment 
Correct 4.16 2.11 8.69 7x10-5 
Incorrect 1.17 0.38 3.26 0.7761 
Unsure 1.11 0.45 2.78 0.8172 
Correct cf. Incorrect p=0.053; Correct cf. Unsure p=0.025; Incorrect cf. Unsure 
p=0.942 
 Three month post target quit-date guess of treatment assignment 
Correct 3.09 1.58 6.31 0.0013 
Incorrect 1.26 0.42 3.52 0.6637 
Unsure 1.81 0.70 4.78 0.2242 
Correct cf. Incorrect p=0.166; Correct cf. Unsure p=0.3766; Incorrect cf. Unsure 
p=0.620 
 Six month post target quit-date guess of treatment assignment 
Correct 2.92 1.40 6.38 0.0053 
Incorrect 3.38 1.22 9.57 0.0194 
Unsure 0.89 0.34 2.31 0.8135 
Correct cf. Incorrect p=0.823; Correct cf. Unsure p=0.057; Incorrect cf. Unsure 
p=0.703 
 
At all times when subjects were asked to guess their treatment assignments, subjects who 




prolonged not smoked on seven consecutive days abstinence than subjects who guessed 
incorrectly. 
Whether subjects guessed they were assigned to active or placebo or were unsure, at baseline 
and at all subsequent follow-ups, was predictive of prolonged six-months not smoked on 
seven consecutive days abstinence when all subjects were analysed together, and when they 
were analysed within their separate treatment groups.   
7.3.9.1 Predictors of unblinding 
Analyses were undertaken to determine if variables collected at baseline and at subsequent 
follow-ups predicted unmasking.  These analyses investigated the extent to which fourteen 
variables predicted whether subjects would correctly cf. incorrectly guess their treatment 
assignment at six time-points (baseline, a week after baseline, a day after subjects’ target quit 
dates and; one, three and six months after subjects’ target quit dates): 
1. actual treatment assignment, (cumulative number of comparisons=1) 
2. subjects’ ages, (cumulative number of comparisons=2) 
3. FTND scores, (cumulative number of comparisons=3) 
4. baseline CPD, (cumulative number of comparisons=4) 
5. whether subjects suffered at least one inhaler adverse event, (cumulative number of 
comparisons=5) 
6. the maximum price subjects would pay for one canister of the inhalers they had been 
assigned; (cumulative number of comparisons=6) 
7. the five CEQ subscale measured at baseline, one, three and six months after the target 
quit date, (cumulative number of comparisons=26) 
8. the extent to which subjects reported their inhalers reduced their urges to smoke a 
week after baseline, (cumulative number of comparisons=27) 
9. whether subjects had difficulty transitioning from the lower to higher dose inhalers, a 
week after baseline, (cumulative number of comparisons=28) 
10. whether they had problems with their inhalers, a week after baseline, (cumulative 
number of comparisons=29) 
11. twenty-four hour and seven-day point-prevalence abstinence at one, three and six 




12. whether subjects had smoked on seven consecutive days since their grace period, 
reported at one, three and six months after the target quit date (cumulative number of 
comparisons=38). 
Thus, Bonferroni correction would require correction for thirty-eight comparisons with 
subjects’ treatment assignment guesses, at six time-point p<0.05/(38*6)= 0.00022, a level of 
significance, for predicting guessing correctly cf. incorrectly, attained only by treatment 
assignment at all time-points, and four variables at six time-points when comparing the values 
of variables between subjects who guessed their assignment correctly cf. incorrectly (Table 
C10, page 409): 
1. Having suffered one or more adverse effects of the inhalers at baseline cf. not 
suffering any adverse effects at baseline. 
2. Psychological Reward a month after the target quit date, was significantly higher for 
subjects who, a month after target quit date, guessed correctly cf. those who guessed 
incorrectly 
3. Aversion scores, measured a month after the target quit date, were significantly higher 
among subjects who, at that time, guessed correctly compared to subjects who guessed 
incorrect.   
4. A month after the target quit date, subjects who correctly guessed their treatment 
assignment scored higher on Craving Reduction at that time, than subjects who 
incorrectly guessed their treatment assignment at that time. 
5. Aversion scores measured a month after the target quit date, were significantly higher 
for subjects who, three months after their target quit date, guessed their treatment 
assignment correct cf. incorrect.  
6. Craving Reduction measured six months after subjects’ target quit dates, were 
significantly higher for subjects who, six months after their target quit dates, guessed 
their treatment assignment correctly cf. incorrectly. 
7.3.9.2 Changes in subjects’ treatment assignment guesses 
A week after baseline, slightly over half of subjects’ treatment assignments guesses were 
equally as correct or incorrect or unsure, as they had been at baseline, with the proportion who 
were just as correct or incorrect or unsure of their treatment assignment at one time-point as 




months follow-up, three-quarters of subjects were just as correct, incorrect, or unsure as they 
had been at their three-months follow-up (Table 7.10).   
Table 7.10 Changes in subjects’ guesses of their treatment assignment from one 
follow-up to another (months after baseline) correct, unsure, incorrect). 
Guess TRUE FALSE Total % True 
Baseline = One week 268 227 495 54.14 
One week = One month 281 177 458 61.35 
One month = Two month 248 127 375 66.13 
Two months = Four months 233 97 330 70.61 
Four months = Seven months 225 72 297 75.76 
 
The rate of subjects guessing their treatment assignments correctly increased significantly in 
both treatment groups between baseline and six months after subjects’ target quit dates.   
7.3.9.3 Research staff guesses of subjects’ treatment assignment 
The patterns of Research staff-members’ guesses of subjects’ treatment assignments, varied 
widely between staff-members, with one staff-member guessing “unsure” ninety percent of 
the time, while another staff-member guessed “unsure” only four percent of the time (Table 
7.11).  Of the 495 guesses Research staff made, 243 (49.09%), 201 (40.61%), and 51 (10.3%) 
were correct, incorrect, and unsure, respectively.  The chance of 243 Research staff-members’ 
guesses being correct and 201 incorrect is not significantly different from chance (p=0.0516, 
as calculated by the binomial test where p=0.50).   
Table 7.11 Percent of Research Staff members’ guesses of subjects’ treatment 








Number of  
guesses 
Staff n % n % n %  
AT 32 37.65 37 43.53 16 18.82 85 
BB 31 34.07 16 17.58 44 48.35 91 
BC 46 30.26 12 7.89 94 61.84 152 
CH 22 29.73 39 52.70 13 17.57 74 
JC 1 4.76 1 4.76 19 90.48 21 
RT 4 20.00 3 15.00 13 65.00 20 





There were no significant differences in subjects’ prolonged six-months not smoked on seven 
consecutive days abstinence based on whether research staff members’ guesses of those 
subjects’ treatment assignments were correct, incorrect or, unsure (Table 7.12). 
Table 7.12 Correctness of research staff members’ guesses of subjects’ treatment 
assignment as a predictor of prolonged six-months not smoked on seven consecutive 
days. 
 Correct, n=243 Incorrect, n=201 Unsure, n=51 
 n % n % n % 
Abstinent (n=123) 55 22.63 50 24.88 18 35.29 
Not abstinent (n=372) 188 77.37 151 75.12 33 64.71 
Abstinent rates when staff guessed correct cf. unsure: 55/243 (22.63%) cf. 18/51 (35.29%), a 
difference of 12.66%, 95%CI:-26.79%—1.47%, p=0.06. 
 
7.4 Discussion 
The addition of nicotine by inhalation, using a standard pMDI, to nicotine patch therapy, 
significantly improved abstinence to six months amongst a population of moderately nicotine 
dependent smokers with a history of repeated quit attempts.  In general, the nicotine pMDI 
was well tolerated but was associated with upper airway side-effects.  Although side-effects 
were more common with the active inhaler, and were predominantly mild, significantly more 
subjects in the active group withdrew from the study due to side-effects of the inhaler.  
Nicotine is an irritant to the airway and is commonly associated with coughing when inhaled, 
a feature that was noted in the pilot study of the nicotine inhaler.(35)  Reported coughing 
tended to diminish in severity over time in the current study and was noted informally to 
diminish in frequency and severity during the one-hour baseline visit, suggesting a rapid 
development of tolerance to the airway irritant effects with tachyphylaxis.  Cough was the 
most common side-effect to be rated as severe.  Of the twelve subjects who had severe 
coughing at baseline, eleven reported their severity of coughing one week later, when nine 
had less than severe coughing, illustrating that even severe coughing diminished with 
tachyphylaxis and the passage of time.  The mCEQ scores showed that although the active 
inhaler provided greater craving reduction, it was more aversive and less enjoyable than the 
placebo inhaler. 
Active inhaler therapy approximately doubled prolonged six months abstinence by the two, 
less stringent, biochemically verified definitions of abstinence in Table 7.2, page 247 (not 




of six months prolonged not smoked even a puff, was significantly improved with active 
inhalers when not biochemically verified but, not when biochemically verified.  The Society 
for Research on Nicotine & Tobacco recommends, that the criterion of not smoking even puff 
should only be used for point prevalence outcomes not for prolonged time-periods because, it 
is too strict and counts as failures subjects who have a single slip and go on to long-term 
abstinence.(68)  
The combination of inhaler therapy with patch therapy did not fully ameliorate the effects of 
withdrawal symptoms lowering the odds of abstinence.  Adherence to use of patches was 
similar between treatment groups, which may explain why higher MNWS scores predicted 
lower abstinence to the same extent in both treatment groups, and why MNWS scores were 
similar between treatment groups at all but two time-points.  This would suggest that 21mg 
patches may not fully expunge the deleterious effects of withdrawal symptoms on abstinence, 
and that the differential abstinence rates between treatment groups was not obtained by 
lowering withdrawal symptoms more in the active cf. control groups. This also suggests that 
the higher abstinence rates with active inhalers was not medicated by ameliorating withdrawal 
symptoms. 
7.4.1 Comparison to other cessation therapies 
A recent Cochrane review showed that combination NRT increased the odds of abstinence by 
1·43 (95% Credible Interval 1·08 to 1·91) compared to nicotine patch monotherapy.(63)  The 
most effective combination therapy was nicotine nasal spray plus nicotine patch,(212) the OR 
for six month abstinence was 2·40; 95%CI:1·30—4·57; p=0·006 (calculated from data in the 
tables in the publication).(67, 400)  Severe side-effects of the nasal spray were common.  The 
nicotine pMDI plus patch combination appears to have similar efficacy and less severe side-
effects compared to the nasal spray plus patch combination; although a head-to-head trial of 
the pMDI and nasal spray would be required to confirm this.   
The systematic literature review conducted for this dissertation,(61) identified no other trials 
of inhaled nicotine by pMDI.  That systematic literature review, along with searches of 
publications’ reference lists, and consultation with experts in smoking cessation and 
pharmaceutical development, identified reports of new nicotine delivery devices that had been 
published after the nicotine pMDI plus nicotine patch trial of this dissertation was designed:    





2. Electronic cigarettes, for which there is limited clinical trial evidence of the extent to 
which they aid smoking cessation. 
3. A nicotine free-base inhaler called Voke which is manufactured by British American 
Tobacco and contains nicotine free-base, ethanol, menthol, propylene glycol and 
saccharin.(232)   
4. A nicotine pyruvate inhaler.(231) 
A trial of electronic cigarettes may provide a useful comparison by which to judge the 
efficacy of the nicotine pMDI and patch combination.  Bullen and colleagues conducted a trial 
of electronic cigarettes which was also conducted among New Zealand smokers in a 
university setting.(401)  The recruitment methods employed by Bullen and colleagues were 
similar to those used in this trial (press releases to community newspapers), however one 
inclusion/exclusion criterion was slightly different (Bullen and colleagues did not exclude 
smokers with an FTND<3, and instead performed a stratified randomisation into FTND>5 
and FTND≤5).  Bullen and colleagues randomised subjects to three conditions: 
1. Nicotine electronic cigarette (n=289) 
2. Nicotine transdermal patches (n=295) 
3. Placebo electronic cigarettes (n=73) 
Subjects were given a week of pre-cessation NRT which they were instructed to use for 
twelve weeks after their target quit dates, and were followed-up for six months after their 
target quit dates.  The outcome of seven-day point-prevalence abstinence six months after 
subjects’ target quit dates, was one outcome that had the same definition for abstinence in the 
INHALE trial.  In this pMDI study, 91/246 (36.99%) cf. 56/256 (21.88%), p=0.0002, subjects 
in the active and control groups, respectively, had met the seven-day point prevalence 
definition of abstinence six months after their target quit dates.  Rates of this abstinence 
outcome in Bullen and colleagues’ trial were 61/289 (21.11%), and 46/295 (15.59%) in the 
electronic cigarette and patch groups respectively, p=0.0850.  The abstinence rates in the 
active nicotine pMDI plus nicotine patch group in the INHALE trial were significantly higher 
than in the active nicotine electronic cigarette monotherapy group in Bullen and colleagues’ 
trial (91/246 (36.99%) cf. 61/289 (21.11%), 95%CI:8.23%—23.54%, p=5x10-5).  Also, the 
seven-day point prevalence abstinence rates at six months in the control group of the 




however this was of borderline statistical significance (56/256 (21.88%) cf. 46/295 (15.59%), 
95%CI:0.26%—12.82%, p=0.0583).   
Meta-analysis of the results of the electronic cigarette trial by Bullen, and this pMDI plus 
patch combination, using the rmeta package in the R language, found that the OR for six-
months seven-day point prevalence abstinence, achieved by the electronic cigarette cf. 
nicotine patches in the study by Bullen and colleagues, was not significantly different from 
the OR for the active pMDI plus patch combination cf. placebo pMDI and active patch 
(OR=1.45; 95%CI:0.95—2.21 cf. OR=2.10; 95%CI:1.41—3.11), respectively, and the test for 
heterogeneity was not significant.  When the sample sizes of both studies and their results, 
were increased one-and-a-half times, the OR of achieving six-months seven-day point-
prevalence abstinence with active pMDI plus patch cf. placebo pMDI plus patch, compared to 
the OR for achieving this definition of abstinence with active electronic cigarettes cf. nicotine 
patches, was significantly higher with pMDI plus patch treatment cf. electronic cigarette 
(OR=2.10; 95%CI:1.52—2.89 cf. OR=1.45; 95%CI:1.03—2.05, respectively). 
Abstinence rates were not separated out according to whether subjects had lower or higher 
FTND scores in Bullen and colleagues’ publication, hence it was not possible to determine if 
the inclusion of subjects who had FTND scores below the lower cut-off for inclusion in the 
nicotine pMDI study contributed to the lower abstinence rates in the INHALE and electronic 
cigarette trials.  Other possible explanations for the discrepant abstinence rates between these 
two trials, include: 
1. the follow-up support in Bullen and colleagues’ trial, which was provided by the New 
Zealand Quitline, rather than the trial’s research staff, and was all done via the 
telephone, may not have been as effective as the minimal brief support provided by the 
research staff to all subjects who had not been lost to follow-up in the INHALE trial.  
This is certainly a possibility, given that less than half of subjects in Bullen and 
colleagues’ trial accessed support from Quitline. 
2. Adherence to use of patches and electronic cigarettes was low in Bullen and 
colleagues’ trial, whereas rates of use of pMDIs and patches were higher in the 
INHALE trial.  In this trial, the average number of puffs subjects in the active group 
reported taking of their inhalers per day was median, mean, (IQR) 74.4, 26, (4—83), 
whereas subjects in the active electronic cigarette group in Bullen and colleagues’ trial 
reported using an average of 0.7 cartridges per day six months after their target quit 




puffs are provided per cartridge nor the number of puffs and cartridges they advised 
subjects to use per day.   
3. It is possible that both the active and placebo pMDIs in the INHALE trials are more 
effective than the electronic cigarette used by Bullen and colleagues. 
4. In the INHALE trial, all subjects received active nicotine patches in combination with 
the active and placebo inhalers; whereas Bullen and colleagues provided subjects with 
either electronic cigarette monotherapy or, nicotine patch monotherapy. 
5. Bullen and colleagues hypothesised that the low abstinence rates in their nicotine 
electronic cigarette group may be the result of their nicotine content being lower than 
what was on their label, and use of one cartridge per day would deliver only twenty 
percent of the daily nicotine inhaled by the average smoker.  
There is considerable worldwide interest in inhaled nicotine through the use of  e-cigarettes, 
though as yet data on their efficacy for smoking cessation is limited.(402)  Concerns have 
been expressed about toxic compounds in e-cigarette vapour following heating of the 
e-cigarette liquid,(403) whereas pMDIs do not alter the chemical composition of their 
contents.  A further advantage of pMDIs is that they are sealed and tamper-proof unlike e-
cigarette brands that require refilling from bottles of liquids that may readily be adulterated.  
Also, the use of pMDIs is very different from the act of smoking, unlike the act of using an 
electronic cigarette.  For instance, the shape of a pMDI is totally different from that of a 
cigarette, whereas the shape of an electronic cigarette is similar to that of a combustible 
cigarette; also, use of a pMDI does not result in a visible cloud of vapour being emitted when 
people exhale after using a pMDI whereas, a cloud that looks like combustible cigarette 
smoke is emitted in the exhaled breath of users of electronic cigarettes.  On the one hand, the 
similarities between the sensory and behavioural effects of inhaling from an e-cigarette, and 
inhaling from a combustible cigarette, may be seen as an advantage, because the similarities 
are likely to facilitate the process by which the sensory qualities of using an e-cigarette 
become secondary reinforcers of the e-cigarette (in addition to the primary reinforcer of 
nicotine from electronic cigarettes).  On the other hand, the similarities may make quitting 
harder for smokers who want to completely break from everything associated with smoking 
cigarettes, and may model smoking behaviour to children.(404, 405) 
A few novel nicotine delivery devices have debuted after the nicotine inhaler plus nicotine 




7.4.1.1 AERx Essence inhaler 
The AERx Essence Inhaler aerosolises respirable particles by using the suction of the user’s 
inhalation, to force liquid nicotine in a reservoir, to pass through a barrier which has very 
small holes in it, through which jets of liquid nicotine are driven from one side of the barrier 
to the other, and once these jets of liquid are emitted from the other side of the barrier, they 
break up into small droplets which are sized in the respirable range.(406)    
In 2015 Igor Gonda and David Cipolla published, that a single dose of aqueous nicotine 
tartrate solution (50µL) containing no other excipients, had a pH of 3.0.  Three nicotine 
concentrations (10, 20, and 30mg/ml), had a MMAD of 2.4—2.8µM, and each dose, 
including the highest dose of 0.73mg, is delivered in one puff.(407)  As there have been no 
clinical trials of this inhaler to date, whether or not a single dose of nicotine would provide 
tolerable sensory effects, and whether the sensory effects of a single dose is sufficient to be 
reinforcing and aid smoking cessation, has yet to be established. 
A brief description of a phase one pharmacokinetic study of AERx essence has been 
published, but it reports the Tmax and Cmax in graphs and does not give the numerical values 
for these results.(407)    
7.4.1.2 Voke 
British American Tobacco manufacture a nicotine inhaler called Voke, which has two 
separate components: 
1. An inhaler that looks like a combustible cigarette. 
2. A pMDI canister that is housed in a small box that looks like a cigarette packet which 
is used to recharge the inhaler with more nicotine.   
The inhaler is breath-activated, after the user sucks air through it with a fair amount of 
suction, it delivers a short high-speed jet of nicotine.  It contains nicotine free-base, ethanol, 
menthol, propylene glycol and saccharin.(232)   
A trial to measure the pharmacokinetics of Voke instructed subjects to inhale from the inhaler 
once every fifteen seconds for two minutes.  Subjects inhaled three different nicotine 
doses:(232)   
1. 0.22mg (0.28% w/w) 




3. 0.67mg (0.084% w/w) 
The arterial and venous Tmax for all doses were approximately eight and eighteen minutes, 
respectively (from inspection of the graphs in the publication).  The venous Cmax for the 
0.45mg formulation was 2.9ng/ml.  Throat irritation during two parts of the study occurred in 
3/18 subjects (arterial pharmacokinetics) and 6/18 subjects (venous pharmacokinetics), cough 
occurred in 3/18 and 0/18 subjects during the arterial and venous blood collections, 
respectively. 
An additional study measured Voke’s venous pharmacokinetics, adverse events, effects on 
urges to smoke and a VAS of Craving to smoke.(408)  Subjects were administered two doses 
of Voke on two separate days, 0.45mg and 0.67mg, and the Nicorette Inhalator 10mg on a 
third day.  The Cmax for the 0.45mg, 0.67mg inhalers and Inhalator were 3.28, 3.92 and 
6.57ng/ml, respectively and the Tmax mean (SD) was 18.7 (8.6), 19.2 (11.8), and 38.0 (11.8) 
minutes, respectively.  The respective mean (SD) AUC values were 453.3 (259.0), 563.0 
(322.9), and 987.7 (487.7).  VAS Craving scores and total QSU scores were significantly 
lower at a minority of time-points for both doses of Voke cf. Inhalator.  The incidence of 
cough was not reported, throat irritation was suffered by 5/23 (22%), 6/23 (26%), and 7/24 
(29%) subjects, respectively. 
The Cmax for the 50µg and 100µg free-base pMDIs were 12.5 and 9.4 ng/ml, Tmax six and five 
minutes, AUC 202 and 365, respectively.  Thus, compared to the two doses of Voke, the 50µg 
and 100µg free-base pMDIs had 12.5/3.28 (381%) and 9.4/3.92 (240%) higher Cmax values, 
respectively; Tmax values that were three times shorter (6/18.7 (32%) and 5/19.2 (26%), 
respectively) but marginally lower AUCs. 
7.4.1.3 Vype 
In addition to the pMDI-based Voke, BAT has also invented an electronic cigarette called 
Vype.  The design of a trial to compare the pharmacokinetics of a cigarette, four dosages of 
Vype, and a non-BAT electronic cigarette, was published in 2017.(409) 
7.4.1.4 Nicotine pyruvate inhaler 
An inhaler that uses bespoke technology that harnesses the suction created by users’ 
inspiration from the inhaler, to cause pyruvic acid vapour to pass through a membrane soaked 
with free-base nicotine, thereby creating a nicotine pyruvate vapour, which can be inhaled.  A 




pyruvate inhaler (10, 20, and 30 µg/puff), a Nicotrol/Nicorette inhalator, and a placebo inhaler 
was conducted in Christchurch, New Zealand.(231)   
The mean Cmax was 5.0ng/ml (SD=3.4) and 8.3ng/ml (SD=3.1) for the 20µg/puff and 
30µg/puff inhalers, respectively.  The Tmax was not reported numerically but, inspection of the 
graph of the pharmacokinetic profile, suggested it was approximately one minute.  The means 
(SD) of subjects’ scores on items of a different version of mCEQ to the one used in this trial, 
were reported; the values of four items were significantly (p<0.05) lower for the 20µg 
nicotine pyruvate inhalers compared to the scores for the inhalator, all of which related to how 
harsh/irritating the inhalers were in various parts of the airway; irritation was not different 
between the inhalator and the other doses of the nicotine pyruvate.  
Both the ten and twenty microgram nicotine pyruvate inhalers produced a statistically 
significant bigger reduction in nicotine withdrawal scores cf. placebo but not cf. inhalator.  I 
was unable to find any other publications that tested the nicotine pyruvate inhaler.  The Cmax 
for the 100µg/puff nicotine free-base pMDI was 9.4/8.3=1.13 higher than that of the 
30µg/puff nicotine pyruvate inhaler, which had the largest Cmax of the different doses of the 
nicotine pyruvate inhalers. 
7.4.2 Limitations 
There are limitations to this pMDI plus patch trial. It was not possible to follow subjects for 
twelve months after the target quit date as planned, because of budgetary constraints, although 
following subjects in this trial for a further six months is unlikely to have added further useful 
information, given that the shape of the relapse curve for smoking cessation is the same 
regardless of the type of smoking cessation assistance used, and this shape indicates the vast 
majority of smokers relapse very early after attempting to quit and the rate of relapse is very 
slight beyond six months after the attempt to quit.(9, 142, 337).  Stapleton and colleagues go 
so far as to state that it is only necessary to follow subjects for six weeks in order to 
demonstrate the relative efficacy of different smoking cessation therapies.(142)   
The risk of bias from imputing those lost to follow-up as smokers is minimal because the rate 
of loss to follow-up was similar between groups, and a per-protocol analysis of abstinence 
had similar results. Although biochemical verification of abstinence was only performed a 
month after the target quit date, the rates of self-report of abstinence, when expired CO 




Subjects were unmasked to their treatment assignment at baseline and all follow-ups.  The 
effect size of active cf. placebo pMDI, was the same among subjects who guessed correctly, 
subjects who guessed incorrectly, and subjects who guessed unsure, after Bonferroni 
correction, suggesting that unmasking had not biased the estimate of the effect of active 
treatment on the odds of subjects achieving abstinence.  Hence when subjects embarked on 
their treatment and for the next seven months, active treatment was equally effective 
regardless of whether they guessed their treatment assignment correctly, incorrectly, or 
unsure.   
The sensory qualities of the placebo inhaler, and the provision of active nicotine patches to 
subjects in the control group, may have engendered similar placebo effects and expectancies 
among subjects in the control group cf. subjects in the active group, since at baseline, subjects 
in the control group had a significantly low probability of guessing their treatment assignment 
correctly of 0.21, 95%CI: 0.15—0.29, p=2x10-12 (31 correct, 145 incorrect), indicating that 
the vast majority thought they were using active inhalers.  Also, at baseline subjects who 
incorrectly thought they were using active inhalers experienced similar psychological reward 
and craving reduction after using their inhalers cf. subjects who correctly thought they were 
using active inhalers.  Additionally, subjects in the control group continued to report they 
used their inhalers regularly at all follow-up time-points.  Further evidence that many subjects 
were blind to their treatment assignments, and that many subjects found it difficult to 
discriminate between the presence or absence of nicotine in their inhalers, can be seen in the 
fact that the vast majority of subjects changed their guesses of their treatment assignments, 
with many changing their guess more than once during the trial. 
7.4.3 Association of greater use of pMDI and abstinence 
The effect that the amount subjects used their inhalers, had on six-months prolonged 
abstinence, was measured in multiple ways: as the number of occasions that the inhalers were 
used per days, the number of puffs used per occasion, and the number of puffs used in the 
seven days before each follow-up, furthermore, these outcomes were analysed to create more 
variables that may better reveal the role of treatment adherence on abstinence, such as the 
percentage of days that subjects had used their inhalers between each follow-up, and puffs 
taken per day (which was the occasions per day multiplied by puffs per occasion).  These 
measures indexed different aspects of the amount of inhalers used by subjects, which may 




also opened the door to the potential for findings to be statistically significant due to multiple 
comparisons. 
The percentage of days that subjects had used their inhalers between each follow-up, from the 
one-week follow-up to six-months after the target quit-date, was significantly greater among 
subjects who attained prolonged six-months abstinence cf. those who did not.  A similar 
measure to the percent of days that subjects used the inhalers (the cumulative days subjects 
used the inhalers) revealed similar results, with greater cumulative days subjects used their 
inhalers being predictive of abstinence in the sample as a whole as well as within each 
treatment group separately.   
The use of more puffs of the inhalers was only significantly higher among subjects who 
achieved prolonged abstinence when it was measured over more than a twenty-four hour 
period, with the number of puffs used per day never being significantly predictive of 
prolonged abstinence, whereas the number of puffs taken in the seven days prior to each 
follow-up was predictive of abstinence a month after subjects target quit dates and all 
subsequent time-points.  This suggests that the pattern of use over an extended duration of 
time has a greater effect on abstinence than the pattern over an arbitrary short period of time. 
The placebo effect may explain why, in the control group, the cumulative days subjects used 
their inhalers was significantly greater among subjects who achieved six-months prolonged 
abstinence cf. subjects who did not;, and why the interaction term between treatment 
assignment and the percent of days that subjects used their inhalers, between the one week 
phone-call and target quit phone-call, predicting prolonged six-months abstinence, was not  
significant. 
An alternative explanation for why greater adherence to the use of the inhalers was associated 
with abstinence, regardless of the nicotine content of the inhalers, might be that subjects who 
are more diligent, are more thorough with the use of their inhalers and possibly people who 
are more conscientious may be more likely to quit smoking.  This argument is consistent with 
the positive association between, filling out diary cards of CPD and inhaler use every day 
during the first fortnight, and prolonged six-months abstinence. 
7.4.4 Potential placebo effects 
Evidence suggestive of the placebo effect was occasionally uncovered in this trial, despite it 
not having a “no treatment” group or, an arm in which subjects received active nicotine 




thoroughly explore the role of the placebo effect.  At baseline, Smoking Satisfaction scores 
for the inhaler were significantly higher in the control group cf. the active group.  
Furthermore, Psychological Reward and Craving Reduction scores for the inhalers at baseline 
were not significantly different between treatment groups (Table C7 in Appendix C, page 
404), reflecting the ability of the placebo inhaler to provide similar and sometimes greater 
reward and reduction of urges to smoke as the active inhalers, at least after a short initial 
experience with the inhalers.   
At the final follow-up, withdrawal symptoms were not substantially different between 
treatment groups, and the scores of three subscales of the mCEQ were similar between 
groups.  Further evidence suggestive of a robust placebo effect was observed in the similar 
rates of use of the inhalers in the control and active groups at many of the follow-up time-
points. 
7.4.5 No evidence of ethnic inequality in pMDI efficacy 
Abstinence rates were similar between Māori and non-Māori and there was no interaction 
between treatment assignment and Māori ethnicity, suggesting that the nicotine inhaler may 
have been equally effective for Māori smokers.  Notably, Māori subjects used the inhalers for 
as many days as non-Māori subjects.  However, these ethnic comparisons were limited by the 
small number of Māori subjects.  The pMDI therefore may offer an important tool to aid 
Māori to reduce their prevalence of smoking and the inequalities in health and well-being they 
suffer because of their high prevalence of smoking.   
7.4.6 Predictors of abstinence 
Variables that are often associated with a lower chance of abstinence in other trials, including 
the nicotine patch plus nicotine mouthspray study reported in this dissertation, were not 
predictive of abstinence in this trial, such as age, gender, Māori ethnicity, and baseline CPD.  
These variables were not predictive in the control group or the active group, hence the 
absence of their negative impact on abstinence in the trial as a whole cannot be attributed to 
the effects of the active inhalers.  The lack of a detrimental effect of these variables on 
abstinence may be due to: 
1. a placebo effect of inhaling a pungent menthol-flavoured aerosol regardless of its 
nicotine content;  




3. the nature of the support that all subjects were provided regardless of their treatment 
assignments;   
4. the study may have been underpowered to show an effect of characteristics that usually 
predict abstinence. 
The effect of the sample size on the statistical significance of secondary analyses is clearly 
seen with the role of Māori ethnicity in the odds of subjects accomplishing abstinence, which 
was statistically significantly predictive of lower abstinence in the mouthspray study with its 
large sample size but, was not significant in the smaller inhaler study.  In the nicotine 
mouthspray plus nicotine patch study, the proportion of subjects who were Māori was 
216/1315 (16.43%), and the percent of Māori cf. non-Māori who achieved prolonged six 
months not smoked on seven consecutive days abstinence was 13/216=6.0% cf. 
170/1099=15.47%, p=0.0002, respectively.  The proportion of subjects who were Māori in the 
nicotine inhaler plus nicotine patch study was 57/502 (11.35%), and the rates of prolonged six 
months not smoked on seven consecutive days for Māori cf. non-Māori was 12/57=21.05% 
cf. 112/445=25.17%, p=0.50.  In order to have 80% power to detect the same difference in 
proportions of Māori and non-Māori who were abstinent in mouthspray study, with an alpha 
of 5%, would require a sample size of 103 Māori and 804 non-Māori subjects.  To have 80% 
power with an alpha of 5% to find a significant difference between the rates of abstinence 
between Māori and non-Māori in INHALE, would require the enrolment of 997 Māori and 
7,787 non-Māori subjects.  It could be argued that to enrol such a large sample in order to find 
such a small difference in abstinence rates between Māori and non-Māori would be a waste of 
resources, and it may be safely concluded that abstinence rates were similar between Māori 
and non-Māori after treatment with a nicotine pMDI plus nicotine patch. 
Similarly, in this nicotine inhaler plus patch study, there were few variables that significantly 
predicted missingness of abstinence outcomes and loss-to-follow-up, unlike in the nicotine 
mouthspray and nicotine patch.  As a result, multiple imputation using the mice package and 
the selection model method were not used to impute missing abstinence outcomes in the 
analyses of the nicotine inhaler plus patch trial, the only method used for imputation was 
penalised imputation, which does not rely on there being variables that predict missingness.  
The absence of significant correlations between variables and missingness may also result 
from the smaller sample size of INHALE cf. ZAP. 
Despite significant differences between treatment groups in the scores of three sub-scales of 




‘Aversion’) none of the mCEQ sub-scale scores at baseline significantly predicted prolonged 
abstinence, suggesting that subjects’ first impressions of the inhalers did not influence their 
ability to quit smoking and maintain their abstinence.  However, by a month after subjects’ 
target quit dates, there were significant differences in the scores of four mCEQ scales between 
treatment assignments (Table C7 in Appendix C, page 404); the scores of three of these four 
scales were significantly predictive of prolonged six-months not smoked on seven 
consecutive days (Table 7.7, page 262).  The large effect on prolonged abstinence of subjects’ 
impressions of the sensory and psychological reward gained from the pMDIs after two 
months of using the pMDIs but, not after the first time the inhalers were used, may be an 
indication of the initial lack of association of the sensory effects of the inhalers with reward, 
and two months experience of the inhalers may have allowed the sensory attributes of the 
active pMDIs to become secondary reinforcers of their use and would make the inhalers more 
rewarding, which may have led to higher abstinence rates.    
7.4.7 Potential role of nicotine pMDI and patch combination therapy 
The active nicotine pMDI plus nicotine patch is a particularly effective therapy for smoking 
cessation, compared to conventional NRT.  If smokers use it each time they attempt to quit, 
they will have better odds of remaining abstinent for six months compared to if they used 
nicotine patches plus a placebo inhaler.  The Number Needed To Treat (NNT) is a useful 
method for comparing the efficacy of different treatments, with NNT closer to one indicative 
of superiority.  The NNT for one extra person to achieve prolonged six-months abstinence, is 
NNT=1/(Control Event Rate-Experimental Event Rate)=1/(Control relapse rate-Active 
relapse rate)= 1/((210/256)-(168/246)) = 7.28.  This compares favourably with 29, which is 
the NNT to assist an extra smoker to achieve sustained six months abstinence using 
conventional NRT cf. placebo, calculated by Moore and colleagues.(410)  However, 
comparing the efficacy of intervention, by comparing absolute values, such as the NNT, 
between trials, rather than comparing ratios such as ORs, is more prone to bias, and if there is 
a difference in baseline risk difference between trials, then the NNT cannot be compared 
between trials.(411, 412)  Bias may be caused by between-trial differences in study design 
and patient characteristics that are associated with the relative treatment effects.(411) 
Thus, the nicotine pMDI and patch combination therapy is considerably more effective than 
other NRTs and would assist more smokers to successfully quit, leading to less tobacco 





7.4.8 Future directions 
Future research is required to improve the tolerability and efficacy of the nicotine pMDI, and 
to assess its safety in a broader population. For example, tolerance to airway irritation may be 
improved by use of a lower nicotine dose per puff, and the provision of a wider range of 
nicotine doses may assist smokers to find the dose which provides them with the ideal 
therapeutic index.  The safety of the inhaler among asthmatics and people with Chronic 
Obstructive Pulmonary Disease would need to be evaluated in a larger sample.  Further 
research is needed to determine if re-treatment of smokers who relapse after using nicotine 
pMDI therapy, with the same therapy, is effective at salvaging them and helping them to 
become abstinent long-term.  Also, given that some subjects were informally observed by 
research staff during clinic visits, to have difficulty coordinating their inspiration with 
manually activating their inhalers, it may be worthwhile to discover a method of enabling the 
pMDI to be breath-activated. 
7.4.9 Conclusion 
This study has shown that a nicotine pMDI and patch combination therapy is a more effective 
treatment for smoking cessation than active nicotine patch plus placebo pMDI and could offer 
smokers a useful additional cessation modality.  The findings of this trial are consistent with 
other trials of rapid-acting NRT combined with slow-release transdermal nicotine delivery, 
which show this combination improves abstinence rates, and the sustained nicotine delivery 
from the patches does not lead to sufficient desensitisation of cerebral nicotine receptors to 
render them unresponsive to the nicotine from a rapid delivery device.  Cough is a common 
side-effect of inhaled nicotine, though most smokers rapidly develop tolerance to it.  
Tobacco smoking addiction is a global problem, remaining disproportionately prevalent 
among socio-economically deprived smokers and poorer nations. The nicotine pMDI is not 
protected by patent and could be readily manufactured inexpensively to help tackle smoking 
globally.  The results suggest that investment in further development and fulfilment of 
medicinal product regulatory requirements is warranted to make this treatment widely 





8 A comparison of the nicotine INHALE combination 
therapy trial and nicotine ZAP combination therapy trial 
8.1 Introduction 
This chapter compares the efficacy of the mouthspray and patch combination therapy, to that 
of the inhaler and patch combination, in assisting smokers to achieve prolonged six-months 
not smoked on seven consecutive days abstinence.   
Any differences in abstinence rates between these two trials may have been caused by any 
single or multiple pre- or post-randomisation differences between the two trials, and these 
differences may have been in the values of variables that were not measured.  Post-
randomisation differences may have been caused by the differences in the types of treatments 
in the two trials, and may explain the mechanisms by which the two treatments exerted their 
differential effects on abstinence, however post-randomisation differences may have been 
caused by societal differences and other temporal differences between the two trials. 
There are a range of potential differences between the trial in addition to the differences in 
their active and placebo treatments: 
1. Differences in characteristics of the subjects who chose to participate in the trials (such 
as FTND scores, CPD, differences in their ability to respond to treatment). 
2. Differences between the designs of the trials. 
3. Differences in the therapeutic efficacy of the active and control interventions. 
4. Differences in the research staff and the manner in which they treated subjects and 
recorded outcomes. 
5. Differences in the trial sites, which influence subjects’ ability to abstain from smoking. 
6. The temporal differences in when the trials were conducted may have had an effect on 
subjects’ ability to achieve prolonged abstinence, for example, there may have been 
effective smoking cessation public health interventions or, a change in social attitudes to 
smoking, after the mouthspray study was complete and before the end of the inhaler 
study. 





1. both used a combination of a rapid-acting NRT plus slow-acting nicotine patch therapy 
cf. placebo NRT plus nicotine patch therapy;  
2. both provided all subjects with six months of an active or placebo rapid-acting NRT; 
3. both provided all subjects active transdermal nicotine for five months; 
4. both had similar inclusion/exclusion criteria; 
5. they used similar methods of subject recruitment; 
6. some of the staff who interacted with subjects were the same in the two trials; 
7. up until the end of the inhaler study, six months after subjects’ target quit dates, with 
one exception (detailed below), subjects in the two trials received the same number and 
type of follow-ups (phone/clinic) and Appreciative Inquiry counselling up to six months 
after subjects’ target quit dates.  
It had initially been planned to employ very similar designs for both trials; however, a small 
number of changes were made to the study design of the inhaler trial, prior to its 
commencement.  The motivations for making these changes were two-fold, first was the need 
to save money due to delays in the manufacture of the inhalers; and secondly, lessons learned 
from the mouthspray study suggested changes that may increase subjects’ engagement with 
maintaining their efforts to quit, to remain abstinent, and to continue to use the inhalers and 
patches.  Research staff had informally noticed that, at the target quit phone-call in the 
mouthspray study, it was not uncommon for subjects to remark that they had reduced their 
smoking considerably but had not yet had a full twenty-four hours of not smoking.  This led 
me to hypothesize that if subjects were allowed four weeks of NRT-assisted smoking 
reduction prior to their target quit dates, instead of the three weeks supply that was given to 
subjects in the mouthspray trial, they may have better success.  Thus, four weeks of pre-
cessation NRT were provided in the inhaler study. 
Also, in an attempt to maintain subjects continued use of the inhalers and patches, an extra 
follow-up contact was added to the inhaler trial, one week after baseline, so that no more than 
a week would transpire after baseline before subjects were contacted by research staff who 
provided subjects with encouragement, Appreciative Inquiry, and advice about how to use 
their inhalers in an ideal manner to gain maximum therapeutic effect and minimise unwanted 
adverse effects.  In the mouthspray trial, subjects were not contacted until three weeks after 
their baseline visit, by which time they had been scheduled to have been abstinent for at least 




stopped using their mouthsprays and patches by this time because, they found the 
mouthsprays to be aversive and did not adequately quench their urge to smoke; but, they had 
not been using their mouthsprays in a way that would minimise unwanted effects and 
maximise rewarding effects.  It was hypothesized that if subjects’ sub-optimal manner of 
using their inhalers could be corrected within a week rather than three weeks after they began 
the trial, this would lead to greater use of the inhalers and higher abstinence rates.  A further 
distinction between the two trials was that the mouthspray trial followed subjects for twelve 
months after their target quit dates, while the inhaler trial followed subjects for half that time. 
After considering the aforementioned differences between the trials, it was concluded that the 
differences between the two trials was likely to be insufficient for it to compete with the 
difference in efficacy of the different rapid-acting NRTs, as an explanation for why the 
abstinence rates the active cf. control groups were different between the trials.  The validity of 
the judgement that heterogeneity between the trials was minimal can be tested by comparing 
the abstinence rates in the control groups of the two trials because, apart from the potential for 
the placebo mouthspray to have a different efficacy to the placebo inhalers, any difference in 
abstinence rates between the control groups of the two trials would be due to the differences 
in trial designs and the way they were conducted.  Therefore, lack of a significant difference 
in abstinence rates between the control groups of the trials would indicate that there was no 
difference in the effects on abstinence of the different types of placebo treatments nor the 
different trial designs or differences in the way they were conducted.  Meta-analysis of the 
two trials provides an objective measure of whether there was statistically significant 
heterogeneity between the trials. 
Below, the results of the two trials are compared, and potential explanations for any 
differences in abstinence rates between the inhaler study are identified, by use of formal 
statistical tests.  Meta-analyses were conducted to compare the INHALE and ZAP trials with 
each other and with the results of other trials of NRT plus nicotine patch combination therapy. 
8.2 Methods 
The values of variables collected at baseline before and after randomisation, and variables 
collected a month after subjects’ target quit dates, were compared between the two trials, to 
determine if the values were significantly different between the trials, and may therefore be 
responsible for any differences in abstinence rates between the trials.  In order to account for 
the possibility that the values of these variables, may differ according to whether subjects had 




were abstinent or not, a series of comparisons were made between the trials based on the 
comparison of:  
1. baseline subject characteristics; 
2. subjects assigned to the active rapid-acting NRT treatments versus subjects who were 
assigned to the placebo rapid-acting NRT treatments; 
3. subjects who were abstinent versus those who were not; 
4. subjects who were assigned to the active rapid-acting NRT treatments who were 
abstinent versus those who were not abstinent; 
5. subjects who were assigned to the placebo rapid-acting NRT treatments who were 
abstinent versus those who were not abstinent. 
The values of five variables recorded before randomisation were compared between trials 
(Gender, Māori ethnicity, Age, CPD, FTND) and five variables recorded at baseline after 
randomisation (the five CEQ scales).  The values of eleven variables recorded a month after 
subjects’ target quit dates were compared between trials (the five CEQ scales, brief-QSU total 
scores, and the five scales of the MNWS), Bonferroni correction for twenty-one comparisons 
would require p<0.05/21=0.0024. 
The version of the MNWS used in these two trials consisted of nine items which make up five 
scales,(413) two of the scales are the average (or sum) of several items (the Negative Affect 
scale, and Insomnia scale), while three scales are composed of the scores of one item each.  
The authors of the MNWS state that the scores of scales can be the sum or the average of the 
scores of the items that comprise the scales,(414) here, the average has been used.  Some 
researchers have taken a different approach by summing all items to gain a single total score, 
which has been shown to predict abstinence and nicotine substitution with NRT, however this 
approach may obscure changes in individual withdrawal symptoms, therefore it is 
recommended to report individual symptoms or clusters of symptoms (such as the five 
scales).(126)   
Meta-analyses of the abstinence rates in the ZAP and INHALE trials along with published 
trials of nicotine patch plus other NRT were conducted using the “rmeta” package of the R 
language, based on trials identified by the Medline search strategy of the systematic literature 




8.3 Results  
8.3.1 Subjects 
Subjects were similar between trials at baseline, with no significant differences after 
Bonferroni correction (p<0.05/5=0.01, Table 8.1, page 289). 
8.3.2 Abstinence 
Self-reported biochemically unverified six months prolonged not smoked on seven 
consecutive days abstinence was achieved by 111/716 (15.50%) and 75/707 (10.61%) 
subjects in the active and control groups, respectively, in the ZAP trial, and by 78/246 
(31.71%) and 46/256 (17.97%) subjects in the active and control groups, respectively, in the 
INHALE study.  The OR for this abstinence outcome in the active cf. control groups of the 
two trials was 1.55, 95%CI=1.13—2.12, p=0.006 in the mouthspray trial, and 2.12, 95%CI= 
1.40–3.23, p<0.001 in INHALE.  The OR for prolonged abstinence with active cf. placebo 
mouthspray, is within the 95%CI of the OR for prolonged abstinence with active cf. placebo 
inhaler, and the OR for prolonged abstinence with active cf. placebo inhaler is equal to the 
upper limit of the 95%CI for the OR for prolonged abstinence with active cf. placebo 
mouthspray, suggesting that there was not a statistically significant difference between the 
ORs between the two trials. 
The abstinence rate in the active group of the INHALE study was significantly higher than the 
abstinence rate for the active group in the ZAP trials 78/246 (31.71%) cf. 111/716 (15.50%), a 
difference of 31.71%-15.50%=16.21%, 95%CI:9.54%—22.87%, p=6x10-8.  Likewise, the 
six-months prolonged abstinence rates were significantly higher in the control group of the 
INHALE study cf. ZAP (46/256 (17.97%) cf. 75/707 (10.61%), a difference of 17.97-
10.61=7.36% 95%CI: 2.14% to 12.58%, p=0.0023.  However, it is not appropriate to compare 
the efficacies of treatments between trials by comparing the active groups, without reference 
to the control groups, instead, meta-analysis should be used because, meta-analyses compare 
the odds ratios of treatment effects in the active/control groups of each trial, thereby taking 
account of the effect of each active treatment in comparison with the effects of that 
treatment’s corresponding control treatment.  Meta-analysis compared ORs, which ensures 





Table 8.1 Baseline pre-randomisation subject characteristics between the mouthspray and inhaler trials 
 















FTND 6 6.13 5 7 1423 6 6.17 5 7 502 0.7094 
Age 46 45.46 38 54 1416 46 45.1 37 53 502 0.5531 




cf. trials Yes No n %  Yes No n %  
Maori 216 1199 1415 15.27  57 445 502 11.35  0.0312 
Male 659 762 1421 46.38  247 254 501 49.3  0.2593 







Several meta-analyses were performed to achieve two purposes: 
1. to compare the odds ratio for prolonged six-months not smoked on seven consecutive 
days abstinence in the two RCTs in a manner which takes into account the comparison 
of abstinence in both the active and control groups of each trial, and  
2. in order to compare these results with those of published trials of other combinations 
of nicotine patches plus NRT. 
A meta-analysis of trials of nicotine patch plus NRT cf. nicotine patch monotherapy, whose 
results were published prior to the conducts of the mouthspray study and which were 
identified by a systematic review of the literature performed by me, calculated that these 
combinations were significantly more effective than patch monotherapy or patch plus placebo 
(Figure 8.1).  Fixed effects Mantel-Haenszel meta-analysis calculated that the odds ratio for 
prolonged six months abstinence with patch plus NRT cf. patch monotherapy 
 
Figure 8.1 Meta-analysis of trials of nicotine patch plus other NRT published prior to 
the conduct of the mouthspray trial 
 
was OR=1.46, 95%CI:1.18—1.81.  The addition of the results of the mouthspray study to this 
meta-analysis, strengthened the OR for combination therapy from OR=1.46 to OR=1.49, 
95%CI:1.25—1.77, there was no evidence of heterogeneity after the mouthspray data were 






Figure 8.2 Meta-analysis of trials of nicotine patch plus other NRT published prior to 
the conduct of the mouthspray trial plus the results of the mouthspray trial 
 
The addition of the results of the inhaler trial to the meta-analysis further increased the OR for 
combination therapy to OR=1.57, 95%CI:1.34—1.85 (Table 8.2, Figure 8.3 page 292).  There 
was no evidence of heterogeneity after the inhaler data were added to the meta-analysis 
(Χ2=7.48, p=0.28).  In all trials in the meta-analysis, the 95%CI for the treatment effect of 
combination therapy in each trial overlapped the 95%CI of one or more of the therapies in the 
other trials, hence there was no definitive evidence that one therapy was more effective than 
another.   
 
Table 8.2 Meta-analysis of nicotine inhaler (pMDI) and patch trial, nicotine ZAP trial, 
and NRT plus patch trials published prior to the mouthspray trial 
Study OR Lwr95%CI Upr95%CI 
Croghan GA 1.18 0.74 1.87 
Blondal T 2.40 1.29 4.50 
Smith SS 1.71 1.14 2.56 
Piper ME 1.22 0.86 1.74 
Cooney NL 1.88 0.61 5.76 
Mouthspray 1.55 1.13 2.12 
pMDI  2.12 1.40 3.22 
Mantel-Haenszel 
meta-analysis 






Figure 8.3 Meta-analysis of trials of nicotine patch plus other NRT published prior to 
the conduct of the mouthspray trial plus the results of the mouthspray and pMDI trials 
 
The p-value for the comparison of the treatment effects of the inhaler and mouthspray study 
was calculated, in a series of steps, from the confidence intervals of the treatment effects in 
the two trials,(415) this calculated that p=0.24, indicating that the treatment effects were not 
statistically significantly different from each other. 
The meta-analysis, conducted by me, of trials of NRT in combination with nicotine patch 
therapy, whose results were published prior to the conduct of the mouthspray study, 
calculated that the odds ratio for prolonged six months abstinence with patch plus NRT cf. 
patch monotherapy was OR=1.46, 95%CI:1.18—1.81.  In this meta-analysis the Absolute 
Risk (AR) in the control (patch monotherapy) groups was (1173-201)/1173=0.83; and in the 
active (patch plus NRT) groups was (1171-267)/1171=0.77; hence the Absolute Risk 
Reduction (ARR) was ((1173-201)/1173)-((1171-267)/1171)=0.0567, and the 
NNT=1/(((1173-201)/1173)-((1171-267)/1171))=17.65.  Therefore, compared to the NNT 
calculated by this meta-analysis of NRT plus nicotine patch therapy, the NNT with 
mouthspray plus patch is (20.43-17.65)/17.65*100= 15.75% higher; while the NNT with 




8.3.2.1 Reasons for higher abstinence with active inhalers plus patch cf. active 
mouthspray plus patch 
8.3.2.1.1 Differences in subjects’ characteristics between trial 
As mentioned previously, there were no significant differences after Bonferroni correction for 
five comparisons of subjects’ baseline characteristics between trials: FTND scores, ages, 
gender, CPD, and the proportion who were of Māori ethnicity (Table 8.1, page 289)).   
8.3.2.1.2 Differences in baseline Cigarette Evaluation Questionnaire scores  
One possible mechanism by which active INHALE therapy led to higher abstinence rates cf. 
active ZAP would be if there was a greater liking of the sensory qualities of the inhaler cf. 
mouthspray, and if this greater liking of the sensory qualities translated into higher abstinence 
rates (such as by motivating subjects to use the inhalers more often than subjects used the 
mouthspray).  The sensory qualities of the inhalers and mouthspray were measured in both 
trials at baseline and again a month after subject’ target quit dates, using the modified 
Cigarette Evaluation Questionnaire, which has five scales: Smoking Satisfaction, 
Psychological Reward, Enjoyment of Respiratory Tract Sensations, Craving Reduction, and 
Aversion.   
At baseline there were eight statistically significant differences in CEQ scores between the 
RCTs (Table 8.3, page 295).  At baseline, the active inhaler treatment group had higher scores 
than the active mouthspray treatment group for:  
1. Psychological Reward. 
2. Immediate Craving Reduction. 
3. Aversion. 
Of these three differences between trials, neither Psychological Reward nor Aversion were 
significantly predictive of abstinence in either RCT, hence the differences in their scores 
between the trials are unlikely to explain the higher treatment effect with the inhalers cf. 
mouthsprays.  However, the significantly higher Immediate Craving Reduction scores for 
active inhalers cf. active mouthsprays, may explain the differential efficacy of the therapies in 
the two RCTs because, they were significantly predictive of abstinence in the inhaler trial. 
At baseline, the placebo inhaler treatment group scored higher than the placebo mouthspray 
for: 




2. Enjoyment of Respiratory Tract Sensations. 
3. Immediate Craving Reduction. 
4. Aversion. 
Of these four differences between RCTs, only ‘Immediate Craving Reduction’ was 
significantly predictive of abstinence in either of the RCTs.   
At baseline, the active mouthspray treatment group did not score higher than the active inhaler 
treatment group for any of the CEQ sub-scales. 
At baseline, the placebo inhaler treatment group scored higher than the placebo mouthspray 
treatment group for: 
1. Smoking Satisfaction (which was significantly predictive of abstinence in the ZAP but 
not INHALE trials).   
8.3.2.1.3 Differences one month after target quit date 
The values of variables measured a month after subjects’ target quit dates were compared 
between the mouthspray and inhaler trials, and between subjects who were abstinent and 
those who were not, in order to determine which variables were associated with subjects’ 
achievement of abstinence and whether the mouthsprays or inhalers were significantly better 
at modifying the values of those variables.   
 This was explored a month after subjects’ target quit dates because, at that stage subjects had 
a month of experiencing what it was like to attempt to quit and the extent to which their 
assigned treatment assisted them to abstain from smoking.  Table 8.4 (page 297) reports the 
results of these analyses, showing only the analyses for variables that were significantly 
different (p<0.05) between trials.  Table 8.4 also reports whether each variable significantly 
predicted abstinence in each trial; since, in order to potentially be responsible for the 
difference in abstinence between trials, the values of the variable must be both, significantly 
different between trials, and significant predictive of abstinence in at least one trial.  The 





Table 8.3 Variables measured at baseline after randomisation that were significantly different between the two RCTs at p<0.05. 
# Variable Comparison, median, mean (Interquartile range). 
(comparisons are displayed from most to least 
statistically significant difference in values of variables 















1 Immediate Craving Reduction Placebo inhalers had significantly higher immediate Craving 
Reduction scores cf. placebo mouthsprays (3.00, 3.66, 
(3.00—5.00) cf. 2.00, 2.52, (1.00—4.00)). 
2x10-16 0.5893 0.0151 
2 Aversion Aversion scores were significantly higher for placebo inhalers 
cf. placebo mouthsprays (1.00, 1.36, (1.000—2.00) cf. 1.00, 
1.15, (1.00—1.00)). 
2x10-16 0.4920 0.3950 
3 Aversion Aversion scores were significantly higher for active inhalers 
cf. active mouthsprays (1.50, 1.62, (1.00—2.00) cf. 1.00, 
1.40, (1.00—1.50)). 
8x10-11 0.4920 0.3950 
4 Psychological Reward Baseline Psychological Reward scores were significantly 
higher for the placebo inhalers cf. placebo mouthsprays 
(2.20, 2.41, (1.40—3.05 cf. 1.60, 2.12, (1.00—2.80)). 
7x10-6 0.4396 0.5341 
5 Immediate Craving Reduction Active inhalers had significantly higher immediate Craving 
Reduction scores cf. active mouthspray (4.00, 3.88, (3.00—
5.00) cf. 3.00, 2.86, (1.00—4.00)). 
4x10-5 0.5893 0.0151 
6 Psychological Reward Baseline Psychological Reward scores were significantly 
higher for the active inhalers cf. active mouthsprays (median, 
mean, (IQR) 2.20, 2.48, (1.40—3.20) cf. 1.80, 2.18, (1.00—
3.00)). 
7x10-5 0.4396 0.5341 
7 Enjoyment of Respiratory Tract 
Sensations 
Enjoyment of Respiratory Tract Sensations scores were 
significantly higher for the placebo inhalers than placebo 
mouthsprays (4.00, 3.64, (3.00—5.00), cf. 3.00, 3.22, (1.00—
5.00)). 




# Variable Comparison, median, mean (Interquartile range). 
(comparisons are displayed from most to least 
statistically significant difference in values of variables 















8 Smoking Satisfaction Baseline Smoking Satisfaction scores were significantly 
higher for the placebo inhaler cf. placebo mouthspray (4.33, 
4.50, (3.67—5.33) cf. 4.00, 4.13, (3.00—5.33)) 
0.0012 0.0204 0.3578 
* p-value for the value of the variable amongst abstinent subjects cf. subjects who were not abstinent (Mann-Whitney test), prolonged six-months not smoked on 






Table 8.4 Variables measured a month after subjects' target quit dates that were significantly different between the two RCTs at p<0.05, 
median, mean, (IQR), p-value. 
# Variable† Comparison between trials Comparison abstinent cf. not 
abstinent mouthspray trial †† 
Comparison abstinent cf. not abstinent 
inhaler trial†† 










cf. -40.45%, -29.00% 
(-58.33%— -10.22%). 
1x10-13 -33.33, -29.68, 
(-60.00— -12.50) 
cf. -35.71, -25.82, 
(-54.85— -8.33) 
0.1347 -70.25%, -60.41%, 
(-78.78%— -53.18%) 












cf. -30.33%, -24.46% 
(-50.46%— -7.92%). 
2x10-11 -33.33, -29.68, 
(-60.00— -12.50) 
cf. -35.71, -25.82, 
(-54.85— -8.33) 
0.1347 -70.25%, -60.41%, 
(-78.78%— -53.18%) 






Placebo inhalers cf. 
placebo mouthsprays 4.00, 
4.16 (3.33—5.00) cf. 3.33, 
3.49 (2.00—4.67). 
2x10-6 3.57, 3.68, (2.33—
5.00) cf. 3.00, 3.32, 
(2.00—4.33) 







Subjects in the active 
groups who achieved 
prolonged one-month 
abstinence in the 
mouthspray cf. inhaler 
studies 1.00, 1.29, (0—
2.00) cf. 0, 0.68, (0—1.00). 
1x10-5 1.00, 1.36, (0—2.00) 
cf. 1.00, 1.12, (0—
2.00) 






# Variable† Comparison between trials Comparison abstinent cf. not 
abstinent mouthspray trial †† 
Comparison abstinent cf. not abstinent 
inhaler trial†† 





Subjects in control 
conditions who failed to 
achieve prolonged one-
month abstinence֍ in the 
mouthspray cf. inhaler trials 
1.00, 0.99, (0—2.00) cf. 0, 
1.00, (0—1.00). 
0.0005 0.50, 0.89, (0—2.00) 












Active inhalers cf. active 
mouthspray 3.67, 3.81 
(2.67—4.67) cf. 3.33, 3.36 
(2.00—4.67). 
0.0016 4.33, 4.25, (3.33—
5.67) cf. 4.00, 3.99, 
(3.00—5.00) 







Placebo inhalers cf. 
placebo mouthsprays 3.00, 
2.89, (1.00—4.00), cf. 1.00, 
2.47, (1.00—4.00). 
0.0022 2.00, 2.58, (1.00—
4.00) cf. 1.00, 2.20, 
(1.00—3.00) 







Active inhalers cf. active 
mouthsprays 5.00, 4.49 
(3.75—6.00) cf. 4.00, 3.96 
(2.00—6.00). 
0.0043 4.00, 4.02, (3.00—
6.00) cf. 4.00, 3.75, 
(2.00—5.00) 







Craving reduction scores 
for placebo inhalers cf. 
placebo mouthsprays (4.00, 
4.06 (3.00—6.00) cf. 4.00, 
3.66, (2.00—5.00). 
0.0210 4.00, 4.02, (3.00—
6.00) cf. 4.00, 3.75, 
(2.00—5.00) 






# Variable† Comparison between trials Comparison abstinent cf. not 
abstinent mouthspray trial †† 
Comparison abstinent cf. not abstinent 
inhaler trial†† 




Subjects in the active 
groups who achieved one-
month prolonged 
abstinence֍, in the 
mouthspray cf. inhaler 
study 0.50, 0.85, (0—1.50) 
cf. 0, 0.57, (0—1.00). 
0.0233 0.50, 0.73, (0—1.00) 
cf. 0.50, 0.98, (0—
1.50) 
0.0369 0.50, 0.61, (0—1.00) cf. 0.50, 
0.81, (0—1.50) 
0.1566 
† rows are ordered from most to least statistically significant difference in the variables’ values in one trial cf. the other.  †† prolonged six months not smoked on 







A month after subjects’ target quit dates, subjects in the active groups, had higher scores in 
INHALE cf. ZAP for: 
1. Percent reduction in total QSU cf. baseline. (Predictive of abstinence in INHALE) 
2. Smoking Satisfaction. (Predictive of abstinence in ZAP and INHALE) 
3. Immediate Craving Reduction (Predictive of abstinence in INHALE) 
A month after subjects’ target quit dates subjects assigned to the placebo conditions had 
higher scores in INHALE cf. ZAP for: 
1. Smoking Satisfaction  
2. Percent reduction in total QSU cf. baseline. 
3. CEQ-Enjoy Respiratory Sensations scores. (Predictive of abstinence in ZAP) 
4. Immediate Craving reduction scores. 
A month after subjects’ target quit dates, subjects assigned to the active groups who were 
abstinent had higher scores in ZAP cf. INHALE for: 
1. MNWS-Increased-Appetite (predictive of abstinence in ZAP and INHALE). 
2. MNWS-Insomnia scores (predictive of abstinence in ZAP). 
A month after subjects’ target quit dates, subjects who were assigned to the placebo 
mouthspray who were not abstinent, had higher scores than subjects assigned to placebo 
inhalers who were not abstinent, for: 
1. MNWS-Increased-Appetite 
8.3.2.1.4 Greater use of active rapid-acting nicotine preparation 
A further potential explanation for why abstinence in the active group of the inhaler trial was 
higher than in the active group of the mouthspray trial, would be if subjects in the former trial 
used their rapid-acting NRT on more days than subjects in the mouthspray study.  Given that 
relapse was highest early on in both trials, the use of the rapid-acting NRTs reported at the 
telephone-call a day after the target quit date, might be expected to have an important bearing 
on quit success.  However, as the paragraph below reveals, there was no evidence of a 
difference between the number of days subjects used their rapid-acting NRTs between 




At the phone-call a day after subjects’ target quit dates, in the ZAP trial, subjects reported the 
number of days they used the mouthspray on a Likert scale from 1=Never, 2=Hardly ever, 
3=Some days, 4=Most days, 5=Every day.  There were no significant differences in the 
number of days subjects reported using their mouthspray at the quit phone-call between 
treatment groups, the median, mean, (IQR) scores were 5.00, 4.03, (3.00—5.00) and 5.00, 
4.05, (3.00—5.00) in the active and control groups, respectively.  A similar result was 
observed in the inhaler trial in which subjects reported the number of days they had used the 
inhalers, which were median, mean, (IQR) 21.00, 18.53, (17.00—21.00) and 21.00, 18.45, 
(16.00—21.00), p=0.68 in the active and control groups, respectively.  Given that almost all 
subjects’ target quit phone-calls were twenty-eight days after baseline in the inhaler trial, the 
median score in both treatment groups in the inhaler trial of twenty-one, is slightly lower than 
the median score of 5=Every day of the Likert scale used in the mouthspray trial.  However, 
the mean score (as opposed to the median score) in the inhaler study which was close to 18.50 
days in both active and placebo inhaler groups, which is 18.50/28*100=66.07% which may be 
considered equivalent to the mean score of four (Most days) in the mouthspray study.  The 
differences between the scales used to measure adherence to the rapid-acting NRT in these 
two trials precludes the use of formal statistical techniques to determine if their values were 
significantly different between trials.  
8.3.2.1.5 Correction for multiple comparisons 
A large number of statistical comparisons were made to identify variables that may explain 
the mechanisms by which the active inhalers caused higher abstinence rates than the active 
mouthsprays.  The number of comparisons between post-randomisation variables was: 
1. five CEQ scales measured at two time-points (ten comparisons), plus 
2. days used active rapid-acting NRT (one comparison), plus 
3. the percent reductions of QSU-total scores a month after subjects’ target quit dates cf. 
baseline (one comparison), plus 
4. five MNWS sub-scales were compared between four groups of subjects (active/control 
group and abstinent/not-abstinent) (twenty comparisons). 
Thus, a total of thirty-two comparisons were made, requiring Bonferroni correction of 
0.05/32=0.00156, a level of significance met by all of the comparisons between post-




which were scores of CEQ sub-scales, Table 8.3, page 295), and five of the eight comparisons 
measured a month after subjects’ target quit dates (Table 8.4, page 297). 
Of the eight variables recorded at baseline after randomisation (Table 8.4), whose values were 
significantly different between the two RCTs, all were significant after Bonferroni correction; 
• none were also significantly different between subjects who achieved prolonged six-
months abstinence, and those who did not, in both trials; 
• one was also significantly different between subjects who achieved prolonged six-
months abstinence, and those who did not, in the mouthspray but not the inhaler trial  
o Smoking Satisfaction scores; 
• one also significantly different between subjects who achieved prolonged six-months 
abstinence, and those who did not, in the inhaler but not the mouthspray trial 
o immediate Craving Reduction;  
• three were not significantly different between subjects who achieved prolonged six-
months abstinence, and those who did not, in either the inhaler nor the mouthspray 
trial 
o Aversion scores;  
o Psychological Reward scores; 
o Enjoyment of Respiratory Tract Sensations scores. 
The post-randomisation variable, recorded a month after subjects’ target quit dates, whose 
value was the most significantly different, and the second-most different, between the 
mouthspray and inhalers studies was the percent change in QSU-total scores a month after 
subjects’ target quit dates cf. baseline, in which there was a significantly greater reduction 
with active inhaler cf. active mouthspray treatment (Table 8.4, page 297).  Although the 
percent change QSU-total scores a month after subjects’ target quit dates, was not a 
significant predictor of prolonged six months not smoked on seven consecutive days 
abstinence in the mouthspray study, it was a highly significant predictor of prolonged 
abstinence in the inhaler trial (Table 8.4). 
The third-most significant post-randomisation difference between trials was that placebo 
inhalers received significantly higher Smoking Satisfaction scores cf. placebo mouthsprays.  
Smoking Satisfaction scores a month after subjects’ target quit dates were also predictive of 




median Smoking Satisfaction score for subjects who were abstinent was 3.57/3.00=1.19 times 
higher amongst subjects who were abstinent cf. not abstinent, p=0.0119.  In the inhaler study, 
the median Smoking Satisfaction score was 4.67/3.67=1.27 times higher amongst subjects 
who were abstinent cf. not abstinent, p=0.00019. 
The fourth and fifth most statistically significant differences between the RCTs, was the 
scores of MNWS-Increased-Appetite, which were significant predictors of six-months 
prolonged abstinence in both RCTs.  Subjects in the active groups who achieved prolonged 
one-month abstinence in the mouthspray study had significantly higher MNWS-Increased-
Appetite scores a month after their target quit dates in the mouthspray cf. inhaler study 
(medians 1 cf. 0, p=1x10-5, (Table 8.4, page 297).  The sixth most significant difference 
between trials was the scores of CEQ-Smoking Satisfaction, specifically, these scores were 
significantly higher for the active inhalers cf. active mouthspray (medians 3.67 cf. 2.67, 
p=0.0016), the unrounded p-value for this comparison was 0.001586, indicating that the sixth 
most significant comparison was not significant after Bonferroni correction for thirty-two 
comparisons. 
The seventh most statistically significant difference between trials was CEQ-Enjoyment-of-
Respiratory-Sensations for the mouthspray cf. inhaler.  The eighth most significant difference 
between trials was the scores of Immediate Craving Reduction, which were 5.00/4.00=1.25, 
p=0.0043 time higher a month after subjects’ target quit dates for subjects using the active 
inhalers cf. active mouthsprays, and although in the mouthspray study immediate craving 
reduction scores did not significantly differ between subjects who later achieved prolonged 
six-months not smoked on seven consecutive days cf. those who did not, in the inhaler study, 
median immediate craving reduction scores were 5.00/4.00=1.25, p=9x10-7 times higher 
among subjects who attained prolonged abstinence cf. those who did not. 
Subject retention six-months after their target quit dates, was significantly (p=2x10—16) higher 
in both groups in the inhaler trial cf. the corresponding groups in ZAP (158/246=64.23%, and 
154/716 (21.51%) in the active groups of INHALE cf. ZAP; and 154/256=60.16% and 
123/707=17.40% in the control groups of INHALE cf. ZAP.    
8.4 Discussion  
This chapter reports meta-analyses that compared the prolonged six-months abstinence rates 
produced by a range of rapid-acting NRTs used in combination with nicotine patches, to the 




These meta-analyses demonstrate that the odds ratio for abstinence rates with combination 
therapy in the ZAP trial, were similar in magnitude to those of previously published trials of 
combination therapy, while the odds ratio for abstinence with combination therapy in the 
inhaler trial was the second highest of all other therapies in the meta-analysis, the highest 
being for the study of nasal spray and patch combination therapy by Blondal and colleagues.  
The inhaler plus patch combination engendered non-significantly higher abstinence rates than 
the mouthsprays plus patch combination however, the studies were underpowered to find 
whether this superiority was statistically significant. 
It is not possible to conclude, without a doubt, that the statistically insignificant higher odds 
ratio for abstinence with active combination therapy cf. placebo combination therapy in the 
inhaler cf. mouthspray trials were the result of the active inhalers being more effective than 
the active mouthsprays because: 
1. subjects were not randomised to either participate in the mouthspray trial or the 
inhaler trial and as a result, baseline subjects characteristics that influence subjects’ 
ability to quit and remain abstinent, that were not measured, may be unequally 
distributed between the trials and may therefore be the true cause of the differential 
abstinence rates between the trials; 
2. the follow-up and study design in the two trials was not exactly the same (as 
mentioned earlier, there was an extra phone-call a week after baseline in the inhaler 
trial and an extra week of pre-cessation NRT was provided in the inhaler trial 
however, Appreciative Inquiry and nicotine patch therapy was provided in both 
trials); 
3. the populations from whence the subjects in each trial came, were not completely the 
same. 
The difference in the odds ratios for abstinence in the two trials was not statistically 
significant, and a larger sample size would be required to find a significant difference in 
prolonged abstinence between the two trials.   
The values of five post-randomisation variables differed significantly between trials after 
Bonferroni correction (Table 8.4, page 297), and although not all were predictive of 
prolonged abstinence, some were and may therefore account for the difference in abstinence 




between trials was a greater reduction in urges to smoke (QSU-total scores) a month after 
subjects’ target quit dates in the inhaler trial for both the active and placebo groups cf. the 
equivalent groups in the mouthspray study.  The greater reduction in QSU-total scores in the 
inhaler trial may be the result of the pMDI plus patch being more effective at reducing urges 
to smoke than the mouthspray combination or, it may be because a greater proportion of 
subjects in the inhaler study were abstinent, and because smokers who have been abstinent for 
a sufficiently long period of time have less severe urges to smoke than smokers who continue 
to smoker,(416) hence the reduced urges in the INHALE trial may be been caused by the 
greater abstinence in that trial rather than the inhalers in that trial.  However, it is not 
necessarily always the case that prolonged abstinence lowers urge scores because, smokers 
who achieved prolonged six-months abstinence in the mouthspray study did not have 
significantly lower QSU-total scores a month after their target quit dates compared to subjects 
who failed to achieve prolonged abstinence (Table 8.4, page 297).  This suggests that the 
combination of inhaler and patch therapy may better supressed the urge to smoke cf. the 
mouthspray and patch combination therapy, and may be responsible, in part, for the lower 
relapse rate in the inhaler cf. mouthspray trial. 
Smoking Satisfaction scores that subjects awarded their mouthsprays and inhalers, a month 
after subjects’ target quit dates, were predictive of higher abstinence.  Smoking Satisfaction 
scores were the third most statistically significant difference between the mouthspray and 
inhaler trials, Smoking Satisfaction scores were highly statistically significantly greater for 
the active and placebo inhalers cf. active and placebo mouthsprays, respectively, a month 
after subjects’ target quit dates.  In both the mouthspray and inhaler studies, Smoking 
Satisfaction scores a month after subjects’ target quit dates significantly predicted prolonged 
six-months abstinence (p=0.0119, and p=0.00019, respectively, Table 8.4, page 297).  
Reverse causation is unlikely because the Smoking Satisfaction scores were measured before 
the outcome of six-months prolonged abstinence was determined in ZAP, and only two-weeks 
after the end of the grace period in INHALE.   
One of the most statistically significant differences between INHALE and ZAP, was the 
higher rate of subject retention in INHALE.  Although the studies were underpowered to 
compare the odds ratio of abstinence with active versus control inhaler therapy to the odds 
ratio of abstinence with active versus control mouthspray therapy, it was possible to 
demonstrate the active and placebo inhalers inspired significantly more subjects to remain in 
the trial cf. the mouthsprays.  The higher retention rate in INHALE cf. ZAP is consistent with 




corresponding group in ZAP.  The greater retention and abstinence rates between the trials 
may be the result of a number of differences between the trials, such as the number and type 
of trial sites, and the capacity for reward from the respiratory stimulations of active and 
placebo inhalers cf. non-respiratory oral stimuli of the active and placebo mouthsprays. 
The traditional conceptualisation of the smoking addiction emphasised the role of withdrawal 
symptoms in motivating lapses to smoking, and the negative reinforcement that smoking 
provides by the relief of withdrawal symptoms when smokers attempting to quit lapse to 
smoking after a period of abstinence.  Hence, the traditional approach to treatment of the 
smoking addiction, has focussed on nicotine delivery devices that ameliorate withdrawal 
symptoms and limit abuse liability by the slow delivery of medicinal nicotine.(11)  This 
pharmacokinetic profile for NRT has been shown to be ineffective in suppressing urges to 
smoke in response to conditioned cues to smoke such as advertising,(202) and the greater 
reduction in urges in the inhaler study cf. mouthspray study was the first and second most 
significant differences between the RCTs, suggesting that the more rapid delivery of nicotine 
by the inhalers was responsible for the higher abstinence rates in the active groups of the 
inhaler cf. mouthspray studies.  This is consistent with research that has shown that among 
conventional NRTs, those that deliver nicotine more rapidly have the biggest effect on 
assuaging urges to smoke.(226)  The slower pharmacokinetic profile of the nicotine 
mouthspray cf. inhaler, may be responsible for why Immediate Craving Reduction scores 
were significantly greater for the active inhalers cf. active mouthsprays, and why these scores 
were predictive of abstinence in the inhaler but not mouthspray trials.   
Although these trials focussed on the provision of positive reinforcement by the rapid delivery 
of nicotine to the brain, withdrawal symptoms played a substantial role in motivating subjects 
return to smoking.  In ZAP, withdrawal measured by the MNWS, predicted lower abstinence 
but were not significantly different between treatment groups, furthermore when prolonged 
six-month abstinence was regressed on treatment assignment and MNWS scores, the 
interaction between treatment and craving was not significant, demonstrating that withdrawal 
symptoms had a similar effect in both treatment groups of the mouthspray trial.  Likewise, in 
INHALE, MNWS scores were predictive of lower abstinence in both active and control 
groups.  More effective methods are required to mitigate withdrawal symptoms, particularly 
the Craving subscale, such as encouraging smokers to use the pMDI more often, use of a 





Many of the scales constructed by me, and the brief-WISDM, were only administered in the 
mouthspray study not the inhaler study.  This precludes any comparison of them between 
trials and confirmation of the psychometric properties that they demonstrated in the 
mouthspray trial.  Moreover, it also prevents the scales that were based on the loadings of 
variables onto the principal components of variables in the mouthspray study from being 
tested in the inhaler trial to confirm their ability to predict abstinence.   
Some variables recorded prior to randomisation were predictive of prolonged abstinence in 
the mouthspray study (particularly the Tolerance and Social/Environmental Goads scales of 
the brief-WISDM) but, in the inhaler trial no variables recorded prior to randomisation were 
predictive of prolonged abstinence after Bonferroni correction.  The fact that no variables 
recorded prior to randomisation were predictive of prolonged abstinence in the INHALE 
study after Bonferroni correction, but some were predictive in the ZAP study, may indicate 
that the active inhalers were more effective than the active mouthsprays at ameliorating the 
effects of characteristics associated with relapse (such as FTND scores).  Alternatively, this 
difference between the trials may be the result of fewer variables having been recorded in the 
INHALE study or, the larger sample size of ZAP cf. INHALE enabling smaller effect sizes to 
be statistically significant. 
Although the abstinence rate in the active group of the inhaler trial was significantly higher 
than the abstinence rate in the active group of the mouthspray trial, meta-analysis 
demonstrated that the odds ratio of abstinence in the active cf. control groups, within each 
study, were not significantly different between the two trials.  The sample size required to 
detect a significant difference between the odds ratios in the two trials is large.  Analysis 
using the “rmeta” package of the R language calculated that, if the sample size of both trials 
were increased one-and-a-half times, the OR for prolonged abstinence with active treatment in 
the inhaler trial would no longer be within the 95%CI of the OR in mouthspray trial however, 
the OR for the mouthspray trial would be within the 95%CI of the inhaler study (OR=2.12, 
95%CI:1.51—2.98, cf. OR=1.55, 95%CI:1.20—2.00).  If the sample size of both trials were 
doubled, the OR for the inhaler trial would not be within the 95%CI of the OR in mouthspray 
trial and the OR for the mouthspray study would not be within the 95%CI of the inhaler study, 
and the OR for the mouthspray study would not be outside the 95%CI for INHALE 
(OR=2.12, 95%CI:1.58—2.85, cf. OR=1.55, 95%CI:1.24—1.93). 
The formal analyses of the differences between the mouthspray and inhaler trials have shown 




groups of these two trials, is that the active inhalers were more effective than the active 
mouthsprays, and that the mechanism of the INHALE combination’s superior efficacy 
involved larger reductions of subjects’ urges to smoke between baseline and two months later, 
higher Smoking Satisfaction scores at that time, and lower MNWS-Increased-Appetite scores 
for smokers who attained one-month prolonged abstinence.   
The studies undertaken for this dissertation have shown that two combination therapies which 
combine a rapid-delivery of nicotine (one via a mouthspray, one via a pMDI) with slow-
delivery of nicotine via a transdermal patch, statistically significantly increase prolonged six-





9 Conclusions and recommendations 
9.1 Summary and conclusions 
The principal aim of this dissertation was to test the hypothesis that NRT which delivers 
nicotine more rapidly to the brain than conventional NRT, when used in combination with 
nicotine patch therapy, would assist smokers to achieve higher long-term abstinence rates 
compared to a placebo NRT plus active nicotine patches.  To date, the evidence that this 
combination of rapid and slow delivery of nicotine would be more effective cf. slow-delivery 
nicotine monotherapy, comes from trials of nicotine nasal spray plus patch by Blondal and 
colleagues and Croghan and colleagues, nicotine lozenge and patch by Piper and colleagues, 
and nicotine gum plus patch by Cooney and colleagues.  The two RCTs conducted as part of 
this dissertation, demonstrated that two other rapid-acting NRTs produce higher abstinence 
rates when used in combination with nicotine patches, compared to placebo plus active 
nicotine patches. 
In both the mouthspray and inhaler trials reported in this dissertation, the comparator group 
not only received a placebo version of the active treatment, they were also given active 
patches.  This meant that the active treatment not only had to be more efficacious than a 
placebo, but also had to be more effective than an active nicotine patch.  The rationale for the 
comparison to an active patch plus placebo, rather than placebo alone, and rather than some 
other active combination therapy, such as use of active patch plus active nasal spray, is two-
fold.  First, it enables the efficacy of the mouthspray and inhaler to be compared to one of the 
most commonly used treatments in New Zealand at the time the trials were designed (patch 
monotherapy), and it enabled double-blinding because both groups would receive similar 
looking treatments. 
There are rational theoretical arguments for, and against, the use of rapid-delivery nicotine in 
combination with slow-delivery nicotine.  On the one hand, the addition of a slow-delivery of 
nicotine would have the advantage of supplying people with supplementary nicotine without 
the need to remember to regularly re-dose themselves with rapid-acting NRT (under-dosing is 
common amongst smokers attempting to quit with the aid of NRT),(170, 214), and the 
continuous release of nicotine from the patch would desensitize nicotine receptors in the brain 
thereby blocking the release of rewarding neurotransmitters in response to a lapse to smoking, 
which would render a lapse less reinforcing of smoking.  On the other hand, the 




the release of rewarding neurotransmitters in response to the rapid-acting NRT, making it less 
reinforcing of its own use, and less attractive as an alternative to smoking.  The meta-analysis 
of trials of rapid-acting NRT plus nicotine patch, performed by me, along with the results of 
the ZAP and INHALE trials, demonstrate that, in vivo, the latter theoretical argument is 
overwhelmed by the former theoretical argument, and the overall effect of the combination 
therapy, has a positive effect of increasing abstinence. 
Although Blondal and colleagues found the combination cf. monotherapy resulted in an 
increase in abstinence rates, this only lasted for three months (37% cf. 25% after three months 
p=0.045).(67)  The advantage lasted an even shorter time of six weeks in the trial by Croghan 
and colleagues.(224)  This dissertation has demonstrated that the combinations of nicotine 
patch plus either nicotine mouthspray or nicotine inhaler, increased abstinence cf. nicotine 
patches plus placebo therapy, and increased prolonged abstinence rates for at least six months, 
one of the longest durations that the combination has been demonstrated to result in superior 
abstinence rates to date, as far as I was able to ascertain. 
The second aim of the RCTs conducted for this dissertation was to discover whether the 
combination of rapid-acting NRTs plus patch improves factors that are known to be involved 
in relapse, such as withdrawal symptoms and urges to smoke.  In the ZAP trial, the first time 
withdrawal was measured, was at the target quit-date phone-call, using an unvalidated Likert 
scale that asked subjects to rate how well they were coping with withdrawal symptoms from 
1=‘Not at all’ to 5=‘Extreme’ (typical withdrawal symptoms were read to subjects so they 
could understand what was meant by the term “withdrawal symptoms); for which the active 
combination had significantly higher scores cf. placebo combination, (mean (IQR) 3.7 (3.0—
5.0) cf. 3.6 (3.0—4.0), p=0.0054, respectively).  Likewise, active mouthspray combination 
therapy had significantly superior scores at this timepoint cf. placebo mouthspray 
combination therapy for how well subjects thought they were coping with urges to smoke 
(mean (IQR) 3.6 (3.0—4.0) cf. 3.4 (3.0—4.0), p=0.0224).  In the ZAP trial after baseline the 
MNWS was first administered a month after subjects’ target-quit dates when higher Craving, 
Negative Affect, and Insomnia scores significantly predicted both six-months and twelve-
months prolonged abstinence.   
In the inhaler trial, the Craving MNWS sub-scale scores were significantly (p<0.05) lower in 
the active cf. control groups at three- and six-months after subjects’ target quit dates (this was 
significant after Bonferroni correction [for five sub-scales measured three times after baseline 




significantly lower (p<0.05) in the active cf. control groups at three time-points after baseline 
but, none would be significant after Bonferroni correction.  This suggests that, either the 
mouthsprays and inhalers did not increase abstinence by lowering withdrawal and urge 
and/or, that the questionnaires used to index withdrawal and urge were not sufficiently 
sensitive and/or, were administered at inopportune times and/or, were administered with an 
unideal regularity and/or, the sample size not sufficiently large enough to detect the effects of 
the mouthsprays and inhalers on urges and withdrawal symptoms.  The need for more 
thorough and frequent measurement of withdrawal symptoms and. measurement of these 
symptoms in smokers’ natural environments, has led researchers such as Saul Shiffman to use 
palm-top computers to record Ecological Momentary Assessments of urges to smoke, 
withdrawal symptoms and other symptoms relating to smoking cessation.(417)  
This dissertation sought to identify variables, other than treatment assignment, that predicted 
abstinence.  In the ZAP trial, two pre-randomisation variables (“WISDM Weight control” and 
“Previously used NRT”) significantly predicted prolonged six-months abstinence in 
multivariate regression after Bonferroni correction.  The three post-randomisation variables 
recorded at the target quit phone-call in the ZAP trial, that had the largest effects on 
abstinence and were significant after Bonferroni correction, were “Intend to continue to try to 
quit / to remain quit”; “How often patches were worn” and “Quit status: not quit/quit late/quit 
on time/quit early”.  Univariate regressions of the number of sprays of mouthspray used per 
occasion, reported at the quit phone-call were highly significantly predictive of six-months 
prolonged abstinence.  There was no interactive effect on abstinence between treatment 
assignment and the number of sprays of mouthspray used per day at the quit phone-call, 
which suggests that abstinence may be the cause of greater use of the mouthsprays; or, that 
greater use of the mouthspray resulted in greater odds of achieving abstinence and that this 
happened regardless of treatment assignment.  If this placebo effect existed, its influence on 
abstinence, would be removed by comparing abstinence rates between the treatment groups. 
In the INHALE trial one of five variables recorded before randomisation was predictive of 
prolonged six-months abstinence (FTND scores) but this was only just within the p<0.05 
threshold of significance (p=0.0217).  Some variables recorded after randomisation in the 
INHALE trial were significantly predictive of abstinence.  Regardless of treatment 
assignment, the number of days subjects had used their inhalers since their previous follow-up 
was significantly higher among subjects who achieved prolonged abstinence than those who 
did not, after Bonferroni correction, at three out of five time-points when this variable was 




abstinence had used significantly more puffs of their inhalers in the past seven days than 
subjects who had relapsed at two of the four time-points (one and three-months post-target 
quit date) when this outcome was recorded after Bonferroni correction (p<0.05/4=0.0125).  
Akin to the ZAP trial, the association of greater use of the inhalers with abstinence suggests 
that; either, greater use of the inhalers predicted abstinence or abstinence predicted greater use 
of the inhalers.  Just as in the mouthspray study, the amount of rapid-acting NRT used, 
reported at the target quit phone-call, was predictive of prolonged abstinence, regardless of 
treatment assignment, and it is not possible to determine if the greater use of the inhalers had 
a beneficial effect on abstinence; or, if abstinence caused greater use of the inhalers, given this 
trial design.  Answering the question of the causal direction between the amount the inhalers 
are used and abstinence, would require a factorial design that randomises subjects to use 
varying amounts of inhaler, in both the active and control groups. 
A further aim of the dissertation was to determine if simple single-item Likert scales designed 
by me significantly predict abstinence.  These scales were designed to index smokers’ desire 
and determination to quit and/or reduce their smoking, and their degree of self-efficacy to 
forgo the pleasure of smoking and handle stressful events without smoking, the number of 
smokers that subjects spend time with on typical day; previously used NRT (yes cf. no); and 
the number of personal acquaintances who have quit.  Thus, the ability of nine variables to 
predict abstinence was measured, requiring Bonferroni correction of p<0.05/9=0.00556.  Two 
variables were significant predictors of abstinence after Bonferroni correction (“Previously 
used NRT (yes cf. no)” and “Number of personal acquaintances who have quit”), Table 3.13, 
page 122. 
Finally, this dissertation aimed to identify the roles of the speed of nicotine delivery, 
ororespiratory sensations, and people’s perceptions about whether they were on active or 
placebo therapy, in predicting the likelihood that smokers quit smoking.  These aims were 
achieved by formal statistical comparisons of abstinence rates between the INHALE study, 
and the mouthspray study, with the INHALE trial using a more rapid nicotine delivery device 
than the ZAP trial, and are discussed in the following paragraphs.  Meta-analyses 
demonstrated that the active cf. control treatments in the ZAP and INHALE trials were 
amongst the most effective therapies when combined with nicotine patches but were 
underpowered to demonstrate a statistically significant higher odds ratio for abstinence with 




The quality of subjects’ ororespiratory sensations produced by the rapid delivery devices was 
measured by the mCEQ in both trials, which found that some mCEQ scales were significantly 
different between treatment groups of the ZAP trial at baseline (Table 3.5, page 103), 
however none of the baseline mCEQ scale scores were predictive of six-months prolonged 
abstinence after Bonferroni correction in the ZAP study (Table 3.20, page 158).   
A similar picture was seen in the INHALE trial, where at baseline the scores of three scales of 
the mCEQ were significantly different between treatment groups (‘Smoking Satisfaction’, 
‘Enjoy Respiratory Sensations’, and ‘Aversion’; while by one month after the target quit date 
the scores of all mCEQ scale were significantly different between groups.  The baseline 
scores of only one of the five scales of the mCEQ (Craving Reduction) predicted prolonged 
six-months not smoked on seven consecutive days abstinence at the p<0.05 level of 
significance however, this would not remain significant after Bonferroni correction for 
comparisons between the five scales (Table 7.7, page 262).  Three of the five mCEQ scale 
scores, recorded a month after subjects’ target quit dates, were significantly predictive of 
prolonged six-months not smoked on seven consecutive days (Smoking Satisfaction; 
Psychological Reward; Craving Reduction) and would remain significant after Bonferroni 
correction (Table 8.4, page 297).  Collectively, the mCEQ scores from the ZAP and INHALE 
trials demonstrate the important role that the ororespiratory and psychological effects of NRT 
have in modifying smokers’ odds of achieving long-term abstinence from smoking.  Other 
researchers have shown that these sensory and psychological effects are contingent on the 
rapid delivery of nicotine to the brain because, the shorter the time that elapses between the 
sensory effects and the neurological reward, the more likely that they will be paired 
consciously and by subconscious neurological processes involved in learning. 
In both the ZAP and INHALE trials, unmasking occurred however, in both trials, unmasking 
did not bias the estimate of the effect of active treatment on abstinence.  In both trials, 
whether subjects guessed they were assigned to active or placebo treatment or were unsure; 
and whether their guesses were correct or incorrect, was never statistically predictive of 
prolonged abstinence. Publications of trials that report the role of unmasking and subjects’ 
perceived treatment assignments on abstinence have used a variety of analytical approaches, 
which makes it difficult to compare their findings to those of these trials.  Analyses of this 
trials followed Hughes’ and Krahn’s(245) advice on how to determine if unblinding and bias 
had occurred, using techniques that did not require the modelling of perceived and actual 
treatment as independent variables in the same bivariate model and therefore avoided 




abstinence regressed on perceived and actual treatment assignment,(250) without regard to the 
potential for these variables to be correlated which may cause collinearity if the rate of 
guessing treatment assignment correctly is high; while other researchers, such as Bailey and 
colleagues(42) only reported the role of perceived treatment assignment in predicting 
abstinence, not the role of correctly, incorrectly guessing or being unsure in predicting 
abstinence.  In these mouthspray and patch studies, neither the treatment group subjects 
guessed they were to nor, the correctness of those guesses, were predictive of prolonged 
abstinence in either the active nor control groups, whereas Bailey found that subjects’ 
perceived treatment allocations were correlated with abstinence in the active but not control 
groups, although this correlation was only significant at p<0.02. 
The efficacy of, and subjects’ reactions to, Appreciative Inquiry was not measured in these 
trials.  In my opinion, Appreciative Inquiry aided in the development of rapport with subjects 
and the building of a therapeutic relationship, which may have augmented the other 
interventions and may have encouraged subjects to adhere to the interventions and may have 
discouraged loss to follow-up.  In my experience, Appreciative Inquiry also enabled subjects 
to feel empowered and inspired. 
Evidence from this trials supports advising smokers using the mouthspray and inhaler in 
combination with nicotine patches, to continue to use these therapies for at least six months, 
so that the sensory qualities of the mouthsprays/inhalers and the processes that underlie 
subjects’ appreciation of those qualities, will be paired with the rewarding and reinforcing 
properties of nicotine and become better able to help them quit, and so that their nicotine 
levels are maintained after quitting smoking thereby avoiding withdrawal symptoms and 
urges to smoke. 
9.2 Recommendations for future research 
Future research is required to minimise the irritating effects of the nicotine pMDI.  This 
research needs to explore a range of different methods to reduce irritation, including: 
• Coating the nicotine to make it less aversive, such as coating it with cyclodextrins (a 
complex sugar molecule), as long as this does not slow the delivery of nicotine to the 
brain.(418) 
• Methods of training people to inhale from the inhaler in a way that minimises 




• Reducing the amount of ethanol used as a co-solvent (which will reduce aversiveness 
caused by ethanol and reduce the MMAD).(419) 
Research is also needed to find ways to encourage more smokers to use the nicotine pMDI, 
including: 
• Methods of promoting the usefulness and desirability of the nicotine pMDI to 
smokers, so that smokers use the pMDI often enough that the sensory qualities of the 
inhaler become secondary reinforcers of pMDI use. 
• Social interventions, such as social gatherings and social places where people use their 
pMDIs and socialise while using their pMDIs.  This is important because higher 
Social/Environmental Goads had a detrimental effect on abstinence, particularly 
among Māori, in ZAP. 
Adverse reactions to nicotine patches were common in the two RCTs upon which this 
dissertation was based.  Future research is required to test combinations of NRTs that do not 
include nicotine patches, such as nasal spray plus mouthspray or nasal spray plus nicotine 
pMDI, for use by people who cannot tolerate nicotine patches.  Also, trials are required, to 
measure the effect of nicotine pMDI monotherapy cf. nicotine pMDI plus nicotine patch, to 
see if nicotine pMDI monotherapy would be an effective approach for smokers who cannot 
tolerate patches.  
Further research is required to determine the optimal duration of pre-cessation pMDI plus 
patch combination therapy.  The extra week of pre-cessation combination therapy in the 
inhaler trial cf. mouthspray trial may have, in part, been responsible for the higher abstinence 
rates with active pMDI plus patch cf. active mouthspray plus patch because it is possible that 
the extra week of active nicotine pMDI prior to the target quit date in the active group had a 
greater positive effect on abstinence compared to the extra week of placebo pMDI in the 
control group. 
Research is required to identify effective therapies to salvage smokers who relapse despite use 
of nicotine patches plus nicotine pMDI therapy.  Such salvage treatments may include: 
• A wider range of dosage strengths of nicotine in the pMDI to enable the dose to be 
more finely titrated to each smoker’s individual neurobiology and preferences. 
• A wider range of flavourings other than menthol, that have been proven to be safe to 




• The addition of Cognitive Behavioural Therapy(420, 421) or Motivational 
Interviewing(422) in conjunction with nicotine pMDI plus nicotine patch combination 
therapy. 
It remains to be discovered whether smokers who relapse after commencing patch plus pMDI 
treatment would be willing to try the same treatment again despite their initial lack of success 
using it or, whether smokers would prefer to try a different therapy.  It also remains to be seen 
how efficacious re-treatment with the combination of nicotine patch and nicotine pMDI 
treatment would be for smokers who relapse after using it.  The addiction to smoking is a 
chronic relapsing disease,(79, 423) and it is likely to remain so, despite the use of therapies 
that induce a high percentage of smokers to become abstinent for six months, and therefore, 
the need for therapies that can salvage smokers is likely to always be with us. 
Future research is also warranted to investigate: 
• the efficacy of the pMDI and patch in a head-to-head trial of conventional NRT 
combination therapy; 
• the efficacy of the pMDI and patch cf. electronic cigarette plus patch. 
• the efficacy of the pMDI and patch among priority populations such as, Māori and 
Pacific smokers, pregnant women, and smokers with mental illness; 
• effectiveness studies are required to measure the effect in real-world settings where 
support is less intensive and less specialised; 
• the acceptability of long-term use of nicotine inhaler plus nicotine patch combination 
therapy for nicotine maintenance therapy as a long-term substitute for smoking. 
This dissertation resulted in the development of several scales to identify smokers who are at 
greater risk of relapse, one scale identified smokers who are at greater risk before they 
commence their attempt to quit, and one that can be used after smokers have commenced their 
attempt.  Further work is required to validate these scales and test whether abstinence rates are 
higher if these scales are used to target the offer of further and more intensive therapy.  This 
would necessitate the development of suitable therapies, and research to test their ability to 
improve abstinence in smokers who these scales have identified are at greater risk of relapse. 
9.3 Recommendations for clinical use 
This dissertation offers clinicians reliable evidence of the efficacy of two therapies for their 




developed and this dissertation has shown them to be safe, tolerable, and effective compared 
to active nicotine patch therapy which is one of the most commonly used conventional 
therapies.   
Clinicians should be advised that age, gender, FTND, baseline CPD, and Māori ethnicity are 
not always reliable criteria by which to judge whether smokers are more likely or less likely 
to benefit from nicotine pMDI plus nicotine patch combination therapy because, in the 
INHALE study, none of these five variables were predictive of which subjects would achieve 
prolonged six-months abstinence.  This is counter to the advice of the New Zealand Ministry 
of Health whose guideline titrate treatment according to whether smokers smoke within an 
hour after waking in the morning and whether they smoke ten or more cigarettes per day, 
which are items of the FTND.(424)   
Clinicians may wish to use the pMDI patch combination therapy as first-line treatment, based 
on the rationale that, as pMDI combination therapy is very effective, it is likely to help more 
people succeed, and it is important for smokers attempting to quit to have early success 
because, failure may lead to the Abstinence Violation Effect, may reduce people’s self-
efficacy, and it may be many years before they try to quit again and they may suffer 
irreversible smoking-related ill-health in the meantime.  Alternatively, clinicians may wish to 
retain the pMDI plus patch therapy as the last resort to salvage smokers who have failed 
conventional therapies. 
Both the nicotine mouthspray plus patch and nicotine pMDI plus patch combination therapies 
were demonstrated to be equally effective among Māori and non-Māori, and by promoting 
these therapies over nicotine patch monotherapy, clinicians will contribute to reducing the 
inequitably higher prevalence of smoking for Māori. 
9.4 Conclusion 
The trials upon which this dissertation was based have demonstrated that, rapid-acting NRT 
plus nicotine patch combination therapy, outperforms placebo plus nicotine patch therapy but, 
the studies were underpowered to determine if the abstinence rates with the faster of the two 
rapid-acting NRTs plus patch combination therapy outclassed the abstinence rates produced 
by the slower rapid-acting NRT plus patch combination therapy.   
The findings of this dissertation offer treatment providers and public health bodies evidence 
of the effectiveness of two particularly effective therapies, one of which had never before 




smokers to promote it to each other in a similar manner to how electronic cigarette users 
promote electronic cigarettes to other smokers,(425) if the inhaler was to be made as widely 
available as electronic cigarettes are in countries with liberal legislation regulating their 
supply, such as the USA.  If smokers can be encouraged to use more effective therapies, such 
as the combination of nicotine pMDIs and patches, the reduction in smoking prevalence may 
be accelerated, leading to more smokers surviving, with good health, into older age and being 
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Appendix A. Definitions of behavioural research 
terminology and “laws” 
The following laws and definitions are paraphrased from Skinner’s seminal textbook on 
classical and operant conditioning (also known as conditioning of type S and type R, 
respectively), and give an introduction to the knowledge that behavioural researchers gleaned 
from their animal experiments prior to the establishment of direct experimentation on neurons 
(89):  
 
Stimulus: an external element of the environment that induces a behavioural response in an 
organism. 
Response: the activity that an organism undertakes whenever a particular stimulus occurs. 
Reflex: A reflex is the observed relationship between a stimulus and its response.  Skinner 
uses “reflex” to encompass all such responses without distinguishing them on the basis 
of whether they are voluntary choices or involuntary responses, a reflex is a response 
that predictably occurs in relationship to a stimulus.  Reflexes are behaviours that are 
“elicited” from the organism as a result of a stimulus to that organism.  Reflexes are 
thereby distinguished from spontaneous activity, for which there are no identifiable 
stimuli, and are therefore “emitted”, rather than “elicited” responses.   
Conditioning is the process of learning that there is an association between a stimulus, the 
performance of a behaviour in response to that stimulus, and the experience of the 
consequences of that behaviour.   
Unconditioned reflex: a behaviour that is elicited by a stimulus because of an innate 
characteristic of the organism, and does not have to be learned. 
Respondant: a behaviour that has an identifiable stimulus which elicits a predictable response 
which is innate. 
Operant: a behaviour that occurs without an identifiable eliciting stimulus, such behaviours 
are learned from the correlation of a stimulus with a reinforcing response. For this 
reason the process may be referred to as of type R (page 21 in the book by Skinner 
(89)).  Type R is when the ability of something to act as a conditioned stimulus is 
contingent upon an organism making a response to it, and whether that response 
results in reward or punishment.  Another definition of an operant is that it is a 
behaviour that is not a response to a prior stimulus but instead is initially spontaneous, 




Reflex Reserve is the extent to which a reflex will increase in strength when the stimulus is 
repeated, and the speed with which fatigue develops.  Reflex reserve applies to both 
conditioned and unconditioned reflexes. 
 
The static laws of the reflex - The static laws hold when either only one stimulus is given, or 
when two stimuli are given and their effects are additive.  The following five laws are static 
laws of the reflex:  
The law of threshold - The intensity of the stimulus must reach or exceed a certain value 
(threshold) in order to elicit a response 
The law of latency - An interval of time elapses (the latency) between receipt of the 
stimulus and the beginning of the behavioural response.  The latency is different for 
different types of stimuli and reflexes, and the length of the latency is usually 
inversely proportional to the strength/intensity of the stimulus.  
The law of the magnitude of the response - The magnitude of the response is 
proportional to the intensity of the stimulus, and the ratio of the magnitude of the 
response to the magnitude of the stimulus is called the R/S ratio. 
The law of after-discharge - The response may persist for some time after the cessation of 
the stimulus, and usually the after-discharge is prolonged if the stimulus is more 
intense. 
The law of temporal summation - The response is more intense and has a longer duration 
if the stimulus is repeated, and the increase in the response due to repetition of the 
stimulus, is the same as the increase in the response that occurs when the stimulus is 
more intense. 
 
The dynamic laws of the reflex strength - The dynamic laws describe what happens when 
stimuli are repeatedly administered but their cumulative effect is not additive.  The following 
nine laws are the dynamic laws of the reflex strength. 
The law of the refractory phase - Immediately after a reflex is elicited, if the reflex is 
repeated, its strength is low, and sometimes it is even zero. 
The law of reflex fatigue - When the stimulus is prolonged, or repeated more often, the 
intensity of the response diminishes, its latency increases, the Reflex/Stimulus ratio 
(R/S ratio) declines, and the after-discharge reduces.  The strength of the response 
returns to its original value after a certain period of inactivity. 
The law of exercise - The law of exercise states that behaviour is more strongly 




The law of facilitation - The strength of a response to a stimulus is increased by the co-
presentation of a second stimulus, which on its own does not result in any response. 
The law of inhibition - The strength of a response to a stimulus is reduced by the co-
presentation of a stimulus which on its own does not result in any response. 
Law of Conditioning of Type S - If two stimuli are repeatedly presented at approximately 
the same time, with one of the stimuli being a reinforcer either, as a result of innate 
reflexes or from prior learning, and the other stimulus being neutral with no power to 
evoke a response, then the response to the reinforcing stimulus will be transferred to 
the neutral stimulus so that the neutral stimulus ends up evoking the same response as 
the reinforcing stimulus.  An example of conditioning of Type S is the repeated 
pairing of a neutral stimulus (such as a sound) with an unconditioned stimulus (such as 
the sight and smell of food that innately leads to salivation), which leads to the neutral 
stimulus gaining the ability to evoke the same response (salivation) as is elicited by the 
unconditioned stimulus.   
Law of Conditioning of Type R - A reflex (the association between a stimulus and 
response) is strengthened if the response to the stimulus is followed by a reinforcing 
reward.  An example of Conditioning of Type R ((89)page 65) is a rat in a box with a 
lever is unlikely to press the lever very often, so pressing the lever would be 
considered to be an operant, and a behaviour that must be learned.  If a pellet of food 
is dispensed whenever the lever is depressed, the rat quickly learns to depress the lever 
to get food.   
The law of Extinction of type S - If a reflex, that was strengthened through the law of 
conditioning of type S, is elicited sufficiently often without the co-presentation of the 
unconditioned stimulus, the strength of the reflex decreases.   
The law of Extinction of type R - If a reflex that was strengthened through the law of 
conditioning of type R is elicited sufficiently often without being rewarded, the 
strength of the reflex decreases. 
 
The laws of interaction of reflexes apply to both conditioned and unconditioned reflexes, 
and are listed below. 
The law of compatibility. Two or more responses which do not overlap topographically 
may occur simultaneously without interference (e.g. knee jerk and pupillary reaction 
to light) 
The law of prepotency. When two reflexes overlap topographically and the responses are 




The law of algebraic summation. The simultaneous elicitation of two responses utilizing 
the same effectors, when the two responses are opposite to each other, produces a 
response that has an intensity that is mathematically related to the intensity of each of 
the two responses. Thus, two opposing reflexes may cancel each other out, two similar 
reflexes might produce twice the result. 
The law of blending. Two responses showing some topographical overlap may be elicited 
together but in necessarily modified forms. 
The law of spatial summation.  When two reflexes have the same form of response, the 
response to both stimuli in combination has a greater magnitude and a shorter latency. 
The law of chaining. The response to one stimulus might produce the stimulus of a 
different reflex. 
The law of induction.  A dynamic change in the strength of a reflex may be accompanied 
by a similar but not so extensive change in a related reflex, where the relation is due to 
the possession of common proprieties of their stimuli or responses.  
 
The following are definitions of terms that relate to the dynamic laws of the reflex strength: 
Canalization is the opposite of the law of reflex fatigue.  Canalization is the increase in 
the strength of a reflex, due to the repetition of the stimulus, and is the practical 
application of the law of exercise. 
Adaptation is the change in the response to a stimulus as a result of prior presentation of 






Appendix B. Severity Score of Side-effects and Correlation between predictors of six months 
prolonged abstinence recorded at the phone-call a day after the target quit date. 
Severity score of side-effects: median, mean (IQR, n=number, p-value. P-value by Mann-Whitney test, scores are from all subjects 
including those who had no side-effects – subjects who had no side-effects recorded their severity score as 0: ‘Not at all’; 1: ‘Slight’; 2: 
‘Moderate’; 3: ‘Quite a bit’; 4: ‘Extreme’ 
 
Table B1 Adverse Effects of Nicotine Mouth Spray and Placebo 
Side-effect Baseline One month Three months Six months Twelve months 
 Active Placebo Active Placebo Active Placebo    
Indigestion 0, 0.1 




(0 – 1.0) 
0, 0.2 
(0 – 0) 
0, 0.4 
0 – 0) 
0, 0.1 
(0 – 0) 
0, 0.5 
(0 – 0.5) 
0, 0.1 
(0 – 0) 
0, 0.2 
(0 – 0) 
0, 0.1 
(0 – 0) 
 n=1419, p<0.001 n=659, p<0.0018 n=339 p=0.002 n=162, p<0.001 n=122, p=0.14 
Heartburn 0, 0.1 




(0 – 0) 
0, 0.2 
(0 – 0) 
0, 0.3 
(0 – 0) 
0, 0.1 
(0 – 0) 
0, 0.4 
(0 – 0) 
0, 0 
(0 – 0) 
0, 0.13 
(0 – 0) 
0, 0 
(0 – 0) 
 n=1417, p<0.001 n=658, p<0.001 n=338, p=0.001 n=164, p<0.001 n=118, p=0.20 
Acid reflux 0, 0.2 




(0 – 0) 
0, 0.2 
(0 – 0) 
0, 0.2 
(0 – 0) 
0, 0.1 
(0 – 0) 
0, 0.3 
(0 – 0) 
0, 0.1 
(0 – 0) 
0, 0.1 
(0 – 0) 
0, 0 
(0 – 0) 
 n=1419, p<0.001 n=653, p<0.001 n=334, p=0.03 n=164, p=0.02 n=116, p=0.72 
Cough 0, 0.3 




(0 – 0) 
0, 0.4 
(0 – 0) 
0, 0.2 
(0 – 0) 
0, 0.3 
(0 – 0) 
0, 0.2 
(0 – 0) 
0, 0.3 
(0 – 0) 
0, 0.1 
(0 – 0) 
0, 0.1 
(0 – 0) 
 n=1412, p=0.04 n=655, p=0.01 n=336, p= 0.045 n=162, p=0.12 n=114, p=0.68 
Hiccough 0, 0.4 




(0 – 2.0) 
0, 0.1 
(0 – 0) 
0, 0.9 
(0 – 2.0) 
0, 0 
(0 – 0) 
1.0, 1.0 
(0 – 2.0) 
0, 0 
(0 – 0) 
0, 0.8 
(0 – 2.0) 
0, 0 




Side-effect Baseline One month Three months Six months Twelve months 
 Active Placebo Active Placebo Active Placebo    




Burp 0, 0.2 








(0 – 0) 
0, 0.1 
(0 – 0) 
0, 0.5 
(0 – 1.0) 
0, 0.1) 
(0 – 0) 
0, 0.3 
(0 – 0) 
0, 0.1 
(0 – 0) 
 n=1418, p<0.001 n=656, p<0.001 n=328, p<0.001 n=163, p<0.001 n=115, p=0.02 
Excess saliva 0, 0.8 
(0 - 1.0) 
0, 0.7 
(0 - 1.0) 
1.0, 1.1 
(0 – 2.0) 
0, 0.8 
(0 – 1.0) 
0, 0.8 
(0 – 2.0) 
0, 0.6 
(0 – 1.0) 
0, 0.8 
(0 – 1.0) 
0, 0.4 
(0 – 1.0) 
0, 0.4 
(0 – 0) 
0, 0.2 
(0 – 0) 
 n=1413, p=0.06 n=655, p=0.009 n=336, p=0.07 n=161, p=0.23 n=114, p=0.09 
Hurt mouth 0, 0.2 
(0 – 0) 
0, 0.2 
(0 to 0) 
0, 0.3 
(0 – 0) 
0, 0.4 
(0 – 1.0) 
0, 0.3 
(0 – 0) 
0, 0.4 
(0 – 0) 
0, 0.2 
(0 – 0) 
0, 0.4 
(0 – 1.0) 
0, 0.2 
(0 – 0) 
0, 0.3 
(0 – 0) 
 n=1417, p=0.15 n=657, p=0.01 n=336, p=0.06 n=164, p=0.02 n=114, p=0.79 
Hurt throat 0, 0.2 
(0 – 0) 
0, 0.1 
(0 to 0) 
0, 0.4 
(0 – 0) 
0, 0.3 
(0 – 0) 
0, 0.2 
(0 – 0) 
0, 0.2 
(0 – 0) 
0, 0.2 
(0 – 0) 
0, 0.2 
(0 – 0) 
0, 0.3 
(0 – 0) 
0, 0.1 
(0 – 0) 
 n=1418, p<0.001 n=657, p=0.02 n=336, p=0.45 n=164, p=0.59 n=113, p=0.15 
Other 0, 0.4 
(0 – 1.0) 
0, 0.3 
(0 – 0) 
0, 0.8 
(0 – 1.0) 
0, 0.7 
(0 – 1.0) 
0, 0.5 
(0 – 0) 
0, 0.4 
(0 – 0) 
0, 0.5 
(0 – 0.3) 
0, 0.3 
(0 – 0) 
0, 0.4 
(0 – 0) 
0, 0.4 
(0 – 0) 






Table B2. Adverse effects of nicotine patches, rated on a scale of 0 = ‘Not at all’; 1 = ‘Slight’ 2 = ‘Moderate’; 3 = ‘Quite a bit’; 4 = 
‘Extreme’ 
 Active group Control Group 
p 
 Median Mean 1st Qu. 3rd Qu. n Median Mean 1st Qu. 3rd Qu. n 
Baseline 
Headache 0.00 0.04 0.00 0.00 713 0.00 0.04 0.00 0.00 699 0.94 
Red marks on skin 0.00 0.07 0.00 0.00 713 0.00 0.08 0.00 0.00 700 0.73 
Itch 0.00 0.13 0.00 0.00 716 0.00 0.18 0.00 0.00 700 0.44 
Dizzy 0.00 0.05 0.00 0.00 711 0.00 0.06 0.00 0.00 704 0.49 
Nausea 0.00 0.03 0.00 0.00 710 0.00 0.01 0.00 0.00 699 0.04 
Flushing 0.00 0.04 0.00 0.00 710 0.00 0.04 0.00 0.00 698 0.83 
Other 0.00 0.04 0.00 0.00 419 0.00 0.04 0.00 0.00 390 0.52 
One month post target quit date 
Headache 0.00 0.17 0.00 0.00 353 0.00 0.16 0.00 0.00 300 0.60 
Red marks on skin 1.00 1.04 0.00 2.00 353 1.00 1.02 0.00 2.00 304 0.89 
Itch 1.00 1.05 0.00 2.00 354 1.00 1.09 0.00 2.00 303 0.68 
Dizzy 0.00 0.07 0.00 0.00 353 0.00 0.09 0.00 0.00 302 0.43 
Nausea 0.00 0.07 0.00 0.00 354 0.00 0.09 0.00 0.00 302 0.24 
Flushing 0.00 0.15 0.00 0.00 354 0.00 0.17 0.00 0.00 302 0.73 
Disturbed dreams 0.00 1.22 0.00 3.00 353 0.00 1.09 0.00 2.00 303 0.21 
Other 0.00 0.54 0.00 0.00 251 0.00 0.72 0.00 1.00 215 0.10 
Three months post target quit date 




 Active group Control Group 
p 
 Median Mean 1st Qu. 3rd Qu. n Median Mean 1st Qu. 3rd Qu. n 
Red marks on skin 0.00 0.81 0.00 1.00 203 0.00 1.04 0.00 2.00 167 0.28 
Itch 1.00 0.90 0.00 1.00 203 1.00 1.15 0.00 2.00 167 0.16 
Dizzy 0.00 0.02 0.00 0.00 205 0.00 0.08 0.00 0.00 165 0.12 
Nausea 0.00 0.01 0.00 0.00 204 0.00 0.11 0.00 0.00 165 0.02 
Flushing 0.00 0.08 0.00 0.00 203 0.00 0.18 0.00 0.00 164 0.02 
Disturbed dreams 0.00 0.69 0.00 1.00 205 0.00 0.74 0.00 1.00 165 0.86 
Other 0.00 0.28 0.00 0.00 154 0.00 0.52 0.00 0.00 130 0.07 
Six months post target quit date 
Headache 0.00 0.03 0.00 0.00 109 0.00 0.06 0.00 0.00 90 0.81 
Red marks on skin 0.00 0.63 0.00 1.00 110 0.00 0.91 0.00 1.25 92 0.26 
Itch 0.00 0.58 0.00 1.00 107 0.00 0.83 0.00 1.00 92 0.15 
Dizzy 0.00 0.00 0.00 0.00 108 0.00 0.07 0.00 0.00 90 0.06 
Nausea 0.00 0.02 0.00 0.00 108 0.00 0.09 0.00 0.00 91 0.51 
Flushing 0.00 0.09 0.00 0.00 107 0.00 0.13 0.00 0.00 91 0.93 
Disturbed dreams 0.00 0.28 0.00 0.00 108 0.00 0.54 0.00 0.00 91 0.11 





Table B3. Minnesota Nicotine Withdrawal Scale scores (complete-case analysis). Median, mean change in score compared to one month 
scores, number of subjects who provided data, p-value within group, p-value between groups. Negative numbers indicate a reduction in 
subscale scores, positive numbers indicate an increase.  MNWS was not recorded at baseline. 
 Three month Six month Twelve month 
 Active Control Active Control Active Control 
Craving       
Change in score 0, -0.08 0, -0.06 0, -0.22 0, -0.01 0, -0.44 0, -0.45 
n 210  163 138 111 98 75 
p-value intragroup  <0.001 0.003 <0.001 <0.001 <0.001 <0.001 
p-value intergroup 0.92 0.12 0.92 
Restlessness       
Change in score 0, -0.26 0, -0.04 0, -0.39 0, -0.18 0, -0.51 0, -0.51 
n 209 163 136 111 96 74 
p-value intragroup  <0.001 0.45 <0.001 0.001 <0.001 <0.001 
p-value intergroup 0.06 0.17 0.84 
Increased appetite       
Change in score 0, -0.35 0, -0.20 0, -0.50 -1.00, -0.58 0, -0.77 -1.00, -0.69 
n 210 163 137 111 97 74 
p-value intragroup  0.12 0.04 0.004 <0.001 <0.001 <0.001 
p-value intergroup 0.26 0.46 0.86 
Negative affect       




 Three month Six month Twelve month 
 Active Control Active Control Active Control 
n 209 163 137 108 97 74 
p-value intragroup  0.003 0.43 <0.001 <0.001 <0.001 <0.001 
p-value intergroup 0.08 0.46 0.41 
Insomnia       
Change in score 0, -0.27 0, -0.05 0, -0.96 0, -0.43 -1.00, -0.97 0, -0.89 
Number who provided data 210 162 137 110 97 74 
p-value intragroup  0.07 0.54 <0.001 0.003 <0.001 <0.001 







Table B4 Bivariate regression to determine the effect of two variables on prolonged six months not smoked on seven consecutive days, 
adjusted by each other (note: these models used centred and scaled data to avoid multicollinearity) 
   Univariate GLM  Bivariate GLM   
 %Δ OR  Variable OR 95%CI p OR 95%CI p CoI Cor 
Decreases in OR displaying the largest to smaller decreases 
1 
-45.07 Aged ≥50  2.10 1.54 2.87 3x10-6 1.15 0.89 1.49 0.28 * 1.0 
0.79 
-11.42 Age (years) 1.50 1.28 1.77 1x10-6 1.33 1.02 1.75 0.04 2.9 
2 





0.61 0.51 0.72 6x10-8 0.64 0.54 0.77 1x10-6 1.2 
3 
-34.00 Aged ≥50  2.10 1.54 2.87 3x10-6 1.38 1.19 1.62 4x10-5 1.0 
-0.04 
1.04 WISDM total 0.84 0.71 0.98 0.02726 0.85 0.72 0.99 0.0372 1.0 
4 
-33.69 Aged ≥50  2.10 1.54 2.87 3x10-6 1.39 1.19 1.62 3x10-5 1.0 
-0.05 
1.75 WISDM SDM 0.91 0.77 1.06 0.22882 0.92 0.79 1.08 0.3235 1.1 
5 
-33.67 Aged ≥50  2.10 1.54 2.87 3x10-6 1.39 1.19 1.62 3x10-5 1.2 
0.15 
-4.94 
Age started smoking 
daily 
1.06 1.02 1.10 0.00076 1.20 1.04 1.38 0.0095 1.0 
6 
-33.53 Aged ≥50  2.10 1.54 2.87 3x10-6 1.39 1.19 1.63 2x10-5 1.0 
-0.05 
1.59 NZDep2006 0.81 0.69 0.95 0.00975 0.82 0.70 0.97 0.0176 1.0 
7 





0.92 0.79 1.08 0.30892 0.96 0.82 1.12 0.5885 1.0 
8 
-33.18 Aged ≥50 † 2.10 1.54 2.87 3x10-6 1.40 1.20 1.63 2x10-5 1.0 
-0.10 




   Univariate GLM  Bivariate GLM   
 %Δ OR  Variable OR 95%CI p OR 95%CI p CoI Cor 
† 
9 
-33.01 Aged ≥50  2.10 1.54 2.87 3x10-6 1.40 1.21 1.64 1x10-5 1.0 
0.01 





-33.00 Aged ≥50  2.10 1.54 2.87 3x10-6 1.40 1.21 1.64 1x10-5 1.1 
0.08 
-2.18 Prepared Stress 1.22 1.04 1.44 0.01701 1.19 1.01 1.41 0.0364 1.0 
11 
-32.90 Aged ≥50  2.10 1.54 2.87 3x10-6 1.41 1.21 1.64 1x10-5 1.1 
-0.08 
2.47 WISDM Craving 0.89 0.77 1.04 0.13952 0.91 0.79 1.06 0.2442 1.0 
12 
-32.88 Aged ≥50  2.10 1.54 2.87 3x10-6 1.41 1.21 1.64 1x10-5 1.1 
-0.08 
83.39 Māori trial site 0.39 0.23 0.62 0.00021 0.71 0.57 0.85 0.0006 1.0 
13 
-32.71 Aged ≥50  2.10 1.54 2.87 3x10-6 1.41 1.21 1.64 1x10-5 1.0 
-0.08 
3.09 
Live with other 
smoker(s) 









daily aged ≥16  
1.58 1.16 2.17 0.00437 1.22 1.04 1.43 0.0141 1.0 
15 





0.86 0.73 1.01 0.0728 0.90 0.77 1.06 0.2224 1.0 
16 
-32.68 Aged ≥50  2.10 1.54 2.87 3x10-6 1.41 1.21 1.64 1x10-5 1.0 
-0.06 
0.62 WISDM Tolerance 0.72 0.62 0.83 1x10-5 0.73 0.63 0.84 2x10-5 1.1 




   Univariate GLM  Bivariate GLM   
 %Δ OR  Variable OR 95%CI p OR 95%CI p CoI Cor 
-2.47 
No.  personal 
acquaintances quit 
1.25 1.07 1.46 0.00535 1.22 1.04 1.42 0.0132 1.0 
18 
-32.46 Aged ≥50  2.10 1.54 2.87 3x10-6 1.42 1.22 1.65 8x10-6 1.0 
-0.01 
-0.10 WISDM PDM 0.79 0.68 0.91 0.00172 0.79 0.68 0.91 0.0016 1.0 
19 
-32.09 Aged ≥50  2.10 1.54 2.87 3x10-6 1.42 1.22 1.66 5x10-6 1.0 
0.03 
-8.61 Male gender 1.17 0.86 1.59 0.32698 1.07 0.91 1.25 0.4149 1.0 
20 
-32.00 Aged ≥50  2.10 1.54 2.87 3x10-6 1.43 1.23 1.66 5x10-6 1.0 
0.04 
-1.52 WISDM Taste 1.06 0.91 1.24 0.44287 1.05 0.90 1.23 0.5686 1.0 
21 
-31.70 Aged ≥50  2.10 1.54 2.87 3x10-6 1.43 1.23 1.67 4x10-6 1.0 
-0.01 
0.23 WISDM Affective 0.90 0.78 1.05 0.19616 0.91 0.78 1.06 0.2043 1.0 
22 
-31.54 Aged ≥50  2.10 1.54 2.87 3x10-6 1.43 1.23 1.67 3x10-6 1.0 
0.04 
-1.84 
WISDM Loss of 
Control 
0.87 0.75 1.02 0.07401 0.86 0.74 1.00 0.0407 1.0 
23 
-31.44 Aged ≥50  2.10 1.54 2.87 3x10-6 1.44 1.23 1.68 6x10-6 1.0 
0.00 
0.63 
Number of previous 
quit attempts 
1.09 0.95 1.23 0.15413 1.10 0.96 1.24 0.1326 1.0 
24 
-31.42 Aged ≥50  2.10 1.54 2.87 3x10-6 1.44 1.23 1.68 3x10-6 1.0 
0.04 
-1.56 WISDM Automaticity 0.84 0.73 0.98 0.02259 0.83 0.72 0.96 0.0121 1.0 
25 
-31.41 Aged ≥50  2.10 1.54 2.87 3x10-6 1.44 1.24 1.68 3x10-6 1.0 
-0.01 
-0.92 Baseline FTND 0.76 0.65 0.89 0.00085 0.76 0.64 0.89 0.0006 1.0 




   Univariate GLM  Bivariate GLM   




1.02 0.88 1.20 0.76974 1.03 0.88 1.20 0.7042 1.0 
27 
-31.08 Aged ≥50  2.10 1.54 2.87 3x10-6 1.44 1.24 1.69 3x10-6 1.0 
0.12 
-4.67 WISDM Affiliative 0.95 0.81 1.11 0.53097 0.91 0.78 1.06 0.2202 1.1 
28 
-30.78 Aged ≥50  2.10 1.54 2.87 3x10-6 1.45 1.25 1.69 2x10-6 1.1 
-0.11 
4.40 
Baseline QSU total 
score 
0.96 0.81 1.12 0.57191 1.00 0.85 1.16 0.9763 1.0 
29 





1.14 0.98 1.32 0.09537 1.17 1.01 1.36 0.0401 1.1 
30 
-30.06 Aged ≥50  2.10 1.54 2.87 3x10-6 1.47 1.26 1.71 1x10-6 1.1 
0.07 




daily aged ≥16 
1.58 1.16 2.17 0.00437 1.11 0.91 1.37 0.3068 1.0 
0.68 
-5.83 
Age started smoking 
daily 




daily aged ≥16 













daily aged ≥16 
1.58 1.16 2.17 0.00437 1.19 1.02 1.40 0.0311 1.0 
-0.17 




   Univariate GLM  Bivariate GLM   




daily aged ≥16 
1.58 1.16 2.17 0.00437 1.20 1.02 1.41 0.0273 1.0 
-0.17 




daily aged ≥16 
1.58 1.16 2.17 0.00437 1.20 1.02 1.42 0.0253 1.0 
-0.18 







daily aged ≥16 
1.58 1.16 2.17 0.00437 1.20 1.03 1.41 0.0219 1.1 
0.11 




daily aged ≥16 
1.58 1.16 2.17 0.00437 1.21 1.03 1.42 0.0216 1.2 
-0.14 




daily aged ≥16 
1.58 1.16 2.17 0.00437 1.22 1.04 1.43 0.0165 1.2 
-0.14 




daily aged ≥16 
1.58 1.16 2.17 0.00437 1.22 1.04 1.43 0.0155 1.0 
-0.12 




daily aged ≥16 
1.58 1.16 2.17 0.00437 1.22 1.04 1.43 0.0156 1.0 
-0.14 




   Univariate GLM  Bivariate GLM   




daily aged ≥16 
1.58 1.16 2.17 0.00437 1.22 1.04 1.43 0.0153 1.2 
-0.16 






Eight bivariate models of WISDM’s PDM, SDM, or total, adjusted by other WISDM scales had reductions in the OR for PDM, SDM, and total 
of between -22.88% and -10.00%, Not shown to maintain the readability of the table). 
50 
-10.00 Male gender 1.17 0.86 1.59 0.32698 1.05 0.90 1.23 0.5357 1.0 
0.09 
0.01 Prepared Stress 1.22 1.04 1.44 0.01701 1.22 1.04 1.44 0.0177 1.1 
Increases in estimate of OR displaying the increases from largest to smaller 
1 











0.39 0.21 0.67 0.00146 0.78 0.62 0.96 0.0243 1.4 
0.35 
94.00 
Māori trial site 
† 
0.39 0.23 0.62 0.00021 0.75 0.60 0.91 0.0054 1.0 
3 
94.00 
Māori trial site 
† 





0.39 0.21 0.67 0.00146 0.78 0.62 0.96 0.0243 1.4 




   Univariate GLM  Bivariate GLM   










0.39 0.21 0.67 0.00146 0.74 0.59 0.91 0.0059 1.1 
-0.10 
-33.18 
Aged ≥50  
† 
2.10 1.54 2.87 3x10-6 1.40 1.20 1.63 2x10-5 1.0 
6 
91.22 Māori ethnicity 0.39 0.21 0.67 0.00146 0.74 0.59 0.90 0.0055 1.1 
-0.08 
-1.15 Age (years) 1.50 1.28 1.77 1x10-6 1.48 1.26 1.75 3x10-6 1.0 
7 
91.16 Māori ethnicity 0.39 0.21 0.67 0.00146 0.74 0.59 0.91 0.0060 1.0 
0.24 





89.38 Māori ethnicity 0.39 0.21 0.67 0.00146 0.73 0.58 0.89 0.00417 1.0 
-0.16 
-2.64 
Age started smoking 
daily 
1.27 1.10 1.45 0.00076 1.23 1.07 1.42 0.0037 1.2 
9 




daily aged ≥16 
1.58 1.16 2.17 0.00437 1.22 1.04 1.43 0.0165 1.2 
10 
87.30 Māori ethnicity 0.39 0.21 0.67 0.00146 0.73 0.58 0.88 0.00296 1.0 
-0.01 
-0.42 WISDM Total score 0.84 0.71 0.98 0.02726 0.83 0.71 0.98 0.0259 1.0 
11 
86.61 Māori ethnicity 0.39 0.21 0.67 0.00146 0.72 0.58 0.88 0.0026 1.1 
0.05 
0.30 WISDM Tolerance 0.72 0.62 0.83 1x10-5 0.72 0.62 0.84 2x10-5 1.0 




   Univariate GLM  Bivariate GLM   
 %Δ OR  Variable OR 95%CI p OR 95%CI p CoI Cor 
-0.39 WISDM SDM 0.91 0.77 1.06 0.22882 0.90 0.77 1.06 0.2169 1.0 
13 
85.41 Māori trial site 0.39 0.23 0.62 0.00021 0.71 0.58 0.86 0.0010 1.2 
0.18 





85.24 Māori ethnicity 0.39 0.21 0.67 0.00146 0.72 0.57 0.87 0.00205 1.0 
0.05 
0.40 Baseline FTND 0.76 0.65 0.89 0.00085 0.77 0.65 0.90 0.0013 1.1 
15 
85.09 Māori trial site 0.39 0.23 0.62 0.00021 0.71 0.58 0.86 0.00088 1.0 
-0.03 
-0.67 
Number of previous 
quit attempts 
1.09 0.95 1.23 0.15413 1.09 0.95 1.23 0.1929 1.0 
16 
85.07 Māori ethnicity 0.39 0.21 0.67 0.00146 0.72 0.57 0.88 0.00293 1.0 
0.02 
0.31 
Number of previous 
quit attempts 
1.09 0.95 1.23 0.15413 1.10 0.96 1.24 0.1470 1.0 
17 





0.92 0.79 1.08 0.30892 0.91 0.78 1.06 0.2231 1.0 
18 
84.45 Māori ethnicity 0.39 0.21 0.67 0.00146 0.71 0.57 0.87 0.00177 1.1 
-0.08 
-9.66 Male gender 1.17 0.86 1.59 0.32698 1.05 0.90 1.23 0.5055 1.0 
19 
84.10 Māori ethnicity 0.39 0.21 0.67 0.00146 0.71 0.57 0.87 0.00168 1.1 
-0.09 
-1.53 WISDM Taste 1.06 0.91 1.24 0.44287 1.05 0.89 1.23 0.5734 1.0 
20 
84.07 Māori ethnicity 0.39 0.21 0.67 0.00146 0.71 0.57 0.87 0.00164 1.0 
0.03 
-0.78 
Baseline QSU total 
score 




   Univariate GLM  Bivariate GLM   
 %Δ OR  Variable OR 95%CI p OR 95%CI p CoI Cor 
21 
83.90 Māori ethnicity 0.39 0.21 0.67 0.00146 0.71 0.57 0.87 0.00166 1.0 
-0.02 
-0.35 WISDM PDM 0.79 0.68 0.91 0.00172 0.78 0.67 0.91 0.0017 1.0 
22 
83.86 Māori trial site 0.39 0.23 0.62 0.00021 0.71 0.57 0.86 0.00069 1.0 
-0.13 
-2.91 
Age started smoking 
daily 
1.27 1.10 1.45 0.00076 1.23 1.07 1.41 0.0038 1.1 
23 
83.57 Māori ethnicity 0.39 0.21 0.67 0.00146 0.71 0.57 0.87 0.00152 1.0 
-0.03 
-1.34 
No.  personal 
acquaintances quit 
1.25 1.07 1.46 0.00535 1.23 1.05 1.44 0.0099 1.0 
24 
83.55 Māori ethnicity 0.39 0.21 0.67 0.00146 0.71 0.57 0.87 0.00151 1.0 
-0.03 
-0.36 WISDM Affiliative 0.95 0.81 1.11 0.53097 0.95 0.81 1.11 0.5069 1.0 
25 
83.44 Māori ethnicity 0.39 0.21 0.67 0.00146 0.71 0.57 0.87 0.00150 1.0 
-0.04 
-1.00 WISDM Craving 0.89 0.77 1.04 0.13952 0.88 0.76 1.03 0.1130 1.0 
26 
83.39 Māori trial site 0.39 0.23 0.62 0.00021 0.71 0.57 0.85 0.00062 1.0 
-0.08 
-32.88 Aged ≥50  2.10 1.54 2.87 3x10-6 1.41 1.21 1.64 1.12E-05 1.1 
27 





1.02 0.88 1.20 0.76974 0.99 0.85 1.16 0.90221 1.1 
28 
83.16 Māori ethnicity 0.39 0.21 0.67 0.00146 0.71 0.57 0.86 0.00140 1.0 
-0.01 
0.55 WISDM Affective 0.90 0.78 1.05 0.19616 0.91 0.78 1.06 0.22729 1.0 
29 




daily aged ≥16 




   Univariate GLM  Bivariate GLM   
 %Δ OR  Variable OR 95%CI p OR 95%CI p CoI Cor 
30 
82.96 Māori ethnicity 0.39 0.21 0.67 0.00146 0.71 0.56 0.86 0.00136 1.0 
-0.02 
1.74 WISDM Automaticity 0.84 0.73 0.98 0.02259 0.86 0.74 1.00 0.0431 1.0 
31 





1.14 0.98 1.32 0.09537 1.15 0.99 1.34 0.0637 1.0 
32 
82.85 Māori ethnicity 0.39 0.21 0.67 0.00146 0.71 0.56 0.86 0.00136 1.0 
-0.02 
35.15 Previously used NRT 0.59 0.42 0.85 0.00404 0.80 0.70 0.93 0.00226 1.0 
33 
82.68 Māori trial site 0.39 0.23 0.62 0.00021 0.70 0.57 0.85 0.0005 1.0 
-0.06 
-1.52 Age (years) 1.50 1.28 1.77 1x10-6 1.48 1.26 1.74 3x10-6 1.1 
34 
82.36 Māori ethnicity 0.39 0.21 0.67 0.00146 0.71 0.56 0.86 0.00125 1.1 
0.05 
0.46 Prepared Stress 1.22 1.04 1.44 0.01701 1.22 1.04 1.45 0.01629 1.0 
35 
81.58 Māori trial site 0.39 0.23 0.62 0.00021 0.70 0.57 0.84 0.00042 1.0 
0.08 
1.84 Baseline FTND 0.76 0.65 0.89 0.00085 0.78 0.66 0.91 0.00213 1.1 
36 
81.48 Māori ethnicity 0.39 0.21 0.67 0.00146 0.70 0.56 0.86 0.00108 1.1 
-0.07 
-2.87 
WISDM Loss of 
Control 
0.87 0.75 1.02 0.07401 0.85 0.73 0.99 0.03287 1.0 
37 





0.86 0.73 1.01 0.07282 0.86 0.73 1.02 0.08364 1.1 
38 
81.31 Māori trial site 0.39 0.23 0.62 0.00021 0.70 0.57 0.84 0.00039 1.0 
0.01 
0.16 WISDM SDM 0.91 0.77 1.06 0.22882 0.91 0.77 1.07 0.24076 1.0 




   Univariate GLM  Bivariate GLM   
 %Δ OR  Variable OR 95%CI p OR 95%CI p CoI Cor 
1.68 
Live with other 
smoker(s) 
0.84 0.72 0.99 0.03690 0.86 0.73 1.01 0.06121 1.1 
* 
40 
80.80 Māori trial site 0.39 0.23 0.62 0.00021 0.70 0.56 0.84 0.00037 1.0 
-0.02 
-0.99 WISDM Total score 0.84 0.71 0.98 0.02726 0.83 0.71 0.97 0.02123 1.0 
41 
80.75 Māori ethnicity 0.39 0.21 0.67 0.00146 0.70 0.55 0.86 0.00138 1.0 
0.08 
0.72 
Live with other 
smoker(s) 
0.84 0.72 0.99 0.03690 0.85 0.72 1.00 0.04898 1.1 
42 
80.01 Māori trial site 0.39 0.23 0.62 0.00021 0.69 0.56 0.84 0.00030 1.0 
-0.06 
-1.57 
No.  personal 
acquaintances quit 
1.25 1.07 1.46 0.00535 1.23 1.05 1.43 0.01028 1.1 
43 
79.85 Māori trial site 0.39 0.23 0.62 0.00021 0.69 0.56 0.84 0.00028 1.0 
-0.05 
-1.35 WISDM Taste 1.06 0.91 1.24 0.44287 1.05 0.90 1.23 0.55369 1.1 
44 





0.92 0.79 1.08 0.30892 0.91 0.78 1.07 0.24005 1.1 
45 
79.54 Māori trial site 0.39 0.23 0.62 0.00021 0.69 0.56 0.84 0.00027 1.0 
-0.04 
-1.35 WISDM Craving 0.89 0.77 1.04 0.13952 0.88 0.76 1.03 0.09919 1.1 
46 
79.41 Māori trial site 0.39 0.23 0.62 0.00021 0.69 0.56 0.83 0.00026 1.0 
-0.04 
-8.47 Male gender 1.17 0.86 1.59 0.32698 1.07 0.91 1.25 0.40302 1.0 
47 
79.31 Māori trial site 0.39 0.23 0.62 0.00021 0.69 0.56 0.83 0.00025 1.0 
0.02 
0.50 
Baseline QSU total 
score 
0.96 0.81 1.12 0.57191 0.96 0.82 1.12 0.61943 1.0 




   Univariate GLM  Bivariate GLM   
 %Δ OR  Variable OR 95%CI p OR 95%CI p CoI Cor 
0.17 WISDM Tolerance 0.72 0.62 0.83 1x10-5 0.72 0.62 0.84 0.00001 1.0 
49 





1.14 0.98 1.32 0.09537 1.14 0.98 1.32 0.09285 1.0 
50 





1.02 0.88 1.20 0.76974 1.02 0.87 1.19 0.84459 1.0 
51 
78.58 Māori trial site 0.39 0.23 0.62 0.00021 0.69 0.56 0.83 0.00021 1.0 
0.01 
0.20 WISDM Affective 0.90 0.78 1.05 0.19616 0.91 0.78 1.06 0.20774 1.0 
52 
78.37 Māori trial site 0.39 0.23 0.62 0.00021 0.69 0.56 0.83 0.00020 1.0 
-0.02 
-0.65 WISDM Affiliative 0.95 0.81 1.11 0.53097 0.95 0.81 1.10 0.47817 1.0 
53 
78.02 Māori trial site 0.39 0.23 0.62 0.00021 0.69 0.56 0.83 0.00019 1.0 
-0.04 
-1.08 WISDM Automaticity 0.84 0.73 0.98 0.02259 0.83 0.72 0.97 0.01539 1.0 
54 
77.45 Māori trial site 0.39 0.23 0.62 0.00021 0.68 0.55 0.83 0.00018 1.1 
-0.05 
-1.70 WISDM PDM 0.79 0.68 0.91 0.00172 0.77 0.67 0.90 0.00086 1.0 
55 
77.37 Māori ethnicity 0.39 0.21 0.67 0.00146 0.69 0.54 0.84 0.00077 1.0 
-0.04 
-9.56 Baseline exhaled CO 0.58 0.35 0.95 0.03941 0.53 0.31 0.88 0.01600 1.0 
56 
76.43 Māori trial site 0.39 0.23 0.62 0.00021 0.68 0.55 0.82 0.00014 1.0 
-0.09 
-2.97 
WISDM Loss of 
Control 
0.87 0.75 1.02 0.07401 0.85 0.73 0.99 0.03072 1.1 
57 
76.35 Māori trial site 0.39 0.23 0.62 0.00021 0.68 0.55 0.82 0.00019 1.0 
-0.02 




   Univariate GLM  Bivariate GLM   
 %Δ OR  Variable OR 95%CI p OR 95%CI p CoI Cor 
58 





0.86 0.73 1.01 0.07282 0.88 0.74 1.03 0.11294 1.0 
59 
75.50 Māori trial site 0.39 0.23 0.62 0.00021 0.68 0.55 0.82 0.00016 1.0 
0.02 
37.78 Previously used NRT 0.59 0.42 0.85 0.00404 0.82 0.71 0.94 0.00524 1.0 
60 
72.05 Māori trial site 0.39 0.23 0.62 0.00021 0.66 0.53 0.80 7x10-5 1.0 
0.08 
3.07 Prepared Stress 1.22 1.04 1.44 0.01701 1.26 1.07 1.48 0.00672 1.1 
 
Note: The order in which this table lists each GLM is in the first part of the table from the largest to smallest negative percent change, then in later 
rows from the largest to smallest positive percent change.  For each GLM, the variable that had the largest change is listed first with a grey 
background, with the results of the other variable in each GLM below it, with no background colour.  When the OR of both variables in a GLM had 
large changes, the GLM is listed twice, first with the variables with the largest change in grey, second with the variable with the smaller change in 
grey 
 
CoI Condition Index  
* statistical significance changed after adjustment from significant to non-significant or vice versa 
† repeated in table (both pairs of variables had extreme OR). 
Prepared Stress = How prepared to handle stress without smoking, recorded at baseline. 
Māori trial site = Enrolled at Māori community trial site 
Number smokers typical day = Number smokers typical day  
No.  personal acquaintances quit=Number of personal acquaintances who have quit smoking 







Table B5.  Changes in OR and significance of variables in bivariate compared to univariate GLM for the 42 pairs of variables for which one became insignificant in bivariate regressions whereas the 

































































































NZDep 0.86 0.73 1.01 0.07414 Māori 0.74 0.59 0.91 0.00602 6.09 91.16 now p>0.05 no change 1.3 1.0 0.24 1 
NZDep 0.85 0.73 1.00 0.05630 Māori trial site 0.71 0.58 0.86 0.00101 5.23 85.41 now p>0.05 no change 1.0 1.2 0.18 1 
Lives with other 
smoker 
0.86 0.73 1.01 0.06121 Māori trial site 0.70 0.57 0.84 0.00036 1.68 80.96 now p>0.05 no change 1.1 1.0 0.06 1 
NZDep 0.86 0.73 1.01 0.07414 Māori 0.74 0.59 0.91 0.00602 6.09 91.16 now p>0.05 no change 1.3 1.0 0.24 1 
NZDep 0.85 0.73 1.00 0.05630 Māori trial site 0.71 0.58 0.86 0.00101 5.23 85.41 now p>0.05 no change 1.0 1.2 0.18 1 
Lives with other 
smoker 
0.86 0.73 1.01 0.06121 Māori trial site 0.70 0.57 0.84 0.00036 1.68 80.96 now p>0.05 no change 1.1 1.0 0.06 1 
Aged ≥50 1.15 0.89 1.49 0.27882 Age 1.33 1.02 1.75 0.04002 -45.07 -11.42 now p>0.05 no change 1.0 2.9 0.79 0 
Baseline eCO 0.63 0.37 0.99 0.07994 
Previously used 
NRT 
0.82 0.71 0.95 0.00574 7.65 37.88 now p>0.05 no change 1.0 1.0 0.04 1 
WISDM total 1.12 0.85 1.47 0.42392 WISDM PDM 0.71 0.54 0.92 0.01046 33.47 -10.21 now p>0.05 no change 3.0 1.0 0.80 0 
WISDM PDM 1.03 0.81 1.30 0.81896 WISDM Tolerance 0.71 0.56 0.89 0.00332 30.62 -1.52 now p>0.05 no change 2.7 1.0 0.77 0 
Baseline eCO 0.60 0.36 0.97 0.05932 Aged ≥50 1.40 1.21 1.64 1x10-5 4.06 -33.01 now p>0.05 no change 1.0 1.0 0.01 1 
Aged ≥50 1.41 1.21 1.64 1x10-5 
Lives with other 
smoker 
0.87 0.74 1.02 0.08999 -32.71 3.09 no change now p>0.05 1.0 1.1 -0.08 1 
WISDM Social/ 
environmental 
0.63 0.52 0.75 4x10-7 
Started daily 
smoking aged ≥16 
1.14 0.97 1.34 0.11748 3.39 -27.95 no change now p>0.05 1.0 1.2 -0.20 0 
WISDM Tolerance 0.74 0.64 0.86 8x10-5 Baseline eCO 0.73 0.43 1.06 0.24456 2.36 26.10 no change now p>0.05 1.1 1.0 0.11 0 
WISDM total 0.87 0.74 1.02 0.08474 
Started daily 
smoking aged ≥16 
1.20 1.02 1.42 0.02531 3.69 -23.73 now p>0.05 no change 1.2 1.0 -0.18 1 
WISDM Social/ 
environmental 
0.63 0.52 0.75 4x10-7 
Started daily 
smoking aged ≥16 
1.14 0.97 1.34 0.11748 3.39 -27.95 no change now p>0.05 1.0 1.2 -0.20 0 
WISDM Tolerance 0.74 0.64 0.86 8x10-5 Baseline eCO 0.73 0.43 1.06 0.24456 2.36 26.10 no change now p>0.05 1.1 1.0 0.11 0 
WISDM total 0.87 0.74 1.02 0.08474 
Started daily 
smoking aged ≥16 
1.20 1.02 1.42 0.02531 3.69 -23.73 now p>0.05 no change 1.2 1.0 -0.18 1 
WISDM PDM 0.76 0.61 0.96 0.02252 
WISDM 
Automaticity 
1.04 0.82 1.31 0.74805 -2.84 23.50 no change now p>0.05 1.0 2.7 0.76 0 
WISDM total 1.03 0.85 1.25 0.74640 WISDM Tolerance 0.70 0.58 0.83 8x10-5 23.26 -3.43 now p>0.05 no change 1.0 1.8 0.55 0 
WISDM Tolerance 0.75 0.62 0.91 0.00402 Baseline FTND 0.94 0.76 1.16 0.56015 4.00 23.14 no change now p>0.05 1.0 2.2 0.65 0 
WISDM Automaticity 0.87 0.75 1.01 0.06521 Baseline FTND 1.22 1.04 1.43 0.01534 3.14 -22.88 now p>0.05 no change 1.0 1.2 -0.16 1 
Baseline eCO 0.71 0.42 1.04 0.20786 Baseline FTND 0.79 0.67 0.93 0.00529 22.43 3.48 now p>0.05 no change 1.0 1.1 0.11 0 
Lives with other 
smoker 
0.86 0.73 1.01 0.06580 
Started daily 
smoking aged ≥16 
1.25 1.07 1.47 0.00573 1.93 -20.78 now p>0.05 no change 1.1 1.0 -0.06 1 
WISDM Social/ 
environmental 
0.61 0.50 0.74 4x10-7 
Lives with other 
smoker 




































































































WISDM total 0.95 0.81 1.13 0.59485 
WISDM Social/ 
environmental 
0.63 0.52 0.76 2x10-6 14.08 4.29 now p>0.05 no change 1.0 1.4 0.33 0 
WISDM Tolerance 0.73 0.63 0.86 0.00016 
WISDM 
Automaticity 
0.96 0.81 1.13 0.61295 1.87 13.91 no change now p>0.05 1.6 1.0 0.43 0 
WISDM PDM 0.81 0.69 0.94 0.00558 Baseline eCO 0.66 0.39 1.02 0.11802 2.34 12.94 no change now p>0.05 1.1 1.0 0.09 0 
WISDM Social/ 
environmental 
0.64 0.53 0.77 2x10-6 NZDep 0.90 0.76 1.06 0.21527 5.55 10.93 no change now p>0.05 1.3 1.0 0.27 0 
WISDM Social/ 
environmental 





1.14 0.97 1.34 0.10697 2.68 -8.53 no change now p>0.05 1.0 1.3 -0.22 0 
WISDM total 0.91 0.76 1.07 0.24969 Baseline FTND 0.80 0.67 0.95 0.01157 8.16 4.84 now p>0.05 no change 1.0 1.5 0.36 0 
WISDM Automaticity 0.89 0.77 1.05 0.15782 Baseline FTND 0.79 0.67 0.93 0.00435 6.31 3.02 now p>0.05 no change 1.0 1.3 0.28 0 
Lives with other 
smoker 




0.62 0.51 0.73 1x10-7 
WISDM 
Automaticity 
0.89 0.77 1.04 0.12803 1.53 5.81 no change now p>0.05 1.0 1.2 0.15 0 
WISDM Automaticity 0.85 0.73 0.98 0.02828 Baseline eCO 0.61 0.36 0.98 0.06373 0.45 5.02 no change now p>0.05 1.0 1.0 0.04 0 
Baseline eCO 0.61 0.36 0.97 0.06174 Age 1.47 1.25 1.73 4x10-6 4.78 -2.11 now p>0.05 no change 1.0 1.0 0.02 0 
WISDM total 0.87 0.74 1.02 0.09373 
Age started daily 
smoking 
1.22 1.04 1.41 0.01001 4.10 -3.82 now p>0.05 no change 1.0 1.2 -0.19 0 
WISDM Automaticity 0.87 0.75 1.02 0.07608 
Age started daily 
smoking  
1.24 1.07 1.42 0.00294 3.70 -2.31 now p>0.05 no change 1.2 1.0 -0.16 0 
WISDM total 0.87 0.74 1.02 0.08548 NZDep 0.83 0.70 0.97 0.02163 3.68 1.86 now p>0.05 no change 1.1 1.0 0.06 0 
Age started daily 
smoking  
1.25 1.09 1.44 0.00135 Baseline eCO 0.60 0.36 0.97 0.05031 -0.91 2.81 no change now p>0.05 1.0 1.0 -0.03 0 
WISDM total 0.83 0.71 0.98 0.02456 Baseline eCO 0.60 0.35 0.98 0.05829 -0.50 2.59 no change now p>0.05 1.1 1.0 0.05 0 
WISDM Tolerance 0.73 0.63 0.85 4x10-5 
Lives with other 
smoker 
0.86 0.74 1.01 0.07644 1.89 2.48 no change now p>0.05 1.1 1.0 0.07 0 
WISDM PDM 0.80 0.69 0.93 0.00371 
Lives with other 
smoker 
0.86 0.73 1.01 0.07434 1.57 2.38 no change now p>0.05 1.0 1.0 0.02 0 
Age started daily 
smoking  
1.26 1.09 1.44 0.00119 
Lives with other 
smoker 
0.86 0.73 1.01 0.06971 -0.63 2.13 no change now p>0.05 1.0 1.1 -0.07 0 
NZDep 0.82 0.70 0.96 0.01649 
Lives with other 
smoker 
0.86 0.73 1.01 0.07188 1.21 2.00 no change now p>0.05 1.0 1.1 0.12 0 
Lives with other 
smoker 









































































































Lives with other 
smoker 
0.85 0.73 1.00 0.05494 Baseline FTND 0.77 0.66 0.91 0.00159 1.30 1.24 now p>0.05 no change 1.0 1.1 0.06 0 
Baseline Prepared 
Stress 
1.21 1.03 1.43 0.02112 
Lives with other 
smoker 
0.85 0.73 1.00 0.05233 -0.45 1.12 no change now p>0.05 1.0 1.0 -0.02 0 
Median of column 0.86 0.73 1.01 0.06  0.86 0.73 1.02 0.02 2.91 2.43   1.00 1.00 0.06 Total True 
in column = 
9 Lwr Quartile 0.74 0.62 0.95 0.00 
 0.73 0.58 0.95 0.00 1.31 -2.26   1.00 1.00 -0.05 
Upr Quartile 0.89 0.76 1.05 0.09  1.14 0.97 1.34 0.09 5.47 9.65   1.10 1.20 0.28 
Total False 
in column = 
33 
Mean of column 0.86 0.71 1.04 0.11  0.93 0.76 1.14 0.11 3.41 7.16   1.16 1.20 0.15  
SD of column 0.19 0.19 0.22 0.19  0.25 0.24 0.27 0.21 12.49 26.13   0.41 0.43 0.29  
† number in bold typeface is the member of the pair of variables that had the largest +/- magnitude % Δ in OR  
%ΔOR1st = % change OR 1st variable 
%ΔOR2nd = % change OR 2nd variable 
1st v p Δ = first variable changed statistical significance 
2nd v p Δ = second variable changed statistical significance 
%Δlarger = % change in OR is larger for the variable that became p<0.05 
CI 1stv = Condition Index first variable 






Table B6.  Univariate models of pre-randomisation centred and scaled predictors of six months prolonged not smoked on seven 
consecutive days.   This table is ordered from smallest to largest OR 




for 30 comparisons 
p<0.25 
1 Enrolled at Māori Community Trial Site 0.39 0.23 0.62 0.0002 1 1 
2 Māori ethnicity 0.39 0.21 0.67 0.0015 1 1 
3 Previously used NRT 0.59 0.42 0.85 0.0040 0 1 
4 WISDM Social/environmental Goads 0.61 0.51 0.72 4x10-8 1 1 
5 WISDM Tolerance 0.72 0.62 0.83 1x10-5 1 1 
6 FTND 0.76 0.65 0.89 0.0008 1 1 
7 WISDM PDM 0.79 0.68 0.91 0.0017 0 1 
8 NZDep2006 0.81 0.69 0.95 0.0098 0 1 
9 WISDM total 0.84 0.71 0.98 0.0273 0 1 
10 WISDM Automaticity 0.84 0.73 0.98 0.0226 0 1 
11 Lives with other smoker(s) 0.84 0.72 0.99 0.0369 0 1 
12 Number smokers typical day  0.86 0.73 1.01 0.0728 0 1 
13 WISDM Loss of control 0.87 0.75 1.02 0.0740 0 1 
14 WISDM Craving 0.89 0.77 1.04 0.1395 0 1 
15 WISDM Affective 0.90 0.78 1.05 0.1962 0 1 
16 WISDM SDM 0.91 0.77 1.06 0.2288 0 1 
17 WISDM Cue exposure 0.92 0.79 1.08 0.3089 0 0 
18 WISDM Affiliative Attachment 0.95 0.81 1.11 0.5310 0 0 








for 30 comparisons 
p<0.25 
20 WISDM Cognitive enhancement 1.02 0.88 1.20 0.7697 0 0 
21 WISDM Taste 1.06 0.91 1.24 0.4429 0 0 
22 Number of prior quit attempts 1.09 0.95 1.23 0.1541 0 1 
23 WISDM Weight control 1.14 0.98 1.32 0.0954 0 1 
24 Male Gender 1.17 0.86 1.59 0.3270 0 0 
25 Baseline Prepared Stress 1.22 1.04 1.44 0.0170 0 1 
26 No.  personal acquaintances quit 1.25 1.07 1.46 0.0054 0 1 
27 Age started smoking daily 1.27 1.02 1.10 0.0008 1 1 
28 Current Age (years) 1.50 1.28 1.77 1x10-6 1 1 
29 Started smoking aged 16 years or older 1.58 1.16 2.17 0.0044 0 1 
30 Currently aged 50 or older 2.10 1.54 2.87 3x10-6 1 1 








































































































































































































































































































































































































































































How well subjects think 
they are coping with 
quitting 
 0.24 0.13 0.19 0.27 0.17 0.20 -0.11 -0.17 0.52 0.28 0.38 0.52 0.25 
How often patches were 
worn 
0.24  0.53 0.47 0.43 0.28 0.18 -0.20 -0.07 0.35 0.30 0.27 0.32 0.38 
How often Patch worn at 
night 
0.13 0.53  0.23 0.24 0.21 0.11 -0.35 -0.01 0.18 0.14 0.15 0.23 0.16 
Opinion of Patches 
Score 
0.19 0.47 0.23  0.10 0.04 0.13 -0.23 -0.02 0.27 0.25 0.22 0.23 0.24 
How often mouthspray 
used per day 
0.27 0.43 0.24 0.10  0.65 0.51 -0.04 -0.32 0.33 0.23 0.28 0.25 0.41 
How many sprays used 
per occasion 
0.17 0.28 0.21 0.04 0.65  0.46 -0.06 -0.32 0.25 0.14 0.18 0.21 0.31 
Opinion of mouthspray 
score 
0.20 0.18 0.11 0.13 0.51 0.46  -0.09 -0.41 0.30 0.25 0.25 0.28 0.27 
Severity of side effects of 
patches 
-0.11 -0.20 -0.35 -0.23 -0.04 -0.06 -0.09  0.14 -0.11 -0.07 -0.07 -0.15 -0.06 
Severity of side effects of 
mouthspray 






































































































































































































































































































































































































































































How well subjects think 
they are coping with 
urges to smoke 
0.52 0.35 0.18 0.27 0.33 0.25 0.30 -0.11 -0.21  0.56 0.52 0.59 0.45 
How well subjects think 
they are coping with 
urges to smoke 
0.52 0.35 0.18 0.27 0.33 0.25 0.30 -0.11 -0.21  0.56 0.52 0.59 0.45 
How well subjects think 
they are coping with 
withdrawal symptoms 
0.28 0.30 0.14 0.25 0.23 0.14 0.25 -0.07 -0.12 0.56  0.35 0.33 0.36 
How confident subjects 
are that they are going to 
quit/remain quit 
0.38 0.27 0.15 0.22 0.28 0.18 0.25 -0.07 -0.21 0.52 0.35  0.48 0.58 
Quit status: not quit/ quit 
late/ quit on time/ quit 
early 
0.52 0.32 0.23 0.23 0.25 0.21 0.28 -0.15 -0.21 0.59 0.33 0.48  0.41 
Intend to continue to try 
to quit / to remain quit 
0.25 0.38 0.16 0.24 0.41 0.31 0.27 -0.06 -0.24 0.45 0.36 0.58 0.41  
Summary statistics for each column 
Min -0.17 -0.20 -0.35 -0.23 -0.32 -0.32 -0.41 -0.35 -0.41 -0.21 -0.12 -0.21 -0.21 -0.24 
2nd smallest -0.11 -0.07 -0.01 -0.02 -0.04 -0.06 -0.09 -0.23 -0.32 -0.11 -0.07 -0.07 -0.15 -0.06 






































































































































































































































































































































































































































































3rd largest 0.38 0.43 0.23 0.25 0.43 0.31 0.30 -0.06 -0.02 0.52 0.35 0.48 0.48 0.41 
2nd largest 0.52 0.47 0.24 0.27 0.51 0.46 0.46 -0.04 -0.01 0.56 0.36 0.52 0.52 0.45 
Max 0.52 0.53 0.53 0.47 0.65 0.65 0.51 0.14 0.14 0.59 0.56 0.58 0.59 0.58 
1st quartile 0.17 0.24 0.13 0.10 0.23 0.14 0.13 -0.15 -0.24 0.25 0.14 0.18 0.23 0.24 
3rd quartile 0.28 0.38 0.23 0.24 0.41 0.28 0.28 -0.06 -0.07 0.52 0.33 0.38 0.41 0.41 
Median 0.24 0.30 0.16 0.22 0.27 0.21 0.25 -0.09 -0.21 0.33 0.25 0.27 0.28 0.31 
Mean 0.22 0.27 0.15 0.16 0.26 0.19 0.19 -0.11 -0.17 0.31 0.23 0.26 0.27 0.27 
SD 0.20 0.20 0.19 0.17 0.25 0.23 0.23 0.11 0.15 0.24 0.18 0.22 0.23 0.22 
Outcomes below summarise variables across the entire table (all rows and columns) 
Min = -0.41; 2nd smallest = -0.41; 3rd smallest = -0.35; 3rd largest= 0.59; 2nd largest = 0.65; Max = 0.65; 1st quartile = -0.02; 3rd quartile = 0.33; 





Appendix C. INHALE adverse events, use of patches, 
inhaler satisfaction, urge to smoke, withdrawal symptoms, 
blind integrity, further discussion  
Unlike e-cigarettes, pMDIs do not heat their contents in order to form nicotine vapor and 
therefore do not cause potentially harmful nicotine degradation products to be created (403, 
427); pMDIs do not require the use of potentially unsafe excipients such as propylene glycol 
and glycerin(428); pMDIs do not require handling of toxic high doses of nicotine liquid refill 
cartridges; pMDI canisters are tamper-proof; and pMDIs do not require the expense of batteries 
to operate them. A further advantage of standard pMDIs is that they do not look like cigarettes 
unlike e-cigarettes, which model ‘smoking’ behavior to children,(404) and provoke urges to 
smoke in smokers who observe e-cigarettes being used.(429) 
Adverse Events  
Inhaler side-effects 
At baseline five of thirteen inhaler side-effects were significantly more common and more 
severe with the active cf. placebo inhalers (after Bonferroni correction), but were of mild 
severity for the majority of subjects and tended to resolve (Table C1, page 384).  The most 
common side-effects were mild coughing and mild throat scratch, which remained significantly 
higher in the active group one week after baseline, and progressively declined in prevalence in 
both groups thereafter. Just under half of subjects in the active group (110/225 (49%)) had not 
experienced any coughing, and 81/225 (36%) had experience mild coughing, compared to the 
control group in which 199/235 (85%) of subjects had not coughed, and 32/235 (14%) subjects 
had mild coughing.  Reported throat-scratch also diminished during this time period, with the 
majority of subjects in both groups experiencing none, although the incidence and severity of 
throat-scratch was significantly higher in the active group. After the target quit date, the 






Table C1 Inhaler adverse effects 
 
Baseline One week One day quit 
Active Control Active Control Active Control 
n/N % n/N % n/N % n/N % n/N % n/N % 
Coughing            
None 62/246 25·2 247/256 96·5 68/242 28·1 207/254 81·5 110/225 87/171 87/171 151/179 
Mild 141/246 57·3 8/256 3·1 125/242 51·7 42/254 16·5 81/225 62/171 62/171 25/179 
Moderate 31/246 12·6 1/256 0·4 37/242 15·3 5/254 2·0 21/225 16/171 16/171 3/179 
Severe 12/246 4·9 0/256 0 12/242 5·0 0/254 0 13/225 6/171 6/171 0/179 
p value <0·001 <0·001 <0·001 
Throat scratch            
None 132/246 53·7 235/256 91·8 145/242 59·9 216/254 85·0 157/224 111/171 111/171 111/171 
Mild 98/246 39·8 21/256 8·2 78/242 32·2 36/254 14·2 48/224 45/171 45/171 45/171 
Moderate 14/246 5·7 0/256 0 17/242 7·0 2/254 0·8 13/224 11/171 11/171 11/171 
Severe 2/246 0·8 0/256 0 2/242 0·8 0/254 0 6/224 4/171 4/171 4/171 
p value <0·001 <0·001 <0·001 
Sore throat            
None 210/246 85·4 254/256 99·2 na na na na 199/224 147/170 147/170 147/170 
Mild 32/246 13·0 2/256 0·8 na na na na 20/224 16/170 16/170 16/170 
Moderate 3/246 1·2 0/256 0 na na na na 3/224 5/170 5/170 5/170 
Severe 1/246 0·4 0/256 0 na na na na 2/224 2/170 2/170 2/170 





Baseline One week One day quit 
Active Control Active Control Active Control 
n/N % n/N % n/N % n/N % n/N % n/N % 
Difficulty breathing            
None 216/246 87·8 255/256 99·6 na na na na 214/224 164/170 164/170 164/170 
Mild 21/246 8·5 1/256 0·4 na na na na 7/224 4/170 4/170 4/170 
Moderate 5/246 2·0 0/256 0 na na na na 2/224 2/170 2/170 2/170 
Severe 4/246 1·6 0/256 0 na na na na 1/224 0/170 0/170 0/170 
p value <0·001  0·041 
Dizzy lightheaded            
None 202/246 82·1 223/256 87·1 201/241 83·4 229/254 90·2 200/224 152/170 152/170 152/170 
Mild 40/246 16·3 32/256 12·5 36/241 14·9 23/254 9·1 20/224 17/170 17/170 17/170 
Moderate 4/246 1·6 1/256 0·4 3/241 1·2 2/254 0·8 3/224 1/170 1/170 1/170 
Severe 0/246 0 0/256 0 1/241 0·4 0/254 0 1/224 0/170 0/170 0/170 
p value 0·111 0·026 0·008 
Headache             
None 235/246 95·5 249/256 97·3 214/241 88·8 231/254 90·9 204/224 161/170 161/170 161/170 
Mild 11/246 4·5 6/256 2·3 24/241 10·0 18/254 7·1 16/224 7/170 7/170 7/170 
Moderate 0/246 0 1/256 0·4 3/241 1·2 3/254 1·2 3/224 2/170 2/170 2/170 
Severe 0/246 0 0/256 0 0/241 0 2/254 0·8 1/224 0/170 0/170 0/170 





Baseline One week One day quit 
Active Control Active Control Active Control 
n/N % n/N % n/N % n/N % n/N % n/N % 
Nausea            
None 233/246 94·7 254/256 99·2 224/241 92·9 245/254 96·5 212/224 156/171 156/171 156/171 
Mild 13/246 5·3 1/256 0·4 13/241 5·4 9/254 3·5 10/224 12/171 12/171 12/171 
Moderate 0/246 0 1/256 0·4 3/241 1·2 0/254 0 2/224 2/171 2/171 2/171 
Severe 0/246 0 0/256 0 1/241 0·4 0/254 0 0/224 1/171 1/171 1/171 
p value 0·003 0·076 0·034 
Chest discomfort            
None 243/246 98·8 255/256 99·6 na na na na 223/224 168/170 168/170 168/170 
Mild 3/246 1·2 1/256 0·4 na na na na 1/224 2/170 2/170 2/170 
Moderate 0/246 0 0/256 0 na na na na 0/224 0/170 0/170 0/170 
Severe 0/246 0 0/256 0 na na na na 0/224 0/170 0/170 0/170 
p value 0·297  0·307 
Palpitations            
None 243/246 98·8 256/256 100 na na na na 218/224 166/170 166/170 166/170 
Mild 3/246 1·2 0/256 0 na na na na 6/224 3/170 3/170 3/170 
Moderate 0/246 0 0/256 0 na na na na 0/224 1/170 1/170 1/170 
Severe 0/246 0 0/256 0 na na na na 0/224 0/170 0/170 0/170 





Baseline One week One day quit 
Active Control Active Control Active Control 
n/N % n/N % n/N % n/N % n/N % n/N % 
Vomiting            
None 246/246 100 256/256 100 na na na na 220/224 169/171 169/171 169/171 
Mild 0/246 0 0/256 0 na na na na 1/224 1/171 1/171 1/171 
Moderate 0/246 0 0/256 0 na na na na 3/224 0/171 0/171 0/171 
Severe 0/246 0 0/256 0 na na na na 0/224 1/171 1/171 1/171 
p value NA  0·161 
Headrush            
None 226/246 91·9 241/256 94·1 na na na na 215/224 161/170 161/170 161/170 
Mild 19/246 7·7 15/256 5·9 na na na na 7/224 8/170 8/170 8/170 
Moderate 1/246 0·4 0/256 0 na na na na 2/224 1/170 1/170 1/170 
Severe 0/246 0 0/256 0 na na na na 0/224 0/170 0/170 0/170 
p value 0·313  0·238 
Jittery            
None 232/246 94·3 242/256 94·5 na na na na 216/224 167/170 167/170 3/170 
Mild 14/246 5·7 14/256 5·5 na na na na 8/224 3/170 3/170 0/170 
Moderate 0/246 0 0/256 0 na na na na 0/224 0/170 0/170 0/170 
Severe 0/246 0 0/256 0 na na na na 0/224 0/170 0/170 0·755 





Baseline One week One day quit 
Active Control Active Control Active Control 
n/N % n/N % n/N % n/N % n/N % n/N % 
Heartburn            
None 244/246 99·2 255/256 99·6 229/241 95·0 239/254 94·1 208/224 154/170 154/170 14/170 
Mild 2/246 0·8 1/256 0·4 11/241 4·6 13/254 5·1 13/224 14/170 14/170 1/170 
Moderate 0/246 0 0/256 0 1/241 0·4 2/254 0·8 2/224 1/170 1/170 1/170 
Severe 0/246 0 0/256 0 0/241 0 0/254 0 1/224 1/170 1/170 0·020 
p value 0·540 0·645 0·042 
Other            
None 229/245 93·5 251/255 98·4 214/240 89·2 229/254 90·2 196/221 159/170 159/170 159/170 
Mild 15/245 6·1 4/255 1·6 16/240 6·7 23/254 9·1 18/221 8/170 8/170 8/170 
Moderate 1/245 0·4 0/255 0 5/240 2·1 2/254 0·8 4/221 2/170 2/170 2/170 
Severe 0/245 0 0/255 0 5/240 2·1 0/254 0 3/221 1/170 1/170 1/170 






Table C1 Inhaler adverse effects (continued) 
 
One month quit Three month quit Six month quit 
Active Active Active Active Active Active 
n/N n/N n/N n/N n/N % n/N % n/N % n/N % 
Coughing            
None 87/171 50·9 151/179 84·4 90/147 61·2 125/143 87·4 105/128 82·0 112/119 94·1 
Mild 62/171 36·3 25/179 14·0 40/147 27·2 17/143 11·9 16/128 12·5 7/119 5·9 
Moderate 16/171 9·4 3/179 1·7 10/147 6·8 1/143 0·7 2/128 1·6 0/119 0 
Severe 6/171 3·5 0/179 0 7/147 4·8 0/143 0 5/128 3·9 0/119 0 
p value <0·001 <0·001 0·003 
Throat scratch            
None 111/171 64·9 147/179 82·1 114/147 77·6 124/143 86·7 106/128 82·8 108/119 90·8 
Mild 45/171 26·3 28/179 15·6 25/147 17·0 17/143 11·9 14/128 10·9 9/119 7·6 
Moderate 11/171 6·4 4/179 2·2 5/147 3·4 2/143 1·4 3/128 2·3 2/119 1·7 
Severe 4/171 2·3 0/179 0 3/147 2·0 0/143 0 5/128 3·9 0/119 0 
p value <0·001 0·034 0·057 
Sore throat            
None 147/170 86·5 169/179 94·4 114/147 77·6 124/143 86·7 118/128 92·2 116/119 97·5 
Mild 16/170 9·4 7/179 3·9 25/147 17·0 17/143 11·9 8/128 6·3 2/119 1·7 
Moderate 5/170 2·9 3/179 1·7 5/147 3·4 2/143 1·4 1/128 0·8 0/119 0 
Severe 2/170 1·2 0/179 0 3/147 2·0 0/143 0 1/128 0·8 1/119 0·8 





One month quit Three month quit Six month quit 
Active Active Active Active Active Active 
n/N n/N n/N n/N n/N % n/N % n/N % n/N % 
Difficulty breathing            
None 164/170 96·5 174/179 97·2 138/147 93·9 141/143 98·6 126/128 98·4 119/119 100 
Mild 4/170 2·4 4/179 2·2 3/147 2·0 2/143 1·4 1/128 0·8 0/119 0 
Moderate 2/170 1·2 1/179 0·6 4/147 2·7 0/143 0 0/128 0 0/119 0 
Severe 0/170 0 0/179 0 2/147 1·4 0/143 0 1/128 0·8 0/119 0 
p value 0·689 0·033 0·172 
Dizzy lightheaded            
None 152/170 89·4 168/179 93·9 137/147 93·2 135/143 94·4 123/128 96·1 118/119 99·2 
Mild 17/170 10·0 8/179 4·5 5/147 3·4 7/143 4·9 4/128 3·1 0/119 0 
Moderate 1/170 0·6 2/179 1·1 4/147 2·7 1/143 0·7 1/128 0·8 1/119 0·8 
Severe 0/170 0 1/179 0·6 1/147 0·7 0/143 0 0/128 0 0/119 0 
p value 0·147 0·633 0·122 
Headache            
None 161/170 94·7 172/179 96·1 137/147 93·2 139/143 97·2 128/128 100 118/118 100 
Mild 7/170 4·1 4/179 2·2 4/147 2·7 4/143 2·8 0/128 0 0/118 0 
Moderate 2/170 1·2 2/179 1·1 6/147 4·1 0/143 0 0/128 0 0/118 0 
Severe 0/170 0 1/179 0·6 0/147 0 0/143 0 0/128 0 0/118 0 





One month quit Three month quit Six month quit 
Active Active Active Active Active Active 
n/N n/N n/N n/N n/N % n/N % n/N % n/N % 
Nausea            
None 156/171 91·2 175/179 97·8 139/147 94·6 140/143 97·9 122/128 95·3 118/119 99·2 
Mild 12/171 7·0 4/179 2·2 5/147 3·4 3/143 2·1 5/128 3·9 1/119 0·8 
Moderate 2/171 1·2 0/179 0 3/147 2·0 0/143 0 1/128 0·8 0/119 0 
Severe 1/171 0·6 0/179 0 0/147 0 0/143 0 0/128 0 0/119 0 
p value 0·007 0·132 0·069 
Chest discomfort            
None 168/170 98·8 179/179 100 143/147 97·3 143/143 100 128/128 100 119/119 100 
Mild 2/170 1·2 0/179 0 4/147 2·7 0/143 0 0/128 0 0/119 0 
Moderate 0/170 0 0/179 0 0/147 0 0/143 0 0/128 0 0/119 0 
Severe 0/170 0 0/179 0 0/147 0 0/143 0 0/128 0 0/119 0 
p value 0·146 0·047 NA 
Palpitations            
None 166/170 97·6 177/179 98·9 146/147 99·3 141/143 98·6 126/128 98·4 119/119 100 
Mild 3/170 1·8 2/179 1·1 1/147 0·7 2/143 1·4 2/128 1·6 0/119 0 
Moderate 1/170 0·6 0/179 0 0/147 0 0/143 0 0/128 0 0/119 0 
Severe 0/170 0 0/179 0 0/147 0 0/143 0 0/128 0 0/119 0 





One month quit Three month quit Six month quit 
Active Active Active Active Active Active 
n/N n/N n/N n/N n/N % n/N % n/N % n/N % 
Vomiting            
None 169/171 98·8 179/179 100 146/147 99·3 143/143 100 127/128 99·2 119/119 100 
Mild 1/171 0·6 0/179 0 1/147 0·7 0/143 0 1/128 0·8 0/119 0 
Moderate 0/171 0 0/179 0 0/147 0 0/143 0 0/128 0 0/119 0 
Severe 1/171 0·6 0/179 0 0/147 0 0/143 0 0/128 0 0/119 0 
p value 0·147 0·324 0·335 
Headrush            
None 161/170 94·7 171/179 95·5 141/147 95·9 140/143 97·9 126/128 98·4 118/119 99·2 
Mild 8/170 4·7 7/179 3·9 3/147 2·0 3/143 2·1 1/128 0·8 1/119 0·8 
Moderate 1/170 0·6 0/179 0 3/147 2·0 0/143 0 1/128 0·8 0/119 0 
Severe 0/170 0 1/179 0·6 0/147 0 0/143 0 0/128 0 0/119 0 
p value 0·723 0·321 0·602 
Jittery            
None 167/170 98·2 175/179 97·8 146/147 99·3 140/143 97·9 124/128 96·9 119/119 100 
Mild 3/170 1·8 4/179 2·2 1/147 0·7 3/143 2·1 4/128 3·1 0/119 0 
Moderate 0/170 0 0/179 0 0/147 0 0/143 0 0/128 0 0/119 0 
Severe 0/170 0 0/179 0 0/147 0 0/143 0 0/128 0 0/119 0 





One month quit Three month quit Six month quit 
Active Active Active Active Active Active 
n/N n/N n/N n/N n/N % n/N % n/N % n/N % 
Heartburn            
None 154/170 90·6 173/179 96·6 132/147 89·8 138/143 96·5 123/128 96·1 116/119 97·5 
Mild 14/170 8·2 5/179 2·8 9/147 6·1 4/143 2·8 3/128 2·3 2/119 1·7 
Moderate 1/170 0·6 1/179 0·6 5/147 3·4 1/143 0·7 1/128 0·8 1/119 0·8 
Severe 1/170 0·6 0/179 0 1/147 0·7 0/143 0 1/128 0·8 0/119 0 
p value 0·020 0·023 0·536 
Other            
None 159/170 93·5 170/179 95·0 135/146 92·5 133/143 93·0 124/128 96·9 117/119 98·3 
Mild 8/170 4·7 6/179 3·4 10/146 6·8 8/143 5·6 3/128 2·3 0/119 0 
Moderate 2/170 1·2 2/179 1·1 1/146 0·7 2/143 1·4 1/128 0·8 2/119 1·7 
Severe 1/170 0·6 1/179 0·6 0/146 0 0/143 0 0/128 0 0/119 0 






Severe side-effects from the inhaler were rare, the most common severe side-effect was 
coughing reported by 13/225 (13%) of subjects in the active group one day after the target 
quit date. 
Difficulty breathing was the term used to measure any adverse change in the subjective 
quality of breathing. At all time-points difficulty breathing was significantly associated with 
coughing, and most likely was caused by coughing (Table C2, page 394). At baseline, 30 
subjects coughed after using the inhaler compared to one subject in the placebo group whose 
coughing was mild. Of the four subjects who had severe breathlessness at baseline, all of them 
had severe coughing. Of the 12 subjects who had severe coughing at baseline, 6 had no 
difficulty breathing, 2 had moderate difficulty breathing, and 4 had severe difficulty 
breathing. A description of the four subjects who had severe difficulty breathing at baseline is 
provided in Table C3 (page 395). 
Coughing was of very short duration. Duration was formally recorded at the twenty-four-hour 
post target quit data phone-call, and the one-month post target quit date visit. At the 24 hours 
post target quit date phone-call, the duration of coughing was median (IQR) 0·17 (0·08, 0·50) 
minutes with the active inhaler, and 0·08 (0·08, 0·50) with the placebo inhaler, p=0·90. At the 
one month visit the duration of coughing was median (IQR) 0·08 (0·05, 0·05) minutes with the 
active inhaler, and 0·08 (0·05, 0·17) with the placebo inhaler, p=0·37.  
13 subjects with asthma were enrolled with their family physician’s approval. Having asthma 
was neither associated with difficulty breathing severity nor with coughing severity (data not 
shown).  Although the majority of side-effects were of mild severity, a significantly greater 
number of subjects withdrew due to inhaler side-effects in the active compared to control 
groups (15/246 (6·1%) cf. 3/256 (1·2%), 95%CI 1·7%, 8·2%, p=0·003).  Serious adverse 
events were uncommon and not significantly different between groups (Table C4, page 396). 
Nicotine patch side-effects 
Side-effects from nicotine patches were common, but predominantly mild (Table C5, page 
397). The most common side-effects were itchy skin at one week after baseline (71/239 (30%) 
and 105/254 (41%) in the active and control groups respectively), and red skin marks at one 
month after quit date (84/178 (47%) and 83/164 (51%) in the active and control groups 
respectively). The most common severe nicotine patch side-effects were disturbed 
sleep/dreams (5.1% of active subjects at one month after the target quit date), and red marks 




Table C2 Association of difficulty breathing with coughing 
  Difficulty breathing 
  Baseline 24 hours post target quit date One month post target quit date 









None 306 3 0 0 304 3 1 0 234 3 1 0 
Mild 134 14 1 0 109 4 0 0 82 4 1 0 
Moderate 25 5 2 0 20 1 2 0 17 1 1 0 
Severe 6 0 2 4 12 1 0 1 5 0 0 0 
p-value <0·001 <0·001 0·17 
  Difficulty breathing 
  Three months post target quit date 6 months post target quit date  









None 213 2 0 0 217 0 0 217     
Mild 53 2 2 0 23 0 0 23     
Moderate 8 1 2 0 1 1 0 1     
Severe 5 0 0 2 4 0 1 4     












Active Baseline Severe coughing and breathlessness. At screening this subject reported that he was not taking inhaled steroid 
medicines. He was withdrawn at baseline due to severe coughing and breathlessness. After he was withdrawn, 
his family practitioner was contacted who reported that the subject had chronic obstructive pulmonary disease 
and had been prescribed daily inhaled corticosteroid. 
Active One week 
phone-call 
Severe coughing and breathlessness· At baseline only had four puffs of low dose and no puffs of high dose· 
Subject was withdrawn at the one week phone-call due to side-effects. 
Active One week 
phone-call 
Severe coughing and breathlessness· Often coughs when he smokes. Withdrawn shortly after his one week 
phone-call due to breathlessness that was often not related to recent use of the inhaler. This subject withdrew 
consent at this time and had stopped using the inhaler and nicotine patches. He was advised to see his family 
practitioner. 
Active One day quit 
phone-call 
Severe coughing and breathlessness at baseline, became tolerant during baseline visit.  After baseline he 
predominately used 100µg and occasionally used 200µg. He found the inhalers very effective but could not 
totally quit smoking.  He was always very difficult to contact and was lost to follow-up. 





Table C4 Serious adverse events 






Timing of SAE Relation to 
study 
treatment 
Throat/lung cancer and 
hospitalization 
2 0 One reported this event at the one month post target quit date visit and withdrew 
consent at this time.  One reported this event after completing Three month post-
target quit date visit, and withdrew consent at this time. 
Both unrelated 
Hospitalization 1 0 After quit phone-call. Withdrew consent after quit phone-call Unrelated 
Severe depression 1 0 After quit call· Withdrew consent after quit phone-call Possibly 
Serious difficulty 
breathing after using 
inhaler 
1 0 During baseline* Withdrawn at baseline Definitely 
* This subject had severe shortness of breath after using the active inhaler at baseline. He had reported at screening that he had not been prescribed an inhaled 
corticosteroid, but after he was withdrawn his general practitioner reported that this subject had been prescribed an inhaled corticosteroid for severe Chronic 





Table C5 Side-effects of patches 
 Baseline One week 1 day quit 
Active Control Active Control Active Control 
n/N % n/N % n/N % n/N % n/N % n/N % 
Itchy skin            
 None 212/246 86·2 227/256 88·7 167/238 70·2 149/254 58·7 143/219 65·3 137/234 58·5 
 Mild 32/246 13·0 26/256 10·2 64/238 26·9 93/254 36·6 63/219 28·8 80/234 34·2 
 Moderate 2/246 0·8 3/256 1·2 6/238 2·5 9/254 3·5 11/219 5·0 11/234 4·7 
 Severe 0/246 0 0/256 0 1/238 0·4 3/254 1·2 2/219 0·9 6/234 2·6 
 p value 0·413 0·007 0·138 
Red mark            
 None 232/246 94·3 237/256 92·6 168/238 70·6 166/254 65·4 139/219 63·5 152/234 65·0 
 Mild 12/246 4·9 18/256 7·0 61/238 25·6 74/254 29·1 70/219 32·0 67/234 28·6 
 Moderate 2/246 0·8 1/256 0·4 8/238 3·4 11/254 4·3 8/219 3·7 9/234 3·8 
 Severe 0/246 0 0/256 0 1/238 0·4 3/254 1·2 2/219 0·9 6/234 2·6 
 p value 0·445 0·191 0·881 
Sleep/dreams            
 None na na na na 124/237 52·3 132/253 52·2 136/216 63·0 159/229 69·4 
 Mild na na na na 63/237 26·6 67/253 26·5 42/216 19·4 35/229 15·3 
 Moderate na na na na 25/237 10·5 28/253 11·1 27/216 12·5 28/229 12·2 
 Severe na na na na 25/237 10·5 26/253 10·3 11/216 5·1 7/229 3·1 




 Baseline One week 1 day quit 
Active Control Active Control Active Control 
n/N % n/N % n/N % n/N % n/N % n/N % 
Other            
 None 242 98·4 252 98·4 220/236 93·2 233/253 92·1 207/219 94·5 214/230 93·0 
 Mild 4 1·6 3 1·2 7/236 3·0 8/253 3·2 9/219 4·1 7/230 3·0 
 Moderate 0 0 0 0 5/236 2·1 8/253 3·2 2/219 0·9 6/230 2·6 
 Severe 0 0 0 0 4/236 1·7 4/253 1·6 1/219 0·5 3/230 1·3 






Table C5 Side-effects of patches (continued) 
 One month quit Three months quit 6 months quit 
Active Control Active Control Active Control 
n/N % n/N % n/N % n/N % n/N % n/N % 
Itchy skin             
 None 88/164 53·7 94/178 52·8 96/141 68·1 92/143 64·3 80/104 76·9 84/111 75·7 
 Mild 58/164 35·4 63/178 35·4 30/141 21·3 40/143 28·0 18/104 17·3 23/111 20·7 
 Moderate 14/164 8·5 17/178 9·6 9/141 6·4 6/143 4·2 5/104 4·8 2/111 1·8 
 Severe 4/164 2·4 4/178 2·2 6/141 4·3 5/143 3·5 1/104 1·0 2/111 1·8 
 p value 0·845 0·668 0·899 
Red mark             
 None 81/164 49·4 101/178 56·7 96/141 68·1 86/143 60·1 72/103 69·9 74/111 66·7 
 Mild 71/164 43·3 59/178 33·1 33/141 23·4 44/143 30·8 28/103 27·2 32/111 28·8 
 Moderate 10/164 6·1 15/178 8·4 5/141 3·5 7/143 4·9 1/103 1·0 4/111 3·6 
 Severe 2/164 1·2 3/178 1·7 7/141 5·0 6/143 4·2 2/103 1·9 1/111 0·9 
 p value 0·333 0·205 0·580 
Sleep/dreams             
 None 99/158 62·7 125/168 74·4 112/139 80·6 112/137 81·8 85/104 81·7 98/110 89·1 
 Mild 33/158 20·9 24/168 14·3 14/139 10·1 16/137 11·7 15/104 14·4 7/110 6·4 
 Moderate 18/158 11·4 16/168 9·5 9/139 6·5 3/137 2·2 2/104 1·9 3/110 2·7 
 Severe 8/158 5·1 3/168 1·8 4/139 2·9 6/137 4·4 2/104 1·9 2/110 1·8 




 One month quit Three months quit 6 months quit 
Active Control Active Control Active Control 
n/N % n/N % n/N % n/N % n/N % n/N % 
Other             
 None 152/164 92·7 164/178 92·1 135/141 95·7 137/142 96·5 98/102 96·1 106/109 97·2 
 Mild 10/164 6·1 9/178 5·1 3/141 2·1 4/142 2·8 4/102 3·9 2/109 1·8 
 Moderate 1/164 0·6 3/178 1·7 3/141 2·1 1/142 0·7 0/102 0 1/109 0·9 
 Severe 1/164 0·6 2/178 1·1 0/141 0 0/142 0 0/102 0 0/109 0 
 p value 0·820 0·735 0·647 
Side-effects were recorded by self-report on four-point Likert scales: none, mild (no change in lifestyle), moderate (alter lifestyle 
occasionally), severe (major lifestyle impairment). 





had greater severity of itchy skin at one-week p=0·007, and active group had greater severity 
of disturbed sleep/dreams at one month after target quit data p=0·022, only the difference 
initchy skin would remain significant after Holm-Bonferroni correction for four side-effects.  
Use of Patches 
Use of nicotine patches was similar in both groups after Holm-Bonferroni correction (Table 
C6, page 402).  Although subjects were instructed to use Step1 patches for the first four 
months of the trial, half of subjects in both groups had used them for less than two thirds of 
the days between one and three months after target quit date.   
Inhaler satisfaction 
The subjective experience of inhaling from the pMDIs was evaluated at baseline, and one- 
and three-months post target quit date, using the modified Cigarette Evaluation Questionnaire 
(mCEQ).(305) Both the active and placebo inhalers scored well on the mCEQ (Table C7, 
Appendix C, page 404), for example at baseline over half of subjects in both groups scored 
moderately or higher for Smoking Satisfaction.  At baseline, the active inhaler did not have 
significantly higher scores for any of the four positive domains; whereas the placebo inhaler 
had significantly higher scores for two of the positive domains (Smoking Satisfaction, and 
Enjoy Respiratory Sensations) and significantly lower scores for Aversion.  One month after 
the target quit date, the active inhaler had significantly higher scores for two positive domains 
(Psychological Reward, and Craving Reduction); while the placebo inhaler had significantly 
higher scores for two positive scores (Smoking Satisfaction, Enjoyable Respiratory 
Sensations), and significantly lower scores for Aversion. By the six-month phone-call, the 
active inhaler retained its significantly higher score for Craving Reduction, and the placebo 
inhaler its lower score for Aversion. 
Urge to Smoke 
There were few differences between groups in subjects’ brief Questionnaire of Smoking 
Urges (QSU) scores (Table C8, Appendix C, page 405), the only significant differences 
(p<0·05) were a lower post-inhaler total score and a larger pre/post-inhaler reduction in total 
score at baseline in the active compared to control groups; and lower total scores at the one- 




Table C6 Use of patches 
  Active group Control group  
    Mean Median IQR n Mean Median IQR n p value 
One Week                   
  Step1 Days Used 87 100 86, 100 241 87 100 86, 100 253 0·43 
  Step1 Nights Used 69 100 29, 100 241 69 87 30, 100 254 0·70 
  Step2 Days Used 3 0 0, 0 152 1 0 0, 0 150 0·16 
  Step2 Nights Used 1 0 0, 0 152 0 0 0, 0 149 0·32 
  Step3 Days Used 0 0 0, 0 152 0 0 0, 0 149 NA 
  Step3 Nights Used 0 0 0, 0 152 0 0 0, 0 149 NA 
Quit call                   
  Step1 Days Used 83 100 80, 100 225 80 100 67, 100 237 0·20 
  Step1 Nights Used 60 86 0, 100 225 56 68 0, 100 237 0·24 
  Step2 Days Used 2 0 0, 0 149 0 0 0, 0 159 0·08 
  Step2 Nights Used 1 0 0, 0 149 0 0 0, 0 159 0·04 
  Step3 Days Used 0 0 0, 0 148 0 0 0, 0 159 0·33 
  Step3 Nights Used 0 0 0, 0 149 0 0 0, 0 159 NA 
One month quit visit                   
  Step1 Days Used 67 92 29, 100 184 66 86 33, 100 196 0·89 
  Step1 Nights Used 48 40 0, 100 184 47 48 0, 100 196 0·71 
  Step2 Days Used 3 0 0, 0 155 1 0 0, 0 175 0·11 
  Step2 Nights Used 2 0 0, 0 154 1 0 0, 0 174 0·33 




  Active group Control group  
    Mean Median IQR n Mean Median IQR n p value 
  Step3 Nights Used 0 0 0, 0 154 0 0 0, 0 172 NA 
Three month quit visit                   
  Step1 Days Used 50 58 0, 94 164 53 61 10, 95 166 0·52 
  Step1 Nights Used 34 0 0, 79 165 35 8 0, 78 165 0·62 
  Step2 Days Used 4 0 0, 0 157 2 0 0, 0 161 0·15 
  Step2 Nights Used 3 0 0, 0 158 1 0 0, 0 159 0·06 
  Step3 Days Used 1 0 0, 0 152 1 0 0, 0 160 0·92 
  Step3 Nights Used 0 0 0, 0 154 0 0 0, 0 159 0·96 
6 Month quit visit                   
  Step1 Days Used 8 0 0, 0 157 11 0 0, 7 152 0·09 
  Step1 Nights Used 6 0 0, 0 157 6 0 0, 0 150 0·85 
  Step2 Days Used 7 0 0, 14 158 6 0 0, 12 150 0·28 
  Step2 Nights Used 5 0 0, 7 158 4 0 0, 0 149 0·35 
  Step3 Days Used 5 0 0, 12 155 4 0 0, 8 150 0·86 
  Step3 Nights Used 3 0 0, 0 154 3 0 0, 0 148 0·82 






Table C7 Modified Cigarette Evaluation Questionnaire 
  
Active Group Control Group  
 








Smoking Satisfaction 4·0 4·0 3·0, 4·7 246 4·5 4·3 3·7, 5·3 256 0.000007 
Psychological Reward 2·5 2·2 1·4, 3·2 246 2·4 2·2 1·4, 3·1 256 0.487210 
Aversion 1·6 1·5 1·0, 2·0 246 1·4 1·0 1·0, 2·0 256 0.000318 
Enjoy Respiratory Sensations 3·0 3·0 1·0, 4·0 246 3·6 4·0 3·0, 5·0 256 0.000009 












Smoking Satisfaction  3·8 3·7 2·7, 4·7 175 4·2 4·0 3·3, 5·0 187 0.018806 
Psychological Reward  2·6 2·6 1·6, 3·6 175 2·4 2·2 1·6, 3·0 187 0.033358 
Aversion  1·4 1·0 1·0, 1·5 175 1·2 1·0 1·0, 1·0 187 0.000101 
Enjoy Respiratory Sensations  2·3 1·0 1·0, 3·0 175 2·9 3·0 1·0, 4·0 188 0.000189 
















Smoking Satisfaction 4·1 4·0 2·7, 5·3 146 4·2 4·2 3·3, 5·3 142 0.352172 
Psychological Reward 2·9 2·8 1·6, 3·8 145 2·7 2·6 1·6, 3·4 142 0.295846 
Aversion 1·3 1·0 1·0, 1·0 146 1·2 1·0 1·0, 1·0 142 0.041810 
Enjoy Respiratory Sensations 2·8 2·0 1·0, 4·0 146 2·9 3·0 1·0, 4·0 142 0.507748 














Smoking Satisfaction 4·3 4·3 3·3, 5·4 128 4·2 4·0 3·3, 5·0 119 0.503347 
Psychological Reward 2·9 2·8 1·8, 3·8 128 2·7 2·6 1·6, 3·6 119 0.152682 
Aversion 1·3 1·0 1·0, 1·0 128 1·1 1·0 1·0, 1·0 118 0.004350 
Enjoy Respiratory Sensations 3·0 3·0 1·0, 4·0 128 2·9 3·0 1·0, 4·0 119 0.957049 
Craving Reduction 5·0 5·0 4·0, 6·0 128 4·2 5·0 3·0, 5·0 119 0.002132 




Table C8 brief-Questionnaire of Smoking Urges 
 Active Control  
  Mean Median IQR n Mean Median IQR n p 
Baseline before inhaler 43·0 45·0 32·0, 54·0 246 42·7 43·0 33·0, 54·0 246 0·739 
Baseline after inhaler 25·3 22·0 15·0, 32·8 246 27·7 25·5 17·0, 37·0 246 0·016 
Baseline post inhaler minus pre inhaler -17·7 -15·5 -26·0, -8·0 246 -15·0 -13·0 -22·3, -6·0 246 0·040 
One Month Visit 19·1 14·0 10·0, 23·0 175 21·0 17·5 11·0, 29·0 175 0·020 
One Month Visit minus Baseline pre-inhaler -24·9 -27·0 -38·5, -12·0 175 -21·3 -22·5 -34·0, -9·0 175 0·075 
Three Month Phone-call  18·1 11·0 10·0, 22·0 162 20·7 16·0 10·0, 26·3 162 0·011 
Three Month Phone-call minus Baseline pre-
inhaler 
-25·5 -26 -39, -13 162 -21·8 -25 -35, -8·8 162 0·121 
Three Month Phone-call minus One Month Visit 0·0 0·0 -2·8, 2·0 158 0·2 0·0 -6·0, 3·0 158 0·457 
Six Month Phone-call 18·4 10·0 10·0, 23·0 157 20·3 14·0 10·0, 28·0 157 0·031 
Six Month Phone-call minus Baseline pre-inhaler -25·4 -28·0 -40, -12 157 22·4 -23·0 -36·7, 10·3 157 0·150 
Six Month Phone-call minus Three Month Phone-
call 






Table C9 modified Minnesota Nicotine Withdrawal Scale 
  Active Control  
 








Craving 2·7 3·0 2·0, 3·0 246 2·7 3·0 2·0, 3·0 256 0·362 
Restlessness 1·0 1·0 0·0, 2·0 246 0·9 1·0 0·0, 2·0 256 0·244 
Increased Appetite 0·4 0·0 0·0, 0·0 246 0·3 0·0 0·0, 0·0 256 0·176 
Negative Affect 0·8 0·5 0·3, 1·3 246 0·8 0·5 0·3, 1·0 256 0·763 









Craving 1·5 1·0 1·0, 2·0 175 1·7 2·0 1·0, 2·0 189 0·090 
Restlessness 0·9 1·0 0·0, 1·5 175 0·9 1·0 0·0, 1·0 189 0·841 
Increased Appetite 0·7 0·0 0·0, 1·0 175 0·8 0·0 0·0, 1·0 189 0·286 
Negative Affect 0·8 0·3 0·0, 1·3 175 0·8 0·5 0·3, 1·0 189 0·322 









 Craving 1·2 1·0 0·0, 2·0 163 1·6 2·0 0·0, 2·0 165 0·009 
Restlessness 0·6 0·0 0·0, 1·0 163 0·7 0·0 0·0, 1·0 164 0·731 
Increased Appetite 0·5 0·0 0·0, 1·0 163 0·5 0·0 0·0, 1·0 164 0·876 
Negative Affect 0·6 0·3 0·0, 0·8 163 0·6 0·3 0·0, 0·8 164 0·668 








Craving 1·2 1·0 0·0, 2·0 157 1·7 2·0 0·0, 3·0 150 0·001 
Restlessness 0·5 0·0 0·0, 1·0 157 0·7 0·0 0·0, 1·0 150 0·249 
Increased Appetite 0·4 0·0 0·0, 0·0 157 0·5 0·0 0·0, 1·0 150 0·133 
Negative Affect 0·5 0·0 0·0, 0·8 157 0·6 0·3 0·0, 1·0 150 0·172 




Subjects in the two groups had similar nicotine withdrawal scores at all time-points except for 
highly statistically significant lower Craving scores at three- and six-months post target quit 
date (Table C9, page 406). 
Integrity of the blind 
Here, assessments of the integrity of the blind are reported along with the predictors of 
unblinding.  Table C10, page 409 displays the results of analyses that identified which 
variables, and which time-points they were measured at, that significantly predicted 
unblinding at a variety of time-points.  Different levels of Bonferroni correction are reported.  
These analyses show that, subjects were unmasked at all time-points but this did not bias the 
estimation of the primary outcome of the extent to which the active inhaler combination 
therapy increased prolonged six-months abstinence cf. control combination therapy. 
Baseline 
At baseline, significantly more subjects guessed their treatment assignment correctly than 
incorrectly, the probability of being correct/incorrect was 178/305 = 0.58, 95%CI:0.53—0.64, 
p=0.0041, indicating that subjects were unmasked.  Subjects who guessed correctly had 
significantly higher abstinence rates than subjects who were unsure, albeit only at the level of 
p<0.05, (31.46% cf. 21.43%, a difference of 10.03%, 05%CI:1.11%—18.95%, p=0.0276.   
At baseline, significantly more subjects in the active group correctly guessed their treatment 
assignment than in the control group (147 cf. 31), while more subjects in the control group 
guessed incorrectly than in the active group (114 cf. 13), and there was more uncertainty 
among control subjects than active subjects (111 cf. 85), the p-value for all these comparisons 
was 0.00047.   
One week after baseline 
A week after baseline, 190 subjects guesses of their treatment assignment were correct, 133 
were incorrect, and 172 were unsure.  The probability of guessing correctly cf. incorrectly was 
190/(190+133), 190/323, which is 0.59 (95%CI:0.53—0.64), p=0.0018, and is significantly 
better than chance, hence subjects were unblinded at this time-point.   
 
 408 
One month after baseline 
A day after the target quit date, the probability of subjects who correctly cf. incorrectly 
guessed their treatment assignments was significantly better than chance (0.58, 95%CI: 
0.53—0.63, p=0.0034).  Hence subjects were unmasked at this timepoint.   
A month after baseline, significantly more subjects in the active group guessed they were 
probably or definitely on active inhalers than in the control group (103/190 (57.37) cf. 71/182 
(39.01%), respectfully; while significantly more subjects in the control group guessed they 
were using placebo inhalers (49/182 (26.92%) cf. 24/90 (12.63%), Χ2=16.63, d.f.=2, 
p=0.0002 for both comparisons. 
Two months after baseline 
The probability of guessing correctly rather than incorrectly a month after subjects’ target quit 
dates was 184/290, which is 0.63, 95%CI:0.58—0.69, p=5x10-6, indicating that subjects were 
unmasked a month after their target quit dates.   
Three months after the target quit date 
Three months after subjects’ target quit dates, 159, 103, and 71 guessed their treatment 
assignments correctly, incorrectly, and unsure, respectively.  The probability of being correct 
was significantly greater than being incorrect (0.61, 95%CI:0.54—0.67, p=0.0007).   
Six months post-target-quit-date 
Six months after subjects’ target quit dates, 142, 87, and 72 subjects guessed their treatment 
assignments correctly, incorrectly, and unsure, respectively.  The probability of guessing 
correctly was significantly greater than guessing incorrectly (142/229= 0.62, 95%CI:0.55—





Table C10.  Variables associated with subjects correctly guessing their treatment assignment compared to incorrectly.  Note Bold 
typeface and grey highlighting indicate different levels of significance which are explained at the end of each time-point. 
 Variable name Correct cf. incorrect 
# Baseline 
1 Age n.s. 
2 Baseline FTND 6.00, 5.85, (5.00—7.00), cf. 6.00, 6.44, (5.00—8.00), p=0.0057 
3 Screening CPD 18.00, 18.06, (15.00—20.00) cf. 20.00, 20.16, (15.00—25.00), 
p=0.0278 
4 Suffered ≥1 adverse effect  141/178 (79.21%) cf. 46/127 (36.22%), p=3x10-14 
5 Smoking Satisfaction 4.33, 4.23, (3.33—5.00) cf. 4.33, 4.52, (3.67—5.33), p=0.0323 
6 Psychological Reward n.s. 
7 Aversion n.s. 
8 Enjoyment of Respiratory Tract Sensations 3.00, 3.21, (2.00—4.00) cf. 4.00, 3.71, (3.00—5.00), p=0.0076 
9 Craving Reduction n.s. 
10 Maximum price for one cannister n.s. 
11 Treatment assignment 147:13 and 31:114 subjects’ guesses were correct:incorrect in 
the active cf. control groups, respectively, p=2x10-16. 
 0.05/11=0.0045 0.00061<p<0.0045 
 0.05/(38*6))  p<0.00022 
 One week after baseline 
1 How happy subjects were with their inhaler 3.00, 3.13, (3.00—4.00) cf. 3.00, 2.84, (2.00—4.00), p=0.0266 
2 Had a problem with their inhaler n.s. 




 Variable name Correct cf. incorrect 
4 Number of times subjects used the inhaler when they had an 
urge to smoke 
n.s. 
5 Used inhaler correctly n.s. 
6 Age n.s. 
7 Baseline FTND n.s. 
8 Inhaler reduced urges score (ad hoc scale) 3.00, 2.53, (2.00—3.00) cf. 2.00, 2.05, (1.00—3.00), p=0.0025 
9 Severity of coughing† 1.00, 0.67, (0—1.00), cf. 0, 0.44, (0—1.00), p=0.0058 
10 100mcg/puff number of puffs used per occasion 0, 1.44, (0—2.00), cf. 0, 0.82, (0—0), p=0.0061 
11 100mcg/puff number of occasions used per day 0, 1.95, (0—2.00) cf. 0.73, (0—0), p=0.0037 
12 number of puffs of 200mcg/puff inhaler used per occasion n.s. 
13 200mcg/puff occasions per day n.s. 
14 Whether reduced smoking by the target amount in first week n.s. 
15 Treatment assignment 142:72 and 96:100 subjects correctly:incorrectly guessed their 
treatment assignments in active and control groups, 
respectively, p=1x10-6. 
 0.05/28=0.00179 
15 variables +13 other adverse effects 
0.00061<p<0.00179 
 0.05/(38*6) p<0.00022 
 One month after baseline (a day after target quit date) 
1 Number of days that had elapsed since subjects had last puffed 
on their inhaler 
n.s. 






 Variable name Correct cf. incorrect 
3 Maximum price subjects would pay for one canister $10.00, $13.15, ($5.00—$15.00), cf. $9.00, $9.88, ($2.50—$15.00), 
p=0.00180 
4 CPD past 24 hours n.s. 
5 24-hour point prevalence abstinence n.s. 
6 Quit smoking early, on-time, or late n.s. 
7 Headache ۞ n.s. 
8 Number of puffs of inhaler taken per occasion inhaler was used n.s. 
9 Occasions per day inhaler was used n.s. 
10 Number of days used inhaler n.s. 
11 Number of puffs of inhaler used in past seven days n.s. 
12 CPD in 4th week as a proportion of screening CPD n.s. 
13 CPD at screening n.s. 
14 Treatment assignment 128:39 and 91:83 subjects correctly:incorrectly guessed a day 
after target quit date in active and control groups respectively, 
p=5x10-6. 
 0.05/27=0.00185 
14 variables+13 other adverse effects 
0.00061<p<0.00185 
 0.05/(38*6) p<0.00022 
 One month after target quit date 
1 Baseline age n.s. 
2 Baseline FTND  n.s. 
3 CPD at screening n.s. 




 Variable name Correct cf. incorrect 
5 24-hour point prevalence abstinence n.s. 
6 7-day point prevalence abstinence n.s. 
7 30-day point prevalence abstinence n.s. 
8 Occasions of inhaler use per day n.s. 
9 Number of puffs of inhaler used in previous seven days 185.0, 378.2, (28.0—455.0), cf. 60.0, 278.6 (0—326.0), p=0.0009 
10 Puffs inhaled per occasion of inhaler use n.s. 
11 Number of days used inhaler since target quit phone-call 28.00, 25.43, (21.00—30.00) cf. 26.00, 20.91, (7.00—30.00), 
p=0.0392 
12 Cough severity†† 0, 0.44, (0—1.00)) cf. 0—0.25, (0—0)), p=0.0206 
13 Throat-scratch severity n.s. 
14 Nausea n.s. 
15 Smoking Satisfaction at baseline, guess a month after target 
quit date 
4.00, 4.19, (3.33—5.00) cf. 4.33, 4.55, (4.00—5.67), p=0.0090 
16 Psychological Reward at baseline, guess a month after target 
quit date 
n.s. 
17 Aversion at baseline, guess a month after target quit date n.s. 
18 Enjoyment of Respiratory sensations at baseline, guess a 
month after target quit date 
3.00, 3.22, (2.00—4.00) cf. 4.00, 3.69, (3.00—5.00), p=0.0280 
19 Craving reduction at baseline, guess a month after target quit 
date 
n.s. 
20 Smoking Satisfaction a month after target quit date, guess a 
month after target quit date 
n.s. 
21 Psychological Reward a month after target quit date, guess a 
month after target quit date 




 Variable name Correct cf. incorrect 
22 Aversion a month after target quit date, guess a month after 
target quit date 
1.00, 1.36, (1.00—1.50), cf. 1.00, 1.16, (1.00—1.00), p=9x10-5 
23 Enjoyment of Respiratory Tract Sensations a month after target 
quit date, guess a month after target quit date 
n.s. 
24 Craving Reduction a month after target quit date, guess a 
month after target quit date 
5.00, 4.74, (4.00—6.00), cf. 4.00, 3.63, (1.00—5.00), p=2x10-5 
25 Prolonged one-month not smoked on seven consecutive days 
abstinence 
110/185 (59.46%) cf. 46/105 (43.81%) p=0.0102 
26 Prolonged one-month not smoked in two consecutive weeks 
abstinence 
n.s. 
27 eCO one-month after target quit date <10ppm n.s. 
28 Days since last smoked a cigarette 2.00, 14.23, (0.08—29.00) cf. 0.28, 10.13, (0.06—20.25), p=0.0385 
29 Highest price subjects would pay for one canister of inhalers to 
which they had been assigned 
$10.00, $13.55, ($5.00—$17.00) cf. $6.00, $8.95, ($2.00—$15.00), 
p=0.00111 
30 MNWS Craving n.s. 
31 MNWS Restlessness n.s. 
32 MNWS Increased Appetite n.s. 
33 MNWS Negative Affect n.s. 
34 MNWS Insomnia n.s. 
35 “inhaler reduced urge” (ad hoc scale) n.s. 
36 Total QSU score one month after target quit date n.s. 
37 Absolute change in total QSU score one month after target quit 





 Variable name Correct cf. incorrect 
38 % change in total QSU score one month after target quit date 
cf. baseline 
60.87%, 48.83% (75.71% to 40.48%) cf. 51.79%, 41.94% (70.73% to 
27.40%), p=0.0393). 
39 Treatment assignment 117:24 and 68:81 correctly:incorrectly guessed in active and control 
groups, respectively, p=9x10-11 
 0.05/50=0.001 
39 variables + 11 other adverse effects 
0.00061<p<0.001 
 0.05/(38*6) p<0.00022 
 Three months after target quit date 
1 Baseline age n.s. 
2 Baseline FTND  n.s. 
3 CPD at screening n.s. 
4 Number of days since last used inhaler 0.21, 14.25, (0.03—19.50) cf. 4.50, 23.90, (0.06—43.50), p=0.0070 
5 24-hour point prevalence abstinence n.s. 
6 7-day point prevalence abstinence n.s. 
7 30-day point prevalence abstinence n.s. 
8 Occasions of inhaler use per day n.s. 
9 Number of puffs of inhaler used in previous seven days 100.0, 316.9, (0.0—376.0) cf. 173.3, 249.5, (0.0—1120.0), p=0.0221 
10 Puffs inhaled per occasion of inhaler use n.s. 
11 Number of days used inhaler since one-month quit visit n.s. 
12 Cough severity††† n.s. 
13 Throat-scratch severity n.s. 
14 Heart-burn n.s. 




 Variable name Correct cf. incorrect 
16 Smoking Satisfaction at baseline, guess three months after 
target quit date 
4.00, 4.18, (3.33—5.00) cf. 4.33, 4.59, (4.00—5.67), p=0.0033 
17 Psychological Reward at baseline, guess three months after 
target quit date 
n.s. 
18 Aversion at baseline, guess three months after target quit date n.s. 
19 Enjoyment of Respiratory Tract Sensations at baseline, guess 
three months after target quit date 
3.00, 3.13, (2.00—4.00) cf. 4.00, 3.65, (3.00—5.00), p=0.0127 
20 Craving Reduction at baseline, guess three months after target 
quit date 
n.s. 
21 Smoking Satisfaction a month after target quit date, guess three 
months after target quit date 
n.s. 
22 Psychological Reward a month after target quit date, guess 
three months after target quit date 
2.80, 2.79, (1.80—3.60) cf. 2.40, 2.36, (1.40—3.00), p=0.0021 
23 Aversion a month after target quit date, guess three months 
after target quit date 
1.00, 1.42, (1.00—2.00) cf. 1.00, 1.11, (1.00—1.00), p=7x10-5 
24 Enjoyment of Respiratory Tract Sensations a month after target 
quit date, guess three months after target quit date 
n.s. 
25 Craving Reduction a month after target quit date, guess three 
months after target quit date 
5.00, 4.88, (4.00—6.00) cf. 4.00, 3.95, (2.00—6.00), p=0.0013 
26 Smoking Satisfaction 3 months after target quit date, guess 
three months after target quit date 
n.s. 
27 Psychological Reward 3 months after target quit date, guess 
three months after target quit date 
2.80, 2.97, (1.80—3.80) cf. 2.40, 2.50, (1.60—3.40), p=0.0228 
28 Aversion 3 months after target quit date, guess three months 
after target quit date 




 Variable name Correct cf. incorrect 
29 Enjoyment of Respiratory Tract Sensations 3 months after 
target quit date, guess three months after target quit date 
n.s. 
30 Craving Reduction 3 months after target quit date, guess three 
months after target quit date 
5.00, 4.84, (4.00—6.00) cf. 4.00, 4.20, (3.000—5.00), p=0.0136 
31 Not smoked on seven consecutive days abstinence between 
one and three months after target quit date  
n.s. 
85/173 (49.13%) cf. 36/89 (40.45%), p=0.1818 
32 Not smoked in two consecutive weeks abstinence between one 
and three months after target quit date 
n.s. 
33 Days since last smoked a cigarette n.s. 
34 Highest price subjects would pay for one canister of inhalers to 
which they had been assigned 
n.s. 
36 MNWS Craving  n.s. 
37 MNWS Restlessness n.s. 
38 MNWS Increased Appetite n.s. 
39 MNWS Negative Affect n.s. 
40 MNWS Insomnia n.s. 
41 “inhaler reduced urge” ad hoc Likert scale n.s. 
42 Total QSU score three months after target quit date n.s. 
43 Absolute change in total QSU score three months after target 
quit date cf. baseline 
n.s. 
44 % change in total QSU score three months after target quit date 
cf. baseline 
65.01, 50.78, (77.78 to 40.98) cf. 54.72, 40.71 (74.48 to 29.78), 
p=0.0474 
45 Treatment assignment 109:23 and 64:66 subjects guessed correct:incorrect in the active 




 Variable name Correct cf. incorrect 
 0.05/55=0.0009 
45 variables + 10 other adverse effects 
p<0.0009 
 0.05/(38*6) p<0.00022 
 Six months after target quit date 
1 Baseline age n.s. 
2 Baseline FTND  n.s. 
3 CPD at screening n.s. 
4 Number of days since last used inhaler 1.50, 34.24, (0.04—52.00) cf. 30.00, 51.02, (0.34—88.25), p=0.0020 
5 24-hour point prevalence abstinence n.s. 
6 7-day point prevalence abstinence n.s. 
7 30-day point prevalence abstinence n.s. 
8 Occasions of inhaler use per day n.s. 
9 Number of puffs of inhaler used in previous seven days 22.0, 357.9, (0—280.0) cf. 0, 167.3, (0—106.8), p=0.0069 
10 Puffs inhaled per occasion of inhaler use n.s. 
11 Number of days used inhaler since three-month quit visit 60.00, 50.03, (10.00—89.00) cf. 42.50, 40.68, (1.75—70.00), 
p=0.0483 
12 Cough severity†††† n.s. 
13 Throat-scratch severity n.s. 
14 Heart-burn n.s. 
15 “other” adverse effect(s) n.s. 
16 Smoking Satisfaction at baseline, guess six months after target 
quit date 




 Variable name Correct cf. incorrect 
17 Psychological Reward at baseline, guess six months after target 
quit date 
2.40, 2.60, (1.60—3.20) cf. 2.00, 2.23, (1.40—2.80), p=0.0057 
18 Aversion at baseline, guess six months after target quit date 1.00, 1.00, (1.60—2.00) cf. 1.00, 1.35, (1.00—1.63), p=0.0359 
19 Enjoyment of Respiratory Tract Sensations at baseline, guess 
six months after target quit date 
n.s. 
20 Craving Reduction at baseline, guess six months after target 
quit date 
4.00, 4.07, (3.00—5.00) cf. 4.00, 3.51, (2.00—4.25), p=0.0186 
21 Smoking Satisfaction a month after target quit date, guess six 
months after target quit date 
n.s. 
22 Psychological Reward a month after target quit date, guess six 
months after target quit date 
2.90, 2.88, (1.80—3.65) cf. 2.40, 2.52, (1.60—3.20), p=0.0124 
23 Aversion a month after target quit date, guess six months after 
target quit date 
1.00, 1.44, (1.00—2.00) cf. 1.00, 1.14, (1.00—1.00), p=0.0004 
24 Enjoyment of Respiratory Tract Sensations a month after target 
quit date, guess six months after target quit date 
n.s. 
25 Craving Reduction a month after target quit date, guess six 
months after target quit date 
5.00, 4.89, (4.00—6.00) cf. 4.00, 4.02, (2.00—6.00), p=0.0036 
26 Smoking Satisfaction 3 months after target quit date, guess six 
months after target quit date 
n.s. 
27 Psychological Reward 3 months after target quit date, guess six 
months after target quit date 
n.s. 
28 Aversion 3 months after target quit date, guess six months after 
target quit date 
1.00, 1.29, (1.00—1.50) cf. 1.00, 1.10, (1.00—1.00), p=0.0053 
29 Enjoyment of Respiratory Tract Sensations 3 months after 





 Variable name Correct cf. incorrect 
30 Craving Reduction 3 months after target quit date, guess six 
months after target quit date 
5.00, 4.91, (4.00—6.00) cf. 4.00, 4.23, (3.00—5.00), p=0.0181 
31 Smoking Satisfaction 6 months after target quit date, guess six 
months after target quit date 
n.s. 
32 Psychological Reward 6 months after target quit date, guess six 
months after target quit date 
n.s. 
33 Aversion 6 months after target quit date, guess six months after 
target quit date 
1.00, 1.30, (1.00—1.00) cf. 1.00, 1.12, (1.00—1.00), p=0.0455 
34 Enjoyment of Respiratory Tract Sensations 6 months after 
target quit date, guess six months after target quit date 
n.s. 
35 Craving Reduction 6 months after target quit date, guess six 
months after target quit date 
5.00, 5.10, (4.00—6.00) cf. 4.00, 3.94, (3.00—5.00), p=2x10-5 
36 Not smoked on seven consecutive days abstinence between 
three and six months after target quit date  
80/145 (55.17%) cf. 33/84 (39.29%), p=0.0205 
37 Not smoked in two consecutive weeks abstinence between 
three and six months after target quit date 
74/145 (51.03%) cf. 31/84 (36.90%), p=0.0386 
38 Days since last smoked a cigarette 15.00, 72.55, (0.08—182.25) cf. 0.29, 47.00, (0.04—89.75), p=0.0307 
39 Highest price subjects would pay for one canister of inhalers to 
which they had been assigned 
n.s. 
40 MNWS Craving  n.s. 
41 MNWS Restlessness n.s. 
42 MNWS Increased Appetite n.s. 
43 MNWS Negative Affect n.s. 
44 MNWS Insomnia n.s. 




 Variable name Correct cf. incorrect 
46 Total QSU score six months after target quit date n.s. 
47 Absolute change in total QSU score six months after target quit 
date cf. baseline 
n.s. 
48 % change in total QSU score six months after target quit date 
cf. baseline 
n.s. 
49 Prolonged six months not smoked on seven consecutive days 
abstinence 
66/145 (45.52%) cf. 23/84 (27.38%), p=0.0067 
50 Treatment assignment 99:24 and 46:60 correctly:incorrectly guessed in the active and 
control respectively, p=1x10-8.  
 0.05/60=0.0008 
50 variables + 10 other adverse effects 
p<0.0008 
 0.05/(38*6) p<0.00022 
ns = p>0.05 
† one week after baseline, apart from severity of coughing, none of the other six adverse effects of the inhalers, reported one week after baseline, (throat-
scratch, Dizzy/Light-headedness, headache, nausea, heartburn, ‘other’) was significantly predictive of guessing treatment assignment one week after baseline 
correctly, incorrectly, or being unsure.   
†† There were no differences in severity of sore throat, difficulty breathing, dizziness/light-head, headache, angina, palpitations, headrush, feeling jittery, 
heartburn, vomiting, or “other” adverse effects, after use of the inhaler, between subjects who, one month after their target quit date, guessed their treatment 
assignment correctly, incorrectly, or unsure. 
††† Apart from the severity of cough and heartburn, there were no significant differences in the severity of any of the other adverse effects recorded. 
†††† There were no significant differences in the severity of any of the adverse effects recorded   erse effectapart from headache the severity of no other adv 






The active nicotine inhaler had significantly more severe side-effects than the placebo inhaler. 
Despite the majority of subjects rating the inhaler side-effects as mild, the side-effects may 
explain the mixed outcome of the mCEQ (high craving reduction but also high aversion and 
low enjoy respiratory sensation scores) for the active inhaler. The fact that there were few 
differences between groups in QSU scores, and no differences in MNWS scores, despite the 
higher number of subjects who had returned to regular smoking in the control group, suggests 
that the active inhaler provided an effective alternative to smoking when subjects’ 






Appendix D.  Psychological Batteries used in the trials 
reported here 
1 The brief Wisconsin Inventory of Smoking Dependence Motives 
 
The brief Wisconsin Inventory of Smoking Dependence Motives consists of 37 items rated on 
a seven-point scale from 1 = Not true of meat all, to 7= Extremely true of me. 
The 37 items are: 
1. I often smoke without thinking about it  
2. Cigarettes control me  
3. I usually want to smoke right after I wake up  
4. It’s hard to ignore an urge to smoke  
5. The flavor of a cigarette is pleasing  
6. I frequently smoke to keep my mind focused  
7. I rely upon smoking to control my hunger and eating  
8. My life is full of reminders to smoke  
9. Smoking helps me feel better in seconds  
10. I smoke without deciding to  
11. Cigarettes keep me company, like a close friend  
12. There are particular sights and smells that trigger strong urges to smoke  
13. Smoking helps me stay focused  
14. I frequently light cigarettes without thinking about it  
15. Most of my daily cigarettes taste good  
16. Sometimes I feel like cigarettes rule my life  




18. Most of the people I spend time with are smokers  
19. Weight control is a major reason that I smoke  
20. Some of the cigarettes I smoke taste great  
21. I’m really hooked on cigarettes  
22. Sometimes I feel like cigarettes are my best friends  
23. My urges to smoke keep getting stronger if I don’t smoke  
24. Seeing someone smoke makes me really want a cigarette  
25. I find myself reaching for cigarettes without thinking about it  
26. I would feel alone without my cigarettes  
27. A lot of my friends or family smoke  
28. Other smokers would consider me a heavy smoker  
29. When I haven’t been able to smoke for a few hours, the craving gets intolerable  
30. Most of my friends and acquaintances smoke  
31. I smoke within the first 30 min of awakening in the morning  
32. Smoking helps me think better  
33. Smoking really helps me feel better if I’ve been feeling down  
34. Smoking keeps me from overeating  
35. My smoking is out of control  
36. I consider myself a heavy smoker 
37. Even when I feel good, smoking helps me feel better 
The items are summed to form 11 subscales and three synthetic scales (PDM, SDM, total). 
The subscales are (44): 





3. Loss of Control 
4. Cognitive Enhance 
5. Craving 
6. Cue exposure/Associative Processes 
7. Affective Enhancement 
8. Social/Environment Goads 
9. Taste 
10. Tolerance 
11. Weight Control 
12. WISDM total score – this is the mean of 11 subscale scores. 
13. Primary Dependence Motives scale (PDM) 
14. Secondary Dependence Motives scale (SDM) 
 
Brief WISDM subscale Scoring procedure: 
Affiliative Attachment Mean of items 11, 22, 26 
Automaticity Mean of items 1, 10, 14, 25 
Loss of Control Mean of items 2, 16, 21, 35 
Cognitive Enhancement Mean of items 6, 13, 32 
Craving Mean of items 4, 17, 23, 29 
Cue Exposure/Associative Processes Mean of items 8, 12, 24 
Social/Environmental Goads Mean of items 18, 27, 30 
Taste Mean of items 5, 15, 20 
Tolerance Mean of items 3, 28, 31, 36 




Affective Enhancement Mean of items 9, 33, 37 
Primary Dependence Motives (PDM) scale Mean of means for Automaticity, Loss of Control, 
Craving, and Tolerance 
Secondary Dependence Motives (SDM) scale Mean of means for Affiliative Attachment, 
Cognitive Enhancement, Cue Exposure/Associative Processes, Social/Environmental Goads, 
Taste, Weight Control, and Affective Enhancement 
Total score Sum of means for the 11 subscales (do not include the PDM or SDM scales)  
2 The modified Cigarette Evaluation Questionnaire  
There are twelve items: 
1. Was smoking satisfying? 
2. Did cigarettes taste good? 
3. Did you enjoy the sensations in your throat and chest? 
4. Did smoking calm you down? 
5. Did smoking make you feel more awake? 
6. Did smoking make you feel less irritable? 
7. Did smoking help you concentrate? 
8. Did smoking reduce your hunger for food? 
9. Did smoking make you dizzy? 
10. Did smoking make you nauseous? 
11. Did smoking immediately relieve your craving for a cigarette? 
12. Did you enjoy smoking? 
For each item the word smoking and cigarette, were replaced with Zonnic or “the inhaler”.  
The items are rated on a seven-point scale: please mark the number that best represents how 
smoking made you feel (1—not at all, 2—very little, 3—a little, 4—moderately, 5—a lot, 6—
quite a lot, 7—extremely). 
There are five sub-scales, two of which are composed of a single item for each sub-scale.   
1. Smoking Satisfaction is the sum or mean of Items 1, 2, and 12  
2. Psychological Reward is the sum or mean of Items 4 through 8  




4. Enjoyment of Respiratory Tract Sensations is equal to Item 3 
5. Craving Reduction was equal to 11. 
1 The brief-Questionnaire of Smoking Urges 
 
There are ten items rated on a seven-point Likert scale from strongly disagree to strongly 
agree. 
1. I have a desire for a cigarette right now 
2. Nothing would be better than smoking a cigarette right now 
3. If it were possible, I probably would smoke now 
4. I could control things better right now if I could smoke 
5. All I want right now is a cigarette 
6. I have an urge for a cigarette 
7. A cigarette would taste good now 
8. I would do almost anything for a cigarette now 
9. Smoking would make me less depressed 
10. I am going to smoke as soon as possible 
In this dissertation the total score calculated by summing all ten items was used. 
3 Minnesota Nicotine Withdrawal Scale (MNWS) 
The MNWS consists of nine items rated on a Likert scale from 0:‘not at all’, 1:‘slight’, 
2:‘moderate’, 3: ‘Quite a bit’, 4: ‘Extreme’. 
Subjects are requested to rate how they have been feeling over the past twenty-four hours and 
to mark the number that applies to them.  The items are: urge to smoke; depressed mood; 
anxiety; difficulty concentrating; restlessness; increased appetite; difficulty going to sleep; 
difficulty staying asleep. 




1. Craving  = ‘Urge to smoke’ 
2. Restlessness = ‘Restlessness’ 
3. Increased appetite = ‘Increased Appetite’ 
4. Negative Affect = sum of ‘Depressed mood’; ‘Irritability, frustration, or anger’; 
‘Anxiety’; ‘Difficulty concentration’ 





4 Fagerström Test for Nicotine Dependence 
The FTND consists of six items rated on a variety of scales, frequently it is the total score that 
is reported for which the lowest possible score is zero, and the highest is 10. 
# Item Answers Points 
1 How soon after you wake up do you smoke your first 
cigarette? 
Within 5 minutes 
6-30 minutes 
1-60 minutes 





2 Do you find it difficult to refrain from smoking in places 












4 How many cigarettes/day do you smoke? 10 or less 
11-20 
21-30 





5 Do you smoke more frequently during the first hours 





6 Do you smoke if you are so ill that you are in bed most 









Appendix E. Generalized Linear Model building strategy for 
multivariate analyses in ZAP; and details of PCA 
regression. 
A multivariate logistic regression of pre-randomisation variables was constructed, using the 
‘purposeful selection’ method outlined in chapter four of Hosmer and colleagues’ textbook 
(257); ensuring that only one of the variables per pair of the five pairs of variables that caused 
collinearity, was included in the same GLM, and ensuring that only one variable of the pairs 
of variables that were mathematically coupled was included.  First, all variables that were 
significant at p<0.25 in univariate regressions, were included (except for the aforementioned 
exclusions of the five pairs that caused collinearity) in a multifactorial logistic regression of 
pre-randomisation variables that may predict prolonged six months abstinence.   
New more parsimonious models were then constructed, in a step-wise fashion, in which only 
one variable was removed at a time, that being the variable with least statistical significance 
in the most recently constructed multivariate model.  After each model was run, the change in 
OR compared to the complete model (that contained all variables that had a significance of 
<0.25 in univariate models) was assessed to determine if the values changed by more than 
twenty-percent which would suggest that the variable that had been removed had acted as an 
important adjustor.  The relative performance of the larger and smaller multivariate models 
was assessed by the likelihood ratio test within R’s anova command.   
This process continued iteratively, removing the variable with the highest p-value of the 
remaining variables, until this caused a larger than twenty-percent change in the OR of one of 
the remaining variables.  Once a variable was found to cause more than a twenty-percent 
change in the OR it was added back into the model.  Once anova demonstrated the smaller 
model was superior, a series of models were then constructed based on the model that anova 
demonstrated was superior, each containing a variable that had been excluded because it had a 
p>0.25 in univariate regression, to identify variables that, by themselves, were not 
significantly related to the outcome but become significant in the presence of other variables.  
No interactions were tested, as I thought that there were no clinically plausible interactions.  
Finally, the adequacy of the model’s fit was assessed.  Each step of this process is described 
in detail below. 
Twenty-four centred and scaled variables recorded prior to randomisation had a significance 




twenty-four variables to use as independent variables in a multivariate logistic regression, five 
were rejected due to mathematical coupling and/or a high correlation between variables:  
1. WISDM PDM since it is the mean of the means of WISDM Tolerance and other 
WISDM scales;  
2. WISDM Total score because it is the mean of the means of all the other WISDM 
subscales;  
3. WISDM SDM because it is mean of the means of Social/Environmental Goads and six 
other WISDM subscales;  
4. Age as a continuous variable measured in years because it is unlikely that an increase 
of one year of age would have the same effect on abstinence for someone who is in 
their twenties compared to someone in their sixties, whereas it is biologically plausible 
that being older than the median age would have a significant effect on abstinence cf. 
being younger than the median age, furthermore Age in years is correlated with other 
variables; and  
5. the categorical variable of started smoking daily aged sixteen or younger because it is 
mathematically coupled with age started smoking daily.   
The correlation matrix of the remaining variables was calculated, which showed that a 
number of variables were highly correlated.  For each correlated pair of variables, one of the 
variables in the pair was removed from the model in an attempt to avoid multicollinearity, 
starting with the most highly correlated variables.  The highest correlation was 0.65 between 
WISDM Tolerance and FTND.  Because bivariate regression demonstrated that Tolerance 
rendered FTND non-significant while remaining significant itself, FTND was removed from 
the multivariate model while WISDM-Tolerance was retained.   
The next highest correlation was 0.64 between WISDM Craving and WISDM Loss of 
Control.  Considering that in a bivariate model, Loss of Control had a smaller Condition 
Index than Craving, and had nearly half the percent change in its OR in bivariate compared to 
univariate regression as Craving had, Craving was removed from the multivariate model.  
This removal avoided the next highest correlation of 0.52 between WISDM Craving and 
WISDM Affective. 
The fourth highest correlation was 0.46 between Social/Environmental Goads and ‘Number of 
other smokes spend time with on a typical day’, since the latter variable had a significance of 




value of the OR for Social/Environmental Goads changed by only six percent compared to the 
univariate model, whereas the value of the OR for ‘Number of other smokes spend time with 
on a typical day’ altered by twenty-eight percent compared to univariate regression and 
became insignificant, this variable was removed from the multivariate model.   
The next highest correlation was 0.44 between WISDM Automaticity and Loss of Control.  
The bivariate model containing these variables calculated that the percent change in OR 
compared to univariate regressions was small, and although the significance of Automaticity 
was no longer p<0.05 in bivariate cf. univariate models, its p-value was below 0.25 in the 
bivariate model, so at this point no further variables were removed due to their degree of 
correlation.   
Thus, the multivariate model of pre-randomisation predictors of six months prolonged not 
smoked on seven consecutive days contained sixteen independent variables.  Four of these 
variables retained a p-value of <0.05 in multivariate regression (WISDM Weight control; 
Previously used NRT; Aged 50 or older; WISDM Social/environmental), while only the first 
two of these four variables, were significant after Bonferroni correction (Table E1, page 432).   
The next step in model building was to remove from the GLM, the variables that had not 
achieved a significance of p<0.05 in the multivariate model, removing them one at a time 
(one GLM per removed variable, starting with the variable that had the largest p-value), and 
determining if the OR for the other variables in the model changed by more than twenty 
percent compared to their values in the larger GLM.   
Table E1 shows that twelve variables of the multivariate model had a significance of p>0.05.  
However, when variables were removed one at a time, and the decision about which variable 
to remove next was based on which variable had the largest p-value (if it was >0.05) in the 
model that had most recently had a variable removed from it, only a total of eight variables 
were removed.  This was because after the ninth variable that had a significance of p>0.05 
(Number of previous quit attempts) had been removed, although all the remaining 
independent predictors in the model had a significance of p<0.05, there was a greater than 
twenty percent change in the OR of one of the independent variables (a 27.42% increase in 
the OR for “Enrolled at Māori Community Trial site” compared to the OR for this variable in 
the full model (in which no independent variables had been removed), although there was less 
than a twenty percent change compared to the model in which eight non-significant variables 
been removed.  After the removal of the eighth variable that had a significance of p>0.05, 




Table E1 Multivariate model of pre-randomisation predictors of six months prolonged 
not smoked on seven consecutive days.  The variables are ordered from most, to 
least, statistically significant 
  OR 95%CI p 
Intercept 0.20 0.13—0.30 3x10-14 ‡ 
WISDM Weight control 1.37 1.14—1.65 0.0008 ‡ 
Previously used NRT 0.52 0.34—0.81 0.0027 ‡ 
Aged 50 or older 1.65 1.15—2.38 0.0069 † 
WISDM Social/environmental 0.74 0.59—0.92 0.0071 † 
Number of previous quit attempts 1.14 0.99—1.31 0.0638 
Enrolled at a Māori Community Trial Site 0.59 0.32—1.02 0.0689 
How prepared to handle stress without 
smoking 
1.18 0.98—1.43 0.0929 
Age started smoking daily 1.12 0.94—1.33 0.1830 
Māori ethnicity 0.64 0.31—1.22 0.1987 
WISDM Tolerance 0.87 0.71—1.08 0.2030 
WISDM Affective 0.89 0.72—1.10 0.2684 
Number of personal acquaintances who quit 1.09 0.91—1.31 0.3341 
WISDM Loss of control 0.92 0.73—1.15 0.4484 
WISDM Automaticity 1.04 0.86—1.28 0.6741 
NZDep2006 0.96 0.80—1.16 0.7014 
Live with other smoker(s) 1.00 0.83—1.21 0.9651 
† p<0.05; ‡ p<0.003125 (Bonferroni for 16 comparisons) 
 
In order to obtain the preliminary main effects model, each of the variables that had a 
significance of p≥0.25 in univariate regressions, was added, one at a time, to the multivariate 
model containing eight independent variables which was reported in Table 3.20, to check 
whether the variables that had a significance of p≥0.25 in univariate regressions, became 
significant when adjusted by the other variables in the multivariate model.  If a variable was 
found to have a significance of p≥0.05 after it had been added to the model, it was removed 
from the model before any other independent variables were added.  Six pre-randomisation 
variables had a significance of p≥0.25 in univariate regressions (Table E1, page 432), none of 
which had a significance of p<0.05 when added to the multivariate model.   
Whether or not this model, the preliminary main effects model, met the assumptions of GLM 
logistic regression was tested.  The Hosmer-Lemeshow statistic was insignificant (Χ2=5.15, 
d.f.=8, p=0.74) demonstrating lack of evidence of ill-fit.  To assess if the error terms were 




time-series, so it is not appropriate to test for invariance across time), the residuals were 
plotted against trial site locations and the correlations of the residuals with locations were 
tested, both the plots and correlation tests showed no relationship.  There was no suggestion 
of collinearity in this model, with the highest Condition Index and VIF for the variables in 
this model being 0.96 and 1.07, respectively.  Since the preliminary main effects model met 
all the assumptions of GLM, it can be considered the final model of pre-randomisation 
predictors. 
Details of PCA regression 
Having established the preliminary main effects model, it is necessary to test its adequacy by 
confirming that the model meets the assumptions of GLM, namely (257):   
1. GLM assumes a linear relationship between the transformed response in terms of 
the link function and the explanatory variables; for example, for binary logistic 
regression logit(π) = β0 + βX. 
2. The errors are independent but are not required to be normally distributed. 
The assumption that the logit changed linearly as a function of the covariates was confirmed 
by plotting the logit (log odds) against each of the independent variables in the model, and 
observing a linear relationship in the plot.  Errors are assumed to be uncorrelated unless the 
data are temporally or spatially related.  The data in this trial were not temporally related 
because they were collected during a single time-period.  A spatial relationship can be 
assessed by plotting the errors (residuals) against trial locations.(338)  Use of these statistical 
tests showed that the logit was linear, and there were no correlations between the errors and 
trial locations. 
The next step, was to check for the existence of biologically plausible interactions between 
the independent variables.(257)  The author of this dissertation did not think there were any 
plausible potential interactions between pre-randomisation variables, or between the 
components derived from the PCA.  At this point, the model can be considered to be the 
preliminary final model, and all that remains to be done, is to measure its fit with the data, 
after which it can be considered the final model and be used for inferential purposes.   
The fit of the preliminary final model was assessed by the deviance of the intercept (null 
deviance) compared to the residual deviance (the deviance of the fitted model); the null 




Table E2.  Loadings of variables onto Components of pre-randomisation PCA.  (displays loadings ≤-0.10 or ≥0.10.) 
 
Comp01 Comp02 Comp03 Comp04 Comp05 Comp06 Comp07 Comp08 Comp09 Comp10 Comp11 Comp12 Comp13 
Enrolled at Māori community trial site 
 
-0.32 -0.16 0.10 
 







-0.16 -0.17   0.21 -0.41 






-0.31   0.11 0.29 -0.43 -0.37 




-0.12 0.42 -0.39  0.35 -0.17 0.37  0.15 






-0.17 -0.16 -0.27 0.16 0.22 0.32 0.55 0.33 






      






  0.14 -0.15   




0.50 0.10 -0.10 -0.16   0.12    






-0.10 -0.16   0.10    
NZDep2006 
 
-0.22 -0.16 -0.22 
 
0.10 0.37  -0.13   -0.23 0.60 
Previously used NRT 
    
0.24 0.33 -0.24 -0.29 0.30 0.50 -0.49   
eCO 
    
0.10 0.14 -0.27 -0.60 -0.49 -0.38 0.12 -0.20 0.14 
Age (years) 
 
0.26 -0.14 0.16 
 





0.41 0.33  0.14 -0.22 0.16   
Number of prior quit attempts 
     
0.42 
 
0.34 -0.57 0.48 0.22   
Age started smoking daily 
 
0.19 
   
-0.34 0.30 -0.26  0.30 0.41 -0.13  
WISDM Automaticity -0.27 
 
-0.17 
   
-0.11 0.16 0.19 -0.10  -0.35 0.15 
WISDM Loss of control -0.32 0.18 -0.11 
    
     0.15 
WISDM Craving -0.34 
      
0.12     0.10 
WISDM Social/environmental goads -0.13 -0.36 
 
-0.38 
   
    -0.13  






 -0.10   0.19 -0.16 






-0.32   -0.21  -0.13 




-0.13 0.10 0.18       
WISDM PDM -0.39 0.12 -0.19 
    
0.12      






      












Table E2 (continued).  Loadings of variables onto Components of pre-randomisation PCA.  (displays loadings ≤-0.10 or ≥0.10.) 
 Comp14 Comp15 Comp16 Comp17 Comp18 Comp19 Comp20 Comp21 Comp22 Comp23 Comp24 Comp25 Comp26 
Enrolled at Māori community trial site -0.12 0.30 0.54 0.37  -0.15        
FTND 0.14 -0.31   0.12 0.20  -0.33 0.44     
Number of smokers spend time with on typical day  -0.14  -0.12  -0.24 0.38 0.17      
Number of smokers know personally who have quit -0.10 -0.40 0.16   0.19 -0.22       
Live with other smoker(s) 0.26 0.17     0.23       
How prepared to handle stress without smoking -0.14  0.14  -0.65 0.10 0.21       
How prepared to forgo the pleasure of smoking -0.11   -0.13 0.66  -0.16       
Desire to reduce smoking           0.70   
Determined to reduce smoking           -0.71   
NZDep2006  -0.44 0.26    0.10       
Previously used NRT -0.24 0.12   -0.12         
eCO -0.13 0.25            
Age (years) 0.59 0.10  -0.14  -0.18  -0.14 -0.14     
Māori ethnicity -0.15  -0.67 -0.13   0.10       
Number of prior quit attempts    0.25          
Age started smoking daily -0.53  -0.11 0.22  0.15 -0.10       
WISDM Automaticity 0.17 0.14 -0.11 0.56  0.36 0.14  0.12   -0.30 0.13 
WISDM Loss of control -0.11   -0.10  -0.50 -0.18 0.34 0.54   -0.24 0.10 
WISDM Craving -0.25   -0.13 0.12 -0.31 0.19 -0.63 -0.33 -0.15  -0.24 0.10 
WISDM Social/environmental goads  0.10   -0.17  -0.66 -0.26  -0.32    
WISDM Tolerance  -0.18   -0.11  -0.17 0.43 -0.59   -0.25 0.11 
WISDM Weight control  -0.44 -0.21 0.42  -0.27    -0.26    
WISDM Affective Enhancement  0.16 0.17 -0.33  0.42 0.24 0.24  -0.54    
WISDM PDM    0.14        0.85  
WISDM SDM    -0.12  0.13    0.58   0.57 





degrees of freedom, thus the fitted model reduced the deviance by sixty-one, and the degrees 
of freedom by five.  The goodness of fit of GLM can be calculated by the Hosmer and 
Lemeshow goodness of fit (GOF) test, in which lack of statistical significance at the p<0.05 
level, indicates that there is no significant evidence that the model does not fit the data well.  
The Hosmer and Lemeshow statistic for the preliminary final model, was Χ2=3.55, df=8, 
p=0.90, demonstrating that there was no evidence that the model did not have good fit, and 
could be considered to be the final model (final pre-randomisation predictor model), and be 
used to make inferences.  
The loading pattern of the components is displayed in Table E2, page 434.  The next step in 
the process of building the statistical model in Table 3.26 (page 160), according to Hosmer 
and colleagues,(257) is to remove all variables that are not statistically significant at the 
p<0.05 level and if this results in a <20% change in the ORs of all of the remaining 
independent variables in the smaller model compared to larger model, this means that none of 
the removed variables had been acting as an important effect-modifier or an important 
minimiser of confounding, whereas if there is a ≥20% change, the removed variable should be 
added back into the model.  Six independent variables had a significance of p>0.05 in the 
multivariate model: Components 3, 9, 11, 14, 17 and 23.  These components were removed 
from the model, one at a time, each time the component with the least statistical significance 
was removed until all remaining components were significant at p<0.05.  After each 
component was removed, the values of the ORs of the remaining components changed by less 
than 1.2% and there were no changes in whether the statistical significance of components 
was below the threshold of Bonferroni correction.  At the end of this process, the independent 
variables remaining in the model were Components 1,2,4,5, and 15, all of which had a 
significance of p<0.05.   
In order to obtain a preliminary main effects model, all the variables not selected for inclusion 
in the multivariate model because, they had a significance of p>0.25 in univariate GLM, were 
added to the model, one at a time, to determine if the added variables attained a significance 
of p<0.05 when they were adjusted by the other variables in the model; if they did not reach 
this level of significance they were removed from the model.  None of the variables that had a 
significance of p>0.25 in univariate regressions, became significant at p<0.05 when they were 
added to the multivariate model, indicating that they played no role as adjusters or effect-





After construction of the models that contained a single independent variable, in order to 
determine if the inclusion of scores of more than one Component, as independent variables in 
a single GLM, would lead to collinearity, the scores of the eleven components that were 
significant at the p<0.25 level of significance in univariate regressions, were entered as 
independent variables, into bivariate GLMs with every unique pairing of those eleven 
component scores, and the changes in the OR and p-value for each of the component scores, 
compared to their values in univariate models, were calculated.  In the bivariate models, of all 
unique combinations of pairs of pre-randomisation component scores, predicting prolonged 
six-months not smoked on seven consecutive days, three component scores became 
significant at p<0.05, which had not been significant in univariate regressions (Component3 
when adjusted by Component9, Component11 when adjusted by Component9, Component11 
when adjusted by Component2).  No component score, that had been significant at p<0.05 in 
univariate models, lost this significance in bivariate models.  One component score that had a 
significance of p<0.25 in univariate models, lost this significance in a bivariate model 
(Component9 when adjusted by Component11).  The percent changes in magnitude of the 
ORs in bivariate compared to univariate models had a mean of 0.06%, (SD:0.50), 
median:0.04%; IQR:-0.23%—0.21%; Range:-1.23%—2.08%.   
Having demonstrated that the values of the ORs of the principal components changed 
minimally when they were in bivariate models with each of the other principal component 
scored, and therefore there was no evidence of collinearity between the principal component 
scores, multivariate regression was undertaken.  The scores of the eleven components that had 
been significant at p<0.25 in univariate regressions, were centred and scaled and entered as 
independent variables into a single multivariate GLM with six months prolonged not smoked 
on seven consecutive days as the dependent variable.  The OR and p-values calculated from 
this single multivariate model were compared to those from univariate GLMs (Table E3, page 
439).  Neither the VIF scores nor Condition Indices for this multivariate GLM were above the 
commonly used cut-offs indicative of the need to investigate if multicollinearity had occurred, 
the VIF scores had a Range=1.01—1.02, while the Condition Indices had a Range of 0.001—
1.000.  The percent change in the ORs for the eleven components that had been significant at 
p<0.25 in univariate regressions, when they were entered as independent variables in 
multivariate, compared to univariate, models was minimal (mean=0.69%, median=0.94%, 
IQR=‑0.64%—2.11%, Range=‑4.10%—4.90%), Table E3, page 439.  In this multivariate 
model, the scores of three components were significant after Bonferroni correction for twenty-




Components 2 and 5 had also achieved in univariate regressions, Component 4 only attained 
this level of significance in the multivariate model.  Components 2 and 4 increased the odds 
of abstinence (by OR 1.51, and 1.36, respectively), while component5 decreased the 
likelihood of abstinence (OR=0.68).  
When the final pre-randomisation model was fitted to the data, three independent variables 
were significant after Bonferroni correction for the twenty-six component scores that were 
calculated by the PCA (p<0.00192): Components2, 4 and 5, the first two of which increased 





Table E3.  Multivariate logistic regression of centred and scale component scores of PCA of variables measured prior to randomisation, 
that were p<0.25 in univariate logistic regressions predicting six-months prolonged abstinence.  Rows are displayed in order of increasing 
p-value. Bonferroni correction for eleven comparisons p<0.004545, for 26 comparisons p<0.001923 
Component 
Univariate Multivariate 
% Δ OR multi- cf. 
univariate OR 95%CI p OR 95%CI p 
2 1.44 1.20—1.73 8x10-5 1.51 1.24—1.84 4x10-5 4.90 
5 0.68 0.57—0.81 2x10-5 0.68 0.57—0.82 5x10-5 0.94 
4 1.33 1.11—1.60 0.0021 1.36 1.13—1.64 0.0012 2.40 
15 0.78 0.65—0.93 0.0061 0.77 0.64—0.92 0.0048 -1.82 
1 1.26 1.06—1.50 0.0080 1.27 1.07—1.52 0.0073 1.13 
14 1.16 0.97—1.38 0.1082 1.16 0.97—1.40 0.1003 0.81 
23 1.13 0.95—1.35 0.1601 1.17 0.97—1.41 0.1072 2.78 
11 1.19 1.00—1.41 0.0448 1.14 0.96—1.36 0.1341 -4.10 
3 1.15 0.96—1.37 0.1231 1.13 0.94—1.36 0.1808 -1.25 
17 1.13 0.95—1.34 0.1667 1.13 0.94—1.35 0.1822 -0.03 






Appendix F: Supplementary tables 
Table F1 Correlations of baseline pre and post randomisation variables with missing not smoked on seven consecutive days abstinence outcomes. 
(Negative correlation coefficients indicate higher values of the variable are correlated with not being missing, while positive correlation coefficients 
indicate higher values of the variable are correlated with a greater chance of missingness). 
Missing abstinence, Pearson correlation coefficient, 95%CI, p 
 Quit phone-call 
n=150 
One month visit 
n=712 
Three month visit 
n=1014 






Baseline pre-randomisation predictors 
Age NS -0.12; -0.17 
to -0.07; 5x10-6‡ 
-0.17; -0.22 to -0.12; 
9x10-11‡ 
-0.17; -0.18 






to -0.09;  
4x10-8‡ 
CPD 0.07; 0.02 to 
0.12; 0.006 
0.09; 0.04 to 
0.14; 0.0006 
0.08; 0.03 to 0.13; 
0.0016 
0.08 0.03 to 
0.13; 0.0031 
0.06; 0.01 to 
0.12; 0.0165 
0.06; <0.01 to 
0.11; 0.0329 
FTND NS 0.10; 0.05 to 
0.15; 0.0001‡ 
0.11; 0.06 to 0.16; 
5x10-5‡ 
0.11; 0.05 to 
0.16; 7x10-5‡ 
0.10; 0.05 to 
0.16; 8x10-5‡ 
0.10; 0.05 to 
0.15; 0.0002 
CO NS NS NS NS NS NS 
Māori NS 0.12; 0.07 to 
0.17; 1x10-5‡ 
0.14; 0.09 to 0.19; 
2x10-7‡ 
0.13; 0.08 to 
0.18; 8x10-7‡ 
0.11; 0.05 to 
0.16; 7x10-5‡ 
0.10; 0.04 to 
0.15; 0.0003 
Male NS -0.08; -0.13 
to -0.02; 0.0044 
-0.06; -0.12 to -0.01; 
0.0145 
-0.06; -0.11 to 
<-0.01; 0.0271 
-0.06; -0.11 to 
<-0.01; 0.02223 
NS 
NZDep2006 0.07; 0.02 to 
0.13; 0.006 
0.13; 0.08 to 
0.18; 1x10-6‡ 
0.13; 0.08 to 0.18; 
8x10-7‡ 
0.10; 0.05 to 
0.16; 0.0001‡ 
0.08; 0.02 to 
0.13; 0.0047 
0.06; <0.01 to 
0.11; 0.0218 
In good health NS NS NS NS -0.06; -0.11 to 
<-0.01; 0.0345 
NS 
Standard Drinks Alcohol -0.06; -0.12 to -
0.01; 0.016 




Missing abstinence, Pearson correlation coefficient, 95%CI, p 
 Quit phone-call 
n=150 
One month visit 
n=712 
Three month visit 
n=1014 






Age started smoking daily NS -0.08; -0.14 
to -0.03; 0.0017 






to -0.03; 0.0032 
-0.10; -0.16 
to -0.05;  
9x10-5‡ 
Previously tried to quit -0.09; -0.14 to -
0.04; 0.0006 
NS NS NS NS NS 
Previously used NRT NS NS NS NS 0.05; <0.01 to 
0.11; 0.0403 
0.05; <0.01 to 
0.11; 0.0400 
Talked to professional NS NS NS NS NS NS 
History of Addiction NS NS NS 0.08; 0.02 to 
0.13; 0.0084 
NS 0.07; 0.01 to 
0.13; 0.0193 
Live with another smoker NS 0.07; 0.01 to 
0.12; 0.0134 
0.05; <0.01 to 0.11; 
0.0403 
0.07; 0.02 to 
0.12; 0.0104 
0.06; <0.01 to 
0.11; 0.0359 
0.06; <0.01 to 
0.11; 0.0333 
Number of smokers spend 
time with on typical day 
NS 0.10; 0.05 to 
0.15; 0.0001‡ 
0.07; 0.02 to 0.12; 
0.0080 
NS 0.08; 0.02 to 
0.13; 0.0040 
0.06; <0.01 to 
0.11; 0.0216 
Know personally other quit NS -0.07; -0.12 
to -0.02; 0.0096 
-0.07; -0.12 to -0.01; 
0.0121 
-0.07; -0.12 
to -0.02; 0.0108 
-0.09; -0.14 
to -0.03; 0.0011 
-0.09; -0.14 
to -0.04; 0.0008 
Desire to quit NS NS NS NS NS NS 
Determined to quit NS NS NS NS NS NS 
Desire to reduce -0.10; -0.15 to -
0.05; 0.0002 
NS 0.07; 0.02 to 0.12; 
0.0097 
0.07; 0.02 to 
0.12; 0.0096 
0.05; <0.001 to 
0.11; 0.0424 
0.07; 0.01 to 
0.12; 0.0121 
Determined to reduce -0.11; -0.16 to -
0.05; 6x10-5‡ 
NS 0.06; 0.01 to 0.11; 
0.0284 
0.06; <0.01 to 
0.11; 0.0243 
NS NS 
Prepared to forgo pleasure -0.06; -0.11 to -
0.01; 0.0292 




Missing abstinence, Pearson correlation coefficient, 95%CI, p 
 Quit phone-call 
n=150 
One month visit 
n=712 
Three month visit 
n=1014 






Prepared Stress -0.05; -0.10 to -
0.01; 0.0458 
NS NS NS NS NS 
Affiliative Attachment† NS NS NS NS NS NS 
Automaticity† NS NS 0.09; 0.03 to 0.14; 
0.0019 
NS NS 0.07; 0.01 to 
0.12; 0.0134 
Loss of Control† NS NS 0.06; <0.01 to 0.12; 
0.0231 
0.06; <0.01 to 
0.11; 0.0410 
0.06; <0.01 to 
0.11; 0.0410 
0.07; 0.01 to 
0.12; 0.0151 
Cognitive enhancement† NS NS NS NS NS NS 




NS NS NS NS NS 0.06; <0.01 to 
0.11; 0.0369 
Social & Environmental 
Goads† 
NS 0.16; 0.11 to 
0.22; 8x10-9‡ 
0.14; 0.09 to 0.19; 
3x10-7‡ 
0.13; 0.07 to 
0.19; 3x10-6‡ 
0.13; 0.07 to 
0.18; 3x10-6‡ 
0.12; 0.07 to 
0.18; 9x10-6‡ 
Taste and Sensory 
Processes† 
NS NS NS NS NS NS 
Tolerance† NS 0.09; 0.03 to 
0.14; 0.0017 
0.12; 0.07 to 0.17; 
1x10-5‡ 
0.10; 0.05 to 
0.16; 0.0002 
0.10; 0.05 to 
0.16; 0.0002 
0.11; 0.06 to 
0.17; 5x10-5‡ 
Weight control† NS NS NS -0.06; -0.11 to -
0.00; 0.0397 
-0.06; -0.11 to -
0.00; 0.0397 
NS 
Affective† NS NS NS NS NS NS 
PDM† NS NS 0.09; 0.03 to 0.14; 
0.0019 
NS NS 0.07; 0.01 to 
0.12; 0.0134 




Missing abstinence, Pearson correlation coefficient, 95%CI, p 
 Quit phone-call 
n=150 
One month visit 
n=712 
Three month visit 
n=1014 






WISDM-37 Total score† NS NS NS NS NS 0.06; <0.01 to 
0.11; 0.0423 
QSU total score NS NS NS NS NS NS 
University Trial site -0.02, -0.07 to 
0.03, 0.42 
-0.13, -0.10 
to -0.08, 4x10-7‡ 
-0.18, -0.23 to -0.13, 
2x10-11‡ 
-0.14, -0.19 
to -0.09, 2x10-7‡ 
-0.14, -0.19 
to -0.09, 1x10-7‡ 
-0.12, -0.17 
to -0.07, 3x10-6‡ 
Baseline Post-randomisation predictors 
Active Treatment NS -0.07; -0.12 to -
0.01; 0.0160 
-0.06; -0.11 to 
<-0.01; 0.0283 
NS NS NS 
Satisfaction†† NS -0.08; -0.13 
to -0.03; 0.0023 
-0.11; -0.17 to -0.06; 
2x10-5‡ 
-0.09; -0.14 
to -0.03; 0.0011 
-0.09; -0.14 
to -0.04; 0.0007 
-0.10; -0.15 
to -0.05; 0.0002 
Psychological Reward†† NS -0.06; -0.11 
to -0.01; 0.0254 
-0.06; -0.11 to 
<-0.01; 0.0328 
NS NS NS 
Enjoy Respiratory 
Sensations†† 
NS -0.01; -0.15 
to -0.05; 0.0002 
-0.14; -0.19 to -0.09; 
6x10-8‡ 
-0.08; -0.14 
to -0.03; 0.0013 
-0.08; -0.13 
to -0.03; 0.0023 
-0.09; -0.14 
to -0.04; 0.0007 
Craving Reduction 
Immediate†† 
NS NS NS NS NS NS 
Craving Reduction within 
15 minutes†† 
NS NS NS NS NS NS 
Aversion†† NS NS NS NS NS NS 
Indigestion* NS NS NS NS NS NS 
Heartburn* NS NS NS NS NS NS 
Acid reflux* NS NS NS NS NS NS 




Missing abstinence, Pearson correlation coefficient, 95%CI, p 
 Quit phone-call 
n=150 
One month visit 
n=712 
Three month visit 
n=1014 






Hiccough* 0.06, 0.01 to 
0.11, 0.0204 
NS NS NS NS NS 
Cough* NS NS NS NS NS NS 
Excess saliva* NS NS NS NS NS NS 
Hurt mouth* NS 0.05; <0.01 to 
0.10; 0.0451 
NS NS NS NS 
Hurt throat* NS NS NS NS NS NS 
Other Adverse effect* NS NS NS NS NS NS 
Total adverse effects* NS NS NS NS NS NS 
NS: Not Significant (p≥0.05); CPD: number of cigarettes smoked per day; FTND: Fagerström Test for Nicotine Dependence; CO: exhaled carbon monoxide; Good 
Health: generally in good health; Standard Drinks Alcohol: average number of standard units of alcohol consumed per week; Talked to professional: previously talked 
to a health professional about quitting smoking; History of Addiction: has a history of addiction to substances other than nicotine; See other smoker: number of smokers 
spent time with on a typical day; Know other quit: personally know smokes who have quit; Prepared to forgo pleasure: prepared to forgo the pleasure of smoking; 
Prepared stress: prepared to handle stress without smoking; WISDM-37: Wisconsin Inventory of Smoking Dependence Motives; PDM: Primary Dependence Motives 
of the WISDM-37; SDM Secondary Dependence Motives of the WISDM-37; QSU: modified Questionnaire of Smoking Urges; † components of WISM-37; †† 
components of the modified Cigarette Evaluation Questionnaire; * side-effect score; ‡ significant after Bonferroni adjustment for 366 comparisons (61 variables acting 
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